Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
25300.0 | 2018-10-23 00:00:00 UTC | 10 Blue-Chip Stocks to Buy for an Earnings Bump | ABBV | https://www.nasdaq.com/articles/10-blue-chip-stocks-buy-earnings-bump-2018-10-23 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It's here. We're now entering the thick of earnings season, with more companies scheduled to report their numbers this week than any other week of the quarter. And an already-volatile time of year is made even more volatile this time around as investors start to wonder if the recent earnings growth pace can be sustained. Even the bluest of the blue-chip stocks aren't immune price jolts, if the right headlines catch investors' attention in the right way.
Not all volatility has to be bad volatility, however. Sometimes, earnings news can push a stock firmly higher without any warning.
To that end, here's a run-down of the top 10 blue-chip stocks to buy for investors willing to take a bit of a gamble on an earnings-driven pop.
7 Growth Stocks That Could Be Derailed Soon
Obviously there are never any guarantees, but in all 10 cases there's either a history or a special situation (if not both) that suggests an earnings bump may be in the cards.
Source: Shutterstock
Salesforce.com (CRM)
Salesforce.com (NYSE: CRM ) isn't a cheap stock by anybody's standards. Even on a forward-looking basis, the forward P/E of 52 is tough to swallow.
This is a name, however, where the valuation just hasn't mattered. It has been all about the growth story and its reliability. The top line is projected to grow more than 25% this year, and more than 20% next year, with even faster earnings growth in the cards. And, Salesforce.com hasn't failed to beat a quarterly earnings estimate in years .
In that light, Bret Kenwell was right on Monday when he explained the 13% pullback that CRM stock has made since its record high from four weeks ago (the biggest correction ithas suffered in years) is a gift to investors who've been biding their time.
Apple (AAPL)
It's almost a little bit cliche to name the world's biggest and most profitable companies - as well as a consistently-growing company - to a list of blue-chip stocks that should see a bit of a bump on the heels of yet-another solid earnings report. But, Apple (NASDAQ: AAPL ) is a name that you don't want to bet against.
The past couple of earnings reports created particularly strong, bullish responses. AAPL stock jumped 6% on Aug. 1 following the release of its fiscal Q3 numbers , and it was up more than 4% on May 2 on the heels of its fiscal Q2 report . And more than that, both earnings reports ultimately prompted what's become a 30% gain since early May.
5 Marijuana Stocks to Ride Canada's Legalization Wave
Apple will post its fiscal Q4 results on Nov. 1.
Source: Shutterstock
Herbalife Nutrition (HLF)
Herbalife Nutrition (NYSE: HLF ) is one of those names that has severely punished anyone who bet against it in front of recent earnings reports. Granted, the post-earnings pops are short-lived events. The stock ultimately ended up moving lower than it was right before the company released its quarterly numbers in early May and early August. But, what a ride while it lasted!
The specifics: HLF stock surged 4.4% on May 4, and was up 13% on Aug. 3, following its prior two earnings reports … and was also up a little more two days after their last two earnings releases. That, however, was about as far as the post-earnings bullishness went.
Herbalife has managed to beat its earnings estimates for three straight quarters now, and will hopefully make it four in a row come Oct. 30.
Source: Shutterstock
Becton Dickinson (BDX)
Becton Dickinson (NYSE: BDX ) isn't exactly a household name. Though it sports a market cap of $61 billion, the medical equipment company just doesn't turn many heads.
But, maybe it should. The company has topped quarterly earnings estimates in years, and hasn't failed to grow them in years.
Let the Marijuana Boom Begin
That said, know that BDX stock isn't one that normally takes flight immediately after better-than-expected reports of earnings growth. But, down 7% just since the end of last month, Becton Dickinson could be ripe for a news-based reversal.
Source: iStockphoto
AbbVie (ABBV)
AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. The stock's down 34% from its February high, and hasn't always responded well to the company's earnings news.
The company itself, however, has done everything it's supposed to do … and more. Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. Better still, sales of its lymphoma drug Imbruvica are still in ramp-up mode after winning approval for new indications, growing 35% during the second quarter to $850 million. The company anticipates peak sales of $7 billion for Imbruvica , leaving the company plenty of room to keep growing its top and bottom lines despite its Humira headwind.
All of a sudden the stock's big pullback this year looks like an opportunity, underscored by a forward-looking P/E of only 9.3.
Source: Shutterstock
UnitedHealth Group (UNH)
The advent of the Affordable Care Act may have flooded UnitedHealth Group (NYSE: UNH ) with revenue-bearing customers, but this business wasn't necessarily profitable. Though revenue has grown every quarter since 2012 , net income has been flat, and occasionally negative on a year-over-year basis.
That is, until 2016 when the health insurer started to drop participation in ACA exchanges in more and more states. It turned out to be the right move . And now, President Donald Trump's version of what healthcare should look like in the United States could prove even more beneficial to the company . Thing is, most investors have yet to take a good long look at how well UnitedHealth is growing again. Revenue is on pace to grow 12% this year , driving a 27% increase in per-share profits.
7 Momentum Stocks to Scrape From the Bottom
Though the company won't post its next quarterly report until January, it may be worth the wait if that's when the market finally realizes what's going on.1
Adobe (ADBE)
Curiously, Adobe (NASDAQ: ADBE ) shares have not responded favorably to any of the company recent quarterly reports … a strange outcome in light of the fact that revenue and earnings have both been growing like crazy since 2015. The organization has developed an entire suite of cloud-based business tools, and the world loves them.
Take a closer look at the stock's chart though. While ADBE stock often peels back following an earnings report, the bigger-picture trend is still bullish. Adobe shares are up more than 200% since their early 2016 low, and despite the pullback from their peak early last month, the bigger trend is still a bullish one.
It may take a while for Adobe stock to respond bullishly to a positive earnings report, but it will likely be worth the wait.
Boeing (BA)
Boeing (NYSE: BA ) shares don't have much of a history of jumping following quarterly earnings reports. In fact, BA stock doesn't have much of a bullish history at all for the past several months. The current price of $347 is right where the stock was back in February. Shares just can't get airborne.
Something has changed for the better though. That is, the perception of Boeing's future is much brighter than it was just a few quarters ago. With its most recent passenger jet market outlook, Boeing opined that the airline industry would need to take delivery of more than 42,000 aircraft over the course of the next 20 years to meet the demand stemming from an annualized increase 4.7% in air travel for the same timeframe. Better yet, investors are starting to understand how Boeing fits into the picture. It's still the preferred provider of the world's passenger jets, setting the stage for a bullish response to proof that it's growing.
10 Defense Stocks to Buy for a Changing World
The company will get another chance to prove it on Oct. 24, when it's expected to post its quarterly results.
Source: Shutterstock
Texas Instruments (TXN)
It's often left out of the discussion about the broad technology market, as it doesn't make the microprocessors, graphics cards and memory chips that dominate the landscape. Don't let the lack of attention fool you though. Texas Instruments (NASDAQ: TXN ) is as much of a tech name as any other player, supplying many of the less-touted components that are still just as necessary to make the Internet of Things and artificial intelligence work.
TXN stock doesn't necessarily bolt higher in response to earnings reports; it very much does its own thing, with bad news or good. But, down more than 15% just since August's high, the earnings news due after the closing bell rings on Oct. 23 may remind the market that the company has topped estimates in eleven of its prior twelve quarters. Tuesday's could be the thirteenth.
Source: Don O'Brien via Flickr
CSX (CSX)
Finally, the industry be old, but railroading is still relevant. That's why CSX (NASDAQ: CSX ) is one of the few blue-chip stocks to buy for traders looking to juice their portfolio.
Yes, the meltdown of oil and coal prices a couple of years back proved problematic. This year has been a different story though. With the United States now the world's biggest producer of crude and coal at least making some sort of comeback, this year's rail traffic in the U.S. is as robust as it has been in four years . That bodes well for CSX, which has not only topped earnings estimates in each of its past four quarters, but has logged outstanding earnings growth. The bottom line is expected to grow 66% this year, and keep growing next year.
15 Tech Stocks With Hidden Potential
CSX stock has pulled back since last week's third-quarter release , and wont reportagain until January. It's one of those names, though, that could be worth the wait. This company is quietly standing in the middle of the economic revival, even if few people have taken notice yet.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter , at @jbrumley.
More From InvestorPlace
10 Cheap Consumer Stocks for an Uncertain Market
7 Momentum Stocks to Scrape From the Bottom
5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout
The 3 Best Stocks to Short on the Street
Compare Brokers
The post 10 Blue-Chip Stocks to Buy for an Earnings Bump appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. In that light, Bret Kenwell was right on Monday when he explained the 13% pullback that CRM stock has made since its record high from four weeks ago (the biggest correction ithas suffered in years) is a gift to investors who've been biding their time. | Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. Source: Shutterstock Salesforce.com (CRM) Salesforce.com (NYSE: CRM ) isn't a cheap stock by anybody's standards. | Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. The company has topped quarterly earnings estimates in years, and hasn't failed to grow them in years. | Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. The company has topped quarterly earnings estimates in years, and hasn't failed to grow them in years. |
25301.0 | 2018-10-23 00:00:00 UTC | AbbVie Becomes Oversold (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-becomes-oversold-abbv-2018-10-23 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 30.4. A bullish investor could look at ABBV's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares:
Looking at the chart above, ABBV's low point in its 52 week range is $81.50 per share, with $125.86 as the 52 week high point - that compares with a last trade of $82.74.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. A bullish investor could look at ABBV's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $81.50 per share, with $125.86 as the 52 week high point - that compares with a last trade of $82.74. | The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $81.50 per share, with $125.86 as the 52 week high point - that compares with a last trade of $82.74. In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. A bullish investor could look at ABBV's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $81.50 per share, with $125.86 as the 52 week high point - that compares with a last trade of $82.74. A bullish investor could look at ABBV's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. A bullish investor could look at ABBV's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $81.50 per share, with $125.86 as the 52 week high point - that compares with a last trade of $82.74. |
25302.0 | 2018-10-22 00:00:00 UTC | Insiders Now Seeing Red With ABBV At New 52-Week Low | ABBV | https://www.nasdaq.com/articles/insiders-now-seeing-red-abbv-new-52-week-low-2018-10-22 | nan | nan | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week low of $83.50/share. That's a $42.36 share price drop, or -33.66% decline from the 52-week high of $125.86 set back on 01/26/2018. Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the 52-week high. For a move like that, AbbVie Inc would need fundamental strength at the business level.
Here's a rhetorical question: Who knows more about fundamentals at the business level than the company's own insiders? So let's take a look to see whether any company insiders were taking the other side of the trade as ABBV shares were being sold down to this new 52-week low, focusing on the most recent trailing six month period. As summarized by the table below, ABBV has seen 2 different instances of insiders buying over the past six months.
In the short run, while the new 52-week low suggests the stock is at the cheapest price and perhaps therefore the best bargain it has been over the last 52 weeks, the low print also means anyone who has purchased the stock over that timeframe is staring at an unrealized loss. Oftentimes, that factor drives a stock's technical analysis metrics by creating overhead resistance, with investors who bought higher now anxious to reverse their trade once they are back to breakeven. The chart below shows where ABBV has traded over the past year, with the 50-day and 200-day moving averages included.
Time will tell whether the insider purchases foretell a future rebound for ABBV shares, which are presently showing a last trade of $85.20/share, a 2.04% rebound off of the new 52-week low.
Ten Bargains You Can Buy Cheaper Than The Insiders Did »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the 52-week high. The chart below shows where ABBV has traded over the past year, with the 50-day and 200-day moving averages included. In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week low of $83.50/share. | Time will tell whether the insider purchases foretell a future rebound for ABBV shares, which are presently showing a last trade of $85.20/share, a 2.04% rebound off of the new 52-week low. In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week low of $83.50/share. Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the 52-week high. | Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the 52-week high. So let's take a look to see whether any company insiders were taking the other side of the trade as ABBV shares were being sold down to this new 52-week low, focusing on the most recent trailing six month period. Time will tell whether the insider purchases foretell a future rebound for ABBV shares, which are presently showing a last trade of $85.20/share, a 2.04% rebound off of the new 52-week low. | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week low of $83.50/share. Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the 52-week high. As summarized by the table below, ABBV has seen 2 different instances of insiders buying over the past six months. |
25303.0 | 2018-10-21 00:00:00 UTC | 3 Dividend Stocks That Pay You More Than Coca-Cola Does | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-pay-you-more-coca-cola-does-2018-10-21 | nan | nan | With a better than 50-year history of paying dividends, Coca-Cola (NYSE: KO) is seen as an icon of stable, strong, secure payouts. Yet as consumers move away from soda consumption toward healthier beverages, there will be challenges ahead for its business, which is why it is branching out into new areas, such as its $5.1 billion acquisition of coffee company Costa.
Although Coke and its dividend are not in trouble, there are better investments to be found. Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) .
Higher yield, faster dividend growth
Neha Chamaria(Dominion Energy): As a Dividend Aristocrat , Coca-Cola undeniably has one of the strongest dividend track records in the industry. I don't doubt Coke's dividend sustainability, but I'm unsure whether the company can dole out meaningful dividend increases given the challenging business conditions that include health concerns associated with its sugary drinks. As an income investor, you might therefore want to consider another dividend stock that offers a bigger yield and better dividend growth visibility. One such top stock I recommend is Dominion Energy.
To be sure, Dominion's 15-year run of annual dividend increases pales in comparison to Coke's streak, but this utility stock comes out a winner on other important dividend aspects. To start, Dominion Energy offers a good 4.65% dividend yield versus Coke's 3.5%, and that yield looks pretty sustainable thanks to the company's dividend growth potential.
You see, Dominion Energy is one of the largest electricity and gas utilities in the U.S., serving nearly 6 million customers across 19 states. The company aims to grow its earnings per share at a compound annual rate of 6% to 8% between 2017 and 2020, and 5% or more thereafter, backed by multibillion-dollar capital investments in power generation, power delivery, and gas infrastructure. Some of its major projects include solar expansion in Virginia and grid modernization.
Management believes its earnings growth should be able to support annual dividend increases of 6% to 10% through 2020. Combine that dividend growth with a 4%-plus yield, and you could even end up with double-digit total annual returns from Dominion Energy shares. It's difficult to have such a conviction for Coke right now.
A bargain dividend play
George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. But AbbVie -- the maker of the world's best-selling drug in Humira -- is arguably an even more attractive income play right now.
AbbVie comes across as a downright better buy than Coke for two reasons. First, AbbVie's dividend yield of 4.23% is slightly higher than Coke's yield of 3.5%. Second, AbbVie's shares are trading at a dirt-cheap 10 times forward-looking earnings; Coke is presently valued at over 20 times its forward-looking earnings.
Why is AbbVie's stock trading at such a rock-bottom price? The obvious reason is Humira's long-term outlook. This all-star drug is expected to start facing generic competition in earnest in 2023. AbbVie will also need a bit of luck to ensure that its host of new growth products and late-stage clinical candidates are, in fact, able to pick up the slack once Humira's rapid growth starts to reverse course.
That said, AbbVie has laid the groundwork to achieve this goal. Its new endometriosis drug, Orilissa, and blood cancer medication Venclexta, for instance, are both projected to generate billions in sales within the next five years. AbbVie's robust clinical pipeline is also close to bringing several other high-value assets on line in the near future.
All told, AbbVie's downside risk -- stemming from Humira's upcoming loss of exclusivity -- appears to be baked into its valuation at this point. This top dividend stock, therefore, might be worth adding to your income portfolio right now.
Worth a gamble
Rich Duprey(MGM Growth Properties): This casino-focused real estate investment trust (REIT) might be a way for investors to bet on the coming boom arising from the legalization of sports betting.
As with all REITs, casino REITs don't pay income tax like regular companies do: They are required to pay 90% of their income back to shareholders, allowing them to remain exempt from income taxes on the profits paid to investors. Their dividends also tend to have higher yields than most, and that's the case with the payout from MGM Growth Properties, which currently yields 6.3% annually.
MGM Growth remains closely tied toMGM Resorts International (NYSE: MGM) , the casino operator from which it was spun off, but which still owns 73% of its business. That makes it different from other casino REITs like Gaming and Leisure Properties , a spinoff from Penn National Gaming ; and VICI Properties , which was born from Caesars Entertainment . Those REITs are independent of their former parents.
But MGM Resorts says that over the next three years, it intends to reduce it financial interest in its REIT from the current 73% to 50%.
Legalized sports betting should bolster all casino stocks, even if it's not about to become their primary profit center. And coupled with the geographic diversity MGM's properties enjoy -- from Vegas, where it's the dominant player, to Macau, and in various regional markets -- it helps soften gaming's ups and downs.
10 stocks we like better than Dominion Energy, Inc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Dominion Energy, Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Rich Duprey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . But AbbVie -- the maker of the world's best-selling drug in Humira -- is arguably an even more attractive income play right now. | Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. But AbbVie -- the maker of the world's best-selling drug in Humira -- is arguably an even more attractive income play right now. | Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. But AbbVie -- the maker of the world's best-selling drug in Humira -- is arguably an even more attractive income play right now. | Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. But AbbVie -- the maker of the world's best-selling drug in Humira -- is arguably an even more attractive income play right now. |
25304.0 | 2018-10-19 00:00:00 UTC | Noteworthy Friday Option Activity: SBNY, FRPT, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-sbny-frpt-abbv-2018-10-19 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Signature Bank (Symbol: SBNY), where a total volume of 2,215 contracts has been traded thus far today, a contract volume which is representative of approximately 221,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.3% of SBNY's average daily trading volume over the past month, of 511,410 shares. Especially high volume was seen for the $115 strike call option expiring November 16, 2018 , with 2,031 contracts trading so far today, representing approximately 203,100 underlying shares of SBNY. Below is a chart showing SBNY's trailing twelve month trading history, with the $115 strike highlighted in orange:
Freshpet Inc (Symbol: FRPT) saw options trading volume of 1,027 contracts, representing approximately 102,700 underlying shares or approximately 43.2% of FRPT's average daily trading volume over the past month, of 237,525 shares. Especially high volume was seen for the $35 strike put option expiring November 16, 2018 , with 1,000 contracts trading so far today, representing approximately 100,000 underlying shares of FRPT. Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange:
And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Particularly high volume was seen for the $89.50 strike put option expiring October 19, 2018 , with 3,054 contracts trading so far today, representing approximately 305,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $89.50 strike highlighted in orange:
For the various different available expirations for SBNY options , FRPT options , or ABBV options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $89.50 strike put option expiring October 19, 2018 , with 3,054 contracts trading so far today, representing approximately 305,400 underlying shares of ABBV. Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $89.50 strike highlighted in orange: For the various different available expirations for SBNY options , FRPT options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Particularly high volume was seen for the $89.50 strike put option expiring October 19, 2018 , with 3,054 contracts trading so far today, representing approximately 305,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $89.50 strike highlighted in orange: For the various different available expirations for SBNY options , FRPT options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Particularly high volume was seen for the $89.50 strike put option expiring October 19, 2018 , with 3,054 contracts trading so far today, representing approximately 305,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $89.50 strike highlighted in orange: For the various different available expirations for SBNY options , FRPT options , or ABBV options , visit StockOptionsChannel.com. | Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the past month, of 5.1 million shares. Particularly high volume was seen for the $89.50 strike put option expiring October 19, 2018 , with 3,054 contracts trading so far today, representing approximately 305,400 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $89.50 strike highlighted in orange: For the various different available expirations for SBNY options , FRPT options , or ABBV options , visit StockOptionsChannel.com. |
25305.0 | 2018-10-17 00:00:00 UTC | EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq | ABBV | https://www.nasdaq.com/articles/eyepoint-eypt-gets-fda-approval-for-eye-therapy-yutiq-2018-10-17 | nan | nan | EyePoint Pharmaceuticals, Inc.EYPT announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis affecting the posterior section of the eye.
Yutiq is a tiny micro-insert that utilizes EyePoint's Durasert drug delivery technology, containing 0.18 mg fluocinolone acetonide, designed to release consistently over a period of 36 months and is the first long-lasting micro-insert to be approved by the FDA.
The nod was based on clinical data from two phase III randomized, sham injection-controlled, clinical studies with patient follow-up continuing for three years. Both evaluations met the primary efficacy endpoint of preventing recurrent uveitis flares after six and 12 months. The analyses demonstrated that Yutiq considerably reduced the rate of recurrent uveitis flares.
EyePoint expects to report the 24-month and 36-month patient follow-up from the first phase III clinical study on Yutiq by the end of 2018 and the first half of 2019, respectively.
Notably, in March 2018, the FDA accepted EyePoint's New Drug Application (NDA) for Yutiq and set an action date of Nov 5, 2018. However, this approval comes before the stipulated time and is a great boost to the company. EyePoint plans to launch Yutiq in the United States during the first quarter of 2019.
The company is also designing a next-generation, shorter-duration treatment for the same indication, based on the Durasert drug delivery technology. The company plans to file an application for this insert next year.
However, EyePoint is likely to face stiff competition from the already available products approved for the given indication. AbbVie's ABBV Humira and Allergan's AGN Ozurdex are approved for a similar disease.
The company currently has strategic collaboration with Alimera Sciences ALIM and several other pharma companies.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan plc (AGN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report
pSivida Corp. (EYPT): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's ABBV Humira and Allergan's AGN Ozurdex are approved for a similar disease. Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this article on Zacks.com click here. EyePoint Pharmaceuticals, Inc.EYPT announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis affecting the posterior section of the eye. | Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this article on Zacks.com click here. AbbVie's ABBV Humira and Allergan's AGN Ozurdex are approved for a similar disease. Yutiq is a tiny micro-insert that utilizes EyePoint's Durasert drug delivery technology, containing 0.18 mg fluocinolone acetonide, designed to release consistently over a period of 36 months and is the first long-lasting micro-insert to be approved by the FDA. | Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this article on Zacks.com click here. AbbVie's ABBV Humira and Allergan's AGN Ozurdex are approved for a similar disease. EyePoint Pharmaceuticals, Inc.EYPT announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis affecting the posterior section of the eye. | Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this article on Zacks.com click here. AbbVie's ABBV Humira and Allergan's AGN Ozurdex are approved for a similar disease. Yutiq is a tiny micro-insert that utilizes EyePoint's Durasert drug delivery technology, containing 0.18 mg fluocinolone acetonide, designed to release consistently over a period of 36 months and is the first long-lasting micro-insert to be approved by the FDA. |
25306.0 | 2018-10-15 00:00:00 UTC | Company News For Oct 15, 2018 | ABBV | https://www.nasdaq.com/articles/company-news-for-oct-15-2018-2018-10-15 | nan | nan | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million
The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan growth for the rest of 2018
AbbVie Inc.'s ABBV shares rose 1.1% after the company settled a patent infringement litigation related to its drug Humira with Sandoz, a division of Novartis AG (NVS)
Shares of Intel Corp. INTC advanced 1.5% after the chipset behemoth reduced its stake to under 3% in supplier ASML Holding
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
First Republic Bank (FRC): Free Stock Analysis Report
Intel Corporation (INTC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan growth for the rest of 2018 AbbVie Inc.'s ABBV shares rose 1.1% after the company settled a patent infringement litigation related to its drug Humira with Sandoz, a division of Novartis AG (NVS) Shares of Intel Corp. INTC advanced 1.5% after the chipset behemoth reduced its stake to under 3% in supplier ASML Holding Want the latest recommendations from Zacks Investment Research? Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report First Republic Bank (FRC): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan growth for the rest of 2018 AbbVie Inc.'s ABBV shares rose 1.1% after the company settled a patent infringement litigation related to its drug Humira with Sandoz, a division of Novartis AG (NVS) Shares of Intel Corp. INTC advanced 1.5% after the chipset behemoth reduced its stake to under 3% in supplier ASML Holding Want the latest recommendations from Zacks Investment Research? Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report First Republic Bank (FRC): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan growth for the rest of 2018 AbbVie Inc.'s ABBV shares rose 1.1% after the company settled a patent infringement litigation related to its drug Humira with Sandoz, a division of Novartis AG (NVS) Shares of Intel Corp. INTC advanced 1.5% after the chipset behemoth reduced its stake to under 3% in supplier ASML Holding Want the latest recommendations from Zacks Investment Research? Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report First Republic Bank (FRC): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan growth for the rest of 2018 AbbVie Inc.'s ABBV shares rose 1.1% after the company settled a patent infringement litigation related to its drug Humira with Sandoz, a division of Novartis AG (NVS) Shares of Intel Corp. INTC advanced 1.5% after the chipset behemoth reduced its stake to under 3% in supplier ASML Holding Want the latest recommendations from Zacks Investment Research? Click to get this free report The PNC Financial Services Group, Inc (PNC): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report First Republic Bank (FRC): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
25307.0 | 2018-10-15 00:00:00 UTC | 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better | ABBV | https://www.nasdaq.com/articles/2-pharmaceutical-stocks-buy-dividends-3-or-better-2018-10-15 | nan | nan | During a tough week for the overall market, pharmaceutical stocks across the board fell a few notches despite a lack of significant news for the industry itself. That brought already attractive dividend yields for Pfizer Inc. (NYSE: PFE) and Gilead Sciences Inc. (NASDAQ: GILD) firmly into the 3% range.
A yield above 3% won't do you much good if the underlying businesses can't fuel its continued growth. Here's what puts these big pharma payouts on better footing than most.
Pfizer Inc.: Time to shine
Over the past five years, Pfizer has been able to raise its dividend 42% despite declining sales for aging blockbusters that lost patent protection and a sterile injectibles business that suffered major product shortages after it was acquired. Now that the worst is over, a strong product lineup and bulging pipeline could allow America's largest pharmaceutical company to direct a ton of cash toward its shareholders. That means the 3.1% yield the stock offers now will probably rise a lot faster than the pace of inflation.
Over the past year, Pfizer has generated a stunning $15.3 billion in free cash flow but used just 51% to meet its dividend commitment. That leaves plenty of room for big payout bumps ahead fueled by drugs like Eliquis. Sales of the next-generation blood thinner jumped 41% in the first half of 2018 to $1.7 billion, and that isn't the only growth driver at the moment.
Pfizer's rheumatoid arthritis tablet, Xeljanz, recently earned approvals that expand its addressable patient population to include people with psoriatic arthritis and ulcerative colitis. The expansions helped Xeljanz sales jump 34% higher in the first half to $788 million, and unmet need for these conditions could push annual sales of the drug beyond $2.5 billion within a few more years.
Pfizer kicked off 2018 with expectations to earn approvals for up to 15 indications worth at least $1 billion in annual sales. Some have already been approved, such as Xtandi, which recently became the first oral treatment for prostate cancer patients before and after their disease has spread. Pfizer's also looking forward to an FDA approval decision in December, or earlier, that could make talazoparib a blockbuster oral treatment for advanced-stage breast cancer patients.
Gilead Sciences Inc.: Turnaround time
This drugmaker offers an above-average 3.1% yield at recent prices because investors are worried about sinking hepatitis C antiviral (HCV) sales. The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise.
Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Despite a lower list price, net sales for the company's HCV franchise will probably stabilize at an annualized run rate of around $4 billion based on second-quarter sales.
Hospitals and insurers have had a hard time working out how to pay for Gilead Sciences' recently launched cellular cancer therapy, Yescarta, which hit a $272 million annual run rate in the second quarter. Now that more details have been hammered out, though, sales could top $2 billion annually within a couple short years if incoming competition doesn't get in the way first.
The company's biggest growth driver is far and away Biktarvy, the first and only single-tablet regimen approved to treat newly diagnosed HIV patients as well as those already on another drug. Plenty of patients are already beginning Biktarvy treatment, and they're expected to drive overall sales of the drug past $6 billion annually at its peak.
Gilead and its collaboration partner Galapagos NV (NASDAQ: GLPG) recently posted data that suggests their oral rheumatoid arthritis candidate, filgotinib, has what it takes to become a blockbuster drug as well. Filgotinib is behind similar new drug candidates on the development timeline, but way ahead in terms of its safety profile. If the oral rheumatoid treatment can launch with its safety profile intact, it could end up leading the pack.
Gilead has raised its payout by a double-digit percentage every year since beginning a dividend program in 2016, yet used just 34% of free cash flow generated over the past year to make all the payouts. That gives new shareholders a good chance to see similar payout bumps down the road.
Remember the risks
It's important for investors to remember that Pfizer and Gilead aren't bulletproof. Gilead is relying heavily on Biktarvy for growth -- if anything impedes its progress, the stock price could take a hit. Pfizer isn't reliant on any single drug, but legacy products with declining sales need constant replacement.
Strings of bad luck happen to the best of them, but growth drivers pushing up the needle now make these above-average pharmaceutical dividends the best you'll find in the industry.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Gilead Sciences Inc.: Turnaround time This drugmaker offers an above-average 3.1% yield at recent prices because investors are worried about sinking hepatitis C antiviral (HCV) sales. | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Pfizer's rheumatoid arthritis tablet, Xeljanz, recently earned approvals that expand its addressable patient population to include people with psoriatic arthritis and ulcerative colitis. | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Pfizer Inc.: Time to shine Over the past five years, Pfizer has been able to raise its dividend 42% despite declining sales for aging blockbusters that lost patent protection and a sterile injectibles business that suffered major product shortages after it was acquired. | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Gilead Sciences Inc.: Turnaround time This drugmaker offers an above-average 3.1% yield at recent prices because investors are worried about sinking hepatitis C antiviral (HCV) sales. |
25308.0 | 2018-10-12 00:00:00 UTC | Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-abbv-nvs-humira-biosimilar-agreement-bmys-new-cancer-deal-2018-10-12 | nan | nan | This week was a relatively quiet one for the pharma sector ahead of earnings. In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drugs for advanced solid tumors.
Recap of the Week's Most Important Stories
AbbVie's Fourth Licensing Deal for Humira Biosimilar: AbbVie signed its fourth licensing deal to protect revenues from its blockbuster arthritis drug, Humira. This time the settlement is with Sandoz, the generic arm of Novartis NVS , per which the latter will have a non-exclusive license to launch Humira in the United States on Sep 30, 2023. In Europe, Sandoz can launch Humira biosimilar from Oct 16. AbbVie has similar licensing deals with Amgen, Mylan and Samsung Bioepis/Biogen. Amgen, Mylan and Samsung Bioepis' biosimilar versions are expected to be launched in the United States in January, June and July 2023, respectively while in the EU, Amgen and Biogen's biosimilars are expected to be launched this month.
Bristol Myers' Cancer Collaboration With Compugen: Bristol-Myers and Israel-based small cancer drugmaker, Compugen Ltd. CGEN announced a new collaboration to study a combination of cancer drugs, Compugen's anti-PVRIG antibody, COM701 and Bristol Myers' PD-1 inhibitor Opdivo in patients with advanced solid tumors. Bristol-Myers will also buy an equity stake worth $12 million in Compugen. Bristol-Myers agreed to buy about 2.4 million shares of Compugen at $4.95 a share.
J&J's Blood Thinner Gets FDA Nod for New Patient Population: The FDA granted approval to a supplemental new drug application (sNDA) seeking label expansion of its blood thinner, Xarelto (2.5 mg tablets twice daily) to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease and/or peripheral artery disease (CAD/PAD). With approval for the new vascular indication, Xarelto will be the only Factor Xa inhibitor indicated for these patient groups. J&J gained approval for a similar label update in the EU in August
J&J also presented data from a pivotal phase III study, which showed that its drug Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy. Stelara is not yet marketed for the UC indication. Stelara is presently marketed for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis and Crohn's disease. (Read more: J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study ).
Novartis' Multiple Sclerosis Candidates in Focus: Novartis announced that both the FDA and the European Medicines Agency (EMA) have accepted its regulatory application seeking approval of siponimod for the treatment of secondary progressive multiple sclerosis (SPMS) in adults. Novartis used a priority review voucher to expedite the review of siponimod in the United States. A decision is expected in March 2019 in the United States and late 2019 in Europe. (Read more: Novartis' Applications for MS Drug Accepted by FDA & EMA ).
Novartis also announced top-line data from a phase IIIb head-to-head study, ASSESS, evaluating its marketed multiple sclerosis drug, Gilenya versus Teva's Copaxone in patients with relapsing remitting multiple sclerosis. Data from the study showed that the patients on Gilenya 0.5mg tablets once-daily experienced significantly fewer relapses than patients taking once daily subcutaneous injection of Copaxone 20mg. Treatment with Gilenya 0.5mg led to a 40.7% relative reduction in the rate of relapses over a period of one year versus Copaxone. Meanwhile, though a numerical risk reduction in relapses was achieved in patients taking Gilenya 0.25mg, the result did not reach statistical significance.
The NYSE ARCA Pharmaceutical Index declined 4.3 in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions:
All stocks have recorded a decline of more than 4% this week. Bristol-Myers declined the most (7.8%) in the last five trading sessions.
In the past six months, Lilly LLY has been the biggest gainer (35.4%) while Glaxo GSK declined the most (5.2%).
(See the last pharma stock roundup here: PFE to Get New CEO, LLY Presents Impressive Diabetes Data )
What's Next in the Pharma World?
Watch out for J&J and Novartis' third-quarter earnings, and several pipeline and regulatory updates next week.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Compugen Ltd. (CGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drugs for advanced solid tumors. Recap of the Week's Most Important Stories AbbVie's Fourth Licensing Deal for Humira Biosimilar: AbbVie signed its fourth licensing deal to protect revenues from its blockbuster arthritis drug, Humira. AbbVie has similar licensing deals with Amgen, Mylan and Samsung Bioepis/Biogen. | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drugs for advanced solid tumors. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Compugen Ltd. (CGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Recap of the Week's Most Important Stories AbbVie's Fourth Licensing Deal for Humira Biosimilar: AbbVie signed its fourth licensing deal to protect revenues from its blockbuster arthritis drug, Humira. | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drugs for advanced solid tumors. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Compugen Ltd. (CGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Recap of the Week's Most Important Stories AbbVie's Fourth Licensing Deal for Humira Biosimilar: AbbVie signed its fourth licensing deal to protect revenues from its blockbuster arthritis drug, Humira. | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drugs for advanced solid tumors. Recap of the Week's Most Important Stories AbbVie's Fourth Licensing Deal for Humira Biosimilar: AbbVie signed its fourth licensing deal to protect revenues from its blockbuster arthritis drug, Humira. AbbVie has similar licensing deals with Amgen, Mylan and Samsung Bioepis/Biogen. |
25309.0 | 2018-10-12 00:00:00 UTC | Bristol-Myers Inks Deal and Invests $12 Million in Compugen | ABBV | https://www.nasdaq.com/articles/bristol-myers-inks-deal-and-invests-%2412-million-in-compugen-2018-10-12 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that it has entered a clinical trial collaboration with Compugen CGEN . Per the deal, the companies will evaluate the safety and tolerability of Compugen's COM701, an investigational antibody, in combination with Bristol-Myers' immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors.
Bristol-Myers also announced that it will make a $12-million equity investment in Compugen, purchasing 2,424,243 shares, which is equal to a 4.1% stake, at $4.95 each. The investment represents a 33% premium over the average closing price in the last 20 trading days and is expected to close on Oct 12. Shares of Compugen rose about 7% following the news. However, year to date, shares of Bristol-Myers have declined 6.1%, against the industry 's growth of 2.7%.
With this collaboration, Compugen will have access to Bristol-Myers' high profile drug, Opdivo, which will speed up the development process of COM701.
Notably, Opdivo is currently approved in several countries, including the United States, the EU and Japan for several cancer indications. Opdivo became the first PD-1 inhibitor to be approved for a hematological malignancy - classical Hodgkin lymphoma - in both the United States (May 2016) and the EU (November 2016).
Bristol-Myers is working on expanding the label of Opdivo further. The drug has been performing impressively due to demand resulting from the rapid commercial acceptance for several indications, including melanoma, renal cell carcinoma and second-line non-small-cell lung cancer ("NSCLC"). Label expansion to include additional indications would give the drug access to a higher patient population and increase its commercial potential significantly.
Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination with their cancer treatments.
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote
Zacks Rank
Bristol-Myers currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Compugen Ltd. (CGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination with their cancer treatments. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Compugen Ltd. (CGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Per the deal, the companies will evaluate the safety and tolerability of Compugen's COM701, an investigational antibody, in combination with Bristol-Myers' immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination with their cancer treatments. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Compugen Ltd. (CGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb Company Price Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote Zacks Rank Bristol-Myers currently carries a Zacks Rank #2 (Buy). | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination with their cancer treatments. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Compugen Ltd. (CGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb Company Price Bristol-Myers Squibb Company Price | Bristol-Myers Squibb Company Quote Zacks Rank Bristol-Myers currently carries a Zacks Rank #2 (Buy). | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination with their cancer treatments. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Compugen Ltd. (CGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Opdivo is currently approved in several countries, including the United States, the EU and Japan for several cancer indications. |
25310.0 | 2018-10-12 00:00:00 UTC | AbbVie Settles With Novartis to Delay Humira Biosimilar in US | ABBV | https://www.nasdaq.com/articles/abbvie-settles-with-novartis-to-delay-humira-biosimilar-in-us-2018-10-12 | nan | nan | AbbVie, Inc.ABBV announced that it has settled a litigation with Sandoz, the generic arm of Novartis NVS , involving AbbVie's blockbuster arthritis drug, Humira (adalimumab). The company has signed a non-exclusive licensing deal with Sandoz related to Novartis' proposed biosimilar version of Humira, in the United States, Europe and other countries where AbbVie has intellectual property. Per the agreement, Sandoz will have the license to launch its biosimilar Humira in the United States on Sep 30, 2023. A launch can be scheduled in Europe on or after Oct 16, 2018.
Per the terms of the settlement, Sandoz will pay royalties to AbbVie for the license and all pending litigations between the companies will be dismissed. AbbVie will make no payments to Sandoz.
AbbVie's stock has declined 6.2% this year so far against the industry 's rise of 5.5%.
AbbVie has similar licensing deals with Amgen, Inc. AMGN , Mylan MYL and Samsung Bioepis. Amgen can launch Amjevita, its biosimilar version of Humira in the United States on Jan 31, 2023; Samsung Bioepis can launch Imraldi, its biosimilar version on Jun 30, 2023 and Mylan can launch its biosimilar, Hulio, on Jul 31, 2023. While Amgen and Samsung Bioepis' biosimilar versions are already approved by the FDA, Sandoz and Mylan are yet to gain FDA approval. Both Sandoz and Mylan have received approval for their biosimilars in Europe. In most countries of Europe, Samsung Bioepis' partner Biogen and Amgen have license to launch their biosimilar versions from Oct 16 this year.
AbbVie made it clear that Sandoz's U.S. license will not be accelerated by Amgen's, Mylan's or Samsung Bioepis' biosimilar launch.
Humira is the key driver of AbbVie's revenues, accounting for around 65% of its total sales. Currently approved for 13 indications, Humira sales have increased consistently - 11.7% in 2015, 16.1% in 2016 and 14.6% in 2017 - backed by robust demand trends. The product continues to see strong growth in the dermatology and gastroenterology markets. The company recorded sales of $9.9 billion from the drug in the first half of 2018 and expects Humira sales to approach $21 billion in 2020. The entry of biosimilars will have a huge impact on AbbVie's financials as the drug generates a significant percentage of the company's revenue.
Other than Amgen, Sandoz, Mylan and Samsung Bioepis, Coherus BioSciences, Boehringer Ingelheim and Pfizer are also looking to get approval for a biosimilar version of Humira. However, AbbVie has successfully struck licensing deals with four companies to protect its revenues from HumiraThis gives AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company has signed a non-exclusive licensing deal with Sandoz related to Novartis' proposed biosimilar version of Humira, in the United States, Europe and other countries where AbbVie has intellectual property. AbbVie, Inc.ABBV announced that it has settled a litigation with Sandoz, the generic arm of Novartis NVS , involving AbbVie's blockbuster arthritis drug, Humira (adalimumab). Per the terms of the settlement, Sandoz will pay royalties to AbbVie for the license and all pending litigations between the companies will be dismissed. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that it has settled a litigation with Sandoz, the generic arm of Novartis NVS , involving AbbVie's blockbuster arthritis drug, Humira (adalimumab). | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that it has settled a litigation with Sandoz, the generic arm of Novartis NVS , involving AbbVie's blockbuster arthritis drug, Humira (adalimumab). | However, AbbVie has successfully struck licensing deals with four companies to protect its revenues from HumiraThis gives AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched. AbbVie, Inc.ABBV announced that it has settled a litigation with Sandoz, the generic arm of Novartis NVS , involving AbbVie's blockbuster arthritis drug, Humira (adalimumab). The company has signed a non-exclusive licensing deal with Sandoz related to Novartis' proposed biosimilar version of Humira, in the United States, Europe and other countries where AbbVie has intellectual property. |
25311.0 | 2018-10-12 00:00:00 UTC | 3 Big Pharma Stocks Racing Along the Road to China | ABBV | https://www.nasdaq.com/articles/3-big-pharma-stocks-racing-along-road-china-2018-10-12 | nan | nan | China has an immense cancer problem, but it's about to get a lot better. The country's National Health Insurance Administration recently added 17 well-known cancer drugs to the list of treatments it's willing to pay for.
In the quarters ahead, a handful of products from Pfizer Inc. (NYSE: PFE) , AstraZeneca PLC (NYSE: AZN) , and Johnson & Johnson (NYSE: JNJ) will become available for new populations that are larger than the ones they serve in the U.S. Here's what it could mean for these three big pharma stocks down the line.
AstraZeneca: Tagrisso
Tagrisso is an easy-to-swallow tablet for the treatment of lung cancer patients with tumors that harbor certain genetic mutations. Despite having a highly targeted audience, Tagrisso sales in the U.S. hit an annualized $1.4 billion run rate in the second quarter and could climb much higher following a recent approval to treat certain newly diagnosed patients.
It's hard to say just how many Chinese patients have tumors with certain EGFR mutations that make them eligible for Tagrisso, but there's going to be a lot. An estimated 781,000 people will receive their first lung cancer diagnosis in China this year, around three and a half times more than in the U.S. Moreover, we know that EGFR mutations occur in around 30% to 40% of people in the Asia-Pacific region, compared with just 10% to 15% in Western markets.
In the first half of 2018, AstraZeneca's sales to China rose 33% to $1.9 billion, or 18% of total revenue during the period. Now that just about everyone can get the government to pay for Tagrisso, it could help lift the entire boat in 2019.
Johnson & Johnson: Imbruvica
Since earning FDA approval to treat newly diagnosed patients with the most common form of leukemia, Imbruvica has become one of Johnson & Johnson's lead growth drivers. J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle.
Leukemia isn't nearly as common as lung cancer in either country, but in 2008, there were 60% more people of all ages diagnosed with leukemia in China than in the U.S. In the U.S., sales of Imbruvica are on pace to hit $2.8 billion this year, and a much larger addressable patient population with access to the treatment could help Imbruvica's impressive run continue.
Johnson & Johnson's share of global Imbruvica sales surged 62% in the first half of 2018 to $1.8 billion. While that would be enough to send most companies' entire top lines to the moon and back, Johnson & Johnson expects total sales to reach $81 billion this year. Chinese Imbruvica sales aren't going to send J&J soaring, but they could sure help the healthcare giant continue moving in the right direction.
Pfizer Inc.: Adding three
With an enormous lineup of branded drugs, Pfizer has already benefited a great deal from increasing access in the Chinese market. Lipitor lost patent protection in the U.S. years ago, but it's more popular in China than you might think. Pfizer reported emerging market sales growth of 32% to $781 million in the first half of the year.
Going forward, Pfizer can look forward to increased access to three different oral therapies. Sutent is an oral treatment approved in the U.S. to treat the most common form of kidney cancer, and some less common forms of pancreatic and stomach cancer. Chinese oncologists treating relapsed kidney cancer patients can also add Inlyta to their arsenals.
Pfizer's Xalkori treats a limited cross-section of lung cancer patients with tumors that test positive for two mutations that are more common in the Asian-Pacific region. Xalkori may be intended for just a small percentage of all Chinese lung cancer patients, but the overall population is huge. Don't be surprised if Xalkori generates enough new sales in the region to make a significant contribution to total revenue, which is expected to reach $53 billion this year.
High-volume strategy
Before you run out and buy up these stocks because of their exposure to the Chinese market, there's something you'll want to bear in mind first. These drugs launched in the U.S. with six-figure list prices, but the Chinese government won't be paying nearly as much. All three of these companies can look forward to growth from the region, but just how much is still too hard to tell.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer owns shares of Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and has the following options: short October 2018 $135 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Despite having a highly targeted audience, Tagrisso sales in the U.S. hit an annualized $1.4 billion run rate in the second quarter and could climb much higher following a recent approval to treat certain newly diagnosed patients. Pfizer's Xalkori treats a limited cross-section of lung cancer patients with tumors that test positive for two mutations that are more common in the Asian-Pacific region. | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Johnson & Johnson: Imbruvica Since earning FDA approval to treat newly diagnosed patients with the most common form of leukemia, Imbruvica has become one of Johnson & Johnson's lead growth drivers. In the U.S., sales of Imbruvica are on pace to hit $2.8 billion this year, and a much larger addressable patient population with access to the treatment could help Imbruvica's impressive run continue. | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Johnson & Johnson: Imbruvica Since earning FDA approval to treat newly diagnosed patients with the most common form of leukemia, Imbruvica has become one of Johnson & Johnson's lead growth drivers. While that would be enough to send most companies' entire top lines to the moon and back, Johnson & Johnson expects total sales to reach $81 billion this year. | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Johnson & Johnson: Imbruvica Since earning FDA approval to treat newly diagnosed patients with the most common form of leukemia, Imbruvica has become one of Johnson & Johnson's lead growth drivers. While that would be enough to send most companies' entire top lines to the moon and back, Johnson & Johnson expects total sales to reach $81 billion this year. |
25312.0 | 2018-10-10 00:00:00 UTC | AbbVie (ABBV) Stock Moves -1.54%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-1.54%3A-what-you-should-know-2018-10-10 | nan | nan | AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. This move was narrower than the S&P 500's daily loss of 3.29%. Meanwhile, the Dow lost 3.15%, and the Nasdaq, a tech-heavy index, lost 4.08%.
Prior to today's trading, shares of the drugmaker had gained 1.49% over the past month. This has outpaced the Medical sector's loss of 1.22% and the S&P 500's gain of 0.44% in that time.
Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be November 2, 2018. On that day, ABBV is projected to report earnings of $2.01 per share, which would represent year-over-year growth of 42.55%. Meanwhile, our latest consensus estimate is calling for revenue of $8.21 billion, up 17.37% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $7.86 per share and revenue of $32.91 billion, which would represent changes of +40.36% and +16.64%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ABBV. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0% higher within the past month. ABBV is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that ABBV has a Forward P/E ratio of 12.03 right now. This valuation marks a discount compared to its industry's average Forward P/E of 16.61.
We can also see that ABBV currently has a PEG ratio of 0.93. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.99 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 21, which puts it in the top 8% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On that day, ABBV is projected to report earnings of $2.01 per share, which would represent year-over-year growth of 42.55%. AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be November 2, 2018. | AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be November 2, 2018. On that day, ABBV is projected to report earnings of $2.01 per share, which would represent year-over-year growth of 42.55%. | AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be November 2, 2018. On that day, ABBV is projected to report earnings of $2.01 per share, which would represent year-over-year growth of 42.55%. | On that day, ABBV is projected to report earnings of $2.01 per share, which would represent year-over-year growth of 42.55%. AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be November 2, 2018. |
25313.0 | 2018-10-10 00:00:00 UTC | Neurocrine Inks Deal with Private Biotech to Make CNS Drugs | ABBV | https://www.nasdaq.com/articles/neurocrine-inks-deal-with-private-biotech-to-make-cns-drugs-2018-10-10 | nan | nan | Neurocrine Biosciences, Inc.NBIX announced that it has struck a research collaboration deal with privately held small biotech Jnana Therapeutics to identify novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders. The partnership will leverage Jnana's proprietary drug discovery platform focused on solute carrier (SLC) family of transporters with Neurocrine's expertise in developing new medicines for CNS diseases.
Per the agreement, Neurocrine will make an undisclosed upfront payment and provide continuous funding for research to support the drug discovery. Moreover, Jnana is eligible to receive future milestones and royalties on net sales of the product. Both the companies will jointly lead the discovery phase, after which Neurocrine will take care of future development and commercialization.
Shares of Neurocrine have rallied 40.6% year to date versus the industry's decline of 1.7%.
We remind investors that Neurocrine has ample experience in developing new medicines, which target the SLC family of transporters like VMAT2. VMAT2 led to the development of the company's marketed drug, Ingrezza (valbenazine). Ingrezza is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia (TD), a movement disorder.
In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. Earlier this week, Health Canada also approved Orilissa for the same indication.
Zacks Rank & Stocks to Consider
Neurocrine currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector are United Therapeutics Corp. UTHR and GlycoMimetics, Inc. GLYC both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
United Therapeutics' earnings estimates have moved 3.6% north for 2018 and 2.3% for 2019 over the past 60 days. The stock has inched up 1.8% in the past three months.
GlycoMimetics' loss per share estimates has narrowed 7.5% for 2018 and 4.2% for 2019 over the past 60 days.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report
United Therapeutics Corporation (UTHR): Free Stock Analysis Report
GlycoMimetics, Inc. (GLYC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report GlycoMimetics, Inc. (GLYC): Free Stock Analysis Report To read this article on Zacks.com click here. Neurocrine Biosciences, Inc.NBIX announced that it has struck a research collaboration deal with privately held small biotech Jnana Therapeutics to identify novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders. | In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report GlycoMimetics, Inc. (GLYC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report GlycoMimetics, Inc. (GLYC): Free Stock Analysis Report To read this article on Zacks.com click here. In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. The partnership will leverage Jnana's proprietary drug discovery platform focused on solute carrier (SLC) family of transporters with Neurocrine's expertise in developing new medicines for CNS diseases. | In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report GlycoMimetics, Inc. (GLYC): Free Stock Analysis Report To read this article on Zacks.com click here. The partnership will leverage Jnana's proprietary drug discovery platform focused on solute carrier (SLC) family of transporters with Neurocrine's expertise in developing new medicines for CNS diseases. |
25314.0 | 2018-10-10 00:00:00 UTC | J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study | ABBV | https://www.nasdaq.com/articles/jjs-stelara-succeeds-in-phase-iii-ulcerative-colitis-study-2018-10-10 | nan | nan | Johnson & JohnsonJNJ announced new data from a phase III study, evaluating its drug Stelara in adults with moderate-to-severe ulcerative colitis ("UC"). The eight-week induction data from the pivotal phase III UNIFI study showed that a single intravenous (IV) dose of the medicine induces clinical remission and response in UC patients who had failed prior therapy.
Please note that Stelara is not yet marketed for the UC indication. Stelara is presently marketed for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis and Crohn's disease.
The data from UNIFI showed that after eight weeks of treatment, clinical remission was achieved in 15.6% of UC patients who received the 130 mg dose of Stelara and 15.5% of patients receiving the 6 mg/kg dosing compared to 5.3% for those receiving placebo. The secondary endpoints included the proportion of patients in clinical response, endoscopic healing, as well as improvement in health-related quality of life.
These measures were also significantly higher at week 8 in the Stelara treatment arm compared to placebo arm. Meanwhile, adverse events proportion was similar in both the Stelara and placebo arms. However, one death was reported in the 6mg/kg dose group in a patient with no known history of cirrhosis or portal hypertension.
Ulcerative colitis is a complicated immune disease in which the patients suffer from persistent diarrhea, abdominal pain, blood in stool, loss of appetite, weight loss and fatigue. More than half of the UC patients fail to achieve remission with currently available conventional or biologic therapies. The successful induction data from the UNIFI study highlights the potential of Stelara for UC patients in the future.
The stock has dipped 0.3% this year so far against an increase of 7.1% recorded by the industry .
Stelara sales rose 33% to $2.4 billion in the first half of 2018. Stelara is gaining market share particularly driven by strong uptake in the new indication for Crohn's disease for which approval was received both in the United States and the EU in 2016.
Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda.
J&J currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Shire plc (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & JohnsonJNJ announced new data from a phase III study, evaluating its drug Stelara in adults with moderate-to-severe ulcerative colitis ("UC"). | Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The data from UNIFI showed that after eight weeks of treatment, clinical remission was achieved in 15.6% of UC patients who received the 130 mg dose of Stelara and 15.5% of patients receiving the 6 mg/kg dosing compared to 5.3% for those receiving placebo. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda. The eight-week induction data from the pivotal phase III UNIFI study showed that a single intravenous (IV) dose of the medicine induces clinical remission and response in UC patients who had failed prior therapy. | Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The eight-week induction data from the pivotal phase III UNIFI study showed that a single intravenous (IV) dose of the medicine induces clinical remission and response in UC patients who had failed prior therapy. |
25315.0 | 2018-10-10 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, ConnectOne Bancorp and Pennymac Mortgage Investment Trust | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder-abbvie-connectone-bancorp-and-pennymac-mortgage-investment-trust-2018 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on 11/15/18, ConnectOne Bancorp Inc will pay its quarterly dividend of $0.075 on 11/1/18, and Pennymac Mortgage Investment Trust will pay its quarterly dividend of $0.47 on 10/30/18. As a percentage of ABBV's recent stock price of $94.07, this dividend works out to approximately 1.02%, so look for shares of AbbVie Inc to trade 1.02% lower - all else being equal - when ABBV shares open for trading on 10/12/18. Similarly, investors should look for CNOB to open 0.32% lower in price and for PMT to open 2.32% lower, all else being equal.
Below are dividend history charts for ABBV, CNOB, and PMT, showing historical dividends prior to the most recent ones declared.
AbbVie Inc (Symbol: ABBV) :
ConnectOne Bancorp Inc (Symbol: CNOB) :
Pennymac Mortgage Investment Trust (Symbol: PMT) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 4.08% for AbbVie Inc, 1.28% for ConnectOne Bancorp Inc , and 9.27% for Pennymac Mortgage Investment Trust.
In Wednesday trading, AbbVie Inc shares are currently off about 0.5%, ConnectOne Bancorp Inc shares are trading flat, and Pennymac Mortgage Investment Trust shares are up about 0.5% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As a percentage of ABBV's recent stock price of $94.07, this dividend works out to approximately 1.02%, so look for shares of AbbVie Inc to trade 1.02% lower - all else being equal - when ABBV shares open for trading on 10/12/18. If they do continue, the current estimated yields on annualized basis would be 4.08% for AbbVie Inc, 1.28% for ConnectOne Bancorp Inc , and 9.27% for Pennymac Mortgage Investment Trust. Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on 11/15/18, ConnectOne Bancorp Inc will pay its quarterly dividend of $0.075 on 11/1/18, and Pennymac Mortgage Investment Trust will pay its quarterly dividend of $0.47 on 10/30/18. AbbVie Inc (Symbol: ABBV) : ConnectOne Bancorp Inc (Symbol: CNOB) : Pennymac Mortgage Investment Trust (Symbol: PMT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on 11/15/18, ConnectOne Bancorp Inc will pay its quarterly dividend of $0.075 on 11/1/18, and Pennymac Mortgage Investment Trust will pay its quarterly dividend of $0.47 on 10/30/18. AbbVie Inc (Symbol: ABBV) : ConnectOne Bancorp Inc (Symbol: CNOB) : Pennymac Mortgage Investment Trust (Symbol: PMT) : In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABBV's recent stock price of $94.07, this dividend works out to approximately 1.02%, so look for shares of AbbVie Inc to trade 1.02% lower - all else being equal - when ABBV shares open for trading on 10/12/18. If they do continue, the current estimated yields on annualized basis would be 4.08% for AbbVie Inc, 1.28% for ConnectOne Bancorp Inc , and 9.27% for Pennymac Mortgage Investment Trust. |
25316.0 | 2018-10-08 00:00:00 UTC | AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis | ABBV | https://www.nasdaq.com/articles/abbvies-orilissa-gets-canadian-nod-to-treat-endometriosis-2018-10-08 | nan | nan | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. Orilissa was approved in the United States in July 2018 for the same indication.
The approval was supported by positive data from two replicate phase III studies, which evaluated Orilissa for the given indication in women. The detailed data from the analysis showed that treatment with Orilissa resulted in statistically significant reductions in menstrual and non-menstrual pelvic pain associated with endometriosis compared with placebo. Orilissa is expected to be launched in Canada early November.
Endometriosis affects an estimated one in 10 women of reproductive age and is associated with pain symptoms. The pain associated with it is currently managed with oral contraceptives, progestins, danazol, NSAIDS, opioids and GnRH agonists. Many medicines are not specifically indicated for treating endometriosis. With Orilissa approved to treat pain associated with endometriosis, it can address a market with significant unmet need to bring in more revenues for AbbVie.
Shares of AbbVie have lost 2.2% year to date versus the industry's increase of 7.1%.
We remind investors that Orilissa is also being studied for the treatment of uterine fibroids in women. In August, the company announced positive top-line data from phase III extension study on Orilissa for the same. Outcomes data from the phase III ELARIS UF-EXTEND (M12-816) study demonstrated that Elagolix (300 mg twice daily) in combination with low-dose add-back therapy reduced heavy menstrual bleeding in 87.9% of women with uterine fibroids at month 12 of the regime.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank & Stocks to Consider
AbbVie currently has a Zacks Rank #3 (Hold).
Bristol-Myers Squibb Co. BMY and Roche AG RHHBY are better-ranked stocks from the same space, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Bristol-Myers' earnings per share estimates have increased from $3.59 to $3.63 for 2018 and from $3.83 to $3.92 for 2019 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters with an average beat of 6.39%. Share price of the company has increased 2.0% year to date.
Roche's earnings per share estimates have increased from $2.14 to $2.24 for 2018 and from $2.15 to $2.28 for 2019 over the past 60 days. Share price of the company has increased 1.8% year to date.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. With Orilissa approved to treat pain associated with endometriosis, it can address a market with significant unmet need to bring in more revenues for AbbVie. Shares of AbbVie have lost 2.2% year to date versus the industry's increase of 7.1%. | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report To read this article on Zacks.com click here. | With Orilissa approved to treat pain associated with endometriosis, it can address a market with significant unmet need to bring in more revenues for AbbVie. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. |
25317.0 | 2018-10-08 00:00:00 UTC | 3 Top Biotech Stocks to Buy in October | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-october-2018-10-08 | nan | nan | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher and that AbbVie has become a top stock on sale. Are these stocks worth including in your portfolio? Read on to find out.
This biopharma stock has big news coming
Todd Campbell(Regeneron Pharmaceuticals): If it's been a while since you last considered owning Regeneron Pharmaceuticals in your portfolio, now could be a good time to revisit it .
The company is best known for its multibillion-dollar blockbuster vision drug, Eylea, but over the past few years, it's won a slate of FDA approvals that are diversifying it into cardiovascular and autoimmune disease.
Its cholesterol-lowering drug, Praluent, got off to a disappointing start, but it's been picking up the pace since an outcomes study earlier this year showed it can reduce the risk of heart attack and stroke. In the second quarter, Praluent's sales grew 59% year over year to $73.5 million.
Demand for its eczema drug, Dupixent, has been strong from the get-go, and it's on track to become a blockbuster. Its sales were $209.2 million in Q2, up from $29 million in the same quarter last year.
Growing sales from those drugs are welcome, but I think it makes sense to buy Regeneron now because of near-term catalysts that could spark a rally. On Sept. 28, it won the FDA OK for Libtayo, the first approved treatment for advanced cutaneous squamous cell carcinoma, the second-most-common skin cancer. Roughly 7,000 Americans die annually because of this cancer, so this drug could begin adding meaningfully to sales soon.
On Oct. 20, the FDA is expected to weigh in on whether to expand Dupixent's use to include asthma patients. If approved, that could provide an additional bump-up for its sales. Furthermore, the FDA plans to decide next year if Praluent's outcomes study data can be included on its label and whether Eylea can be used in diabetic retinopathy (DR), an indication that could increase its addressable market by a few million patients in the United States. Because these catalysts could add meaningfully to Regeneron's financial performance, I think this is a good time to buy shares.
Current products + pipeline = reasonable risk/reward trade-off
Chuck Saletta(Incyte Corporation): In the high-risk world of biotech investing, it's incredibly hard to pick winners among the dozens of companies whose compounds are still in the research phase. With three approved products already in the market, Incyte has real revenues coming in that can support its operations and enable it to continue to invest in its pipeline.
On average, analysts expect Incyte to deliver $1.15 per share in profits in 2018 and $2.29 per share in 2019, levels that indicate continued demand for its treatments. That gives the company ample runway to continue clinical trials to hopefully bring more of its pipeline to market and discover even more new compounds.
Incyte's primary focus is cancer therapies. Its pipeline includes expanding its Ruxolitinib compound to treat graft vs. host disease, a potentially fatal side effect that affects people who receive stem cell transplants as part of other therapies. Results from published trials look strong, and it's often more straightforward to expand the scope of approved compounds than it is to get brand-new ones approved. That plus the rest of its pipeline provides reasons to believe Incyte's growth can continue.
At a forward price-to-earnings ratio of around 30, the market is expecting Incyte to deliver in 2018, 2019, and beyond. With solid existing revenues and a pipeline that looks promising, it looks like a reasonable risk/reward trade-off in an industry known for wild volatility and high risk.
Too cheap to ignore
Brian Feroldi (AbbVie): Biotech giant AbbVie hasn't gotten any love from the market recently. Shares have pulled back more than 20% from their recent high. The plunge has pulled the company's valuation to the point that shares currently trade for less than 11 times forward earnings . That's dirt cheap for a cash-gushing giant.
What's with all the doom and gloom? One answer is that AbbVie was recently on the receiving end of a short-attack . Another problem is that FDA Commissioner Scott Gottlieb recently stated that he wants to make it easier for biosimilars to come to market. If he's successful, then sales growth of AbbVie cash cow Humira might slow (or even head in reverse).
While this situation is certainly worth monitoring, I think it's likely that the current pessimism is overblown for a few reasons.
First, doctors tend to remain brand loyal to biologic drugs even after biosimilar competition comes to market. When combined with the drug's patent protection through 2023 in the U.S., Humira will likely remain a ridiculously profitable drug for years to come.
Second, the rest of AbbVie's stable is performing well. Drugs like Imbruvica and Mavyret are pumping out billions in annual sales. Newly launched Orilissa and Venclexta are also expected to turn into top sellers eventually.
Third, AbbVie's pipeline has a number of promising compounds in it that could help offset the eventual decline in Humira sales.
When these factors are combined, market watchers project that AbbVie's profits will grow in excess of 15% annually over the next five years. Adding a dividend yield of 4% to the picture only sweetens the pie further.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Brian Feroldi has no position in any of the stocks mentioned. Chuck Saletta has no position in any of the stocks mentioned. Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher and that AbbVie has become a top stock on sale. Too cheap to ignore Brian Feroldi (AbbVie): Biotech giant AbbVie hasn't gotten any love from the market recently. | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. Too cheap to ignore Brian Feroldi (AbbVie): Biotech giant AbbVie hasn't gotten any love from the market recently. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher and that AbbVie has become a top stock on sale. | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher and that AbbVie has become a top stock on sale. Too cheap to ignore Brian Feroldi (AbbVie): Biotech giant AbbVie hasn't gotten any love from the market recently. | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher and that AbbVie has become a top stock on sale. Too cheap to ignore Brian Feroldi (AbbVie): Biotech giant AbbVie hasn't gotten any love from the market recently. |
25318.0 | 2018-10-05 00:00:00 UTC | Roche's Hemlibra Receives FDA Approval for Label Expansion | ABBV | https://www.nasdaq.com/articles/roches-hemlibra-receives-fda-approval-for-label-expansion-2018-10-05 | nan | nan | RocheRHHBY announced that the FDA has approved a label expansion of its hemophilia drug, Hemlibra.
The drug is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, aged new born and older, with haemophilia A without factor VIII inhibitors.
The drug was approved based on positive results from the phase III studies - HAVEN 3 and HAVEN 4. Data from the studies showed that Hemlibra prophylaxis led to statistically significant and clinically meaningful reductions in treated bleeds compared to no prophylaxis (primary endpoint) and across all other bleed-related endpoints in the HAVEN 3 study. It also led to a clinically meaningful control of bleeding in the HAVEN 4 study.
Per the company, Hemlibra is now the only prophylactic treatment for patients suffering from haemophilia A with or without factor VIII inhibitors that can be administered subcutaneously (under the skin) and at multiple dosing options (once weekly, every two weeks or every four weeks).
We note that Hemlibra was granted Breakthrough Therapy designation by the FDA for haemophilia A without factor VIII inhibitors. The drug was also granted Priority Review. Meanwhile, Roche's Marketing Authorisation Application (MAA) variation for haemophilia A without factor VIII inhibitors is under review by the European Medicines Agency (EMA). The company also plans to submit applications to regulatory authorities around the world.
We remind investors that the FDA approved Hemlibra in November 2017 for the treatment of adults and children suffering from haemophilia A with factor VIII inhibitors.
Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . The pipeline includes polatuzumab vedotin/RG7596 and a small molecule antagonist of MDM2 (idasanutlin/RG7388).
Roche has a strong presence in the oncology market. In particular, the company dominates the breast cancer space with strong demand for its HER2 franchise drugs, which include Herceptin, Perjeta and Kadcyla.
The company is making efforts to develop its portfolio beyond oncology into immunology and neuroscience. Roche has more than a dozen investigational medicines in clinical development for diseases like multiple sclerosis, Alzheimer`s disease, spinal muscular atrophy, Parkinson`s disease, Huntington`s disease and autism spectrum disorder.
Approval of new drugs and diagnostics tests, and label expansion of existing key drugs bode well for Roche, given its current challenges.
Year to date, shares of Roche have declined 0.1% against the industry 's growth of 11%. Roche's legacy drugs like Herceptin and MabThera are facing competition from biosimilars. Novartis NVS has already launched its biosimilar version of Rituxan/MabThera in Europe. Amgen AMGN too has got its biosimilar of Avastin.
Zacks Rank
Roche currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The drug is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, aged new born and older, with haemophilia A without factor VIII inhibitors. | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that the FDA approved Hemlibra in November 2017 for the treatment of adults and children suffering from haemophilia A with factor VIII inhibitors. | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The drug is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, aged new born and older, with haemophilia A without factor VIII inhibitors. | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Hemlibra was granted Breakthrough Therapy designation by the FDA for haemophilia A without factor VIII inhibitors. |
25319.0 | 2018-10-03 00:00:00 UTC | Merck & Other Pharma Players Await FDA Decisions in October | ABBV | https://www.nasdaq.com/articles/merck-other-pharma-players-await-fda-decisions-october-2018-10-03 | nan | nan | In the United States, there has been a huge increase in FDA approvals for cancer and rare- to-treat diseases' drugs, thanks to efficient and effective regulatory processes. The FDA has already approved 41 novel drugs till September. Last year, the FDA had given nod to 34 new drugs till September and approved 46 drugs in the full year.
The 46 drug approvals last year were the highest number of drugs approved by the FDA in more than a decade. Looking at the trend this year so far, it appears that the number of drug approvals will easily surpass 2017's tally. With President Trump supporting streamlined FDA policies with an expedited drug approval process, innovation has picked up pace in the sector, thus increasing the possibility of approvals.
Landmark decisions this year so far include J&J's JNJ Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals' cystic fibrosis (CF) medicine Symdeko; Amgen AMGN /Novartis NVS , Eli Lilly LLY and Teva Pharma's TEVA calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and Ajovy respectively; AbbVie's ABBV Orilissa for pain associated with endometriosis; Merck's MRK two new HIV drugs - Pifeltro and Delstrigo; and BioMarin Pharmaceuticals' Palynziq to treat phenylketonuria (PKU).
The drug development process is lengthy and requires a lot of funds and resources. Consequently, pipeline events including data readouts and regulatory updates act as major catalysts.
Let's take a look at a few important regulatory events scheduled for the month of October.
FDA Decision on Merck's Keytruda for a Difficult Lung Cancer: On Oct 30, the FDA is expected to give its decision on Merck's sNDA seeking label expansion of Keytruda, in combination with chemotherapy, as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC)- a difficult-to-treat lung cancer patient population. The sNDA filing was based on data from the phase 3 KEYNOTE-407 study.
Data from the study presented at ASCO showed that the combination of Keytruda plus chemotherapy led to significant improvement in both overall survival (OS) and progression-free survival regardless of PD-L1 expression. The data was termed "practice changing" by CNBC - changing the way doctors look at prescribing these drugs to cancer patients. If Merck gets approval for this label expansion, it will further cement its position in the lung cancer market, which is the most lucrative oncology sector.
New Indication for Regeneron/Sanofi's Dupixent: On Oct 20, the FDA is expected to give its decision on Regeneron/Sanofi's supplemental biologics license application (sBLA) for label expansion of its eczema drug, Dupixent for a new indication - as an add-on maintenance treatment of adults and adolescents with moderate-to-severe asthma.
Dupixent is already approved for the treatment of atopic dermatitis (AD) or eczema. Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases such as nasal polyposis, eosinophilic esophagitis and grass immunotherapy.
Approval of Roche's and Jazz Pharmaceuticals' Drugs in Expanded Patient Populations: This week, a decision is expected on Roche's sBLA seeking approval of its drug Hemlibra for treatment of hemophilia A patients without factor VIII inhibitors. Hemlibra is presently marketed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia A patients with factor VIII inhibitors.
On Oct 27, the FDA is expected to give its decision on Jazz Pharmaceuticals' sNDA, looking for approval of its key drug Xyrem in pediatric patients for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients.
Ionis Pharma's Tegsedi and Therapeutics MD's TX-001HR Await FDA Nod: The FDA will give its decision on Akcea Therapeutics and Ionis Pharmaceuticals' Tegsedi (inotersen) on Oct 6. Tegsedi has been developed for the treatment of hereditary TTR amyloidosis (hATTR), an inherited, progressive and fatal disease with limited treatment options. Tegsedi was approved in the European Union in July this year.
On Oct 28, the FDA is expected to give its decision on TherapeuticsMD's pipeline candidate TX-001HR, a bio-identical hormone therapy combination of estradiol and progesterone. TherapeuticsMD is seeking approval of TX-001HR as a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
FDA Approval of Bausch Health's Jemdel Lotion Due: On Oct 5, the FDA is expected to give its decision on Bausch Health Companies' high-potency topical steroid treatment, Jemdel for plaque psoriasis.
Stay Tuned for Additional Updates
Some key FDA decisions expected in the near term include Acorda Therapeutics' Inbrija for treating OFF periods in patients with Parkinson's disease (PD), Sanofi's sotagliflozin for type I diabetes, Alexion's ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and Jazz Pharmaceuticals' solriamfetol for excessive sleepiness in narcolepsy & obstructive sleep apnea among others. Hence, investors are expected to keep a close watch on the FDA's actions in the next few months
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Landmark decisions this year so far include J&J's JNJ Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals' cystic fibrosis (CF) medicine Symdeko; Amgen AMGN /Novartis NVS , Eli Lilly LLY and Teva Pharma's TEVA calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and Ajovy respectively; AbbVie's ABBV Orilissa for pain associated with endometriosis; Merck's MRK two new HIV drugs - Pifeltro and Delstrigo; and BioMarin Pharmaceuticals' Palynziq to treat phenylketonuria (PKU). Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases such as nasal polyposis, eosinophilic esophagitis and grass immunotherapy. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Landmark decisions this year so far include J&J's JNJ Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals' cystic fibrosis (CF) medicine Symdeko; Amgen AMGN /Novartis NVS , Eli Lilly LLY and Teva Pharma's TEVA calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and Ajovy respectively; AbbVie's ABBV Orilissa for pain associated with endometriosis; Merck's MRK two new HIV drugs - Pifeltro and Delstrigo; and BioMarin Pharmaceuticals' Palynziq to treat phenylketonuria (PKU). FDA Decision on Merck's Keytruda for a Difficult Lung Cancer: On Oct 30, the FDA is expected to give its decision on Merck's sNDA seeking label expansion of Keytruda, in combination with chemotherapy, as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC)- a difficult-to-treat lung cancer patient population. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Landmark decisions this year so far include J&J's JNJ Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals' cystic fibrosis (CF) medicine Symdeko; Amgen AMGN /Novartis NVS , Eli Lilly LLY and Teva Pharma's TEVA calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and Ajovy respectively; AbbVie's ABBV Orilissa for pain associated with endometriosis; Merck's MRK two new HIV drugs - Pifeltro and Delstrigo; and BioMarin Pharmaceuticals' Palynziq to treat phenylketonuria (PKU). FDA Decision on Merck's Keytruda for a Difficult Lung Cancer: On Oct 30, the FDA is expected to give its decision on Merck's sNDA seeking label expansion of Keytruda, in combination with chemotherapy, as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC)- a difficult-to-treat lung cancer patient population. | Landmark decisions this year so far include J&J's JNJ Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals' cystic fibrosis (CF) medicine Symdeko; Amgen AMGN /Novartis NVS , Eli Lilly LLY and Teva Pharma's TEVA calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and Ajovy respectively; AbbVie's ABBV Orilissa for pain associated with endometriosis; Merck's MRK two new HIV drugs - Pifeltro and Delstrigo; and BioMarin Pharmaceuticals' Palynziq to treat phenylketonuria (PKU). Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The 46 drug approvals last year were the highest number of drugs approved by the FDA in more than a decade. |
25320.0 | 2018-10-03 00:00:00 UTC | Here's Why J&J (JNJ) is a Good Bet in a Troubled Market | ABBV | https://www.nasdaq.com/articles/heres-why-jj-jnj-is-a-good-bet-in-a-troubled-market-2018-10-03 | nan | nan | In a bull market, it is easy to pick stocks and stay invested as shares of the majority of the listed companies move up on strong macroeconomic factors as well as positive sentiments. However, stock picking gets difficult in a bear market. A wrong choice can severely impact investors' portfolio as had been the case at the time of the 2008 market crash.
We have been in a bull run since the crash, the longest one so far, taking the S&P 500 to its all-time high. However, investors are now becoming skeptical of the market's continuation as it nears the psychological level of 3000. Although the U.S. economy is growing as evident from robust GDP and rising interest rates, it is exposed to several negative factors like trade wars among major economies and rising crude oil prices . In this turmoil, several investors are wary of putting their money into stocks.
However, avoiding markets can be a lost opportunity in hindsight as we have seen on several occasions since 2009. While it is impossible to predict the onset of a bear market, it is possible to choose stocks with low risk and good long-term growth opportunity.
Johnson & Johnson JNJ is one of the companies, which meets the criteria discussed below.
Good Rank and Solid VGM Score
J&J currently carries a Zacks Rank #2 (Buy) and has a favorable VGM Score of B. Back-tested results show that only stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2, offer the best upside potential. You can see the complete list of today's Zacks #1 Rank stocks here .
Shareholder Return
J&J also returns value to shareholders through buybacks and dividend payments. Dividend payouts have increased for 55 consecutive years. The company's total shareholder return was more than 24% in 2017.
The stock has gained 5.7% in the past year.
Johnson & Johnson Price
Johnson & Johnson Price | Johnson & Johnson Quote
Consistent Sales Growth
J&J is the biggest pharma company in terms of market-cap as well as sales and also boasts a well-diversified product portfolio comprising pharmaceuticals, medical devices and consumer products.
Pharma products generate nearly half of the company's total revenues. Its sales grew at an impressive rate of 20% in the second quarter of 2018 compared with the year-ago period. The company has already raised its organic sales guidance for 2018 twice this year. The company expects sales at Consumer and Medical Device segments to improve in the second half.
The growth in Pharma segment sales was led by J&J's oncology drugs including Imbruvica, Darzalex and Zytiga. Worldwide sales of J&J's cancer drugs rose 42.2% in the second quarter. Moreover, along with established products, the new products also performed well. The new drugs launched in the past five years constitute almost a fifth of segment sales.
Strong Pipeline
J&J also boasts a strong pipeline and has plans to launch 10 new products over the next three years with blockbuster potential. It is also targeting 50 line extensions of its approved drugs. These factors will help the company to fight competition from generics. The company is also boosting its rare drug pipeline through acquisitions and focusing on emerging markets for expansion.
The company is also developing treatments in collaboration with other pharma/biotech companies which include TESARO's TSRO Zejula. J&J is also developing its and AbbVie's ABBV Imbruvica in combination with Roche's RHHBY Rituxan to treat a rare form of Non-Hodgkin's lymphoma.
Conclusion
As evident from the discussion, J&J has a lower risk profile than its pharmaceuticals peers. Its risk is also lower than several other similar sized companies from other sectors. Moreover, growth in dividend payout creates an increasing flow of income every year.
A sudden increase in competition for certain products due to the launch of an improved drug by a competitor may unfavorably impact margins over the short term. But a solid pipeline, exceptional growth of new drugs and a consistent dividend growth trend will boost the company's value over the longer term in spite of market turmoil.
Best Electric Car Stock? You'll Never Guess It.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
TESARO, Inc. (TSRO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | J&J is also developing its and AbbVie's ABBV Imbruvica in combination with Roche's RHHBY Rituxan to treat a rare form of Non-Hodgkin's lymphoma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. In a bull market, it is easy to pick stocks and stay invested as shares of the majority of the listed companies move up on strong macroeconomic factors as well as positive sentiments. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. J&J is also developing its and AbbVie's ABBV Imbruvica in combination with Roche's RHHBY Rituxan to treat a rare form of Non-Hodgkin's lymphoma. Johnson & Johnson Price Johnson & Johnson Price | Johnson & Johnson Quote Consistent Sales Growth J&J is the biggest pharma company in terms of market-cap as well as sales and also boasts a well-diversified product portfolio comprising pharmaceuticals, medical devices and consumer products. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. J&J is also developing its and AbbVie's ABBV Imbruvica in combination with Roche's RHHBY Rituxan to treat a rare form of Non-Hodgkin's lymphoma. Johnson & Johnson Price Johnson & Johnson Price | Johnson & Johnson Quote Consistent Sales Growth J&J is the biggest pharma company in terms of market-cap as well as sales and also boasts a well-diversified product portfolio comprising pharmaceuticals, medical devices and consumer products. | J&J is also developing its and AbbVie's ABBV Imbruvica in combination with Roche's RHHBY Rituxan to treat a rare form of Non-Hodgkin's lymphoma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. The new drugs launched in the past five years constitute almost a fifth of segment sales. |
25321.0 | 2018-10-03 00:00:00 UTC | Noteworthy Wednesday Option Activity: FIT, ROST, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-fit-rost-abbv-2018-10-03 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Fitbit Inc (Symbol: FIT), where a total of 23,959 contracts have traded so far, representing approximately 2.4 million underlying shares. That amounts to about 45.2% of FIT's average daily trading volume over the past month of 5.3 million shares. Especially high volume was seen for the $5 strike call option expiring October 05, 2018 , with 1,784 contracts trading so far today, representing approximately 178,400 underlying shares of FIT. Below is a chart showing FIT's trailing twelve month trading history, with the $5 strike highlighted in orange:
Ross Stores, Inc. (Symbol: ROST) saw options trading volume of 13,365 contracts, representing approximately 1.3 million underlying shares or approximately 44.6% of ROST's average daily trading volume over the past month, of 3.0 million shares. Especially high volume was seen for the $100 strike call option expiring October 19, 2018 , with 8,143 contracts trading so far today, representing approximately 814,300 underlying shares of ROST. Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange:
And AbbVie Inc (Symbol: ABBV) options are showing a volume of 23,027 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.3% of ABBV's average daily trading volume over the past month, of 5.2 million shares. Particularly high volume was seen for the $100 strike call option expiring November 16, 2018 , with 7,391 contracts trading so far today, representing approximately 739,100 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $100 strike highlighted in orange:
For the various different available expirations for FIT options , ROST options , or ABBV options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $100 strike call option expiring November 16, 2018 , with 7,391 contracts trading so far today, representing approximately 739,100 underlying shares of ABBV. Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 23,027 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.3% of ABBV's average daily trading volume over the past month, of 5.2 million shares. | Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 23,027 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.3% of ABBV's average daily trading volume over the past month, of 5.2 million shares. Particularly high volume was seen for the $100 strike call option expiring November 16, 2018 , with 7,391 contracts trading so far today, representing approximately 739,100 underlying shares of ABBV. | Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 23,027 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.3% of ABBV's average daily trading volume over the past month, of 5.2 million shares. Particularly high volume was seen for the $100 strike call option expiring November 16, 2018 , with 7,391 contracts trading so far today, representing approximately 739,100 underlying shares of ABBV. | That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.3% of ABBV's average daily trading volume over the past month, of 5.2 million shares. Particularly high volume was seen for the $100 strike call option expiring November 16, 2018 , with 7,391 contracts trading so far today, representing approximately 739,100 underlying shares of ABBV. Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 23,027 contracts thus far today. |
25322.0 | 2018-10-03 00:00:00 UTC | Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again | ABBV | https://www.nasdaq.com/articles/why-abbvie-abbv-is-poised-to-beat-earnings-estimates-again-2018-10-03 | nan | nan | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). This company, which is in the Zacks Large Cap Pharmaceuticals industry, shows potential for another earnings beat.
This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 2.45%.
For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98 per share, representing a surprise of 1.01%. For the previous quarter, the company was expected to post earnings of $1.80 per share and it actually produced earnings of $1.87 per share, delivering a surprise of 3.89%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for AbbVie. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time . In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
AbbVie has an Earnings ESP of +0.06% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on November 2, 2018.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98 per share, representing a surprise of 1.01%. Price and EPS Surprise With this earnings history in mind, recent estimates have been moving higher for AbbVie. | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98 per share, representing a surprise of 1.01%. Price and EPS Surprise With this earnings history in mind, recent estimates have been moving higher for AbbVie. | For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98 per share, representing a surprise of 1.01%. If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). Price and EPS Surprise With this earnings history in mind, recent estimates have been moving higher for AbbVie. | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98 per share, representing a surprise of 1.01%. Price and EPS Surprise With this earnings history in mind, recent estimates have been moving higher for AbbVie. |
25323.0 | 2018-10-03 00:00:00 UTC | Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors | ABBV | https://www.nasdaq.com/articles/gilead-hifibio-collaborate-to-develop-t-cell-receptors-2018-10-03 | nan | nan | Gilead Sciences, Inc . GILD announced that it entered into a collaboration agreement with HiFiBiO Therapeutics.
Both companies have entered into a research collaboration and license agreement to develop technology, supporting the discovery of neoantigen-reactive T-cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors.
Per the terms, Kite, which was acquired by Gilead in 2017, will adapt HiFiBiO's proprietary single cell technology platform to create a high throughput approach that will enable in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies.
HiFiBiO will receive a $10-million upfront payment along with milestone payments. In exchange, Kite will have an exclusive option to license HiFiBiO's platform to screen T-cell repertoires and identify TCRs for use in TCR engineered T-cell therapies with a corresponding payment to HiFiBiO.
Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. ABBV , the company is looking to HIV and newer avenues to boost its top line.
During the first quarter of 2018, Gilead announced an agreement with Sangamo Therapeutics, Inc. SGMO to use Sangamo's zinc finger nuclease technology platform for the development of next-generation ex vivo cell therapies in oncology.
Earlier this month, Gilead announced that it has entered into a strategic collaboration with privately held Precision BioSciences to develop therapies aimed at eliminating hepatitis B virus (HBV) using the latter's gene editing platform, ARCUS.
Gilead's stock has gained 13.1% in the year so far against the industry's decline of 2.5%.
We note that Gilead acquired Kite Pharma to foray into the emerging field of cell therapy. Kite is a pioneer in cell therapy, having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), depending on the type of cancer. The approval of lead candidate Yescarta, for the treatment of refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL), is a significant boost for the company.
Meanwhile, Gilead is a dominant player in the HIV market with an impressive portfolio. However, the company will have to generate substantial revenues from its HIV franchise and Yescarta to offset the HCV sales decline. This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline GSK in the HIV market.
Zacks Rank
Gilead carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Best Electric Car Stock? You'll Never Guess It
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. ABBV , the company is looking to HIV and newer avenues to boost its top line. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. Both companies have entered into a research collaboration and license agreement to develop technology, supporting the discovery of neoantigen-reactive T-cell receptors (TCRs) for the potential treatment of various cancers, including solid tumors. | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. ABBV , the company is looking to HIV and newer avenues to boost its top line. In exchange, Kite will have an exclusive option to license HiFiBiO's platform to screen T-cell repertoires and identify TCRs for use in TCR engineered T-cell therapies with a corresponding payment to HiFiBiO. | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. ABBV , the company is looking to HIV and newer avenues to boost its top line. Per the terms, Kite, which was acquired by Gilead in 2017, will adapt HiFiBiO's proprietary single cell technology platform to create a high throughput approach that will enable in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies. | Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. ABBV , the company is looking to HIV and newer avenues to boost its top line. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. In exchange, Kite will have an exclusive option to license HiFiBiO's platform to screen T-cell repertoires and identify TCRs for use in TCR engineered T-cell therapies with a corresponding payment to HiFiBiO. |
25324.0 | 2018-10-02 00:00:00 UTC | Here's Why Antares Pharma Jumped Higher Today | ABBV | https://www.nasdaq.com/articles/heres-why-antares-pharma-jumped-higher-today-2018-10-02 | nan | nan | What happened
Shares of Antares Pharma (NASDAQ: ATRS) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for its testosterone treatment Xyosted.
The approval comes about a year after Antares disclosed that the FDA wasn't going to approve Xyosted on the first attempt. A complete response letter -- the agency's euphemism for a rejection -- followed a week later. After meeting with the FDA, Antares determined that it could address the agency's concerns by reanalyzing existing data and through changes to the proposed label and potential post-approval risk mitigation strategies.
The strategy clearly worked.
So what
The testosterone market is a fairly large but competitive space. The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year.
Unlike Abbvie's gel, Xyosted is injected once a week. Normally a gel would be preferred over an injection by most patients, but Antares has a couple of things going for it that should make it easier to compete with the market leader:
Xyosted is injected with a single-dose, disposable auto injector, so it's fairly simple to use.
It's a once-weekly injection (daily injection versus daily gel would certainly be less appealing).
Gels run the risk of accidental dosing by people the patient comes in contact with -- a major concern with testosterone, especially for women and children.
Xyosted's label includes warnings about increases to blood pressure, which could give doctors pause about using the drug, but high blood pressure is also listed as a side effect of the higher dose of AndroGel, so it might not be a huge sticking point for doctors.
Now what
Antares is working on getting a sales force in place and plans to launch Xyosted before the end of this year. Investors should expect a slow launch. But with a couple of drugs already on the market and partners using Antares' injection system for their own drugs, it won't take much in the way of sales of Xyosted to justify Antares' market cap of around $600 million.
10 stocks we like better than Antares Pharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Antares Pharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Unlike Abbvie's gel, Xyosted is injected once a week. What happened Shares of Antares Pharma (NASDAQ: ATRS) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for its testosterone treatment Xyosted. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Unlike Abbvie's gel, Xyosted is injected once a week. | The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Unlike Abbvie's gel, Xyosted is injected once a week. What happened Shares of Antares Pharma (NASDAQ: ATRS) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for its testosterone treatment Xyosted. | Unlike Abbvie's gel, Xyosted is injected once a week. The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Now what Antares is working on getting a sales force in place and plans to launch Xyosted before the end of this year. |
25325.0 | 2018-10-02 00:00:00 UTC | The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-exxonmobil-disney-abbvie-bristol-myers-and-united | nan | nan | For Immediate Release
Chicago, IL - October 2, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Monday's Analyst Blog:
Top Analyst Reports for ExxonMobil, Disney & AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked ExxonMobil 's shares have gained +16.1% over the past six months, outperforming the Zacks Integrated Oil industry, which gained +12.4% over the same period. The Zacks analyst thinks the company has a leading position in the energy industry owing to its size and diverse asset base, both in terms of business mix and geographical footprint.
With a stable cash position, the company's balance sheet is one of the best in the industry. This has allowed ExxonMobil to reward stockholders with a 6.3% average annual dividend hike over the past 35 years. The company owns some of the most prolific upstream assets globally along with the largest global refining operations.
Notably, ExxonMobil continues to gain on ramped-up oil-equivalent production from Hebron field. Moreover, to address the transport constraints and pump out five times more oil from the Permian through 2025, ExxonMobil is investing billions in the basin's midstream infrastructure.
(You can read the full research report on ExxonMobil here >>> ).
Shares of Disney have increased +8.8% year to date, outperforming the Zacks Media Conglomerates industry's +8.5% gain in that same time period. The Zacks analyst thinks Disney's top-line will benefit from the solid line-up of big-budget movies slated to be released over the next 18 months.
Parks & Resorts segment continues to show robust performances both domestically and internationally owing to a rise in customer spending, higher ticket prices and attendance. ESPN+, the company's sports streaming service, achieved the 1 million subscriber base milestone, which is positive for Disney's upcoming direct-to-consumer service.
However, Disney's ongoing investments on its technology platform are expected to keep margins under pressure. Additionally, higher programming costs at ESPN remains a concern. Moreover, weakness in the Consumer Products & Interactive Media segment is a headwind.
(You can read the full research report on Disney here >>> ).
Buy-ranked AbbVie 's shares have lost -2.2% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +7.1%. The Zacks analyst thinks AbbVie's key drug, Humira has been performing well based on strong demand trends, despite new competition.
Moreover, Imbruvica has multibillion-dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret's launch has also been stronger than expected. Mavyret has become a major growth driver for AbbVie in a short time on the market.
AbbVie has an impressive late-stage pipeline with the launch of several products with multibillion-dollar potential expected in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. However, potential biosimilar competition to Humira in Europe this year is an overhang.
(You can read the full research report on AbbVie here >>> ).
Other noteworthy reports we are featuring today include Bristol-Myers and United Continental.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Continental Holdings, Inc. (UAL): Free Stock Analysis Report
The Walt Disney Company (DIS): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL . Here are highlights from Monday's Analyst Blog: Top Analyst Reports for ExxonMobil, Disney & AbbVie The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. | Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL . Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report The Walt Disney Company (DIS): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Monday's Analyst Blog: Top Analyst Reports for ExxonMobil, Disney & AbbVie The Zacks Research Daily presents the best research output of our analyst team. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report The Walt Disney Company (DIS): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL . | Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL . Here are highlights from Monday's Analyst Blog: Top Analyst Reports for ExxonMobil, Disney & AbbVie The Zacks Research Daily presents the best research output of our analyst team. |
25326.0 | 2018-10-01 00:00:00 UTC | Health Care Sector Update for 10/01/2018: TLRY,MNTA,TARO,ABBV,REGN,MYL | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-10012018-tlrymntataroabbvregnmyl-2018-10-01 | nan | nan | Top Health Care Stocks
JNJ Unch
PFE Unch
ABT Unch
MRK +0.42%
AMGN Unch
Health care stocks still were little changed ahead of Monday's opening bell.
Among health care stocks likely to move on news:
(+) Tilray ( TLRY ) jumped almost 9% in Monday's pre-market trading after the cannabis grower said it received a license to sell medical marijuana in Canada through its High Park farms unit. Under the Health Canada sales license, High Park will be able to supply and sell finished cannabis products for medical uses, including sales ahead of the Oct. 17 launch of the adult-use market in Canada.
In other sector news:
(-) Momenta Pharmaceuticals ( MNTA ) was falling almost 5% early Monday after saying it was narrowing its corporate focus to two drug candidates as part of a broader reorganization that will also include job cuts for about 110 employees, and is expected to save the biotech company around $250 million over the next five years. Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. It also has begun talks with Mylan ( MYL ) to exit their collaboration on the development of five other biosimilar programs.
(=) Taro Pharmaceutical Industries (TARO) was unchanged early Monday after the drugmaker said it has terminated its license agreement with NovaBiotics and the privately held biotech company's Novexatin product candidate. The move follows additional analysis and evaluation of the prospective onychomycosis drug after Novexatin failed to meet the primary endpoint of recent phase IIb testing, Taro said.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. Among health care stocks likely to move on news: (+) Tilray ( TLRY ) jumped almost 9% in Monday's pre-market trading after the cannabis grower said it received a license to sell medical marijuana in Canada through its High Park farms unit. In other sector news: (-) Momenta Pharmaceuticals ( MNTA ) was falling almost 5% early Monday after saying it was narrowing its corporate focus to two drug candidates as part of a broader reorganization that will also include job cuts for about 110 employees, and is expected to save the biotech company around $250 million over the next five years. | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. Top Health Care Stocks JNJ Unch PFE Unch ABT Unch Under the Health Canada sales license, High Park will be able to supply and sell finished cannabis products for medical uses, including sales ahead of the Oct. 17 launch of the adult-use market in Canada. | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. Among health care stocks likely to move on news: (+) Tilray ( TLRY ) jumped almost 9% in Monday's pre-market trading after the cannabis grower said it received a license to sell medical marijuana in Canada through its High Park farms unit. In other sector news: (-) Momenta Pharmaceuticals ( MNTA ) was falling almost 5% early Monday after saying it was narrowing its corporate focus to two drug candidates as part of a broader reorganization that will also include job cuts for about 110 employees, and is expected to save the biotech company around $250 million over the next five years. | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. AMGN Unch Health care stocks still were little changed ahead of Monday's opening bell. Among health care stocks likely to move on news: (+) Tilray ( TLRY ) jumped almost 9% in Monday's pre-market trading after the cannabis grower said it received a license to sell medical marijuana in Canada through its High Park farms unit. |
25327.0 | 2018-10-01 00:00:00 UTC | Health Care Sector Update for 10/01/2018: SYK,TLRY,TARO,MNTA,ABBV,REGN,MYL | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-10012018-syktlrytaromntaabbvregnmyl-2018-10-01 | nan | nan | Top Health Care Stocks
JNJ +1.03%
PFE +0.37%
ABT +0.85%
MRK +0.70%
AMGN -0.14%
Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a more than 0.4% gain for the NYSE Health Care Index in late trade. Shares of health care companies in the S&P 500 also were up over 0.4% as a group although the Nasdaq Biotechnology index dropped more than 0.8% today.
Among health care stocks moving on news:
(+) DaVita Inc ( DVA ) was holding on to most of a 4% gain on Monday that followed the company saying its HealthCare Partners Holdings subsidiary has finalized a settlement agreement ending a three-year probe by the U.S. Office of Inspector General Medicare Advantage Civil Investigation. According to a regulatory filing by the company, DaVita previously established an escrow account setting aside a portion of the purchase price from its 2012 acquisition of HealthCare Partners to idemnify the company from any costs associated with the investigation. HealthCare Partners now makes up the company's DaVita Medical Group business.
In other sector news:
(+) Tilray ( TLRY ) jumped over 20% during Monday trading after the cannabis grower said Health Canada has issued a license to its High Park farms unit to supply and sell finished cannabis products for medical uses throughout the country, including sales ahead of the Oct. 17 launch of the adult-use market in Canada.
(-) Taro Pharmaceutical Industries ( TARO ) was fractionally lower this afternoon, giving back a slim gain previously in Monday trading that followed the drugmaker saying it has terminated its license agreement with NovaBiotics for the privately held biotech company's Novexatin product candidate. The move follows additional analysis and evaluation of the prospective onychomycosis drug after Novexatin failed to meet the primary endpoint of recent Phase IIb testing, Taro said.
(-) Momenta Pharmaceuticals ( MNTA ) fell almost 9% at one point on Monday after saying it was trimming its corporate focus to only two drug candidates as part of a broader reorganization that will also include job cuts for about 110 employees - or roughly 50% of its current workforce - and is expected to generate around $250 million in savings for the biotech company over the next five years. Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. In other sector news: (+) Tilray ( TLRY ) jumped over 20% during Monday trading after the cannabis grower said Health Canada has issued a license to its High Park farms unit to supply and sell finished cannabis products for medical uses throughout the country, including sales ahead of the Oct. 17 launch of the adult-use market in Canada. The move follows additional analysis and evaluation of the prospective onychomycosis drug after Novexatin failed to meet the primary endpoint of recent Phase IIb testing, Taro said. | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a more than 0.4% gain for the NYSE Health Care Index in late trade. Among health care stocks moving on news: (+) DaVita Inc ( DVA ) was holding on to most of a 4% gain on Monday that followed the company saying its HealthCare Partners Holdings subsidiary has finalized a settlement agreement ending a three-year probe by the U.S. Office of Inspector General Medicare Advantage Civil Investigation. | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a more than 0.4% gain for the NYSE Health Care Index in late trade. Among health care stocks moving on news: (+) DaVita Inc ( DVA ) was holding on to most of a 4% gain on Monday that followed the company saying its HealthCare Partners Holdings subsidiary has finalized a settlement agreement ending a three-year probe by the U.S. Office of Inspector General Medicare Advantage Civil Investigation. | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a more than 0.4% gain for the NYSE Health Care Index in late trade. Among health care stocks moving on news: (+) DaVita Inc ( DVA ) was holding on to most of a 4% gain on Monday that followed the company saying its HealthCare Partners Holdings subsidiary has finalized a settlement agreement ending a three-year probe by the U.S. Office of Inspector General Medicare Advantage Civil Investigation. |
25328.0 | 2018-09-30 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Eli Lilly and Company | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-eli-lilly-and-company-2018-09-30 | nan | nan | This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. Lilly's shares have surged around 26% in 2018 but that doesn't make it the better stock to buy right now.
To figure out which of these pharmaceutical stocks has the best chance of outperforming the market in the years ahead we'll need to look past their recent gains. Let's figure out what's driving growth for both underlying businesses to see which of these pharmaceutical stocks is most likely to pull ahead in the long run.
The case for AbbVie Inc.
The house that Humira built is quickly becoming an impenetrable compound defended by a growing product portfolio. That's critical because Humira's main U.S. patent expired last year. Despite its age, AbbVie's flagship rheumatoid arthritis (RA) drug is expected to rack up $20 billion in sales this year, and it could keep climbing.
Less expensive biosimilar versions of Humira probably won't hit the market until 2023 and by then several of AbbVie's more recent drug launches could help offset the losses. This summer, AbbVie launched Orilissa, the first new treatment for endometriosis pain women have seen in over a decade, and it's expected to generate more than $1 billion annually within a few short years.
AbbVie also has results in hand that show its next RA drug, upadacitinib, could do even better if the Food and Drug Administration approves an application the company plans to submit later this year. During the Select-Early trial with newly diagnosed patients, those given 30 mg upadacitinib tablets were twice as likely to report RA symptoms that improved by 50% or better than those given methotrexate.
If upadacitinib can take methotrexate's place as a standard treatment for new RA patients, annual sales of the drug could reach $6.5 billion at its peak. That would go a long way toward raising the company's dividend payout, which offers a big 4.1% yield at the moment.
The case for Eli Lilly and Company
Eli Lilly's next-generation migraine drug, Emgality, recently earned an approval from the FDA to help prevent debilitating headaches that affect an estimated 30 million adults in the U.S. alone. Initial sales will ramp up slowly as the company absorbs heavy discounts in order to build a brand. Two competing therapies from the same class have already launched, but if Emgality can carve out a reasonable share of the space, it could generate several billion in peak annual revenue.
Emgality will join a new product lineup that already includes eight drugs launched since 2014. Lilly's young guns grew sales by a combined 73% during the first half of 2018 compared to the previous year period.
Lilly's developing another potential blockbuster for the treatment of arthritis pain in partnership with Pfizer called tanezumab that recently succeeded in a pivotal trial. Patients with osteoarthritis of the knee or hip, a large population in need of new treatment options, reported significant improvements in pain and physical function following two injections spread eight weeks apart. Millions suffer from osteoarthritis pain, which means a successful new treatment option could go a long way toward raising Lilly's dividend payouts.
At recent prices, Lilly shares offer a 2.1% dividend yield that's above the market average but far less than AbbVie stock offers.
Running the numbers
Over the past three years, AbbVie's raised its dividend payout 88% higher, and investors can probably look forward to more big bumps in the years ahead. The company needed just 44% of free cash flow to meet its dividend obligations in the past year, leaving plenty of room for further increases. Eli Lilly shelled out 89% of free cash flow to make payments over the same time frame, so don't expect the next raise to be a significant one.
Right now, Lilly shares are priced for growth at 19.8 times this year's earnings expectations, while AbbVie shares can be picked up at the low price of just 12.0 times expected 2018 earnings. As long as Humira sales don't plummet ahead of 2023, it looks like AbbVie shareholders will come out ahead in the long run. That makes it the better buy right now.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This summer, AbbVie launched Orilissa, the first new treatment for endometriosis pain women have seen in over a decade, and it's expected to generate more than $1 billion annually within a few short years. This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. The case for AbbVie Inc. | This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. Right now, Lilly shares are priced for growth at 19.8 times this year's earnings expectations, while AbbVie shares can be picked up at the low price of just 12.0 times expected 2018 earnings. The case for AbbVie Inc. | This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. At recent prices, Lilly shares offer a 2.1% dividend yield that's above the market average but far less than AbbVie stock offers. Right now, Lilly shares are priced for growth at 19.8 times this year's earnings expectations, while AbbVie shares can be picked up at the low price of just 12.0 times expected 2018 earnings. | Running the numbers Over the past three years, AbbVie's raised its dividend payout 88% higher, and investors can probably look forward to more big bumps in the years ahead. Right now, Lilly shares are priced for growth at 19.8 times this year's earnings expectations, while AbbVie shares can be picked up at the low price of just 12.0 times expected 2018 earnings. This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. |
25329.0 | 2018-09-28 00:00:00 UTC | Healthcare: 2 Hot Biotech Stocks on Our Radar | ABBV | https://www.nasdaq.com/articles/healthcare-2-hot-biotech-stocks-our-radar-2018-09-28 | nan | nan | There are lots of exciting biotech stocks that investors can consider owning in their growth portfolios. But according to Motley Fool Industry Focus: Healthcare analyst Shannon Jones and Fool contributor Todd Campbell, Neurocrine Biosciences (NASDAQ: NBIX) and Regenxbio (NASDAQ: RGNX) are two stocks that ought to be top of mind.
Neurocrine Biosciences is already racking up significant revenue growth from one drug it has on the market, and clinical-stage trials could increase sales even more. Meanwhile, Regenxbio is leveraging its proprietary platform of viral vectors to tap into the emerging market for gene therapies. Can these companies generate profit-friendly returns for shareholders?
In today's show, Jones and Campbell discuss:
Sales growth for Neurocrine Biosciences' Ingrezza.
Neurocrine Biosciences' potential to expand Ingrezza's label to include Tourette's syndrome.
An opportunity for Neurocrine Biosciences in Parkinson's disease.
The competitive advantages associated with Regenxbio's viral vectors.
An early stage wet age-related macular degeneration therapy in Regenxbio's pipeline.
How Regenxbio may benefit soon from a relationship with biopharma giant Novartis (NYSE: NVS) .
Also, Jones and Campbell discuss why game-changing data from Amarin 's (NASDAQ: AMRN) cardiovascular outcomes study for Vascepa, a purified fish-oil pill, could send its sales soaring.
A full transcript follows the video.
10 stocks we like better than Walmart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
The author(s) may have a position in any stocks mentioned.
This video was recorded on Sept. 26, 2018.
Shannon Jones: Welcome to Industry Focus , the show that dives into a different sector of the stock market every day. Today is Wednesday, September the 26th, and we're talking healthcare. I'm your host, Shannon Jones. I'm joined in the studio with Motley Fool contributor Todd Campbell via Skype. On today's show, we're diving into one of the most widely anticipated trial readouts for Amarin and their fish oil pill, believe it or not. We'll also be revealing our favorite biotech picks. That's all in this week's episode of Industry Focus: Healthcare .
Todd, I don't know about you, but for me, September has been a wild and very interesting month for the biopharma world.
Todd Campbell: Oh, absolutely! The Amarin Vascepa data that we just got has to rank in the top five, at least, of crazy things that we've seen in biopharma this month, if not higher.
Jones: Yeah, I definitely would say it has to be within the top five. I would dare say it's maybe No. 2 or No. 3, even, given the anticipation leading up to the trial, everything that's happened prior to the trial, and what the results showed. We'll get into all of that.
But first, Todd, I know you and Kristine did an awesome background leading up to this cardiovascular outcome study. That was the first Wednesday in September. I'd really encourage our listeners to go back, listen to that episode. They did an awesome job setting the stage of this binary event for Amarin. But let's give a very brief background to our listeners that are catching up, let's just tell them why this trial was so, so important for Amarin.
Campbell: Amarin markets a drug called Vascepa. Vascepa is a purified omega three fatty acid. We'll call it EPA. It's been on the market since 2012 for use in reducing triglycerides, fat in the blood, in patients that have very high triglyceride readings, greater than 500 milligrams per deciliter. The approval in the very high population, however, only scratches the surface of the addressable market. There are literally tens of millions of patients that have elevated triglyceride levels.
Amarin had conducted a trial to see whether or not patients with moderate triglyceride levels -- 152 to 500 -- would benefit from Vascepa. Sure enough, their triglyceride levels fell in that trial. But the FDA said, "We're not going to approve its use in that moderate patient population because frankly, no one has proven that lowering triglycerides," again, fat in the bloodstream, "actually translates into saving people's lives, reducing the risk of major cardiovascular events like stroke and heart attack and, yes, death." About 800,000 people die every year from cardiovascular events.
Amarin, recognizing that the big money was to be made in being able to roll this drug out to a much bigger, broader population, began conducting a study to tie and make that link that yes, if you take Vascepa, it will lower triglycerides. And yes, if it lowers triglycerides, that will indeed save people's lives and prevent heart attack and stroke.
Seven years in the making, the study has finally read out results. And sure enough, Shannon, it was, I would say, as good as they could have hoped for.
Jones: Yeah, and really even better. I think it's safe to say too, expectations leading up to this trial, while everyone was anxious to see exactly what the readout would be, the expectations were relatively low, given the multiple study failures when it comes to cardiovascular outcome studies. The most recent one was the Ascend study, which effectively found that generic fish oils -- granted, relatively low dose compared to Vascepa in this study -- weren't effective in the prevention of these cardiovascular events.
Of course, Amarin was very quick to come out and counter the results of that study, reiterating and reemphasizing the purity of Vascepa. As you talked about with EPA, not a mixture of all these other types of fatty acids.
Campbell: Right, DHA elevating bad cholesterol levels is thought to have been why the supplements failed. Those supplements also included DHA alongside EPA. That's not the case with Vascepa. It is pure EPA.
Jones: Yes. Amarin been really driving that point home. Leading up to the study, it's really been on the top of everyone's mind looking to see if, indeed, that makes a difference. Just like you said, it sounds like it did. Let's dive right in. What it exactly did Amarin find in this particular trial?
Campbell: They enrolled patients that had bad cholesterol levels that were controlled by statins. We're talking patients who take statins, which are the most commonly prescribed drugs in the world. I think 38 million Americans alone take statins every day for their high bad cholesterol. They enrolled patients that were on cholesterol-controlling medications, but still had high triglyceride levels.
What they found is that taking four grams per day of Vascepa translated into an additional 25% reduction in the risk of a major cardiovascular event, including stroke, heart attack, and death. 25%. That, Shannon, is on top of the 25% reduction in risk that's historically been associated with taking statins. So, a really remarkable finding.
Jones: Absolutely, yes. Honestly, I think Wall Street and the scientific community would have been fine with a 15% reduction in risk. To see 25% really wowed everybody. We'll get more detailed data moving forward. We've got the American Heart Association meeting happening November the 10th.
Specifically for me, I'm really curious to dig into the slicing and dicing of the data a little bit more. What you see with a lot of these cardiovascular outcomes studies are these composite endpoints. The endpoints basically, as you mentioned, Todd, they're looking at a number of different events. You talked about stroke, heart attack, death, even. They combine all of those endpoints into one, and that's really what they reported out on this week. What we'll see coming into November is more detail into that.
I'm also curious to see which patient groups responded better than others. Also, I mean, with so much focus being on triglyceride levels, I'm really curious to see just how much Vascepa was able to lower those levels, too. Those are the things that are in the top of my mind heading into that meeting.
Campbell: The big question that every investor is going to have is, how big could this drug get? They did $180 million in sales last year, I think they were targeting $230 million for this year already. That's just on the severe high triglyceride approval way back in 2012. I think that totally undersells it, now that this data is out. I would not be surprised if cardiologists are going to be talking to their patients about this drug very, very soon. It is, again, potentially a life-saving drug.
Now, I happen to have family members who have a history of stroke. My father, for example, is on statins and other drugs to try and rein in that risk. He had told me in the past that he was on fish oil pills. So, when I saw this data, I called him up and I said, "Hey, did you see this great data?" He goes, "Oh, yeah, I stopped taking my fish oil pills because of that failed study of the over the counter supplements." It wouldn't be shocking to me, if my dad's cardiologist, a lot of people's cardiologists, started having conversations with them about Vascepa. Again, 25% relative risk reduction on top of the statins is pretty remarkable.
This is a massive addressable market. Amarin estimates that over 50 million adults in the United States have triglyceride level readings that are above 150 milligrams per deciliter. Obviously they won't get that big, but is there the potential for this to be a billion-dollar blockbuster drug? I think there is now.
Jones: Absolutely. I've heard the terms being thrown around as a true game changer, paradigm shift in how we treat patients. I really think, to your point, you will start to see the uptake in prescribing habits when it comes to Vascepa. Amarin is actually aiming to file the supplemental MD&A by early 2019. Anticipated approval within this specific indication coming by late 2019. I fully anticipate you'll see a bump up in sales even before that.
Another interesting thing, too, there's not really an immediate direct competitor for Amarin in this space right now. The closest one is actually AstraZeneca . They've got right now a strength trial. They're also looking at a 4 gr daily dose of their drug. It's interesting, though, because for AstraZeneca, their drug is one of those mixed omega three fatty acids. I believe it's called Epanova. That will be reading out in 2019. I think it will be a really interesting read out, to see what we can extract from that study, are there any read throughs when it comes to dosing level. It's just going to be an exciting 2019, to say the least.
Campbell: [laughs] Yeah, very much so! We're definitely going to watch those prescription trends over the course the next few quarters for this company. It's also going to be interesting to see whether or not a larger company decides to step ahead of the AstraZeneca data, or they end up waiting until that data is out to see what that competitive landscape may look like further on down the road. Vascepa really is the only engine in the car that is Amarin. It'll be really interesting to see what ends up happening with this company in the next year or two.
Jones: Yeah, absolutely. Always good to have positive trial news, especially in biopharma land, and especially to see this with a drug that's not your typical biotech drug. It is literally fish oil. We even saw this, too, with CBD and marijuana. Someone even said in the bio Twitter world that this is really the year of natural medicines making a run for it. Fascinating stuff, really great science. We'll be keeping an eye on that. We'll be sure to keep our listeners up to speed with all the comings and goings of who may be entering this market space.
But first, we'll want to switch gears. We're going to talk about our personal top biotech picks on the other side of the break.
As fascinating as Amarin's fish oil pill is, there's an equally fascinating company on Todd Campbell's radar right now, in one of the hottest areas in biotech right now, which is gene therapy. Gene therapy really brings with it the promise of novel one-time treatments that target the underlying causes of disease at the genetic level. Todd, tell us about your top pick, and why you love it so much.
Campbell: This is going to sound kind of funny for me to talk about this, because oftentimes, I'll say to people who ask, I typically try to avoid young, early stage companies. The risk of trial failure is so high. Yet, every once in a while, there'll be a company that has some pretty remarkable competitive advantages that basically makes me stand up go, "This is kind of an interesting company, it's definitely one worth exploring a little bit more." That was the case with this stock, Regenxbio, symbol RGNX.
The reason that I'm really interested and intrigued by this company is twofold. They have a proprietary collection of adeno associated viral vectors. Those AAVs can be used to enable gene therapies, to get into the tissue and actually do the work of creating that change in the way that the genes function.
There are about 6,000 diseases that are caused by genetic mutations. The whole concept with gene therapy is to be able to go in and either restore the gene function by adding some genetic code or restore appropriate gene function by deleting a part of code. We've talked about this in the past on the show, it's called gene editing.
Regenxbio's AAVs are intriguing because what they're used for is to deliver the gene therapy into the tissue to make the change and theoretically restore correct genetic function. They argue that their AAVs are the best there are out there, that their AAV platform will not only create less of an immune reaction within patients that they're given to, which allows for more durable, long lasting results; but they're going to be easier and cheaper to manufacturer, too. That removes a big hurdle that's been overhanging the gene therapy market.
Jones: You've got a really novel platform, and it sounds like they're going to be targeting some really high unmet need areas, as well. What can you tell us about the indications they're going after?
Campbell: They have two business approaches. The first business approach is a licensing approach, where they allow drug makers to come in and license the use of their AAVs in exchange for some upfront money, maybe some milestone payments, depending on their clinical trial success, and then royalties if a drug is eventually commercialized. That's one part of their business model. The other part of their business model is to develop their own internal candidates for genetic diseases that they can usher through their own clinical trials and theoretically partner out later on or just go ahead and launch them on their own.
Their own projects are pretty early stage projects. But, one of those projects that's most advanced is incredibly intriguing because it targets wet age-related macular degeneration, a multibillion dollar market that's dominated by Eylea, $5.2 billion a year drug. Their goal is to develop a gene therapy that can be a one-and-done -- or maybe a twice a year; who knows, we'll see -- therapy that would avoid the need for patients with wet AMD to go into the office every three months or eight weeks or whatever and have to have an injection done in their eye to help restore their vision. That is particularly exciting to me because they reported some data this past summer from a Phase I study that showed that there was a dose-dependent reaction to their medication, to their gene therapy. And, half of the patients in the highest dose cohort were injection-free after six months. They're actually continuing that study, ramping up to include another dose cohort that's a higher dose. Data from that additional cohort could be available before the end of this year. Phase II trials could begin for that medicine as soon as 2019. That's on the internal program side.
On the external program side, the closest drug that's to commercialization is a Novartis gene therapy for spinal muscular atrophy, SMA. Earlier this year, Novartis went out and spent $8.7 billion to acquire AveXis, to get its hands on this drug, AVXS-101. They plan to file for FDA approval of that drug soon, potentially getting that drug on the market next year. If so, if the FDA gives it to go ahead, then Regenxbio should be able to collect mid-single digits to low double-digit royalties on sales. That's significant, Shannon, because the one drug that's out there right now for use in that indication is Biogen 's Spinraza, and that's tracking $1.5 billion in sales per year as of last quarter.
Jones: For our listeners that have been following along, Spinraza had a phenomenal launch trajectory. Granted, it's been tapering off over time. But when you think about the closest competitors, AveXis is top of mind for many investors right now, in terms of how the dynamics would change once they come to market, if they come to market, if the data are worthy of approval.
Going back to what you were mentioning, I'm really intrigued. This wasn't a company I followed, I haven't been following it all, really, until you mentioned it, Todd. That wet AMD indication is extremely intriguing for a couple of reasons. One, you mentioned the patient populations. That's a population that's really only going to increase as you see the baby boomer generation continuing to grow and live longer. You talked about the competitive landscape with Eylea. You've also got Lucentis, Avastin. Those, of course, require multiple doses. If Regenxbio can get a one-and-done or close to one-and-done approach, I think the opportunity is huge here.
It'll be really, really interesting to see, if this gets approved, where pricing will fall. Of course, with gene therapies, we know that they can easily command hundreds of thousands of dollars. Compared to the competitive landscape, that would be a huge jump for many prescribers and patients. I think the opportunity is interesting. It'll be really, really interesting to watch that space, too.
Campbell: Maybe you end up with some novel pricing programs that get announced if this thing ever does make it to market. Again, we're talking way out in the future. I always want to tamp down on a little bit of enthusiasm because the information that we've seen so far is Phase I. That's as early stage data as you can get.
You make a great point. If you're talking about, right now, patients normally getting six or seven injections per year, you multiply the cost of each one of those injections. And then you say, "Well, what if I'm diagnosed with wet AMD, I'm 70, and I end up living until 85? The next 15 years, I'm going to have six of these injections per year." How do you price that? So, that will be interesting.
But, I think it's a multibillion dollar indication. Theoretically, this could shake it up if data in Phase II, and eventually in Phase III, confirm what we saw in this very, very small Phase I cohort.
Jones: Todd, what do you think in terms of their cash runaway right now? Do you feel like they've got enough on the books right now to fund those trials moving forward?
Campbell: They'll need to tap cash at some point, tap investors for cash at some point. Maybe that'll be a little bit dilutive. That's not unexpected for clinical stage companies. But one of the reasons that I like this company is because it does have the potential to bring in those royalty payments beginning next year. That will offset the risk and slow the cash burn for this company. They have about $306 million on the books right now. I think the projecting that they're going to finish the year with somewhere between $250-260 million on the books. That should give them some pretty good runway. Then we'll have to see what happens with AVXS-101 at the FDA, and whether or not Novartis can successfully launch that out against Spinraza.
Jones: So much to look forward to in 2019. This is a truly an interesting company. Gene therapy has really taken off and has gained so much investor enthusiasm and support. We'll see where that one goes.
Let's turn over to my top pick. My top pick is actually a company called Neurocrine Biosciences, ticker NBIX. The reason why this is my top pick, and it's really one of my favorite stocks, primarily because I've actually been holding on to it for about three years now. I got in early, before Ingrezza got approved. Was really impressed with some of the late stage data. And two, they had a really solid cash position, even at the end of 2015. Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. That's still their partner. So, for me, it checked a lot of the boxes.
Kind of like you, Todd, I try not to get too excited with companies that are yet to have an approved drug on the market. But this one really caught my eye. It was kind of floating under the radar, but was really generating some early traction.
Just to give our listeners an overview, Neurocrine Biosciences is focused on neurological and endocrine-based diseases. Their first commercialized drug is Ingrezza. That was actually approved in April 2017, became available commercially in May. This is a drug that's been indicated to treat a disease called tardive dyskinesia. It's an involuntary movement disorder that can often be associated with anti-psychotic medications. That's important for a couple of reasons that I'll get to in a minute. This particular drug, in terms of launch trajectory and sales expectations, has really blown them out of the roof.
Just looking back, Ingrezza generated about $97 million in net product sales in the second quarter of 2018. That's up from $71 million in the first quarter of 2018, giving them about $168 million in net product sales in the first half of the year. This is important because they were really expecting a very slow launch trajectory. When I talk about tardive dyskinesia, and its associated with anti-psychotic medications, one of the reasons is because of the patient population. When you think about it, patients that are on anti-psychotics -- and it's not even confined just to that -- patients that are on that tend to have much lower compliance and adherence rates than other therapeutic classes. So, they were really expecting a much lower launch in trajectory. Generally speaking, for that patient class, you're looking at compliance rates of about 60-70%. Ingrezza has exceeded that, and has been able to hold well above that level. It'll be interesting to see if that does start to taper off over time.
What that says is that not only are prescribers prescribing and that patients are more willing to take it, especially as it relates to being able to suppress many of these involuntary movements that are caused by an irregular dopamine signal that's happening in the brain, Ingrezza is really indicated to stop that mechanism. So far, so good with the launch and the sales.
Campbell: I was actually surprised. I missed this stock. When you started talking about it, I was like, "Wow, I really have to do some more work on this name, because this is a fascinating story." The fact that they're already at $97 million per quarter, and that's up from $71 million from Q1, that's darn impressive. What's even more impressive is, as I was looking through the 10-Q and some of the other filings, looking at the fact that, that may not be it for Ingrezza. It looks like they're also evaluating its use in other indications, specifically Tourette's.
Jones: Yes. That's going to be a really exciting indication, I think, to read through. Tourette's is another neurological movement disorder. I think the read through to that is huge. That's another multibillion-dollar opportunity, as well.
One side thought to that too is, when you look at the marijuana market, you see CBD also potentially being studied in the same indication. You see a lot of darts being thrown at the target. I'll be watching that. But yes, we've got a Tourette's label expansion that's also coming up with Ingrezza.
That's not to say that it stops there. Ingrezza was the first approved therapy. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. Neurocrine receives about a 20% royalty on sales. What's interesting about partnering with AbbVie, AbbVie is really known for being the label expansion king. They do that really well. Granted, they have their ups and downs. But they do that really well. It's really interesting, seeing their partnership with Neurocrine here. Right now, Orilissa is approved for moderate to severe endometriosis pain. It's is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade.
The drug hit the market just last month. It's providing yet another source of revenue for a fairly new commercial stage company. We'll be keeping everything a close eye on the launch numbers heading into the latter half of this year for that. That could be, easily, another $1.5-2 billion opportunity. I talked about label expansions, uterine fibroids is another indication that they'll be looking into. Just had some really positive Phase III data in that indication, too.
They've got multiple shots on target here. Really, if you look at their pipeline, there are some other really interesting products, too.
Campbell: Really quickly on that Orilissa, that $1.5 billion in peak sales. If everything goes its way, like you said, AbbVie being so good at expanding labels, conducting trials, getting the most out of their drugs, you could actually get up to that $300 million run rate in royalties for Neurocrine. That would be pretty fantastic.
You talked a little bit about the pipeline. One of the things I wanted to see what your thoughts were on is, what do you make of this move into Parkinson's? This licensing deal that it did last year for that Parkinson's disease drug?
Jones: That one was interesting to me, Todd. For our listeners, the drug is called Opicapone. It's currently being studied in Parkinson's disease. I will say, it is approved in Europe as an adjunct therapy in the disease. It's got some kind of positive read through here, particularly as they look to file in the U.S., which could happen as soon as the first half of 2019.
Anytime I hear Parkinson's, Alzheimer's, I'm a little hesitant. I try not to get my hopes up too much, just because those are diseases that, honestly, we haven't quite figured out what causes it yet. For me, when I'm looking at a potential investment in biotech, I always like to know that the science is well-backed and well understood. This is just one of those areas where I don't feel like we've got a strong enough hold on what actually causes the disease yet. So, I'm a little on the fence on that one, Todd.
Campbell: I understand, absolutely understand. What's the failure rate in Alzheimer's disease clinical trials? I think it's like 99%.
Jones: 99%, yes.
Campbell: It's really crazy! I do think, though -- I'm just putting on my hat for a second -- this is a little bit de-risked, for two reasons. One, you've got the EU approval already in hand. Two, you've got the fact that this isn't a game-changing medication. It's a medication that helps the most commonly used Parkinson's disease drug work better. I think that that adjunct status also de-risks this compound. If it can get approved, this could be a big deal. I think there are 60,000 people in the U.S. alone that are getting diagnosed with Parkinson's disease every year, and about a million people with Parkinson's disease. If this drug does reduce the off-time that people suffer when they take Levodopa, then I think you'll see it get pretty widely used. And yet again, you have another drug that could push this company toward profitability, right?
Jones: Absolutely. And they're very, very close to profitability, speaking of. Net loss for the most recent quarter was $5.9 million. That was compared to a loss of $60 million in the same period for 2017. Even before accounting for the Orilissa sales that just came onto the market here in August, they're extremely close. To your point, going back to the Parkinson's opportunity, that, to me, could be a huge game changer for this company itself. We're talking about Ingrezza, we're talking about these other drugs that are already approved. This could really put Neurocrine Biosciences on a completely different level, completely different scale, if that works.
Another thing I really, really love about this company is management. This company has been around since the early 90s, but the management team in place right now is particularly tight when it comes to expense control. They do a phenomenal job of level-setting expectations. They will usually tend to set expectations on the lower end when they do. But, just looking at their cash position, they had $800 million at the end of June. Now, you've got sales coming in. Now, you've got royalty payments coming in. They are well-positioned to fund many of these trials, especially in an indication like Parkinson. Feel pretty good there. Granted, I got in on Neurocrine three years ago. The evaluation has jumped up quite a bit since then. I don't plan to sell anytime soon, but definitely is a bit lofty right now.
Campbell: Yeah, I just took a quick look before we started recording the show. The price to book was like 28X, and the price to sales is 33X on future. It's definitely not a cheap stock. That being said, the valuation could get brought in check if the growth happens more quickly than the estimates go up. I went on looked at the average analyst estimates over the last 90 days. $1.89 per share in earnings expected in 2019. That's up from $1.43 90 days ago. That's a pretty significant increase in the past 90 days.
Jones: Absolutely. So, yes, definitely a stock to watch. All the stocks we've talked about today, so many interesting things happening, so many novel disease targets and indications. Certainly be sure to add them to your watch list.
For us, that is it for this week's Industry Focus: Healthcare show. As always, people on the program may have interest in the stocks they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. This show is produced by Austin Morgan. For Todd Campbell, I'm Shannon Jones. Thanks for listening and Fool on!
Shannon Jones owns shares of Neurocrine Biosciences. Todd Campbell owns shares of Twitter. The Motley Fool owns shares of and recommends Biogen and Twitter. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. |
25330.0 | 2018-09-28 00:00:00 UTC | Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-pfe-lly-get-approval-for-new-drugs-novartis-to-cut-jobs-2018-09-28 | nan | nan | It was a busy week for the big drugmakers. The FDA granted approval to Lilly's LLY calcitonin gene-related peptide ("CGRP") antibody, Emgality (galcanezumab) for migraine and Pfizer's PFE Vizimpro (dacomitinib) for an advanced lung cancer indication. Novartis NVS announced plans to cut more than 2000 jobs in Switzerland and U.K. Meanwhile, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave positive opinions recommending marketing approval to several drugs this week.
Recap of the Week's Most Important Stories
Pfizer's New Lung Cancer Drug Gets FDA Approval: The FDA granted approval to Pfizer's EGFR tyrosine kinase inhibitor dacomitinib for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with EGFR activating mutations. Other than dacomitinib, Pfizer has three other cancer medicines under FDA's priority review -glasdegib, lorlatinib and talazoparib. Decisions on all these medicines are expected later this year.
Lilly's New Migraine Treatment Receives FDA Nod: The FDA also granted approval to Lilly's CGRP antibody, Emgality (galcanezumab - 120 mg injection) for the preventive treatment of migraine. This is the third CGRP antibody to get FDA approval this year. While Teva's fremanezumab was approved earlier this month under the trade name of Ajovy, Amgen's CGRP antibody, Aimovig/erenumab was approved and launched in the United States in the second quarter of 2018. Lilly has set the price for Emgality at $575 for once-monthly dosing or $6,900 annually. All the three drugs have an identical annual price tag of $6,900.
CHMP Gives Positive Opinion to Several Drugs: Lilly gained a positive CHMP opinion , recommending approval of Emgality for the prevention of migraine. The CHMP also gave a nod to AbbVie's ABBV application looking for approval of its leukemia drug Venclexta in combination with Roche's Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Regulatory applications seeking approval for the combination use in this broader patient population were approved in the United States in June.
Glaxo's GSK filing looking for inclusion of data from the IMPACT study on the label of its single inhaler triple therapy, Trelegy Ellipta was also given a positive opinion by the CHMP. If approved, Telegy Ellipta can be prescribed as a maintenance treatment to a broader COPD patient population not adequately treated by a LABA/LAMA combination. Until now Trelegy Ellipta was approved as a maintenance treatment to treat those COPD patients who are not adequately treated by an ICS/LABA combination. A similar label update was approved by the FDA in April.
Bayer also won CHMP's nod for its pipeline candidate BAY94-9027 for the treatment and prophylaxis of bleeding in previously treated patients with hemophilia A. BAY94-9027 was approved to be marketed by the trade name of Jivi by the FDA last month.
AstraZeneca AZN said that the CHMP has recommended inclusion of cardiovascular outcomes data from the EXSCEL study in the European label of its type-II diabetes medicine, Bydureon. For Novartis, the CHMP recommended approval of its multiple sclerosis drug Gilenya for the treatment of children and adolescents as well as its one-time gene therapy, Luxturna for the treatment of a rare inherited retinal disease.
The final decision by the European Union on these products is expected in the coming months
Novartis to Cut Jobs in U.K. and Switzerland: Novartis announced plans to cu t some 1,700 jobs in Switzerland including 1,000 manufacturing positions and another 700 service and managerial jobs. The job cuts are expected to be executed over the next four years. Novartis also said it plans to exit its Grimsby manufacturing site by the end of 2020, which will affect jobs of 395 employees. The job cuts in U.K. and Switzerland are part of its previously announced initiative to transform its global manufacturing network and product portfolio.
Novartis also announced new data on pipeline candidate, brolucizumab (RTH258) from two phase III trials - HAWK and HARRIER. Data from the studies showed that brolucizumab 6 mg led to superior reduction in retinal fluid compared to Regeneron Eylea over four visits during weeks 36 to 48. Retinal fluid is a key marker of disease activity in neovascular age-related macular degeneration. Novartis plans to file regulatory application for approval of the candidate in December.
AstraZeneca's Imfinzi Gets EU Approval for Lung Cancer: AstraZeneca's PD-L1 inhibitor, Imfinzi was granted marketing approval in the EU by the European Commission for an early-stage lung cancer indication based on positive progression free survival data from the phase III PACIFIC study. Imfinzi is already approved for this indication in many countries including the United States.
AstraZeneca's type II diabetes drug Farxiga led to statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study. The phase III DECLARE- -TIMI 58 cardiovascular outcomes study was carried out in type-II diabetes who have multiple CV risk factors or established CV disease. The study compared the effect of Farxiga versus placebo in reducing the risk of MACE in such patients.
Roche Presents Data on Lung Cancer Candidate: Roche said that data from two pivotal studies showed that its cancer candidate entrectinib reduced tumors in patients with ROS1-positive non-small cell lung cancer (NSCLC), including in patients whose disease had spread to the central nervous system (CNS). An integrated analysis of phase II STARTRK-2 and phase I STARTRK-1 studies showed that entrectinib shrank tumors (objective response rate; ORR) in 77.4% of such patients and also demonstrated a durable response of more than two years in these patients. Roche plans to submit the data from these studies to the FDA and EMA.
FDA Accepts Allergan's sNDA to Expand Vraylar Label: Allergan AGN said the FDA accepted its regulatory application looking to expand the label of its schizophrenia drug Vraylar (cariprazine) to include treatment of bipolar depression. Approval of the drug for the expanded indication will provide Allergan with access to a wider patient population base suffering bipolar issues. (Read More: Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA )
The NYSE ARCA Pharmaceutical Index rose 0.3% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions:
In the past six months, Lilly has been the biggest gainer (37.9%) while Bristol-Myers declined the most (2%).
(See the last pharma stock roundup here: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus )
What's Next in the Pharma World?
Watch out for several pipeline and regulatory updates next week
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Allergan plc (AGN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The CHMP also gave a nod to AbbVie's ABBV application looking for approval of its leukemia drug Venclexta in combination with Roche's Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA granted approval to Lilly's LLY calcitonin gene-related peptide ("CGRP") antibody, Emgality (galcanezumab) for migraine and Pfizer's PFE Vizimpro (dacomitinib) for an advanced lung cancer indication. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP also gave a nod to AbbVie's ABBV application looking for approval of its leukemia drug Venclexta in combination with Roche's Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Recap of the Week's Most Important Stories Pfizer's New Lung Cancer Drug Gets FDA Approval: The FDA granted approval to Pfizer's EGFR tyrosine kinase inhibitor dacomitinib for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with EGFR activating mutations. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP also gave a nod to AbbVie's ABBV application looking for approval of its leukemia drug Venclexta in combination with Roche's Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Recap of the Week's Most Important Stories Pfizer's New Lung Cancer Drug Gets FDA Approval: The FDA granted approval to Pfizer's EGFR tyrosine kinase inhibitor dacomitinib for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with EGFR activating mutations. | The CHMP also gave a nod to AbbVie's ABBV application looking for approval of its leukemia drug Venclexta in combination with Roche's Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. CHMP Gives Positive Opinion to Several Drugs: Lilly gained a positive CHMP opinion , recommending approval of Emgality for the prevention of migraine. |
25331.0 | 2018-09-28 00:00:00 UTC | AbbVie (ABBV) Stock Moves 0.47%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.47%3A-what-you-should-know-2018-09-28 | nan | nan | In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. The stock outpaced the S&P 500's daily of 0%. Meanwhile, the Dow gained 0.07%, and the Nasdaq, a tech-heavy index, added 0.06%.
Coming into today, shares of the drugmaker had lost 2.74% in the past month. In that same time, the Medical sector gained 2.32%, while the S&P 500 gained 0.78%.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be November 2, 2018. The company is expected to report EPS of $2.01, up 42.55% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.20 billion, up 17.19% from the year-ago period.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.89 billion. These results would represent year-over-year changes of +40.36% and +16.55%, respectively.
It is also important to note the recent changes to analyst estimates for ABBV. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ABBV is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that ABBV has a Forward P/E ratio of 11.97 right now. This represents a discount compared to its industry's average Forward P/E of 16.62.
Meanwhile, ABBV's PEG ratio is currently 0.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.05 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 32, putting it in the top 13% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.89 billion. In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.89 billion. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.89 billion. In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. | ABBV is currently a Zacks Rank #3 (Hold). In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. |
25332.0 | 2018-09-27 00:00:00 UTC | Peek Under The Hood: EQWL Has 10% Upside | ABBV | https://www.nasdaq.com/articles/peek-under-hood-eqwl-has-10-upside-2018-09-27 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell Top 200 Equal Weight ETF (Symbol: EQWL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $62.19 per unit.
With EQWL trading at a recent price near $56.29 per unit, that means that analysts see 10.47% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of EQWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), American International Group Inc (Symbol: AIG), and Booking Holdings Inc (Symbol: BKNG). Although ABBV has traded at a recent price of $94.18/share, the average analyst target is 15.74% higher at $109.00/share. Similarly, AIG has 13.47% upside from the recent share price of $54.05 if the average analyst target price of $61.33/share is reached, and analysts on average are expecting BKNG to reach a target price of $2224.47/share, which is 13.06% above the recent price of $1967.51. Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although ABBV has traded at a recent price of $94.18/share, the average analyst target is 15.74% higher at $109.00/share. Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), American International Group Inc (Symbol: AIG), and Booking Holdings Inc (Symbol: BKNG). | Three of EQWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), American International Group Inc (Symbol: AIG), and Booking Holdings Inc (Symbol: BKNG). Although ABBV has traded at a recent price of $94.18/share, the average analyst target is 15.74% higher at $109.00/share. Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), American International Group Inc (Symbol: AIG), and Booking Holdings Inc (Symbol: BKNG). Although ABBV has traded at a recent price of $94.18/share, the average analyst target is 15.74% higher at $109.00/share. | Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), American International Group Inc (Symbol: AIG), and Booking Holdings Inc (Symbol: BKNG). Although ABBV has traded at a recent price of $94.18/share, the average analyst target is 15.74% higher at $109.00/share. |
25333.0 | 2018-09-26 00:00:00 UTC | Gilead Is Undercutting Its Own Drugs: Here's Why | ABBV | https://www.nasdaq.com/articles/gilead-undercutting-its-own-drugs-heres-why-2018-09-26 | nan | nan | The U.S. drug pricing system is a mess. It's an absolute disaster. Just about every entity involved, from drug companies to consumers to insurers to the government, agrees that offering discounts off the list price is a convoluted way to sell a life-saving product.
The government has plans to try and fix it , but now Gilead Sciences (NASDAQ: GILD) apparently can't wait that long -- or figures a fix might never come to fruition --and is taking matters into its own hands, disrupting the system with a pair of authorized generics of its hepatitis C drugs, Epclusa and Harvoni, which will be launched through a new subsidiary, Asegua Therapeutics.
Authorized generics aren't all that novel. Many large drugmakers launch them -- either on their own or with a generic partner -- after their drug goes off patent to eke out a few more dollars from the drug. The authorized generic competes with their branded version, but since there are already generic competitors, sales of the branded product are already headed toward zero as patients switch to generics.
But Epclusa and Harvoni aren't off patent. Gilead claims to have U.S. patent protection until 2032 and 2030, respectively.
Rather than competing with generics -- that don't exist yet -- Gilead appears to be trying to manipulate the convoluted pricing system in its favor. The generic versions, which will be available in January, will cost $24,000, which is a substantially lower than Epclusa's list prices around $75,000, but fairly close to what the company actually gets after offering discounts.
So why not just lower the price of the branded drugs and be done with it? Here are a couple of reasons Gilead is probably taking this approach with a branded generic:
1. Cutting out the middleman
Discounts off the list price vary widely from disease to disease, but they're largely tied to how many competitors there are in the space. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get steeper discounts than if there's only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation, PBM Express Scripts (NASDAQ: ESRX) was only covering AbbVie's drug for a while, and Express Scripts has removed drugs in other diseases from its formulary for playing hardball on negotiations.
Discounts result in lower price, but the entire discount doesn't go to the PBMs' clients (typically companies offering health insurance to their employees). The PBMs take a cut of the discount for negotiating on behalf of their clients.
By offering a generic version at the same price the PBMs have already negotiated, Gilead appears to be cutting the PBMs out of the equation.
2. Medicare/Medicaid patient preference
Many government drug plans, including Medicare, have wonky rules about negotiating with drug companies over price. By offering a generic version at a lower price, Gilead estimates that seniors using Medicare Part D can save up to $2,500 in out-of-pocket costs per course of therapy.
Arguably, the discounts for people on government plans will result in lower revenue for Gilead, but the company should be able to make up the difference -- and then some -- through higher volume. For example, because of the high cost they have to pay, some state Medicaid programs have limited the use of Gilead's drugs to the most advanced hepatitis C patients. By lowering the cost, the plans can afford to treat more patients.
And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. Of course, AbbVie isn't likely to just sit on its hands and could make a move of its own, potentially offering an authorized generic of its own.
Game changer?
The launch of authorized generics seems like a decent Band-Aid for the drug pricing system, but it certainly isn't a cure-all. They could work for other diseases where there are multiple players resulting in large negotiated discounts -- diabetes comes to mind -- but authorized generics won't solve the overall problem of high drug costs.
The best-case scenario, if enough companies started doing it, is that PMBs would need to change their business model toward a fee-based system, passing on all discounts to clients, which would better align their interests.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get steeper discounts than if there's only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation, PBM Express Scripts (NASDAQ: ESRX) was only covering AbbVie's drug for a while, and Express Scripts has removed drugs in other diseases from its formulary for playing hardball on negotiations. And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. | And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get steeper discounts than if there's only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation, PBM Express Scripts (NASDAQ: ESRX) was only covering AbbVie's drug for a while, and Express Scripts has removed drugs in other diseases from its formulary for playing hardball on negotiations. | And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get steeper discounts than if there's only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation, PBM Express Scripts (NASDAQ: ESRX) was only covering AbbVie's drug for a while, and Express Scripts has removed drugs in other diseases from its formulary for playing hardball on negotiations. | And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get steeper discounts than if there's only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation, PBM Express Scripts (NASDAQ: ESRX) was only covering AbbVie's drug for a while, and Express Scripts has removed drugs in other diseases from its formulary for playing hardball on negotiations. |
25334.0 | 2018-09-25 00:00:00 UTC | Gilead (GILD) to Launch Generics for Leading HCV Treatments | ABBV | https://www.nasdaq.com/articles/gilead-gild-to-launch-generics-for-leading-hcv-treatments-2018-09-25 | nan | nan | Gilead Sciences, Inc . GILD announced that it plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments - Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg).
The generic versions will be launched through a newly created subsidiary, Asegua Therapeutics LLC at a list price of $24,000 for the most common course of therapy. These will be available from January 2019.
We remind investors that a couple of years ago, Gilead was under the scanner of regulatory bodies for high prices of drugs.
Gilead decided to launch generics as the company believes that the discounts provided by the company do not always translate into lower costs for patients.
Of late, there has been a lot of debate on the high prices of drugs and affordable healthcare for all.
The main focus of the company is lower the list price of Epclusa. Per the company, Epclusa was the first HCV therapy proven to effectively treat all six main Hep C genotypes, with a simple one-pill, once-a-day treatment regimen for the majority of patients. The drug was approved in the United States in 2016.
The launch of the generics might boost the dwindling HCV sales of the company. Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier, among others. The franchise suffered a significant plunge in sales due to new competition and fewer patient starts.
Gilead's stock has gained 8.3% in the year so far against the industry's decline of 2.1%.
Consequently, Gilead is now banking on its HIV franchise and newer avenues, like the CAR-T therapy, to drive growth. However, the company will have to generate substantial revenues from its HIV franchise and Yescarta to offset the HCV sales decline. This will be a challenging task for the company with stiff competition from the likes of GlaxoSmithKline GSK in the HIV market.
Zacks Rank
Gilead carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. GILD announced that it plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments - Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg). | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier, among others. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier, among others. Gilead decided to launch generics as the company believes that the discounts provided by the company do not always translate into lower costs for patients. | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead's stock has gained 8.3% in the year so far against the industry's decline of 2.1%. |
25335.0 | 2018-09-24 00:00:00 UTC | AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU | ABBV | https://www.nasdaq.com/articles/abbvie-roches-leukemia-drugs-combo-gets-chmp-backing-in-eu-2018-09-24 | nan | nan | AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for label expansion of its leukemia drug, Venclexta. The label expansion application sought EU approval for the combination use of its cancer drug Venclexta and Roche's RHHBY Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. If approved, Venclexta/Rituxan will become the first chemotherapy-free, fixed duration treatment option for CLL patients.
Regulatory applications seeking approval for the combination use in this broader patient population were approved in the United States in June.
The FDA approval and regulatory applications in the EU for the combination use were based on positive data from the phase III MURANO study of Venclexta plus Rituxan in relapse/refractory CLL. Data from the phase III MURANO study presented last year showed that the combination led to a profound improvement in progression free survival compared to Teva's TEVA Treanda plus Rituxan.
Venclexta is jointly marketed by AbbVie and Roche's Pharma arm, Genentech in the United States and by AbbVie outside the United States. Venclexta is marketed by the trade name of Venclyxto in the EU.
The FDA approval for label expansion of Venclexta for this indication should expand the patient population for the drug significantly and boost its commercial potential.
Meanwhile, AbbVie is studying Venclyxto/Venclexta to expand its label to address the broader relapsed/refractory CLL patient population, expand into earlier lines of therapy and broaden into other hematologic malignancies like multiple myeloma and acute myeloid leukemia (AML).
In July, AbbVie also filed a U.S. regulatory application for Venclexta in first-line AML while data from the phase III program in multiple myeloma is expected in 2019.
So far this year, AbbVie's stock has declined 4.6% against the industry 's increase of 7.1%.
In fact, last week, AbbVie fell 3.6% following a lawsuit filed by the California insurance department. The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions.
AbbVie currently has a Zacks Rank #3 (Hold). A better-ranked large-cap drug stock is Bristol-Myers Squibb Company BMY , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Bristol-Myers' earnings estimates increased 3.4% for 2018 and 2.7% for 2019 over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 6.39%. Shares of the company have risen 13.9% in the past three months.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions. AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for label expansion of its leukemia drug, Venclexta. Venclexta is jointly marketed by AbbVie and Roche's Pharma arm, Genentech in the United States and by AbbVie outside the United States. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for label expansion of its leukemia drug, Venclexta. Venclexta is jointly marketed by AbbVie and Roche's Pharma arm, Genentech in the United States and by AbbVie outside the United States. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for label expansion of its leukemia drug, Venclexta. Venclexta is jointly marketed by AbbVie and Roche's Pharma arm, Genentech in the United States and by AbbVie outside the United States. | AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for label expansion of its leukemia drug, Venclexta. Venclexta is jointly marketed by AbbVie and Roche's Pharma arm, Genentech in the United States and by AbbVie outside the United States. Meanwhile, AbbVie is studying Venclyxto/Venclexta to expand its label to address the broader relapsed/refractory CLL patient population, expand into earlier lines of therapy and broaden into other hematologic malignancies like multiple myeloma and acute myeloid leukemia (AML). |
25336.0 | 2018-09-24 00:00:00 UTC | SPYG, BA, ABBV, ADBE: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/spyg-ba-abbv-adbe-etf-inflow-alert-2018-09-24 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $57.3 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 95,550,108 to 97,050,108). Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average:
Looking at the chart above, SPYG's low point in its 52 week range is $7.6331 per share, with $38.39 as the 52 week high point - that compares with a last trade of $37.91. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6331 per share, with $38.39 as the 52 week high point - that compares with a last trade of $37.91. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6331 per share, with $38.39 as the 52 week high point - that compares with a last trade of $37.91. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $57.3 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 95,550,108 to 97,050,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6331 per share, with $38.39 as the 52 week high point - that compares with a last trade of $37.91. | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $57.3 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 95,550,108 to 97,050,108). For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price performance of SPYG, versus its 200 day moving average: Looking at the chart above, SPYG's low point in its 52 week range is $7.6331 per share, with $38.39 as the 52 week high point - that compares with a last trade of $37.91. |
25337.0 | 2018-09-21 00:00:00 UTC | How Do Drugs Compete Against Each Other? | ABBV | https://www.nasdaq.com/articles/how-do-drugs-compete-against-each-other-2018-09-21 | nan | nan | It's easy to pick a winner when a medication is the only treatment for its indication. But when there's more than one drug on the market, how can investors tell which one will ultimately win more patient share?
In this prerecorded episode of Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor Todd Campbell dive into the world of drug competition. With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. Tune in to learn more about the four most important factors to consider -- efficacy, safety, price, and convenience.
[Don't worry, we'll be back with a live show ASAP!]
A full transcript follows the video.
10 stocks we like better than Walmart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
The author(s) may have a position in any stocks mentioned.
This video was recorded on March 7, 2018.
Shannon Jones: Hey, Fools! This is Shannon Jones here on behalf of the Industry Focus team. Unfortunately, a funny thing happened on the way into work. Headquarters lost power. That means we can't record in the studio today. But never fear, we've got an episode lined up just for you, and we'll be sure to bring you the latest news in the healthcare industry as soon as we are back in action.
--
Kristine Harjes: Welcome to Industry Focus , the podcast that dives into a different sector of the stock market every day. Today is March 7th, and this is the Healthcare edition of the show. I'm your host, Kristine Harjes, and I have healthcare specialist Todd Campbell on the line. Welcome to the show, Todd!
Todd Campbell: Hi, Kristine! How are you today? Happy Wednesday!
Harjes: I'm doing great! Are you familiar with The Motley Fool tradition of Foolympics?
Campbell: No, tell me about them!
Harjes: OK. Every other year, The Fool runs its own version of the Olympics. We're divided up into teams, we name ourselves a country, and we participate in a variety of different physical and mental competitions. That's what we're in the midst of right now here at Fool HQ. And given that competition is a core value here at The Motley Fool, it gets super heated. You know what today's topic is, Todd. Does it make sense why it was top-of-mind?
Campbell: Absolutely. I'm excited for today's show, Kristine, because we get to take off our lab coats, our science hats that we usually wear, and put on our C-Suite suits and our CEO hats.
Harjes: Yes. We're here today to talk about competition. When multiple drugs are competing for the same patients, how do you differentiate one from another, and how can you tell which one will ultimately end up winning the largest patient share? We took a look at the different ways we've seen drugs compete in real life, and we broke them down into four primary factors of competition. We'll dive into each one of them and give an example or two. First, let's take a look at what's at stake here.
Campbell: There's so much at stake. We've talked to listeners over the course of the last few years about different problems and challenges that have to be overcome by these companies that are developing these new drugs. First, you have patent protection. You have a capped, limited period of time that your product is going to be on the market, earning money. Somebody could come out and out-innovate you. And there's a tremendous amount of money at stake, $330 billion spent on prescription drugs. When you think about the fact that 90% of drugs that go into clinical trials end up failing and ending up in the dustbin, you want to make sure that the 10% that do cross the finish line are as successful as they possibly can be.
Harjes: We spend so much time on this show talking about drugs that haven't even hit the market yet and discussing the clinical trials and the data coming out of them. I'm looking forward today to looking a little bit farther down the timeline at what happens when these drugs are on the market. You hit the nail on the head that they only have so much time in which they'll generate money. These businesses are looking to grab as much market share as they possibly can in order to recoup their investment and also in order to further their R&D spending for drugs to come out in the future.
The very first factor to dig into is a no-brainer. This one is efficacy, how well does the drug work?
Campbell: Right. Can we build a better mousetrap than whatever the standard of care currently is for that indication? Can we reshape or revolutionize that indication so that we capture all of the money that's potentially up for grabs? Kristine, just in going through and thinking about how to discuss this with our listeners, I think you'll probably agree that the best example of efficacy and disruption in recent memory is Gilead Sciences and what it did in hepatitis C.
Harjes: Absolutely. When Gilead won approval for its hepatitis C drug Sovaldi in 2014, that was a complete game-changer. Previously, patients were looking at drugs that were just not very good at all. They were mostly effective, and they were a pain. But Gilead came out with Sovaldi, and it totally changed the game, with cure rates of upward of 90%. With that, it ate everybody's lunch. There were no other reasonable competitors at that point.
Campbell: Right, you had these old-style treatments for decades that included Ribavirin and Peginterferon. I think the functional cure rates of taking those over the course of very long treatment periods was only 50%, it was like a coin flip. Then, in 2011, Vertex got approved a drug called Incivek, which at the time was game-changing. But even then, the functional cure rate was only about 80%. So, when Gilead Sciences came out with Sovaldi, and later in the year Harvoni in 2014, and was able to increase those functional cure rates above 90%, it was game-changing.
I think, you look at this and you think back, how Gilead Sciences got to that point. Think about all of the people who were up in arms about how much money Gilead Sciences paid to get its hands on the drug that would eventually become Sovaldi. A lot of people were scratching their heads about that. Again, they did the numbers and they were looking at this saying, "If we can do this and we can come up with a functional cure rate efficacy that's really so much better than anything that's currently out there, well, then it could be a huge drug." And sure enough, these were huge drugs.
Harjes: Yeah. This drug ended up making Gilead Sciences so much money. It basically changed what the story behind Gilead Sciences was. This went from a company that was really just about HIV and added an entire blockbuster franchise.
Campbell: Yeah. At one point, I think they were close to doing $20 billion in annualized sales just from hepatitis C. That's pretty remarkable. It goes to show that, front and center on the minds of anyone involved in this business isn't just the idea of making money, but it's also this whole idea of, if we can disrupt by creating something that really, really works well, this much better drug that will, by the nature of it, end up being successful on its own.
Harjes: Gilead Sciences in hepatitis C is a pretty obvious example. But it's worth pointing out that there's a little bit of nuance here. For, example, you see pretty frequently two different drugs competing in the same market, and one will claim that in its trials, it had, say, a 90% cure rate, vs. the other one only had 80%. Unless you actually have a head-to-head trial, it can sometimes be hard to tell whether the one drug actually is better. That all comes down to trial design. Do you want to dive into that a little bit?
Campbell: Yeah. I'm so happy that you brought that up. I think it's important to remember. Obviously, we have different hurdles of efficacy to clear that we can actually categorize, how good is this drug, really? If you're comparing it to the easiest hurdle, which is a placebo, so, I'm doing nothing vs. taking this drug, well, that tells me something, but it doesn't necessarily tell me that this option is better than, say, the current standard of care. Unless, of course, you do a study that actually compares the two of them head to head, we don't know that.
The other thing, too, that I think investors have to remember is, you can demonstrate efficacy in multiple ways. We've talked about this on the show before with surrogate endpoints vs. the actual overall survival. So, using, say, response rate vs. overall survival, or progression-free survival. I'm talking mostly about cancer drugs here, but you could also look at it in autoimmune disease and say, what's the hurdle that we're actually trying to achieve to show that our Phase III trial pans out? I think investors have to be cognizant of that.
Harjes: Absolutely. So, that's efficacy. Let's turn to our second factor of competition, which is safety.
Campbell: Safety is interesting. You're looking at it and saying, I want to build a drug that works better as far as efficacy is concerned, but it doesn't really do me any good if I pick the wrong target or I use a mechanism of action that isn't going to be safe. If I launch a drug that I think is going to be competitive because it delivers solid efficacy, but then safety signals show up, it's basically going to collapse the commercial opportunity of that drug.
Thinking about a good example for our listeners, turning back to Gilead Sciences, they actually had a drug that wasn't nearly as successful as their hep C franchise, and that's Zydelig, which is a drug for chronic lymphocytic leukemia. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson & Johnson and AbbVie, which we've talked about on the show before, called Imbruvica.
Harjes: Yeah. These two were fierce competitors with one another. They were both targeting the same unmet need. It was an enormous, multi-billion-dollar indication. They were hoping that they'd be able to expand these drugs into earlier lines and potentially other cancers. But, neither drug was perfect. Safety ended up being a huge differentiator between the two of them. In March 2016, Zydelig's expansion trials had to be halted, which caused Gilead to have to discontinue the further development of this drug and add a black box warning, which is the FDA's most severe warning, on the label for the drug itself. And it just decimated Zydelig's commercial opportunity.
Campbell: Yeah. I remember thinking in 2013, before this drug launched, I was writing that Zydelig could be a blockbuster drug, it could have billion-dollar potential, this is a multibillion-dollar opportunity especially if you can move it up into earlier and earlier lines of treatment. But, when all was said and done, Zydelig's mechanism of action was inhibiting something called PI3K-delta, vs. Imbruvica's mechanism of action inhibiting the BtK protein, and BtK turned out to be safer. There were, unfortunately, some very sad fatalities caused in the trials evaluating Zydelig, and I think as a result, they had to shutter of the development. And Zydelig, while it's still on the market today because there are some patients that could still respond well to it, it's basically a niche drug. This was once going to be a billion-dollar blockbuster, and I think last year, the sales were maybe $150 million.
Harjes: Vs. Imbruvica's sales, which were $2.5 billion in 2017. Something that I really want to emphasize here is, you have to consider the doctors' perspective. From that perspective, safety actually matters even more than efficacy. Think for a second about the Hippocratic Oath, to do no harm to your patients. So, even the most well-intentioned doctor is going to care more about avoiding bad outcomes than missing out on the best possible outcome and using a slightly more effective but maybe more dangerous drug. I think it's the logical choice every time to go for the safer drug. So, it really does matter. And labeling is also super important. That black box warning that I talked about, that's a blemish. Even if the black box is just to maybe narrow the patient pool slightly, having it on there is something that makes doctors very jittery and a little bit more hesitant to prescribe drugs that have some sort of safety hiccups.
Campbell: Kristine, that made me think, as investors, whenever we see a press release that comes out touting this great efficacy, I always, and you probably do, too, scan down about halfway and start looking for adverse events. I think that's a good reminder to all of our listeners that, when they're looking through Phase III or Phase II trial data, you want to not just focus on that efficacy. You want to go down there and look, were there any -- I'm most interested, Kristine, and you probably are, too, with the severe adverse events. That's grade III or higher events. And of all of them, I'm really interested in what's happening with liver toxicity. Those are some of the things, if you're trying to figure out, will this drug be better than the other drug, absent to head to head comparison, those are a couple things to take a look at.
Harjes: Yep. And one small tip for listeners that are trying to dig into these details, you'll sometimes see these adverse events referred to as SAE or AE, the acronym for severe adverse event and adverse event. If you're CTRL+F searching through any press releases and you're not finding anything when you spell out the words, try the acronym.
Campbell: Kristine, before we jump, one more point to follow on the back of that. It's important to remember that the safety hurdle will differ depending on the indication. You're going to have a slightly different safety hurdle for someone who has, say, late-stage cancer with very few treatment options vs., say, toenail fungus.
Harjes: Yeah, absolutely. And even in different lines of the same indication, it's a little bit more acceptable to have a questionable side effect profile if you're later down the line in treatment and patients have fewer options left.
Our third factor of competition that we wanted to talk about today is price. This one is, I think, slightly less obvious than the others, and in particular it needs to be balanced with the other two, meaning efficacy and safety, because price alone isn't going to cut it if you have a drug like, say, Sovaldi. Sovaldi was able to price itself very high compared to what was on the market because it knocked it out of the park on safety and efficacy. But, as it turns out, that wasn't the end of the story. Eventually it did face competition from other hepatitis C drugs in this next generation wave of more safe and more effective drugs, based on price.
Campbell: Right, AbbVie and Merck, both of them. And you can imagine, Kristine, being in the war room of these C-Suites trying to figure this out, because they're looking at this and saying, we know we're going up against Sovaldi and Harvoni, which are incredibly efficacious drugs with solid safety profiles. We think we can match or at least come up similarly to them on those two things. So then, how do we differentiate to make sure that we're able to win the market share away from them? And the next logical choice, then, would be on price. Can I battle on price? Can I undercut them, still make a nice profit for my investors, and capture a bulk of the market share?
Harjes: One strategic way that companies can do this is by negotiating directly with the PBMs to get preferred access to their formularies, which essentially blocks out your competition, if your drug is listed on, say, Express Scripts Preferred Formulary and your competition isn't.
Campbell: Right. And that's why the Viekira Pak, which was AbbVie's first hepatitis C drug, when that came out, I think it won approval at the end of 2014, maybe launched in 2015. When they won approval, what they decided to do is, we can't necessarily beat Gilead's drugs on these other things like efficacy and safety. But what we can do is offer a bargain-basement price to Express Scripts, and basically get all of the business that way. And that's exactly what ended up happening. I think Sovaldi was priced at $84,000 for the treatment, I think Harvoni was $94,000, and Viekira Pak's wholesale acquisition cost came in around $83,500, but their net cost was probably much, much lower than that. And of course, that then forces Gilead to have to compete on price and lower their prices. And then when Merck's drug came out, compete again. And then, fast forward to 2017 with AbbVie's most recent drug that just launched, and I think that drug is priced at less than $30,000 for an eight-week course of treatment.
Harjes: And this is why, when you're looking at Gilead Sciences' results, you see hepatitis C sales falling off a cliff. Not only are they treating patients and curing them, which effectively makes your market smaller and smaller, but this price battle has made margins so tight for all of these companies that the market is not nearly the size that it once was.
Campbell: Right, a smaller market. And then, of course, competing on price to try and maintain market share, driving down the revenue on the unit volume that you are driving out the door. I think, from an investor's standpoint, you're looking at it and you have to recognize that drugs aren't your normal thing. When you're looking at this industry and investing in this industry for the first time, one of the things you have to realize right out of the gate is, this isn't like building a widget and saying, "I'm building a widget and then I'm going to mark it up 15%, and that's going to be my profit margin." 90% of the drugs are going to fail in your clinical trials, so you need to not only price for the cost to produce that drug once it wins approval, but you need to absorb the cost on all your failed drugs, and you need to price it to be able to fund future development of whatever the next innovative treatment is that you're going to launch.
Harjes: And of course, all the way, you have to be battling the public outcry about drug pricing. So, for sure, this is something that drug makers and doctors, payers, pretty much everybody in this country, is thinking about, is drug pricing.
But, our fourth and final factor of competition is one that I don't think is really thought about as much, and this is the convenience factor.
Campbell: Right. And it actually dovetails into these other things pretty well. If you can make a drug more convenient to take -- and you can define convenience as, say, the dosing schedule is more favorable, or the time to take the drug, if it's an infusion drug, shrinks. Then, maybe you can eliminate some of the side effects that come along with taking the drug, and possibly carve out some costs that are associated with it. I was thinking this past week; you and I were talking before the show about what we're seeing going on right now in the ongoing battle for market share among PD-1 cancer treatments. That's been an absolute brawl since these drugs won approval in 2014. Bristol-Myers ' Opdivo and Merck & Co's Keytruda.
Harjes: I'm so glad that we're talking about the PD-1 battle in an episode about competition, because this has been one of the most interesting brawls to watch over the past many years. Before we dive into the PD-1 battle, I do want to go back and emphasize the point that you made about convenience being a factor that plays into all of the other three that we talked about, efficacy, safety and price. You were completely right about safety lowering that side effect profile. Price, I also agree, if you're treating people less often, then you're bringing down all sorts of costs, from the direct costs to even less direct costs like time spent in a hospital or fewer office visits, even something like fewer disposables for whatever is used in the delivery of the drug itself.
I'll also add one more, which is how it plays into efficacy. Real life adherence is kind of tough. And sometimes you'll find, in the actual data for a drug that's on the market, it's not as effective as it was in trials. And a huge part of that is because people aren't good at following directions. So, if a drug is completely burdensome to take on the prescribed schedule, people might not be very good at following that schedule, and that can minimize the efficacy of the drug itself. If you can make it more convenient to take, you're decreasing the chance that non-compliance is going to mess with your efficacy.
Campbell: Absolutely. That's an awesome point, Kristine!
Harjes: All that being said, PD-1s. I'm going to kick it to you for this one, Todd.
Campbell: OK. It's probably important to have a little background on what PD-1s are. We've talked about it in the past. It's a checkpoint protein. In immune systems, on T cells, what oftentimes can happen with cancer is, they'll hijack a mechanism that basically flips a switch on that PD-1 protein and tells the T-cell, "Don't attack me, I'm a healthy cell." So, by inhibiting these PD-1s, what they do is inhibit the activity of PD-1, they basically remove or eliminate the ability for the cancer cell to hijack that mechanism.
Harjes: Yeah. Bristol and Merck had been neck-and-neck in developing these two types of drugs for quite a while. Eventually, it came to look like Keytruda was probably pulling ahead, specifically in first-line lung cancer, which is an enormous indication. We're now waiting for some interim data to see if maybe Opdivo can catch up here.
One way in which Opdivo was able to get some pretty good results recently was just yesterday when the FDA approved a four-week dosing for Opdivo. Previously, it had been dosed every two weeks. So, going from every two weeks to every four weeks is doubling the convenience, essentially. For reference, Keytruda is dosed every three weeks. This will be for a majority of its approved indications, and that includes melanoma and second-line lung cancer and bladder cancer. Right now, it's the only PD-1 drug, and there are a lot of them out there besides just the two that we're talking about, that's approved for a four-week dosing schedule.
Campbell: Yeah. This is really a fascinating development. People are going to have to watch the next couple of quarters to see whether or not Opdivo starts to get back some of its mojo. You mentioned that Keytruda had won approval in first-line use in non-small lung cancer. That basically caused sales of Keytruda to skyrocket. And Opdivo sales in the U.S. have pretty much flatlined since then because you're using Keytruda now ahead of Opdivo, you're using Keytruda in the first-line setting and Opdivo isn't used in the first line setting. So, right now, Bristol-Myers' management is saying, how do we make sure that we sure up the market share that we do have in these later lines of treatment until we know that we can actually compete in the first line? And there's opportunity that they're exploring to be able to do that, but that's not approved yet.
So, you look at it and say, if I can make this more convenient to the cancer infusion centers where these are being dosed, maybe I can make sure that I'm solidifying my relationship with those places and this drug continues to get used instead of Keytruda. That will be very interesting, to see how this plays out over the next couple of quarters. As you mentioned, Opdivo was every two weeks, and it was a one-hour infusion. Now, it can be either every two weeks or every four weeks for a half-hour infusion. Now, that infusion time matches Keytruda. But like you mentioned, the four-week dosing schedule is better than Keytruda's three-week.
Harjes: Yeah. If you look at the incentives from the perspective of these infusion centers, this looks pretty favorable, that you have drugs that take the same amount of time to do the infusion, but one of them now has to be done less frequently. That's a good thing. Some analysts are saying that this could help it expand this into the maintenance and adjuvant therapy settings. This is yet another example in this ferocious battle between Keytruda and Opdivo, where one drug is largely ahead and the other one starts to catch up. It's really just been fascinating to watch.
I believe we did an entire episode on this battle about a year ago, if I'm remembering the timeline correctly. Any listeners that are interested in some of the details about the development of these two drugs and how the situation came to be the way it is today, shoot us a note at industryfocus@fool.com and I'd be happy to send that episode along.
Campbell: Yeah. One final takeaway, too, from my end, as to why we're spending time talking about this, Opdivo's sales in the fourth quarter alone were $1.36 billion. Keytruda's in the fourth quarter were $1.3 billion. So, they are literally neck and neck.
Harjes: But the growth rates are totally different, as you alluded to earlier. Opdivo's Q4 sales were only up 4% year over year, vs. Keytruda's, which were up 169%. So, for two nominal numbers that are fairly similar, the growth rates are totally different. But this battle is clearly not over.
We are wrapping up for today. I hope you guys enjoyed this episode on competition and wish me some luck in the Foolympics. We're going through the end of this week. Currently, my country is in first place. I'm very excited, hoping to keep it that way. As always, people on the program may have interests in the stocks they talk about, and The Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. This show is produced by the marvelous Austin Morgan. For Todd Campbell, I'm Kristine Harjes. Thanks for listening and Fool on!
Kristine Harjes owns shares of Johnson & Johnson. Shannon Jones has no position in any of the stocks mentioned. Todd Campbell owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool owns shares of Johnson & Johnson and has the following options: short October 2018 $135 calls on Johnson & Johnson. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson & Johnson and AbbVie, which we've talked about on the show before, called Imbruvica. Campbell: Right, AbbVie and Merck, both of them. | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson & Johnson and AbbVie, which we've talked about on the show before, called Imbruvica. Campbell: Right, AbbVie and Merck, both of them. | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson & Johnson and AbbVie, which we've talked about on the show before, called Imbruvica. Campbell: Right, AbbVie and Merck, both of them. | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson & Johnson and AbbVie, which we've talked about on the show before, called Imbruvica. Campbell: Right, AbbVie and Merck, both of them. |
25338.0 | 2018-09-21 00:00:00 UTC | CRON Stock Is a Long-term Play With Near-Term Challenges | ABBV | https://www.nasdaq.com/articles/cron-stock-long-term-play-near-term-challenges-2018-09-21 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Currently, legal marijuana is one of the most exciting investment sectors. It also appears a resilient sector as well. After demonstrating evidence of being technically overbought, Cronos Group (NASDAQ: CRON ) put up a remarkable performance, up 19% in just two days of trading. For the year, CRON stock has gained 70%.
So what drove sentiment midweek? Two factors are at play. Cronos announced a partnership with Aleafia Health (OTCMKTS: ALEAF ). The scope of the deal involves evaluating cannabis for treating insomnia and daytime drowsiness .
But the second factor is likely more significant . Canadian cannabis firm Tilray (NASDAQ: TLRY ), which recently received federal regulatory approval to import marijuana into the U.S. for medical research. TLRY experienced a dramatic surge, skyrocketing over 38% on Wednesday. Therefore, many investors anticipated that a rising tide would lift Cronos stock.
A few lesser-known companies, including Aleafia, also experienced a bump up on Tilray's good news.
However, CRON stock received a higher portion of the rewards due to the underlying company's core business. As I wrote two weeks ago, Cronos initiated a landmark deal with custom-microbe producer Ginkgo Bioworks. Gingko will produce cannabinoid (CBD) strains without the psychoactive component delta-9 tetrahydrocannabinol, which you (or your "friend") know as THC.
The 8 Best Cash Cow Stocks to Buy for Stable Returns
Successfully developing a THC-free version of CBD will be huge for the medical-cannabis industry. It's a workaround for otherwise strict federal regulations against marijuana; hence, the speculative money towards Cronos stock.
Moreover, Cronos' business aligns with Tilray CEO Brendan Kennedy's vision for legal marijuana . In a recent interview, Kennedy stated emphatically that pharmaceuticals and beverage-makers must seek partnerships with cannabis firms for longer-term viability.
Of course, Cronos is actively seeking such arrangements.
CRON Stock Is Risky in the Short Term, But a Winner in the Long Term
The recent jump in Cronos stock represents the complicated nature of this investment. On one hand, Tilray's CEO laid out the logical pathway of legal marijuana. But on the other hand, CRON has nearer-term risks.
What Kennedy suggested isn't without precedent. For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . This drug alleviates painful symptoms associated with chemotherapy, and helps AIDS patients with appetite restoration.
Other examples include Constellation Brands (NYSE: STZ ) owning a substantial stake in Canopy Growth (NYSE: CGC ), with plans to invest more. Molson Coors Brewing (NYSE: TAP ) recently signed a joint venture with Hydropothecary (OTCMKTS: HYYDF ).
CRON stock could benefit beyond these established synergies because of Gingko's scientific expertise. Presently, extracting CBD is an onerous and expensive process, which involves producing new cannabis plants. Gingko aims to bypass the planting process by extracting CBD through fermentation .
If successful, Cronos could theoretically mass-produce CBD, which would moon CRON stock.
But before you get too excited, we have the obvious problem that Gingko must succeed in this endeavor. That's part of the reason why CRON and Gingko have production-threshold stipulations built into their contract.
Next, you must consider that Cronos doesn't currently have high-level partnerships with mainstream beverage-makers or pharmaceuticals. For management to attract the alpha dogs of the target industries will require significant effort.
But the biggest nearer-term risk is market volatility. Citron Research 's Andrew Left had a field day with CRON stock, publishing what he termed a "reality check." In it, he cited doubts about the company's production capacity and potential, eventually sinking shares.
Naturally, every new investing sector will feature naysayers. But Cronos stock is particularly vulnerable due to overall legal ambiguities.
The Bottom Line for CRON Stock
I'll reiterate my opinion regarding CRON stock: this is an investment that has tremendous upside potential, but one that will face choppy waters. If you are risk-tolerant, you'll likely be very happy with CRON five years out. If you're risk-averse, you may want to sit this one out for a while.
Either way, I don't see Cronos stock as a buy right now. While shares did jump almost double-digits Wednesday, recent trades have gyrated wildly. And despite the move, shares aren't dramatically higher from when they first went bonkers in late August.
8 Long-Term Investments to Give Your Grandchildren
Plus, I'm leery of the short-traders. Left made great money shorting CRON stock recently. Now, with the price back to where it was pre-Left, this will entice the bears. Let them have their way, and reengage this idea with less resistance.
As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities.
More From InvestorPlace
20 Stocks With Massive Post-Millennial Appeal
8 Long-Term Investments to Give Your Grandchildren
5 Red-Hot Machine-Learning Stocks to Buy
5 Great REITs to Buy as Inflation Surges
Compare Brokers
The post CRON Stock Is a Long-term Play With Near-Term Challenges appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . After demonstrating evidence of being technically overbought, Cronos Group (NASDAQ: CRON ) put up a remarkable performance, up 19% in just two days of trading. Canadian cannabis firm Tilray (NASDAQ: TLRY ), which recently received federal regulatory approval to import marijuana into the U.S. for medical research. | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . InvestorPlace - Stock Market News, Stock Advice & Trading Tips Currently, legal marijuana is one of the most exciting investment sectors. Canadian cannabis firm Tilray (NASDAQ: TLRY ), which recently received federal regulatory approval to import marijuana into the U.S. for medical research. | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . CRON Stock Is Risky in the Short Term, But a Winner in the Long Term The recent jump in Cronos stock represents the complicated nature of this investment. The Bottom Line for CRON Stock I'll reiterate my opinion regarding CRON stock: this is an investment that has tremendous upside potential, but one that will face choppy waters. | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . InvestorPlace - Stock Market News, Stock Advice & Trading Tips Currently, legal marijuana is one of the most exciting investment sectors. CRON Stock Is Risky in the Short Term, But a Winner in the Long Term The recent jump in Cronos stock represents the complicated nature of this investment. |
25339.0 | 2018-09-21 00:00:00 UTC | Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status | ABBV | https://www.nasdaq.com/articles/pfizers-pneumococcal-vaccine-gets-breakthrough-therapy-status-2018-09-21 | nan | nan | Pfizer, Inc.PFE announced that it has received Breakthrough Therapy designation for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, from the FDA. The candidate is being developed as a preventive treatment for invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adult patients.
The designation was granted on the basis of positive immunogenicity data from a phase II study of the multivalent pneumococcal conjugate vaccine in adults aged 60 to 64 years. Data from this mid-stage study will be presented at a future date. A phase III study is expected to be initiated in a few months.
The designation is aimed at accelerating the development and review of drugs intended to treat serious or life-threatening diseases. The vaccine candidate also enjoys Fast Track designation, which was granted in October 2017.
Pfizer's stock has outperformed the industry this year so far. Pfizer's shares have risen 20.7% compared with the industry's increase of 6.8%.
The company has four oncology drugs under FDA's priority review with decisions expected this month. A key candidate is its immuno-oncology candidate, Bavencio (avelumab), which is being evaluated for several types of cancer. Bavencio is already approved in metastatic Merkel cell carcinoma in the United States, Europe and Japan. It has also received accelerated approval for second-line treatment of locally advanced or metastatic urothelial carcinoma in the United States.
The company's late-stage pipeline candidates in non-oncology segment include Vyndaqel/tafamidis (transthyretin cardiomyopathy), PF-04965842 (JAK selective inhibitor for atomic dermatitis) tanezumab (osteoarthritis pain, chronic low back pain, and cancer pain) and fidanacogene elaparvovec/PF-06838435 (gene therapy for hemophilia B).
Pfizer also boasts a strong biosimilars pipeline. Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. A biosimilar version of Roche's Herceptin is under review in the United States and was approved in Europe in July
Pfizer is developing 13 biosimilar molecules in different stages of clinical studies. It has plans to launch five biosimilars over the next two years. Pfizer markets Inflectra, a biosimilar version of Merck/J&J's Remicade, in the United States. In Europe, Pfizer markets biosimilar versions of Amgen's AMGN drugs, Neupogen and Epogen. In the United States, a biosimilar version of Epogen was approved in May while a biosimilar of Neupogen was approved in July.
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer, Inc.PFE announced that it has received Breakthrough Therapy designation for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, from the FDA. | Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. In Europe, Pfizer markets biosimilar versions of Amgen's AMGN drugs, Neupogen and Epogen. | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. A biosimilar version of Roche's Herceptin is under review in the United States and was approved in Europe in July Pfizer is developing 13 biosimilar molecules in different stages of clinical studies. | Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The designation was granted on the basis of positive immunogenicity data from a phase II study of the multivalent pneumococcal conjugate vaccine in adults aged 60 to 64 years. |
25340.0 | 2018-09-20 00:00:00 UTC | Company News For Sep 20, 2018 | ABBV | https://www.nasdaq.com/articles/company-news-for-sep-20-2018-2018-09-20 | nan | nan | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials
Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its platform
Copart Inc.'s CPRT shares plunged 13.4% after posting fiscal fourth quarter 2018 adjusted earnings per share of $0.42 missing the Zacks Consensus Estimate of $0.47
Shares of AbbVie Inc. ABBV tumbled 1.7% following news that the company is facing legal challenge from a California insurer following allegations of kickbacks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Facebook, Inc. (FB): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Copart, Inc. (CPRT): Free Stock Analysis Report
Tilray, Inc. (TLRY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its platform Copart Inc.'s CPRT shares plunged 13.4% after posting fiscal fourth quarter 2018 adjusted earnings per share of $0.42 missing the Zacks Consensus Estimate of $0.47 Shares of AbbVie Inc. ABBV tumbled 1.7% following news that the company is facing legal challenge from a California insurer following allegations of kickbacks Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Copart, Inc. (CPRT): Free Stock Analysis Report Tilray, Inc. (TLRY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Copart, Inc. (CPRT): Free Stock Analysis Report Tilray, Inc. (TLRY): Free Stock Analysis Report To read this article on Zacks.com click here. Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its platform Copart Inc.'s CPRT shares plunged 13.4% after posting fiscal fourth quarter 2018 adjusted earnings per share of $0.42 missing the Zacks Consensus Estimate of $0.47 Shares of AbbVie Inc. ABBV tumbled 1.7% following news that the company is facing legal challenge from a California insurer following allegations of kickbacks Want the latest recommendations from Zacks Investment Research? Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its platform Copart Inc.'s CPRT shares plunged 13.4% after posting fiscal fourth quarter 2018 adjusted earnings per share of $0.42 missing the Zacks Consensus Estimate of $0.47 Shares of AbbVie Inc. ABBV tumbled 1.7% following news that the company is facing legal challenge from a California insurer following allegations of kickbacks Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Copart, Inc. (CPRT): Free Stock Analysis Report Tilray, Inc. (TLRY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its platform Copart Inc.'s CPRT shares plunged 13.4% after posting fiscal fourth quarter 2018 adjusted earnings per share of $0.42 missing the Zacks Consensus Estimate of $0.47 Shares of AbbVie Inc. ABBV tumbled 1.7% following news that the company is facing legal challenge from a California insurer following allegations of kickbacks Want the latest recommendations from Zacks Investment Research? Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Copart, Inc. (CPRT): Free Stock Analysis Report Tilray, Inc. (TLRY): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
25341.0 | 2018-09-19 00:00:00 UTC | Validea Joel Greenblatt Strategy Daily Upgrade Report - 9/19/2018 | ABBV | https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-9192018-2018-09-19 | nan | nan | The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . This value model looks for companies with high return on capital and earnings yields.
AUTOZONE, INC. ( AZO ) is a large-cap growth stock in the Auto & Truck Parts industry. The rating according to our strategy based on Joel Greenblatt changed from 70% to 80% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AutoZone, Inc. is a retailer and distributor of automotive replacement parts and accessories in the United States. The Company operates through the Auto Parts Locations segment. The Auto Parts Locations segment is a retailer and distributor of automotive parts and accessories. As of February 10, 2018, the Company operated through 6,088 locations in the United States, Puerto Rico, Mexico and Brazil. The Company's stores carry product lines for cars, sport utility vehicles, vans and light trucks, including new and remanufactured automotive hard parts, maintenance items, accessories and non-automotive products. The Company's other operating segments include ALLDATA, which produces, sells and maintains diagnostic and repair information software used in the automotive repair industry, and E-commerce, which includes direct sales to customers through www.autozone.com.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt changed from 70% to 80% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Joel Greenblatt has returned 109.25% vs. 129.58% for the S&P 500. For more details on this strategy, click here
About Joel Greenblatt : In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.
About Validea : Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The rating according to our strategy based on Joel Greenblatt changed from 70% to 80% based on the firm's underlying fundamentals and the stock's valuation. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . |
25342.0 | 2018-09-19 00:00:00 UTC | AbbVie Faces California Insurance Department Suit for Humira | ABBV | https://www.nasdaq.com/articles/abbvie-faces-california-insurance-department-suit-for-humira-2018-09-19 | nan | nan | Shares of AbbVie, Inc.ABBV fell almost 3% on Tuesday following a lawsuit filed by the California insurance department. The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions.
California State Insurance Commissioner Dave Jones filed the complaint in Alameda County Superior Court on behalf of the State of California.
The lawsuit says that healthcare providers were given cash, trips and other gifts to write prescriptions for Humira. AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors.
The lawsuit stated this was also a means to induce doctors to prescribe Humira by downplaying its dangerous side effects and risks. Jones said $1.2 billion was paid by health insurers for Humira related claims in recent years. This is the largest health insurance fraud case in the department's history, said Jones.
AbbVie defended itself by saying that services like nursing support are not intended to "interfere with interactions between patients and their healthcare providers."
The allegations were brought to the department's attention by a nurse who was hired as an Ambassador by AbbVie some years ago in Florida.
So far this year, AbbVie's stock has declined 4.3% against the industry 's increase of 6.1%.
Humira is key driver of AbbVie's revenues, accounting for more than 60% of its total sales. Currently approved for 13 indications, Humira sales have increased consistently, backed by robust demand trends. Humira recorded sales of almost $10 billion in the first half of 2018.
Several companies including Amgen AMGN /Allergan AGN , Mylan MYL , Coherus, Novartis' Sandoz, Pfizer and Samsung Bioepis are working on biosimilar versions of Humira. The entry of biosimilars will have a huge impact on AbbVie's financials.
Amgen, Mylan and Samsung Bioepis/Biogen's Humira biosimilars are expected to be launched in the United States in 2023 while in the EU, Amgen and Biogen's biosimilars are expected to be launched in October this year.The latest lawsuit adds to AbbVie's Humira related woes.
AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Allergan plc (AGN): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions. Shares of AbbVie, Inc.ABBV fell almost 3% on Tuesday following a lawsuit filed by the California insurance department. AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors. | AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of AbbVie, Inc.ABBV fell almost 3% on Tuesday following a lawsuit filed by the California insurance department. | AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors. Amgen, Mylan and Samsung Bioepis/Biogen's Humira biosimilars are expected to be launched in the United States in 2023 while in the EU, Amgen and Biogen's biosimilars are expected to be launched in October this year.The latest lawsuit adds to AbbVie's Humira related woes. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors. Shares of AbbVie, Inc.ABBV fell almost 3% on Tuesday following a lawsuit filed by the California insurance department. The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions. |
25343.0 | 2018-09-19 00:00:00 UTC | Bristol-Myers' MM Drug Empliciti Application Validated by EMA | ABBV | https://www.nasdaq.com/articles/bristol-myers-mm-drug-empliciti-application-validated-by-ema-2018-09-19 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that the European Medicines Agency (EMA) has validated its type II variation application, seeking approval for Empliciti in combination with Celgene Corporation's CELG Pomalyst and low-dose dexamethasone (EPd), for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including Revlimid and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy.
The validation by the EMA confirms that the submission is complete and consequently EMA can begin its centralized review process.
The application was based on data from the phase II study, ELOQUENT-3, evaluating the EPd combination versus Pomalyst and dexamethasone (Pd) alone in patients with relapsed or refractory multiple myeloma (RRMM).
We note that Bristol-Myers is co-developing Empliciti, with AbbVie, Inc. ABBV . Per the agreement, the company is solely responsible for commercial activities.
Empliciti is already approved in combination with Celgene's Revlimid (lenalidomide) and dexamethasone for the treatment of multiple myeloma in patients who have received one to three prior therapies.
In August 2018, the FDA accepted the company's supplemental Biologics License Application (sBLA) seeking label expansion of Empliciti. The sBLA seeks approval of Empliciti in combination with Pomalyst and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (r/rMM) who have received at least two prior therapies. The FDA granted the application priority review with an action date of Dec 27, 2018.
Shares of Bristol-Myers have declined 0.5% year to date versus the industry 's increase of 5.1%.
The drug generated sales of $119 million in the first half of 2018. However, the combination therapy, if approved, will provide an important treatment option for patients with relapsed/refractory multiple myeloma whose disease has progressed after treatment with lenalidomide and a proteasome inhibitor.
Meanwhile, the company's blockbuster immuno-oncology drug, Opdivo continues to perform well, driven by label expansions. However, the drug faces stiff competition globally from Merck's MRK PD-L1 inhibitor, Keytruda.
Zacks Rank
Bristol-Myers currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We note that Bristol-Myers is co-developing Empliciti, with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that the European Medicines Agency (EMA) has validated its type II variation application, seeking approval for Empliciti in combination with Celgene Corporation's CELG Pomalyst and low-dose dexamethasone (EPd), for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including Revlimid and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Bristol-Myers is co-developing Empliciti, with AbbVie, Inc. ABBV . Bristol-Myers Squibb CompanyBMY announced that the European Medicines Agency (EMA) has validated its type II variation application, seeking approval for Empliciti in combination with Celgene Corporation's CELG Pomalyst and low-dose dexamethasone (EPd), for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including Revlimid and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Bristol-Myers is co-developing Empliciti, with AbbVie, Inc. ABBV . Bristol-Myers Squibb CompanyBMY announced that the European Medicines Agency (EMA) has validated its type II variation application, seeking approval for Empliciti in combination with Celgene Corporation's CELG Pomalyst and low-dose dexamethasone (EPd), for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including Revlimid and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. | We note that Bristol-Myers is co-developing Empliciti, with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that the European Medicines Agency (EMA) has validated its type II variation application, seeking approval for Empliciti in combination with Celgene Corporation's CELG Pomalyst and low-dose dexamethasone (EPd), for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including Revlimid and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. |
25344.0 | 2018-09-18 00:00:00 UTC | 15 Best S&P 500 Stocks to Buy as the Markets Heat Up | ABBV | https://www.nasdaq.com/articles/15-best-sp-500-stocks-buy-markets-heat-2018-09-18 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
One of the more popular strategies among investors today is to seek out "home runs." These are lesser-known companies that have tremendous upside potential, but carry the risk of collapsing should business prospects go awry. While a balanced portfolio allows for some speculation, now is also a great time to consider S&P 500 stocks.
Why? For starters, the oft-cited benchmark index has worked out its choppiness. Since the second half of this year, the S&P 500 has gained nearly 7%. In sharp contrast, the index was much more volatile in the first half, moving a mere 1% since the start of January. The improved sentiment is a chance for investors to benefit from a rising tide.
Another reason to consider S&P 500 stocks is that they're more stable on the way down. Of course, nobody hopes for a decline once a position has been initiated. But in this unpredictable market environment, leading blue chips offer confidence that smaller names can't provide.
10 Best High-Growth Stocks for Young Investors
With that said, let's dive into the best S&P 500 stocks to buy:
S&P 500 Stocks to Buy: AbbVie (ABBV)
Source: Shutterstock
Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. But after enjoying a stellar performance in 2017, sentiment has declined significantly this year. Since the January opener, ABBV is only slightly above parity.
That said, I think this is an ideal time to consider buying one of the most powerful names among S&P 500 stocks. ABBV levers excellent profitability and growth metrics, highlights being its operating margins and double-digit revenue growth rate. In the second quarter, AbbVie rang up nearly $8.3 billion, up over 19% year-over-year.
For Q3, investors expect earnings-per-share to hit $2.01. This is nearer the higher end of individual estimates, which range from $1.94 to $2.06. Although an ambitious goal compared to the year-ago level's $1.41 EPS, ABBV has the goods to deliver a beat.
Primarily known for its Humira drug, AbbVie has several other popular drugs in its pipeline. Additionally, many of them are in the late stages of the clinical-approval process and therefore offer more potential.
S&P 500 Stocks to Buy: Electronic Arts (EA)
Source: Shutterstock
Electronics Arts (NASDAQ: EA ) is one of the most popular video game companies in the world, so it's no surprise that it's included among the top S&P 500 stocks. However, with fame comes hubris apparently. Management badly blundered in its Battlefield franchise , sending EA stock crashing.
Late last month, EA announced that it will delay Battlefield V one month to Nov. 20. Fans didn't appreciate the creative direction the game's producers took the series, and the results showed. Poor pre-sale numbers forced the company's hands, and management decided to move the title into a less-competitive month.
The delay also caused EA to adjust its full-year guidance lower to reflect the lost sales. Understandably, that freaked investors, causing the slide.
However, EA is much bigger than any one franchise. One of its strongest divisions is its pro sports lineup. Thanks to exclusive licensing, EA provides a gaming experience unlike any other. Moreover, the Battlefield V issue isn't unsolvable. Once designers give what the customers want, they'll come running back.
15 Digital Ad Stocks to Buy for the Long Run
As it stands, I view EA stock and its recent volatility as an opportunity to buy on discount.
S&P 500 Stocks to Buy: Best Buy (BBY)
Source: Best Buy
Analysts once feared that the e-commerce revolution would negatively impact consumer-electronics retailers, and for the most part, they were right. Even mighty Best Buy (NYSE: BBY ) had to adjust to the new realities of their industry. But BBY emerged as a success story.
Management focused on longer-term changes, such as incorporating lucrative businesses and getting rid of units that don't work. Currently, their computing and mobile phones division represents the greatest share of total revenue. Coming in second place is consumer electronics, a very encouraging sign considering that Amazon (NASDAQ: AMZN ) has changed the game here.
Another factor that should buoy investor sentiment is the company's earnings performances. Since their fiscal Q1 2016, BBY has not once failed to at least meet consensus earnings targets. In fact, during this time, BBY exceeded expectations except for just one time in Q3 2018.
I don't expect much to change for its fiscal Q3 2019 report. With a consensus EPS forecast of 85 cents, this is a very realistic target. In the prior year Q3, BBY delivered 78 cents EPS.
S&P 500 Stocks to Buy: Visa (V)
Source: Shutterstock
With unemployment near multi-year lows, and consumer sentiment generally moving higher, now is a great time to consider Visa (NYSE: V ). For one thing, Visa dominates the credit-card market, levering 323 million cardholders . Its closest rival is Mastercard (NYSE: MA ), which is some distance away at 191 million cardholders.
Another reason to look into V stock is its technical performance. Since the beginning of this year, V shares have gained over 28%. But I wouldn't consider this to be a fluke. Thanks to the improved sentiment toward the consumer economy, Visa is likely to make steady gains.
7 Small-Cap ETFs Powering the Markets
Of course, I don't expect massive upside. But as long as consumers keep buying, which appears likely at this point, V stock is in good shape. Visa started to come alive in late 2011 (around when we started to recover from the Great Recession ), and it hasn't looked back since.
S&P 500 Stocks to Buy: Darden Restaurants (DRI)
Source: Mike Mozart via Flickr (Modified)
For the longest time, S&P 500 stocks related to the restaurant industry had a giant question mark over them. Facing a difficult road following the recession, and with brick-and-mortars experiencing declining foot traffic, eateries were in a bad position.
But fast forward to this year, and suddenly, the tune has changed. For 2018, Darden Restaurants (NYSE: DRI ) has gained over 24%. And while DRI shares appear overextended at this level, I wouldn't be surprised if it eventually moves significantly higher.
As Bloomberg reported last month, consumers have splurged at restaurants across the country. In fact, we've witnessed a record spike in revenues at food establishments. Part of the reason is related to tax cuts as people are choosing to spend their extra funds on restaurants.
But I think a bigger component is the labor market. While not a perfect situation, those who have college education and in-demand skills are finding ample work. That's a boon for DRI, as it appears Americans are getting hungry again.
S&P 500 Stocks to Buy: Chevron (CVX)
Source: swong95765 via Flickr (Modified)
Wall Street is currently scrutinizing oil prices with a fine comb. Just recently, the White House announced plans to impose fresh tariffs worth $200 billion on Chinese goods. Of course, the implication is negative. Usually, when the number one and number two economies of the world clash, we all suffer.
But we also must consider a twist to this story: simultaneously, President Trump seeks to tighten Iran's oil exports to zero to bring them to the nuclear negotiating table. Since Iran is one of the world's biggest exporters, this factor should more than offset the China tariffs.
That's why investors should look into buying Chevron (NYSE: CVX ) during this market weakness. For one thing, I doubt the negative sentiment toward crude oil will continue. On another level, the vast majority of people drive fossil-fuel powered vehicles . Yes, electric vehicles are the future, but it will take some time for them to make a decisive impact.
7 Benchmark-Clobbering ETFs to Buy
For now, the Iran situation is the most pressing concern. Oil prices will likely trek higher throughout the rest of this year, meaning you'll want exposure to CVX stock.
S&P 500 Stocks to Buy: Harley-Davidson (HOG)
Source: Shutterstock
Among S&P 500 stocks, absolutely none is more American than Harley-Davidson (NYSE: HOG ). Indeed, Harley-Davidson is painfully American. They're big, brash and unapologetic, much like our people. Own a hog from HOG, and you have a piece of Old Glory sitting in your garage, just waiting to terrorize the neighborhood.
So it's a strange twist that Harley-Davidson, among all the S&P 500 companies, that has aroused President Trump's vitriol. HOG and Trump have bickered back and forth over the administration's hardline stance on tariffs and sanctions. In keeping with the times, Harley-Davidson's management wants to shift some operations overseas. Anachronistic Trump isn't having any of it.
Another problem impacting HOG stock are millennials. According to CNBC , young consumers that are steadily growing their income are avoiding motorcycles . And let's face facts: HOG hasn't performed well over the years.
Still, investors can salvage something here. Regarding millennials, analysts have previously made sweeping generalizations about this demographic, only to be proven wrong later. They could very well take up HOG riding when millennials eventually have - God forbid! - their mid-life crises.
Then there's the international expansion. Once the sanctioning boils over, or if Trump gets voted out, HOG will enjoy a clean slate. That would also give them opportunities to boost their presence overseas. It will require some patience, but Harley-Davidson has the ability to surprise.
S&P 500 Stocks to Buy: Facebook (FB)
Source: Shutterstock
This year, Facebook (NASDAQ: FB ) has turned from one of the most respected S&P 500 stocks to buy into one of the most demonized. Frankly, I don't understand the vitriol . FB may have inadvertently assisted the Trump campaign, but come on! The American electorate voted for Donald Trump, not Facebook.
This is why I view antagonism toward Facebook as a political distraction and witch hunt. The difference here, though, is that politics are hurting FB stock, which is a shame. For instance, several analysts have noted with concern that the company generated the slowest growth in daily active users ever.
But isn't this exactly what we should expect? FB has dominated the internet-connected world; they can't reproduce humans. Not only that, the fact that any kind of growth occurred necessarily means that social outrage against the company failed . In late July, I wrote the following:
"The most recent FB earnings report actually proved my argument. North American DAU stats were flat year-over-year, and virtually in line with consensus expectations. That tells me that the aforementioned fiasco that led to the #DeleteFacebook campaign ultimately did nothing.
Facebook is simply too ingrained in our society, and I would argue, too useful for us to give up. Not even Hollywood's self-righteousness and a trendy millennial's exaggerated self-importance could dent Facebook engagement stats."
3 Semiconductor Stocks to Buy for the Long Haul
The volatility makes no sense. I just look at it as an opportunity to buy FB stock on a discount.
S&P 500 Stocks to Buy: HP (HPQ)
Source: sports via Flickr
HP (NYSE: HPQ ) may appear as a strange choice for a stock to buy going into the Q3 earnings season. After all, as PC Magazine 's John C. Dvorak bluntly stated, " the traditional laptop is dead ." Dvorak asks a simple question: "When you look at PCMag's roundup of the best laptops , do you ever think to yourself, 'Wow, I want that now!' Never happens."
I'm actually a little bit surprised that Dvorak still has a job contributing articles for PC Magazine ! And while I respect his opinion in that laptops lack compelling innovations, I disagree with his ultimate conclusion. The laptop and the PC platforms face new competition, but they've proven extremely resilient.
This is one of the reasons why HPQ has performed well since getting booted from the Dow Jones index. While pundits deride traditional computer products, they're much more useful than gimmicky tablets. Plus, higher-end laptops provide the perfect balance between performance and portability.
Finally, to address Dvorak's point, I don't get excited about laptop innovations. That said, I don't get excited about smartphone or tablet innovations, either. At a certain point, a smart device is a smart device.
But one thing that laptop and PC specialists like HPQ advantages is consistent demand. While traditional computers aren't sexy, they get the job done quickly and efficiently. Thus, companies like HPQ aren't going away anytime soon.
S&P 500 Stocks to Buy: FedEx (FDX)
FedEx (NYSE: FDX ) is seemingly one of those S&P 500 stocks that faces an Amazon threat. Critical shipping partners at first, Amazon has made some noise about starting their own courier division. Understandably, the implications worry investors, but FDX is still a long-term buy.
We just need to consider that FedEx is an $81 billion enterprise. Rival UPS (NYSE: UPS ) is a $120 billion enterprise. While it's true that Amazon dwarfs both these stalwarts, even disruptive CEO Jeff Bezos must watch his expenditures. As he's busy taking over disparate industries, he must ensure that his investments make economic sense.
While Amazon can toy around with their various internal courier solutions, it shouldn't drastically impact FDX. The company, along with UPS, has a virtually impenetrable network. To duplicate that wouldn't make financial sense.
6 Monthly Dividend Stocks to Buy
Moreover, e-commerce sales represent a consistently increasing portion of total retail sales. Although Amazon dominates this sector, they're not the only players. With several brick-and-mortars incorporating their own online channels, I like FDX for longer-term, reliable growth despite its recent quarterly miss.
S&P 500 Stocks to Buy: Goodyear (GT)
Source: Mike Mozart via Flickr
Among the most-recognized S&P 500 stocks, Goodyear (NASDAQ: GT ) is one of the more contrarian opportunities. You can tell this simply by looking at its price chart. Year-to-date, GT shares are down nearly 25%.
My frequent readers probably expect me to say something like GT has stabilized over the last several weeks. You're right, and it has. Since the beginning of July, GT stock is up over 4%. Although that's nothing to write home about, it provides some reassurance as the company approaches its Q3 report.
Admittedly, the day-to-day movements for GT stock are difficult to determine. But I'm encouraged that since the five years or so following the Great Recession, Americans have driven noticeably more miles . I expect this trend to continue, especially because our labor market has improved for the educated and upwardly mobile.
Undoubtedly, GT is a risky play due to its prior weak performances. But broader trends suggest that this volatility is a profitable opportunity.
S&P 500 Stocks to Buy: Home Depot (HD)
Source: Shutterstock
A significant and tragic reason why Home Depot (NYSE: HD ) dominates the business news media is Hurricane Florence. The storm has already taken many lives, and intractably, several more families must undergo the rebuilding process. No matter how you cut it, HD revenues will experience a bump up.
Some might view that as an opportunity to profit off HD stock. But as I argued in a prior write-up for Home Depot, the trading benefits are inconclusive . In some cases, HD does rise immediately during major storms. But the data does suggest that particularly devastating storms tend to hurt HD in the nearer-term.
I don't recommend trading HD based on Florence. If anything, these are one-off occurrences that are difficult to gauge. But more importantly, Home Depot has a business that's largely immune to Amazon's intrusions.
10 Tech Dividend Stocks With Growth Potential
That's especially the case for storms and other emergency events. Customers are not going to comparison shop online for necessary supplies. And even in non-emergency situations, Home Depot provides unparalleled conveniences.
S&P 500 Stocks to Buy: Lockheed Martin (LMT)
Source: Shutterstock
Lockheed Martin (NYSE: LMT ) is one of the most renowned defense contractors among S&P 500 stocks. It's also having a surprisingly weak year. Despite a burst in bullish sentiment recently, LMT has gained only 7.3% YTD. For the record, this is just a hair under the S&P 500 index.
In my opinion, LMT is not getting the respect that it deserves. I understand that President Trump boasts consistently about allegedly thawing relations with North Korea. Earlier this year, Trump met North Korean dictator Kim Jong-un in an unprecedented summit .
While I respect the President for taking some kind of action, I'm also firm that I don't trust North Korea. Nor do I trust the maniacal "dear leader" Kim. Sorry, but not sorry.
How does this play into LMT stock? Simple: more than ever, we must demonstrate a show of force. This is physically best done through our advanced fighter jets. There's nothing quite like buzzing around our enemies' airspace, and letting them know we can physically do the business.
Admittedly, it's an immature tactic, but it works. LMT allows us to flex our muscle but still maintain diplomatic channels. In this complicated geopolitical environment, LMT is easily a longer-term buy.
S&P 500 Stocks to Buy: Raytheon (RTN)
Source: Shutterstock
Should a conflict ever escalate into a hot one, I'd like to own Raytheon (NYSE: RTN ) as a hedge. Known primarily for its smart missiles and guidance systems, RTN is one the most relevant defense contractors today.
Don't get me wrong: physical warcraft, as I mentioned for Lockheed Martin, is still a critical component of our military diplomacy. However, the modern battlefield has become increasingly asymmetric. A terrorist with a homemade explosive can wreak untold damage. Or a lone hacker could bring a powerful economy to its knees.
This transition also means that powerful militaries with extensive physical assets are vulnerable to asymmetric attacks. To alleviate this problem, RTN produces next-generation weapons systems, such as combat drones . Such technologies allow military operators to conduct operations in hard-to-reach, inhospitable terrain.
10 Best High-Growth Stocks for Young Investors
The other invaluable benefit is that it keeps our men and women in uniform out of harm's way. Especially in this ever-evolving world, having some exposure to RTN simply makes sense.
S&P 500 Stocks to Buy: Altria Group (MO)
Source: Peyri Herrera via Flickr (Modified)
Altria Group (NYSE: MO ) has simply not had a good year in 2018. Since the January opener, MO has shed 9.5% in the markets. The biggest concern for investors is that Americans are smoking far fewer cigarettes than ever.
The "good news," though, is that American smokers are gravitating toward e-cigarettes or vaporizers. These products heat the tobacco flavoring near the point of combustion, but not beyond it. The resultant plumes are much cleaner and have noticeably fewer chemical byproducts, such as carbon monoxide.
Of course, vaporizer companies compete with big tobacco, but the comparison isn't worth discussing. MO is a multibillion-dollar enterprise. As a whole, experts predict that the vaping market will hit $27 billion in value. Relative to Altria's market capitalization of nearly $118 billion, that's nothing.
Moreover, MO has invested significant resources into its heat-not-burn devices. Although similar in principle to vaporizers, Altria's products are made by smokers, for smokers. The experience is much more attuned to what natural-cigarette aficionados prefer .
So don't butt-out MO stock. This is an underappreciated contrarian opportunity.
As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities.
Compare Brokers
The post 15 Best S&P 500 Stocks to Buy as the Markets Heat Up appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slightly above parity. ABBV levers excellent profitability and growth metrics, highlights being its operating margins and double-digit revenue growth rate. | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slightly above parity. ABBV levers excellent profitability and growth metrics, highlights being its operating margins and double-digit revenue growth rate. | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slightly above parity. ABBV levers excellent profitability and growth metrics, highlights being its operating margins and double-digit revenue growth rate. | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slightly above parity. ABBV levers excellent profitability and growth metrics, highlights being its operating margins and double-digit revenue growth rate. |
25345.0 | 2018-09-18 00:00:00 UTC | Commit To Purchase AbbVie At $47.50, Earn 2.7% Using Options | ABBV | https://www.nasdaq.com/articles/commit-purchase-abbvie-4750-earn-27-using-options-2018-09-18 | nan | nan | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2020 put at the $47.50 strike, which has a bid at the time of this writing of $1.30. Collecting that bid as the premium represents a 2.7% return against the $47.50 commitment, or a 1.6% annualized rate of return (at Stock Options Channel we call this the YieldBoost ).
Selling a put does not give an investor access to ABBV's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $47.50 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless AbbVie Inc sees its shares decline 50.4% and the contract is exercised (resulting in a cost basis of $46.20 per share before broker commissions, subtracting the $1.30 from $47.50), the only upside to the put seller is from collecting that premium for the 1.6% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $47.50 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June 2020 put at the $47.50 strike for the 1.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for AbbVie Inc (considering the last 252 trading day closing values as well as today's price of $95.94) to be 32%. For other put options contract ideas at the various different available expirations, visit the ABBV Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Tuesday, the put volume among S&P 500 components was 1.29M contracts, with call volume at 1.29M, for a put:call ratio of 0.70 so far for the day, which is above normal compared to the long-term median put:call ratio of .65. In other words, if we look at the number of call buyers and then use the long-term median to project the number of put buyers we'd expect to see, we're actually seeing more put buyers than expected out there in options trading so far today. Find out which 15 call and put options traders are talking about today .
Top YieldBoost Puts of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $47.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June 2020 put at the $47.50 strike for the 1.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for AbbVie Inc (considering the last 252 trading day closing values as well as today's price of $95.94) to be 32%. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $47.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June 2020 put at the $47.50 strike for the 1.6% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for AbbVie Inc (considering the last 252 trading day closing values as well as today's price of $95.94) to be 32%. Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $47.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June 2020 put at the $47.50 strike for the 1.6% annualized rate of return represents good reward for the risks. Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABBV's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABBV's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $47.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the June 2020 put at the $47.50 strike for the 1.6% annualized rate of return represents good reward for the risks. |
25346.0 | 2018-09-18 00:00:00 UTC | 3 Top Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-09-18 | nan | nan | Healthcare stocks are handily outpacing the S&P 500 index so far in 2018. With the aging demographics in the U.S. and other major countries serving as a significant tailwind, it's possible that healthcare will remain a hot area for investors for decades to come.
We asked three Motley Fool contributors which healthcare stocks they especially like. Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . Here's why they think these are three healthcare stocks to buy right now.
Not as risky as it might seem
Keith Speights (AbbVie): I get why AbbVie might seem like a very risky stock. After all, the company depends on one drug -- Humira -- for roughly 62% of its total revenue. That drug faces biosimilar competition in Europe beginning in just a few weeks. And biosimilars are only four or so years away from hitting the U.S. market. But this big-pharma stock isn't nearly as risky as it might seem.
For one thing, Humira's revenue isn't going to disappear anytime soon. Market research firm EvaluatePharma projects that Humira will remain the world's top-selling drug at least through 2024 , with sales of $15.2 billion that year. While that's less than the amount Humira hauled in last year, it's still a lot of money.
More important, AbbVie claims several approved products that are already growing by leaps and bounds. Cancer drug Imbruvica and hepatitis C drug Mavyret are approaching $4 billion each in annualized sales. AbbVie thinks that Imbruvica will generate peak annual sales of around $7 billion within the next few years. Recently approved endometriosis drug Orilissa and leukemia drug Venclexta are also expected to become blockbusters.
Then there's AbbVie's pipeline, which EvaluatePharma ranks No. 2 in the biopharmaceutical industry . The most promising candidates in that pipeline are risankizumab and upadacitinib, immunology drugs that could take the baton from Humira.
AbbVie expects $35 billion in non-Humira revenue by 2025. The company made $28.2 billion last year with Humira in the mix. The stock is trading at less than 11 times expected earnings, making AbbVie one of the best healthcare picks around, in my view.
What parent wouldn't sacrifice for his or her children?
Chuck Saletta(Mednax): As more people are becoming covered by high-deductible health insurance plans , folks have to be choosy on where and how they spend their healthcare dollars. As the nation's largest supplier of maternal/fetal, newborn, and pediatric services, Mednax can receive a decent share of those dollars from parents who are willing to prioritize their kids' care over their own.
From an investor's perspective, Mednax's stock is trading near 5-year lows, despite being priced at a level that indicates there's a decent value in those shares. The company trades at around 11 times its anticipated earnings, and those earnings are expected to grow by nearly 15 percent annualized over the next five or so years.
In addition, as would be fitting for a company that focuses more on the services side of healthcare than the equipment side of it, Mednax has a solid balance sheet backing up its business. Its debt-to-equity ratio is around 0.6, and its current ratio is above 1.5, giving it the flexibility to manage through the ever-changing world of medical reimbursements. In addition, as a large physicians' group with a national footprint, it has bargaining power with insurance companies that many smaller providers lack.
Healthy businesses with decent prospects in crucial industries don't generally trade at bargain prices for very long. As a result, if you believe parents will continue to prioritize their children's needs even as they switch to high-deductible insurance plans, now is a great time to consider investing in Mednax.
A winning formula
Brian Feroldi (Xencor): I'm a big believer in the investing maxim "winners tend to keep on winning." When I look for healthcare stocks to buy, I like to see that the company already has a history of creating shareholder value. One small-cap biotech that has certainly been a winner for investors is Xencor . The company's stock is up more than 400% since its IPO in late 2013, which is a return that absolutely crushes the overall market.
With a market cap of just $2.7 billion, you might assume that Xencor's success is being driven by a single drug. I'm happy to report that is not the case at all. Xencor actually boasts 12 drugs in various stages of clinical development and another handful that are about to enter the clinic. The company's two most advanced programs are currently in stage 3 development and are partnered programs that are being co-developed with Alexion Pharmaceuticals and MorphoSys .
The reason Xencor boasts such a large pipeline even though it's still quite small in absolute terms is because of its innovative XmAb engineering platform. This technology enables Xencor to make minute changes to the structure of antibodies in order to alter their properties for the better. That enables the company to quickly churn out drugs that are more potent, more stable, or longer lasting.
What's exciting about the XmAb engineering platform is that it can be applied to almost any antibody, so it can be used to treat a huge variety of diseases. For example, the company's compounds are already in development to treat HIV, blood cancers, asthma, and more.
Another exciting development is that Xencor's technology has already caught the eyes of big pharma. For example, Novartis recently cut Xencor a check for $150 million to gain international commercial rights to two of Xencor's drugs and to co-develop new products. The deal could net Xencor up to $2.4 billion in total milestone payments plus double-digit royalties on any sales if everything goes according to plan. Those are huge numbers for a business that is currently worth less than $3 billion.
Overall, Xencor's technology looks like it is the real deal, and I believe that it has created a winning formula for investors. That makes it a great stock for healthcare investors to get to know.
10 stocks we like better than Xencor
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Xencor wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Brian Feroldi has no position in any of the stocks mentioned. Chuck Saletta has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky stock. More important, AbbVie claims several approved products that are already growing by leaps and bounds. | Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . The stock is trading at less than 11 times expected earnings, making AbbVie one of the best healthcare picks around, in my view. Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky stock. | The stock is trading at less than 11 times expected earnings, making AbbVie one of the best healthcare picks around, in my view. Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky stock. | The stock is trading at less than 11 times expected earnings, making AbbVie one of the best healthcare picks around, in my view. Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky stock. |
25347.0 | 2018-09-17 00:00:00 UTC | The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-jpmorgan-mastercard-abbvie-cvs-health-and-estee-lauder | nan | nan | For Immediate Release
Chicago, IL - September 17, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday's Analyst Blog:
Top Stock Reports for JPMorgan, Mastercard and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Mastercard and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked JPMorgan 's shares have outperformed the Zacks Major Regional Banks industry over the past three months (+5.2% vs. +1.5%). Also, the company has an impressive earnings surprise history, having surpassed expectations in each of the trailing four quarters.
The Zacks analyst thinks expansion into new markets, focus on strengthening the card business, higher interest rates and rising loan demand will benefit the bank's financials. While dismal mortgage banking performance (as originations continue to decline) remains a major concern, lower tax rates and easing of stringent regulations are expected to offer some support. Also, the company's enhanced capital deployment plans reflect strong balance sheet.
(You can read the full research report on JPMorgan here >>> ).
Shares of Mastercard have increased +53.4% over the past year, significantly outperforming the Zacks Financial Transaction Services industry's rally of +36.1%. The Zacks analyst thinks the company is poised for growth, given its solid market position, ongoing expansion and digital initiatives plus significant opportunities from the secular shift toward electronic payments.
The buyouts of VocaLink and NuData Security complement efforts to participate in new payment flows, and enhance safety and security offerings. The company has seen the Zacks Consensus Estimate for 2018 and 2019 earnings being revised upward over the last 30 days. However, escalating costs, higher incentives and rewards will put pressure on its bottom line.
(You can read the full research report on Mastercard here >>> ).
AbbVie 's shares have lost -0.4% year to date, underperforming the Zacks Large Cap Pharmaceuticals industry's rally of +6.6%. The Zacks analyst thinks AbbVie's key drug, Humira has been performing well based on strong demand trends, despite new competition.
Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Mavyret's launch has also been stronger than expected. Mavyret has become a major growth driver for AbbVie in a short time on the market.
AbbVie has an impressive late-stage pipeline with launch of several products with multibillion-dollar potential expected in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. Potential biosimilar competition to Humira in Europe this year is an overhang.
(You can read the full research report on AbbVie here >>> ).
Other noteworthy reports we are featuring today include CVS Health and Estee Lauder.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JPMorgan Chase & Co. (JPM): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
The Estee Lauder Companies Inc. (EL): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
Mastercard Incorporated (MA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL . Here are highlights from Thursday's Analyst Blog: Top Stock Reports for JPMorgan, Mastercard and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Mastercard and AbbVie. | Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL . Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Mastercard and AbbVie. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report The Estee Lauder Companies Inc. (EL): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report Mastercard Incorporated (MA): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Thursday's Analyst Blog: Top Stock Reports for JPMorgan, Mastercard and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report The Estee Lauder Companies Inc. (EL): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report Mastercard Incorporated (MA): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL . | Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Mastercard and AbbVie. Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL . Here are highlights from Thursday's Analyst Blog: Top Stock Reports for JPMorgan, Mastercard and AbbVie The Zacks Research Daily presents the best research output of our analyst team. |
25348.0 | 2018-09-17 00:00:00 UTC | Pfizer's Skin Disease Candidates Positive in Mid-Stage Study | ABBV | https://www.nasdaq.com/articles/pfizers-skin-disease-candidates-positive-in-mid-stage-study-2018-09-17 | nan | nan | Pfizer Inc.PFE announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata ("AA").
Both the candidates met the primary endpoint of improving hair regrowth on the scalp compared to baseline over 24 weeks of treatment. Data from the study was presented at the European Academy of Dermatology and Venereology Congress, which was held in France.
The FDA granted Breakthrough Therapy designation to PF-06651600 based on these data earlier this month.
Pfizer's stock has outperformed the industry this year so far. Pfizer's shares have risen 18.6% compared with the industry 's increase of 6%.
Alopecia areata is an autoimmune dermatologic condition, which results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients.
Pfizer will advance PF-06651600 in phase III stage based on the data. The company is also developing PF-06651600 for rheumatoid arthritis, Crohn's disease ("CD") and ulcerative colitis ("UC"), and PF-06700841 for psoriasis, CD and UC.
Aclaris Therapeutics Inc. (ACRS) is also developing its JAK inhibitor, ATI-502, for treating AA. The company announced positive data from a mid-stage study in July.
Apart from these JAK inhibitors, Pfizer has a strong pipeline and anticipates 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. The company's pipeline candidate, dacomitinib, is under review for first-line treatment of non-small cell lung cancer. A decision is expected by the end of this month.
Pfizer also boasts a strong biosimilars pipeline. Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. A biosimilar version of Roche's Herceptin is under review in the United States and was approved in the EU in July. The company already markets biosimilar version of Merck/J&J's JNJ Remicade.
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Best Electric Car Stock? You'll Never Guess It
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Both the candidates met the primary endpoint of improving hair regrowth on the scalp compared to baseline over 24 weeks of treatment. | Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc. Price Pfizer Inc. Price | Pfizer Inc. Quote Zacks Rank Pfizer currently carries a Zacks Rank #3 (Hold). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Pfizer Inc.PFE announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata ("AA"). | Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc. Price Pfizer Inc. Price | Pfizer Inc. Quote Zacks Rank Pfizer currently carries a Zacks Rank #3 (Hold). |
25349.0 | 2018-09-17 00:00:00 UTC | Why Gilead Stock Is a Sleepy Giant Waiting to Break Out | ABBV | https://www.nasdaq.com/articles/why-gilead-stock-sleepy-giant-waiting-break-out-2018-09-17 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Gilead Sciences (NASDAQ: GILD ) stock is stuck in a range and for good reason. The markets cannot decide if its quarterly revenue declines are permanent or if the company's growth is reaccelerating again. Yet if investors hold Gilead stock and collect its 3% dividend yield, they will get an even bigger reward if two things happen.
Specifically, if drugs in the company's pipeline come to market, causing the company's sales growth to accelerate, and its new launches meaningfully improve its results sooner than expected, GILD stock price could reach its old highs. There are indications that this scenario could indeed play out.
Gilead recently launched Biktarvy, an HIV treatment, after the FDA approved it in February . The once-daily single tablet has demonstrated that it provides a complete regimen for treating HIV-1 infection in those with no history of taking an antiretroviral treatment. In two Phase 3 studies, the drug met its primary objective of non-inferiority at 48 weeks. None of the participants became resistant to the drug, and none of the patients had to discontinue treatment due to renal adverse events.
Despite the success Gilead has had with making drugs for HIV patients, the company is still looking for ways to reduce the side effects caused by its anti-HIV drugs. Even though HIV patients have many treatment options, some are still resistant to or don't respond to Biktarvy. For these 40,000 to 50,000 patients, the company is developing alternative treatments. One option is using its new nucleotide 9131 along with a next-generation protease inhibitor.
6 Monthly Dividend Stocks to Buy
Minimal Impact on Gilead Stock From Generic Drugs
A class of Gilead's HIV drug treatments are still protected by patents. Even though more generic HIV treatments are coming to market, like AZT and 3TC, Gilead faces minimal competition in this area. But it continues to innovate in this space in order to stay ahead.
Rheumatoid Arthritis Treatment Looks Promising
Gilead's Filgotinib drug, which treats patients who have rheumatoid arthritis and previously failed to respond to or were intolerant of biologic agents, met the primary endpoints of a Phase 3 study, Gilead recently reported. The study evaluated Filgotinib, a JAK1 inhibitor, in adult subjects. Compared to the placebo, a statistically significant proportion of the patients' rheumatoid arthritis symptoms improved at least 20%. The positive results suggest that the company has a blockbuster product in the making. More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. (However, there are no trials that directly compare the two drugs.) Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product.
Collaborating on the Development of a Hepatitis B Treatment
On September 12, Gilead announced it would collaborate with Precision BioSciences , a privately-held company, to develop a cure for Hepatitis B, or HBV. Precision has a gene-editing platform called ARCUS. The technology uses a synthetic enzyme, called an ARC nuclease, to recognize and target a DNA sequence.
With 257 million people living with an HBV infection, the companies want to cure the disease by targeting HBV's covalently closed circular DNA. Currently, HBV treatments suppress HBV's viral replication but do not get rid of the virus. According to the agreement, Precision will develop, formulate and clinically evaluate the nucleases, while Gilead will develop the clinical aspect of the technology and will commercialize potential therapies. Under the deal, Precision can obtain up to $445 million in milestone payments.
The Valuation of Gilead Stock
Of the 12 analysts covering Gilead stock, ten have "buy" ratings on GILD stock and two have "hold" ratings on GILD stock. Analysts'average price target suggests that GILD stock price will rise 20%, according to Tipranks .
The Bottom Line on GILD Stock
Even though the days of making easy money from holding Gilead stock is gone, the company is not out. It is in a development phase, and holding GILD stock will pay off for longer term investors.
As of this writing, the author did not hold shares of any of the companies mentioned.
More From InvestorPlace
6 Monthly Dividend Stocks to Buy
5 Reasons to Consider Selling Your Apple Stock
5 5G Stocks to Buy That Will Stream Higher Profits for Investors
3 Tech Stocks With More Bite Than FANG
Compare Brokers
The post Why Gilead Stock Is a Sleepy Giant Waiting to Break Out appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. Yet if investors hold Gilead stock and collect its 3% dividend yield, they will get an even bigger reward if two things happen. | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. 6 Monthly Dividend Stocks to Buy Minimal Impact on Gilead Stock From Generic Drugs A class of Gilead's HIV drug treatments are still protected by patents. | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. 6 Monthly Dividend Stocks to Buy Minimal Impact on Gilead Stock From Generic Drugs A class of Gilead's HIV drug treatments are still protected by patents. | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. Even though HIV patients have many treatment options, some are still resistant to or don't respond to Biktarvy. |
25350.0 | 2018-09-16 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 9/16/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-9162018-2018-09-16 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FRESENIUS MEDICAL CARE AG & CO. (ADR) ( FMS ) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company's segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment. The Company develops and manufactures a range of dialysis machines, systems and disposable products. As of December 31, 2016, the Company sold its products to customers in more than 120 countries and also used in its internal healthcare service operations. The Company's Care Coordination services include coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services, ambulatory surgery center services and urgent care services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
UNIVERSAL HEALTH SERVICES, INC. ( UHS ) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Universal Health Services, Inc. is a holding company. The Company's principal business is owning and operating, through its subsidiaries, acute care hospitals and outpatient facilities, and behavioral healthcare facilities. The Company's segments include Acute Care Hospital Services, Behavioral Health Services and Other. As of August 1, 2018, the Company owned and/or operated more than 326 inpatient facilities, and 32 outpatient and other facilities, located in 37 states, Washington, District of Columbia, the United Kingdom, Puerto Rico and the United States Virgin Islands. The Company's hospitals provide a range of services, such as oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. As of February 28, 2017, its acute care facilities located in the United States included 26 inpatient acute care hospitals; four free-standing emergency departments, and four outpatient surgery/cancer care centers and one surgical hospital.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
HCA HEALTHCARE INC ( HCA ) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 79% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: HCA Healthcare, Inc., formerly HCA Holdings, Inc., is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia. As of December 31, 2016, the American Group included 80 hospitals, which were located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. As of December 31, 2016, the Company operated six hospitals in England. The Company owns, manages or operates hospitals, freestanding surgery centers and freestanding emergency care facilities, walk-in clinics, diagnostic and imaging centers, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ACADIA HEALTHCARE COMPANY INC ( ACHC ) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 62% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. The Company focuses on acquiring and developing behavioral healthcare facilities. The Company operates through two segments: U.S. Facilities and U.K. Facilities. The Company is engaged in operating acute inpatient psychiatric facilities, specialty treatment facilities, residential treatment centers and facilities providing outpatient behavioral healthcare services. As of December 31, 2016, the U.S. Facilities segment included 208 behavioral healthcare facilities with approximately 8,500 beds in 39 states and Puerto Rico, and the U.K. Facilities segment included 365 behavioral healthcare facilities with approximately 8,600 beds in the United Kingdom. As of December 31, 2016, the Company had operated 573 behavioral healthcare facilities with approximately 17,100 beds in 39 states, the United Kingdom and Puerto Rico.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on John Neff has returned 154.66% vs. 161.26% for the S&P 500. For more details on this strategy, click here
About John Neff : While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea : Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. For a full detailed analysis using NASDAQ's Guru Analysis tool, click here UNIVERSAL HEALTH SERVICES, INC. ( UHS ) is a large-cap growth stock in the Healthcare Facilities industry. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's Care Coordination services include coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services, ambulatory surgery center services and urgent care services. | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and the United Kingdom. |
25351.0 | 2018-09-14 00:00:00 UTC | Pharma/Biotech Stocks to Watch This Prostate Cancer Month | ABBV | https://www.nasdaq.com/articles/pharma-biotech-stocks-to-watch-this-prostate-cancer-month-2018-09-14 | nan | nan | September is observed as National Prostate Cancer Month to raise awareness about the disease, which is the leading cause of death in men, second only to skin cancer in the United States. A light blue ribbon is used as a symbol to raise awareness about prostate cancer.
About the Disease
Prostate cancer is a very complex disease with several subtypes. It is a slow growing disease which occurs due to development of abnormal cells in the prostate gland. Sometimes, these abnormal cells grow uncontrollably and spread to other parts of the body.
Some of the subtypes can be fatal and severely impact patients' life ultimately leading to death. However, an early diagnosis can delay the risk of death by almost five years. The risk of the disease increases with age.
The American Cancer Society estimates that approximately 164,690 patients will be newly diagnosed with prostate cancer in 2018. The cancer is also expected to cause death of more than 29,000 patients this year.
Available Treatments
Prostate cancer is mostly diagnosed early and progresses slowly, which makes treatment decisions easier for patients. Early-stage or locally-advanced prostate cancer can be treated with surgery, radiation therapy and systemic treatments.
Systemic treatments include androgen deprivation therapy ("ADT") and chemotherapies. The most common chemotherapies include docetaxel and Sanofi's SNY Jevtana (cabazitaxel). Androgen deprivation therapy includes AstraZeneca's AZN Casodex and Tolmar Pharmaceuticals' Eligard.
However, in advanced cases of prostate cancer wherein the disease has spread to other parts of the body, surgery and radiation therapies are not suitable and less effective. Docetaxel along with ADT and Jevtana in combination with prednisone are used as treatment options for metastatic prostate cancer.
A few large pharma companies and biotechs have developed improved therapies and are exploring different treatment options. Here is a look at some of the drugs with new mechanism of action available or under development in the prostate cancer market.
Johnson & Johnson JNJ
J&J's prostate cancer drugs, Zytiga and Erleada work by controlling hormones that produce androgen, which helps the cancer to spread and grow. Zytiga is a blockbuster drug with sales of more than $1.5 billion in the first half of 2018. In February, Erleada was approved and Zytiga's label expansion in first-line setting received FDA nod.
The company is also supporting/funding development of TESARO's TSRO PARP inhibitor, Zejula, as a new treatment option for prostate cancer.
J&J currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
PfizerPFE
The company in collaboration with Astellas Pharma is commercializing Xtandi for prostate cancer and developing the drug for newer settings and subtypes. Pfizer recorded alliance revenues of $330 million from Xtandi sales in the first half of 2018, up 21.3% year over year.
In July, the drug's label was expanded in the United States to include non-metastatic castration-resistant prostate cancer patient population. A regulatory application for a similar indication is under review in EU.
Pfizer also carries a Zacks Rank #3.
AbbVie ABBV provides a palliative treatment for advanced prostate cancer, Lupron.
Some biotechs are developing new technologies as a treatment option for advanced prostate cancer.
Endocyte, Inc. ECYT is developing its prostate cancer candidate, 177 Lu-PSMA-617, in a phase III study initiated in the second quarter of 2018. The candidate is a radionuclide therapy, an emerging technology, which targets cancerous cells. Privately-held Dendreon Pharmaceuticals has developed a personalized immunotherapy, Provenge, for treating the cancer.
Conclusion
Strong numbers for the marketed drugs show steady demand for prostate cancer treatments. Successful development of new therapies and label expansion of approved drugs will help more patients and also drive sales of the drugs, thereby boosting the top line of the companies.
However, none of the available treatments can completely cure prostate cancer and have side effects. These treatments only delay the progression of the disease. Researchers are continually exploring and developing new treatments that may help completely cure the disease in the future.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Endocyte, Inc. (ECYT): Free Stock Analysis Report
TESARO, Inc. (TSRO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ABBV provides a palliative treatment for advanced prostate cancer, Lupron. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. However, in advanced cases of prostate cancer wherein the disease has spread to other parts of the body, surgery and radiation therapies are not suitable and less effective. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV provides a palliative treatment for advanced prostate cancer, Lupron. Systemic treatments include androgen deprivation therapy ("ADT") and chemotherapies. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV provides a palliative treatment for advanced prostate cancer, Lupron. Available Treatments Prostate cancer is mostly diagnosed early and progresses slowly, which makes treatment decisions easier for patients. | AbbVie ABBV provides a palliative treatment for advanced prostate cancer, Lupron. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. About the Disease Prostate cancer is a very complex disease with several subtypes. |
25352.0 | 2018-09-14 00:00:00 UTC | Noteworthy ETF Outflows: MTUM, ABBV, ISRG, SPGI | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows-mtum-abbv-isrg-spgi-2018-09-14 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $130.0 million dollar outflow -- that's a 1.3% decrease week over week (from 87,950,000 to 86,850,000). Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average:
Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.74 as the 52 week high point - that compares with a last trade of $118.60. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.74 as the 52 week high point - that compares with a last trade of $118.60. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.74 as the 52 week high point - that compares with a last trade of $118.60. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $130.0 million dollar outflow -- that's a 1.3% decrease week over week (from 87,950,000 to 86,850,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.74 as the 52 week high point - that compares with a last trade of $118.60. | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.74 as the 52 week high point - that compares with a last trade of $118.60. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
25353.0 | 2018-09-14 00:00:00 UTC | A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis | ABBV | https://www.nasdaq.com/articles/brawl-brewing-between-abbvie-and-gilead-sciences-arthritis-2018-09-14 | nan | nan | There are more than 23 million people worldwide with rheumatoid arthritis, and despite current treatments, many patients fail to achieve disease remission or significant reductions in disease activity. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line. Are these stocks about to battle for billions of dollars in market share?
The rheumatoid arthritis market today
Currently, most rheumatoid arthritis patients begin treatment on nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, before progressing to disease-modifying antirheumatic drugs (DMARDs), including methotrexate.
NSAIDs attempt to reduce joint-damaging inflammation by blocking production of cyclooxygenase (COX), an enzyme that produces prostaglandins that promote inflammation. DMARDs also attempt to reduce inflammation, but they block cytokines, proteins that help control cell growth and immune responses.
When treatment with traditional DMARDs is inadequate, patients may progress to the use of biologics that block tumor necrosis factor (TNF), an inflammation-causing protein that can be overproduced in rheumatoid arthritis patients. AbbVie's $18 billion-per-year Humira is one of the most widely known of these anti-TNF biologics.
NSAIDs and traditional DMARDs can cause stomach problems, and traditional DMARDs can also cause liver problems and increase risk of infection. Similarly, anti-TNF medications increase patients' risk of infection, including tuberculosis. Anti-TNFs shouldn't be used in patients with heart failure or multiple sclerosis because of increased risks, and while it's rare, anti-TNF patients could be at an increased risk of developing cancer, including lymphoma.
In the U.S., there are about 1.5 million people with rheumatoid arthritis, and because rheumatoid arthritis medications (particularly anti-TNFs) are pricey, spending on rheumatoid arthritis eclipses $19 billion.
An emerging treatment approach
Many rheumatoid arthritis patients don't respond adequately to existing treatments, so drugmakers have been developing drugs that are increasingly specific in targeting enzymes involved in immune response.
Inhibiting the Janus kinases (JAK) family of signaling molecules is one of the most intriguing of these next-generation approaches. Pfizer (NYSE: PFE) became the first company to win FDA approval of a JAK inhibitor for rheumatoid arthritis when Xeljanz got the green light in 2012. Xeljanz, which interacts with three of the four JAKs (JAK-1, JAK-2, and JAK-3), won a regulatory OK after demonstrating it elicited better responses in patients uncontrolled by DMARDs.
Because of its efficacy, Xeljanz has become a blockbuster with annualized sales of $1.8 billion. However, Xeljanz's safety profile is arguably like that of DMARDs and anti-TNFs: it can cause infections, and it may increase the risk of herpes zoster relative to other DMARDs.
Since targeting JAK is effective, but there's still room for improvement in safety, AbbVie and Gilead Sciences are each advancing new drugs that target JAK more selectively.
An emerging battle over market share
Both AbbVie's upadacitinib and Gilead Sciences' filgotinib, which it licensed from Galapagos NV (NASDAQ: GLPG) , selectively target JAK-1, but upadacitinib is closer to the FDA finish line. Results from upadacitinib's phase 3 rheumatoid arthritis trials have already been reported, and AbbVie anticipates filing for an FDA OK before the end of 2018.
Although filgotinib is trailing upadacitinib in the race to commercialization, Gilead Sciences unveiled results from the first of three phase 3 trials earlier this week, and based upon the data, filgotinib appears to match up well against upadacitinib.
In a phase 3 trial evaluating upadacitinib in patients inadequately treated by DMARDs, 65% and 56% of patients receiving 15 mg or 30 mg of upadacitinib once daily, respectively, achieved a 20% improvement on the American College of Rheumatology (ACR20) scoring system. Also, 34% and 36% achieved a 50% improvement (ACR50) and 12% and 23% of patients achieved a 70% improvement (ACR70) on those doses, respectively. In another phase 3 DMARD nonresponder study, ACR20, ACR50, and ACR70 on the 15mg and 30mg doses were 64%/38%/21% and 66%/43%/15% at 12 weeks, respectively.
Filgotinib's first phase 3 study in a similar DMARD population was similarly strong. A 200 mg dose of filgotinib once daily resulted in ACR20 in 66% of patients, ACR50 in 42.9% of patients, and ACR70 in 21.8% of patients.
Who will win?
It's bad science to compare results from separate trials. However, evidence suggests so far that both filgotinib and upadacitinib are effective. Results from two more filgotinib phase 3 studies in slightly different patient populations are expected early next year, so investors will want to keep an eye out for that data.
Assuming filgotinib's remaining two rheumatoid arthritis studies are positive, safety could determine which of these two drugs ends up more widely used.
Based on data from phase 2 trials separately presented at the American College of Rheumatology conference in 2017, filgotinib might have an edge. The rate of serious infection for upadacitinib and filgotinib patients was 2.3% and 1.5%, respectively, and the rates of herpes zoster, deep vein thrombosis, and pulmonary embolism were lower for filgotinib too.
It remains to be seen if these drugs secure FDA OKs and, if they do, how doctors will interpret consolidated phase 3 efficacy and safety trial data. The rheumatoid arthritis market is expected to increase to $30 billion in 2027, so there's enough room for multiple players. If these drugs are determined to be more effective and safer than other DMARDs and anti-TNF therapy, then both drugs could become blockbuster arthritis treatments, making patients the biggest winners from this advance in treatment.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Todd Campbell owns shares of Gilead Sciences and Pfizer. His clients may have positions in the companies mentioned.
The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Results from upadacitinib's phase 3 rheumatoid arthritis trials have already been reported, and AbbVie anticipates filing for an FDA OK before the end of 2018. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line. AbbVie's $18 billion-per-year Humira is one of the most widely known of these anti-TNF biologics. | Since targeting JAK is effective, but there's still room for improvement in safety, AbbVie and Gilead Sciences are each advancing new drugs that target JAK more selectively. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line. AbbVie's $18 billion-per-year Humira is one of the most widely known of these anti-TNF biologics. | The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line. AbbVie's $18 billion-per-year Humira is one of the most widely known of these anti-TNF biologics. Since targeting JAK is effective, but there's still room for improvement in safety, AbbVie and Gilead Sciences are each advancing new drugs that target JAK more selectively. | Since targeting JAK is effective, but there's still room for improvement in safety, AbbVie and Gilead Sciences are each advancing new drugs that target JAK more selectively. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line. AbbVie's $18 billion-per-year Humira is one of the most widely known of these anti-TNF biologics. |
25354.0 | 2018-09-14 00:00:00 UTC | Roche's Child Arthritis Drug's New Formulation Gets FDA Nod | ABBV | https://www.nasdaq.com/articles/roches-child-arthritis-drugs-new-formulation-gets-fda-nod-2018-09-14 | nan | nan | Roche Holding AG'sRHHBY subsidiary, Genentech announced that the FDA has approved a label expansion for its arthritis drug, Actemra. The FDA approved a subcutaneous (SC) formulation - a prefilled syringe that can be injected at home -of Actemra for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years or older.
Shares of the company have lost 2.0% year to date compared with the industry 's growth of 6.6%.
We note that Actemra is already approved for SJIA in an intravenous formulation. It is also approved for several other arthritis indications in adults as well as children. SJIA is the rarest form of juvenile idiopathic arthritis (JIA) with limited treatment options. With the latest approval, juvenile patients have the flexibility to take Actemra at home.
The approval is supported by data from the JIGSAW-117 study, conducted to determine the appropriate dosing regimen of Actemra SC. The study enrolled 51 patients aged one to 17 years with SJIA and previous inadequate response or intolerance to NSAIDs, and corticosteroids who were either Actemra naive or were receiving Actemra IV with adequate disease control. The safety observed for Actemra SC was consistent with the known safety profile of Actemra IV, with the exception of injection site reactions (ISRs).
Sales of Actemra increased 13% year over year in the first half of 2018. A label expansion of the drug should boost sales, further.
Actemra is also marketed for another form of JIA, which is polyarticular juvenile idiopathic arthritis (PJIA). Other drugs marketed for this indication are Abbvie Inc.'s ABBV Humira and Bristol-Myers Squibb Company's BMY Orencia.
Roche Holding AG Price
Roche Holding AG Price | Roche Holding AG Quote
Zacks Rank & Other Stock to Consider
Roche is a Zacks Rank #2 (Buy) stock.
Another similar-ranked stock in the same space is Eli Lilly and Company LLY . You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Lilly's earnings per share estimates have increased from $5.16 to $5.47 for 2018 and from $5.53 to $5.73 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all of the trailing four quarters with an average beat of 10.15%. The stock has rallied 22.7% in the past three months.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other drugs marketed for this indication are Abbvie Inc.'s ABBV Humira and Bristol-Myers Squibb Company's BMY Orencia. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holding AG'sRHHBY subsidiary, Genentech announced that the FDA has approved a label expansion for its arthritis drug, Actemra. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. Other drugs marketed for this indication are Abbvie Inc.'s ABBV Humira and Bristol-Myers Squibb Company's BMY Orencia. The FDA approved a subcutaneous (SC) formulation - a prefilled syringe that can be injected at home -of Actemra for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years or older. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. Other drugs marketed for this indication are Abbvie Inc.'s ABBV Humira and Bristol-Myers Squibb Company's BMY Orencia. The FDA approved a subcutaneous (SC) formulation - a prefilled syringe that can be injected at home -of Actemra for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years or older. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. Other drugs marketed for this indication are Abbvie Inc.'s ABBV Humira and Bristol-Myers Squibb Company's BMY Orencia. The FDA approved a subcutaneous (SC) formulation - a prefilled syringe that can be injected at home -of Actemra for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years or older. |
25355.0 | 2018-09-13 00:00:00 UTC | Should Value Investors Consider AbbVie (ABBV) Stock Now? | ABBV | https://www.nasdaq.com/articles/should-value-investors-consider-abbvie-abbv-stock-now-2018-09-13 | nan | nan | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock's current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, AbbVie has a trailing twelve months PE ratio of 13.8, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.0. If we focus on the long-term PE trend, AbbVie's current PE level puts it below its midpoint over the past five years. Moreover, the current level is fairly below the highs for this stock, suggesting it might be a good entry point.
Further, the stock's PE also compares favorably with the industry's trailing twelve months PE ratio, which stands at 15.7. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that AbbVie has a forward PE ratio (price relative to this year's earnings) of just 11.9, so it is fair to say that a slightly more value-oriented path may be ahead for AbbVie stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock's price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, AbbVie has a P/S ratio of about 4.7. This is higher than the S&P 500 average, which comes in at 3.5 right now. However, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
As we can see, the stock is trading near its median value for the time period from a P/S metric. This does not provide us with a conclusive direction as to the relative valuation of the stock in comparison to its historical trend.
Broad Value Outlook
In aggregate, AbbVie currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. This makes AbbVie a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for AbbVie is 0.9, a level that is lower than the industry average of 2.0. The PEG ratio is a modified PE ratio that takes into account the stock's earnings growth rate. Clearly, ABBV is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though AbbVie might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of B and a Momentum score of D. This gives ABBV a Zacks VGM score-or its overarching fundamental grade-of B. (You can read more about the Zacks Style Scores here >> )
Meanwhile, the company's recent earnings estimates have been encouraging. The current quarter has seen five estimates go higher in the past sixty days compared to one lower, while the full year estimate has seen nine upward and one downward revision in the same time period.
As a result, the current quarter consensus estimate has risen by 1% in the past two months, while the full year estimate has inched up by 0.8%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
AbbVie Inc. Price and Consensus
AbbVie Inc. Price and Consensus | AbbVie Inc. Quote
Even though AbbVie has a better estimates trend, the stock has just a Zacks Rank #3 (Hold). That is why we are looking for in-line performance from the company in the near term.
Bottom Line
AbbVie is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Furthermore, a robust industry rank (among the Top 20%) should boost investor confidence.
However over the past two years, the industry has underperformed the broader market, as you can see below:
Despite the poor past performance of the industry, a good industry rank signals that the stock is likely to benefit from favorable broader factors in the immediate future. Add to this the positive estimate revisions and robust value metrics, and we believe that we have a strong value contender in AbbVie.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Broad Value Outlook In aggregate, AbbVie currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. In particular, it is worth noting that the company has a Growth grade of B and a Momentum score of D. This gives ABBV a Zacks VGM score-or its overarching fundamental grade-of B. Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. | If we focus on the long-term PE trend, AbbVie's current PE level puts it below its midpoint over the past five years. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Even though AbbVie has a better estimates trend, the stock has just a Zacks Rank #3 (Hold). Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Even though AbbVie has a better estimates trend, the stock has just a Zacks Rank #3 (Hold). On this front, AbbVie has a trailing twelve months PE ratio of 13.8, as you can see in the chart below: This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.0. | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. On this front, AbbVie has a trailing twelve months PE ratio of 13.8, as you can see in the chart below: This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.0. If we focus on the long-term PE trend, AbbVie's current PE level puts it below its midpoint over the past five years. |
25356.0 | 2018-09-12 00:00:00 UTC | AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia | ABBV | https://www.nasdaq.com/articles/abbvie-gets-fda-nod-for-venclexta-label-expansion-in-leukemia-2018-09-12 | nan | nan | AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study.
In case of MRD-negativity, chronic lymphocytic leukemia ("CLL") cells fall below the ratio of 1:10000 lymphocytes in the blood or bone marrow of patients, making the disease undetectable during normal diagnosis.
The study evaluated the combination regimen in relapse/refractory CLL patients who have received at least one prior therapy compared to Teva Pharmaceutical's TEVA Treanda (bendamustine) plus Rituxan.
Data from the study showed that more than half of patients (53%) in Venclexta+Rituxan -arm achieved MRD-negativity (undetectable disease) compared to 12% of the patients in Treanda-arm. The MRD-negativity was achieved after approximately nine months on Venclexta+Rituxan therapy.
Notably, in June, the combination therapy was granted approval for the treatment of patients with relapsed/refractory CLL or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. The approval was based on lower risk of disease progression and better overall response rate data compared to Treanda combination in the MURANO study.
Venclexta in combination with Rituxan is the first chemotherapy-free combination therapy, which has shown a fixed treatment duration for previously-treated CLL patients in clinical study. Treatment can be stopped after a duration of approximately two years.
AbbVie's shares have lost 3.7% this year so far against the industry 's gain of 4.7%.
The company states that MRD-negativity is becoming an increasingly important criteria in the treatment of rare blood cancer, CLL, in previously-treated patients. Thus, addition of this data to the drug's label may help physicians to prescribe it to a larger patient base. Per the press release, 20,000 new patients are diagnosed with CLL every year in the United States.
Also, in July, AbbVie filed a regulatory application in the United States for Venclexta in acute myeloid leukemia ("AML") while a phase III program in multiple myeloma is also progressing well.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank & Stock to Consider
AbbVie currently carries a Zacks Rank #3 (Hold). A better-ranked large-cap pharma stock is Eli Lilly & Company LLY , with a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Lilly's earnings estimates increased 6% for 2018 and 3.6% for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with an average beat of 10.15%. Shares of Lilly have gained 25.1% this year so far.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study. Also, in July, AbbVie filed a regulatory application in the United States for Venclexta in acute myeloid leukemia ("AML") while a phase III program in multiple myeloma is also progressing well. AbbVie's shares have lost 3.7% this year so far against the industry 's gain of 4.7%. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study. | AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study. AbbVie's shares have lost 3.7% this year so far against the industry 's gain of 4.7%. Also, in July, AbbVie filed a regulatory application in the United States for Venclexta in acute myeloid leukemia ("AML") while a phase III program in multiple myeloma is also progressing well. |
25357.0 | 2018-09-12 00:00:00 UTC | 5 Growth Stocks to Buy for Reliable Income in Retirement | ABBV | https://www.nasdaq.com/articles/5-growth-stocks-buy-reliable-income-retirement-2018-09-12 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Once investors retire, the priority usually turns to income. Here, they want their assets to generate as much cash as they can with as little risk. In today's lending environment, CDs and bonds will probably not produce enough money. They could turn to distributions from mutual funds or exchange-traded-funds that hold some of these retirement stocks. However, with t he dividend yield of the S&P 500 holding at about 1.9%, they often may not generate the necessary cash either. For this reason, some investors will resort to individual growth stocks.
I do not recommend such an approach without thorough research. I also would discourage buying one or two stocks simply because they pay the highest dividend. However, buying the right dividend stocks while protecting oneself with diversification could yield significant amounts of cash without crazy amounts of risk.
For example, dividend aristocrats, or stocks that have seen at least 25 consecutive years of dividend hikes, could bolster such a portfolio. Also, real estate investment trusts (REITs), firms that consolidate a group of real estate holdings into a stock-oriented vehicle, could also serve this purpose. REITs can avoid federal income tax by paying out at least 90% of the net income generated from properties as dividends.
7 Dividend Stocks to Buy Amid This Tough Market Environment
No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead:
Growth Stocks to Buy: AbbVie (ABBV)
Source: Shutterstock
Dividend Yield: 4.1%
Health issues often compel retirees to spend large amounts of money on pharmaceutical products. To my way of thinking, this stands as a good reason for a retiree to profit from something that otherwise could cost them large sums of money. Such investors benefit from a large number of baby boomers retiring and from Medicare prescription drug plans. Both factors bolster the case for equities such as AbbVie (NYSE: ABBV ) as one of the reliable growth stocks to consider in retirement.
ABBV stock offers several benefits. It owns the patent to the world's best-selling drug, Humira. Humira now faces competition from generics in some markets. Fortunately for AbbVie, its drug pipeline is well-positioned to compensate for this patent expiration. In fact, EvaluatePharma voted AbbVie's pipeline the second-best for value creation .
This value should flow to the company and its stockholders alike. ABBV stock appears well-positioned for bargain hunters (and especially those who are hunting an attractive dividend yield). The stock has fallen nearly 24% from its February highs, which has taken its forward price-to-earnings ratio down to about 11.8.
Despite the low multiple, analysts expect the company to increase its profits by 40% this year. On average, they expect 16% annual growth over the next five years.
Moreover, due to its history as part of Abbott Labs (NYSE: ABT ), it qualifies as a dividend aristocrat despite its founding five years ago. Just last year, annual dividends rose from $2.56-per-share in 2017 to $3.84-per-share. This 50% dividend increase took its dividend yield to above 4%. Its profit growth should enable the company to continue the dividend yield increases in future years. With a low P/E and a high dividend yield that continues to rise, it should stand as one of the growth stocks to which investors turn for years to come.
Growth Stocks to Buy: AT&T (T)
Source: Shutterstock
Dividend Yield: 6%
A fortuitous series of events (at least for buyers) may have made AT&T (NYSE: T ) one of the more exciting growth stocks to consider in retirement. Investors sold off T stock as high costs and its past association with former Trump attorney Michael Cohen plagued the company. The company struggles on several fronts. Consumers increasingly cut the cord on the company's pay-TV business while intense competition hurt the profitability of wireless.
Moreover, the need to upgrade to 5G wireless technology imposes an expense costing the company billions of dollars every year for the next few years as it struggles to remain competitive.
However, as I pointed out in a recent article , T stock may be headed for a "perfect storm" of profits. The company now offers a TV service through its DirecTV unit. Moreover, the first of its 5G will launch soon, so its expensive upgrade will finally begin to generate revenue.
All of this comes at an excellent time for those who want to buy T stock. This year's drop in the stock price has taken its forward P/E down to 9.3. This comes at a time when analysts predict 15.1% profit growth for the year. That will likely slow to levels near the predicted five-year average growth rate of 6.2%. However, with only three (or possibly four) companies controlling a nationwide 5G network, it will find itself in a position to profit.
7 Fabulous Financial ETFs to Buy
Moreover, AT&T holds dividend aristocrat status. This has placed AT&T in the position where the stock's value rests on continual annual dividend increases. This stays true despite its yield of about 6%, more than triple the S&P 500 average. Given its high dividend and single-digit P/E in one of the few companies providing a needed service, T stock should profit its investors with both its dividend and low stock price.
Growth Stocks to Buy: Chevron (CVX)
Source: swong95765 via Flickr (Modified)
Dividend Yield: 3.8%
Early in the year, I was bullish on Chevron (NYSE: CVX ). Despite the delay of my predicted march higher, the fact that the stock price has fallen improves its standing among dividend stocks to consider. Energy prices moved steadily higher in 2016 and 2017, taking CVX stock along with them.
However, WTI crude prices have stagnated since April and Chevron stock has also done little in that time, falling by almost 14% from its 52-week high.
Now that the equity's steady move higher has paused, profits have begun to catch up to the CVX stock price. Assuming forecasted earnings of $7.84-per-share hold, that would bring the forward P/E to about 14.7 at today's prices. A predicted 111.9% profit increase for the fiscal year brought about this low P/E. This increase will likely become a one-time event. However, even though the same analysts' predicted growth will slow to 14.4% next year, it still means Chevron's profits will remain sustainably higher.
Furthermore, like many retirement stocks, CVX stock holds dividend aristocrat status. The annual dividend of $4.48-per-share brings the dividend yield to 3.8%. Even more important, the 31-year record of annual dividend hikes shows the company can maintain these increases during times of both high and low energy prices. That said, higher prices tend to lead to more significant gains. However, no matter the level of increase, this high dividend and the much lower P/E make CVX one of the more attractive growth stocks for retirement.
Growth Stocks to Buy: Senior Housing Properties Trust (SNH)
Source: Shutterstock
Dividend Yield: 8.3%
Given that REITs tend to enjoy dividend yields that are more than twice the size of the S&P 500, those interested in dividend stocks for retirement should look at REITs such as the Senior Housing Properties Trust (NYSE: SNH ).
Since retirees will spend a large percentage of their income on housing, they might as well profit from the increased demand for retiree and healthcare-related properties. Also, with 10,000-baby-boomers-per-day entering Medicare, the need for both senior housing and healthcare will remain strong.
REITs base their dividends on funds-from-operations (FFO) income, or cash flow from operations. FFO income came in at $1.58-per-share last year. This year, analysts expect that to rise to $1.64-per-share. Over the long-term, this keeps income growth in the low-single-digits. However, property tends to appreciate over time. Also, with retirement stocks, cash generation remains the priority. Hence, I would only recommend SNH stock for those who care mostly about generating cash.
3 Risky Dividend Stocks With Fat Yields
Due to the requirement to pay at least 90% of net income in dividends, dividend payments will tend to fluctuate with income. However, SNH stock has managed to keep its annual dividend at $1.56-per-share since 2013. This brings the yield to about 8.25%, about twice the overall REIT average.
Moreover, if the dividend changes over the next few years, it will likely rise to keep the REIT compliant with the 90% payout rule. Either way, its dividend yield should give retirees a way to derive a large payout while benefiting from something that otherwise costs them a lot of money.
Growth Stocks to Buy: Target (TGT)
Source: Mike Mozart via Flickr (Modified)
Dividend Yield: 2.9%
Two years ago, brick-and-mortar retailers such as Target (NYSE: TGT ) seemed to be left for dead as fears of an e-commerce led takeover by the likes of Amazon (NASDAQ: AMZN ) would wipe out all traditional retailers. In fact, Target and its retail peers have now used their store footprint as an advantage over Amazon. The combined online and in-store purchase experience, called omnichannel, places the venerable retailer at a distinct advantage.
Now, TGT stock has returned to levels near record highs. Despite this recovery, Target still trades at a reasonable 16.4-times-forward-earnings. This comes in lower than archrival Walmart (NYSE: WMT ), and much lower than the triple-digit P/E seen in Amazon.
Wall Street also anticipates 14.6% profit growth for the year, driven by its e-commerce platform and improving in-store sales. Although its growth will slow in the coming year, analysts still forecast 7.5% average annual growth over the next five years.
Moreover, like many dividend stocks that are practical for retirement, TGT stock holds dividend aristocrat status with its 47 years of annual dividend increases. This year's annual dividend stands at $2.56-per-share, a yield of about 2.9%.
Now that the company has learned to compete with Amazon, it should find itself well-positioned to continue these increases in future years. No, Amazon will not take over retail. In fact, retailers like Target will thrive as both in-store and e-commerce plays, driving the TGT stock price higher for some time to come. As such, Target certainly earns its place on this list of growth stocks that are worth owning for retirement.
As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You canfollow Will on Twitterat @HealyWriting.
Compare Brokers
The post 5 Growth Stocks to Buy for Reliable Income in Retirement appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large amounts of money on pharmaceutical products. Both factors bolster the case for equities such as AbbVie (NYSE: ABBV ) as one of the reliable growth stocks to consider in retirement. ABBV stock offers several benefits. | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large amounts of money on pharmaceutical products. Both factors bolster the case for equities such as AbbVie (NYSE: ABBV ) as one of the reliable growth stocks to consider in retirement. ABBV stock offers several benefits. | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large amounts of money on pharmaceutical products. Both factors bolster the case for equities such as AbbVie (NYSE: ABBV ) as one of the reliable growth stocks to consider in retirement. ABBV stock offers several benefits. | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large amounts of money on pharmaceutical products. Both factors bolster the case for equities such as AbbVie (NYSE: ABBV ) as one of the reliable growth stocks to consider in retirement. ABBV stock offers several benefits. |
25358.0 | 2018-09-07 00:00:00 UTC | Vertex Completes Enrollment in Triple Combination Studies | ABBV | https://www.nasdaq.com/articles/vertex-completes-enrollment-in-triple-combination-studies-2018-09-07 | nan | nan | Vertex Pharmaceuticals IncorporatedVRTX announced the completion of enrollment in two phase III studies evaluating its next-generation corrector, VX-659, in combination with tezacaftor and Kalydeco (ivacaftor) for treating cystic fibrosis ("CF"). While one study is evaluating the triple combination regimen in patients with one F508del mutation and one minimal function mutation, the other study is in patients with two F508del mutations.
Top-line data from these studies are expected in the fourth quarter of 2018. Apart from VX-659, Vertex is also evaluating another next-generation corrector, VX-445, in combination with tezacaftor and Kalydeco in two more phase III studies in CF patients with similar mutations like VX-659. The studies are currently enrolling patients and the process is expected to be completed in the fourth quarter of this year. The company expects to announce top-line data on VX-445 in the first quarter of 2019.
The company has plans to compare the efficacy of both the triple combination regimens and will select the best regimen based on the interim analysis of these studies. Interim analysis will evaluate the primary endpoint of ppFEV1, a measure of lung function, at four weeks and safety of the regimens over 12 weeks.
A new drug application for the best regimen is expected to be submitted by mid-2019 for CF patients with one F508del mutation and one minimal function mutation.
So far this year, Vertex's shares have gained 20.1% against the industry 's decline of 4.9%.
Vertex has three drugs in its CF portfolio, Kalydeco, Orkambi and Symdeko. Symdeko was launched in February and has allowed the company to address a significantly larger CF patient population in the United States. The drug has shown strong uptake since its launch.
Kalydeco sales grew by almost a third in the first six months of 2018 compared with the year- ago period. However, Orkambi has witnessed modest growth as it faces few obstacles in some European countries related to reimbursement agreements. Total product sales from these three drugs were $1.4 billion in the first half. The company expects full-year sales to be in the range of $2.9 to $3 billion.
The successful development of either of these two triple combination regimens is expected to be favorable for the company's growth going forward. Both these triple combination regimens are of significant importance to the company's progress in CF segment as they are capable to treat almost 90% of CF patients. This will significantly increase the eligible patient population for Vertex's CF drugs, thereby boosting top-line growth for Vertex, if successful.
We remind investors that Galapagos NV GLPG and its partner AbbVie ABBV announced disappointing data from the phase II study of their CF candidate, GLPG2737, in June. GLPG2737 in combination with Orkambi had lower improvement as measured by ppFEV1 compared to VX-659 and VX-445 triple combinations. This had a favorable impact on Vertex as GLPG2737 gives the company a clear leadership in the development of CF treatments.
Meanwhile, Corbus Pharmaceuticals Holdings, Inc. CRBP is also developing a CF candidate, lenabasum, in a mid-stage study.
Vertex Pharmaceuticals Incorporated Price
Vertex Pharmaceuticals Incorporated Price | Vertex Pharmaceuticals Incorporated Quote
Zacks Rank
Vertex currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remind investors that Galapagos NV GLPG and its partner AbbVie ABBV announced disappointing data from the phase II study of their CF candidate, GLPG2737, in June. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex Pharmaceuticals IncorporatedVRTX announced the completion of enrollment in two phase III studies evaluating its next-generation corrector, VX-659, in combination with tezacaftor and Kalydeco (ivacaftor) for treating cystic fibrosis ("CF"). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Galapagos NV GLPG and its partner AbbVie ABBV announced disappointing data from the phase II study of their CF candidate, GLPG2737, in June. Vertex Pharmaceuticals IncorporatedVRTX announced the completion of enrollment in two phase III studies evaluating its next-generation corrector, VX-659, in combination with tezacaftor and Kalydeco (ivacaftor) for treating cystic fibrosis ("CF"). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Galapagos NV GLPG and its partner AbbVie ABBV announced disappointing data from the phase II study of their CF candidate, GLPG2737, in June. While one study is evaluating the triple combination regimen in patients with one F508del mutation and one minimal function mutation, the other study is in patients with two F508del mutations. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Galapagos NV GLPG and its partner AbbVie ABBV announced disappointing data from the phase II study of their CF candidate, GLPG2737, in June. The successful development of either of these two triple combination regimens is expected to be favorable for the company's growth going forward. |
25359.0 | 2018-09-07 00:00:00 UTC | Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC | ABBV | https://www.nasdaq.com/articles/daily-dividend-report-amt-rcl-abbv-amat-nue-krc-2018-09-07 | nan | nan | American Tower Corporation ( AMT ) declared its quarterly cash distribution of $0.79 per share on shares of the Company's common stock. The distribution is payable on October 17, 2018 to such stockholders of record at the close of business on September 28, 2018.
Royal Caribbean Cruises ( RCL ) declared a quarterly dividend of $0.70 per common share payable on October 11, 2018, to shareholders of record at the close of business on September 21, 2018.
AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable Nov. 15, 2018 to stockholders of record at the close of business on Oct. 15, 2018.
Applied Materials has approved a quarterly cash dividend of $0.20 per share payable on the company's common stock. The dividend is payable on December 13, 2018 to shareholders of record as of November 23, 2018.
Nucor declared the regular quarterly cash dividend of $0.38 per share on Nucor's common stock. This cash dividend is payable on November 9, 2018 to stockholders of record on September 28, 2018, and is Nucor's 182nd consecutive quarterly cash dividend.
Kilroy Realty Corporation ( KRC ) declared a regular quarterly cash dividend of $0.455 per common share payable on October 17, 2018 to stockholders of record on September 28, 2018. The dividend is equivalent to an annual rate of $1.82 per share.
VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Royal Caribbean Cruises ( RCL ) declared a quarterly dividend of $0.70 per common share payable on October 11, 2018, to shareholders of record at the close of business on September 21, 2018. | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Royal Caribbean Cruises ( RCL ) declared a quarterly dividend of $0.70 per common share payable on October 11, 2018, to shareholders of record at the close of business on September 21, 2018. | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Royal Caribbean Cruises ( RCL ) declared a quarterly dividend of $0.70 per common share payable on October 11, 2018, to shareholders of record at the close of business on September 21, 2018. | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. American Tower Corporation ( AMT ) declared its quarterly cash distribution of $0.79 per share on shares of the Company's common stock. |
25360.0 | 2018-09-06 00:00:00 UTC | Notable ETF Inflow Detected - MTUM, BA, JPM, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-mtum-ba-jpm-abbv-2018-09-06 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $139.9 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 86,750,000 to 87,950,000). Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average:
Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.66 as the 52 week high point - that compares with a last trade of $116.87. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $139.9 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 86,750,000 to 87,950,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.66 as the 52 week high point - that compares with a last trade of $116.87. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $139.9 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 86,750,000 to 87,950,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.66 as the 52 week high point - that compares with a last trade of $116.87. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $139.9 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 86,750,000 to 87,950,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $118.66 as the 52 week high point - that compares with a last trade of $116.87. |
25361.0 | 2018-09-06 00:00:00 UTC | 3 Top Big Pharma Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-big-pharma-stocks-buy-now-2018-09-06 | nan | nan | Some people stick the word "big" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term "big pharma," though, I'm not intending to be derogatory. My use of the label is to simply refer to the biggest drugmakers on the market.
I think there are three big pharma stocks that investors definitely shouldn't disparage. AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like really good picks for the long run. Here's why these are three top big pharma stocks you can buy now.
1. AbbVie
There are two things that investors especially want when they buy a big pharma stock -- growth and dividends. AbbVie delivers on both very well.
The company should be able to generate double-digit-percentage growth for years to come. Although AbbVie's top-selling drug, Humira, faces competition from biosimilars in Europe in the fourth quarter, the drug should preserve its U.S. position through early 2023. Market research firm EvaluatePharma projects that Humira will remain the No. 1 best-selling drug in the world at least through 2024.
Meanwhile, AbbVie has plenty of other arrows in its quiver. Cancer drug Imbruvica continues to enjoy strong sales momentum. Hepatitis C virus (HCV) drug Mavyret should become AbbVie's latest blockbuster when the company reports its Q3 results. Recently approved endometriosis drug Orilissa has tremendous potential, as does cancer drug Venclexta. In addition to its strong current lineup, AbbVie's pipeline looks very promising, with immunology drugs risankizumab and upadacitinib especially standing out.
AbbVie's dividend is just as impressive. Its dividend yield stands just under 4%. Over the last five years, AbbVie has boosted its dividend by a whopping 140%.
2. Gilead Sciences
How does Gilead Sciences fare in the categories of growth and dividends? Its dividend yield of a little more than 3% looks really good. Although Gilead didn't initiate a dividend program until 2015, the company has increased its payout by nearly 33% since then.
Growth is a different story, though. Slumping sales for its HCV drugs have pulled down Gilead's total revenue and earnings. There are now fewer patients with hepatitis C thanks to the efficacy of drugs marketed by Gilead and a few of its peers. It's now pretty much a one-on-one battle between Gilead and AbbVie for market share.
However, Gilead's HCV sales appear to be stabilizing . Even better, the company's new HIV drug, Biktarvy, is quickly becoming a huge success story. Gilead's other Descovy-based HIV drugs also continue to generate impressive sales growth. Yescarta is slowly but surely establishing itself as the leading cancer cell therapy.
Gilead's pipeline is also underrated, in my view. The company hopes to file for approval for filgotinib in treating rheumatoid arthritis next year. I expect the drug will give Gilead a new blockbuster franchise in immunology. Gilead is also poised to become a leader in treating nonalcoholic steatohepatitis (NASH), an indication that some think will be a $35 billion market .
3. Pfizer
Pfizer is certainly no slouch in the dividend department. The big drugmaker's dividend currently yields 3.28%. Pfizer has paid a dividend for 319 consecutive quarters.
However, the company has struggled in recent years in generating solid revenue and earnings growth. One major factor holding Pfizer back has been several drugs losing patent exclusivity. Pfizer has also been hurt by continuing product shortages with its sterile injectables business.
The good news is that Pfizer should move past both of these issues. Although Pfizer will feel the sting of the loss of exclusivity for Lyrica later this year, the company expects that declining sales for its older drugs won't weigh on its growth after 2020. Pfizer won't have to wait that long for improvement in its sterile injectables business. The company thinks that year-over-year comparisons for this unit will pick up beginning in Q3.
Pfizer CEO Ian Read stated in the company's second-quarter conference call that its pipeline is stronger than it's been in decades. That's no exaggeration. Pfizer's pipeline includes multiple potential winners, notably including pain drug tanezumab and rare-disease drug tafamidis.
Best of the best
I like all three of these big pharma stocks so much that I own all three of them. Which is the best of the group? I think the honor goes to AbbVie.
AbbVie pays the highest dividend yield of the three. It also has the clearest pathway to growth. Also, the stock's forward earnings multiple of 10.6 is most attractive. I think long-term investors should win with all three of these top big pharma stocks, but if you could only buy one of them, my view is to go with AbbVie.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In addition to its strong current lineup, AbbVie's pipeline looks very promising, with immunology drugs risankizumab and upadacitinib especially standing out. *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like really good picks for the long run. | AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like really good picks for the long run. AbbVie There are two things that investors especially want when they buy a big pharma stock -- growth and dividends. AbbVie delivers on both very well. | AbbVie There are two things that investors especially want when they buy a big pharma stock -- growth and dividends. *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like really good picks for the long run. | AbbVie There are two things that investors especially want when they buy a big pharma stock -- growth and dividends. AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like really good picks for the long run. AbbVie delivers on both very well. |
25362.0 | 2018-09-05 00:00:00 UTC | Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock | ABBV | https://www.nasdaq.com/articles/forget-crispr-therapeutics-vertex-pharmaceuticals-incorporated-better-biotech-stock-2018 | nan | nan | Gene-editing pioneer CRISPR Therapeutics AG (NASDAQ: CRSP) has sparked imaginations and puffed up portfolios. Before you dive in, though, you might want to take a look at its much larger partner, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) .
CRISPR Therapeutics recently became the first among its U.S.-traded peers to initiate a clinical trial. That's a big deal, but its stock looks like a big gamble that probably isn't worth the risk. No matter how you feel about the future of gene editing, you really should understand why Vertex is the better biotech stock to buy right now.
Reasons to buy
All cystic fibrosis (CF) patients have difficulty breathing caused by sticky mucus that's hard to clear from their lungs, but there are at least 1,700 known genetic mutations that cause the problem. Right now, Vertex Pharmaceuticals markets the only three treatments that address the root cause of this life-shortening disease.
Without any other options, demand for new CF treatments is so strong that Symdeko hit an annualized run rate of $744 million during the three months ended June despite launching just four months earlier. Total second-quarter revenue jumped 46% compared to the prior-year period, to an annualized $3.0 billion.
Vertex's CF operation still has a lot of room to grow. Across North America, Europe, and Australia, the disease affects around 75,000 people, but Vertex's products are only approved to treat roughly half of them at the moment. Vertex thinks it has experimental treatments in late-stage development that will expand its reach to perhaps 68,000 patients within a few years.
In March, the company began a pivotal study with VX-659, and we should know if it hits a four-week primary efficacy endpoint before the end of the year. Another pivotal study involving VX-561 should have primary efficacy data ready around the same time. Adding it to Symdeko led to an 11% lung function improvement in a mid-stage study, and similar results in the larger trial would give it blockbuster potential. Vertex isn't wasting time and plans to file applications for both candidates by the middle of 2019.
Trying to develop cutting-edge medicines as quickly as possible isn't cheap, and Vertex is on pace to spend around $1.3 billion on research and development alone this year. Despite making such heavy investments, operations are becoming highly profitable. That's because a lack of competing CF drugs has allowed product revenue to accelerate past spending on sales, general, and administration (SG&A) expenses over the past few years.
VRTX Revenue (TTM) data by YCharts .
Vertex has started using the profits its drugs generate to expand its pipeline, and that includes a partnership with CRISPR Therapeutics. In 2015, Vertex handed CRISPR $75 million up front for the right to choose up to six new drug candidates. The first, CTX001, is aimed at two rare blood disorders and a clinical trial at a single site in Germany has already begun.
Reasons to be nervous
Currently, CRISPR Therapeutics is a $2.7 billion company that has yet to give one of its drug candidates to a human. If CTX001 flops, as most experimental treatments do, CRISPR Therapeutics stock will tank.
Vertex shareholders might feel a slight pinch if CTX001 flops, mainly because it would let the air out of an equity stake Vertex has in CRISPR that's ballooned since 2015. More than anything, though, Vertex needs to worry about another viable competitor entering the CF arena.
Luckily for Vertex, the threats don't appear too severe at the moment. A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year.
Better but still risky
Positive cash flows that are growing rapidly today, always beat potential sales for an unproven class of drugs years from a Food and Drug Administration submission. That said, investors have awfully high expectations for Vertex.
A market giddy for biotech has driven Vertex's stock price up to 18 times trailing sales at recent prices, while most commercial-stage biotechs trade in the mid-single-digit range. If a competitive entrant forces Vertex to lower prices over the next few years, the stock's valuation will start to resemble its peers and leave investors sitting on heavy losses.
Without any major threats on the horizon, though, Vertex has a better-than-average chance to outperform for investors who buy now and hang on for the long haul.
10 stocks we like better than Vertex Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. Adding it to Symdeko led to an 11% lung function improvement in a mid-stage study, and similar results in the larger trial would give it blockbuster potential. If a competitive entrant forces Vertex to lower prices over the next few years, the stock's valuation will start to resemble its peers and leave investors sitting on heavy losses. | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. Before you dive in, though, you might want to take a look at its much larger partner, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) . That's because a lack of competing CF drugs has allowed product revenue to accelerate past spending on sales, general, and administration (SG&A) expenses over the past few years. | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. Vertex shareholders might feel a slight pinch if CTX001 flops, mainly because it would let the air out of an equity stake Vertex has in CRISPR that's ballooned since 2015. 10 stocks we like better than Vertex Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. If CTX001 flops, as most experimental treatments do, CRISPR Therapeutics stock will tank. That's right -- they think these 10 stocks are even better buys. |
25363.0 | 2018-09-04 00:00:00 UTC | Is Now a Good Time to Buy Gilead Sciences? | ABBV | https://www.nasdaq.com/articles/now-good-time-buy-gilead-sciences-2018-09-04 | nan | nan | Fierce competition in the hepatitis C market has caused Gilead Sciences ' (NASDAQ: GILD) sales and share price to slide, but the dividend-paying company remains profitable and there are catalysts on the horizon that could reignite interest. Is now a good time to add this biotech behemoth to portfolios?
By the numbers
Gilead Sciences has been selling widely used HIV drugs for over a decade, but its recent woes stem from declining demand for its hepatitis C drugs. The company was the first drugmaker to develop oral medicines that provide functional cures for the liver disease. However, other drugmakers have rolled out their own treatments, sparking a price war that's taken a toll on Gilead Sciences' financial results.
The increased competition has resulted in trailing-12-month sales slipping from over $30 billion to about $23 billion since 2015 and, unsurprisingly, the fall-off in revenue has resulted in a steep decline in net income. In Q2 2018, Gilead Sciences' earnings per share (EPS) totaled $1.91, down significantly from $2.56 in Q2 2017 and $3.08 in Q2 2016. Over the past 12 months, its net income has been only $2.2 billion, down from over $15 billion at its peak.
GILD Revenue (TTM) data by YCharts .
The revenue and profit decline don't appear to be over, either. The company's hepatitis C drug sales fell 65% year over year in Q2, yet they still totaled $1 billion. It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion.
Market-moving news ahead
In order for Gilead Sciences to regain investors' confidence, it's going to need to launch new drugs with billion-dollar blockbuster potential.
Fortunately, it has two research and development programs advancing toward the finish line that could produce top sellers and data from trials for those programs is fast approaching.
First up will be results from the phase 3 study of filgotinib in rheumatoid arthritis.
Gilead Sciences acquired the rights to filgotinib from Galapagos (NASDAQ: GLPG) in 2015 and the two companies are currently evaluating it across a range of automimmune diseases. So far, filgotinib has shown promise in rheumatoid arthritis, ulcerative colitis, Crohn's disease, and psoriatic arthritis.
There are three phase 3 rheumatoid arthritis trials that are fully enrolled and results from its first phase 3 study, which is evaluating its use alongside conventional disease-modifying antirheumatic drugs (DMARDs) who inadequately respond to biologics, is expected later this year. Those results will be followed up by data from a trial evaluating it head-to-head against the commonly used methotrexate and the over-$18 billion biologic Humira early in 2019.
In addition to filgotinib, the company's research is also progressing in nonalcoholic steatohepatitis, a silent liver disease that's quickly becoming a major cause of liver transplant. Gilead Sciences has various trials in NASH ongoing, but the first late-stage data that could support a Food and Drug Administration filing for approval will come from its study of selonsertib, an ASK1 inhibitor being evaluated in patients with F3 and F4 cirrhosis. Results are expected in the first half of next year, and if they're positive, a filing could occur in the middle of 2019.
Is it a buy?
Rheumatoid arthritis and NASH impact millions of people and, thus, they're both potentially huge markets that could kick-start Gilead Sciences' financials. However, Gilead Sciences isn't the only company that's researching new ways to tackle autoimmune disease or liver disease and competitors could outmaneuver it.
Nevertheless, risk-tolerant investors might want to tuck some shares of Gilead Sciences into portfolios ahead of these important data readouts. There's no guarantee that filgotinib and selonsertib will succeed, but if they do, Gilead Sciences shares could rally sharply because they're arguably trading at a discount valuation.
Its 4.5 price-to-book ratio and 4.3 price-to-sales ratio are the lowest in over five years, and its forward price-to-earnings ratio of 11.5 isn't very high, either. If earnings continue to fall, then the P/E ratio could get less attractive, but I think the company's financials could level off next year, and if these drugs pan out, that could position it to return to growth in 2020. In such a scenario, Gilead Sciences' investors could end up being nicely rewarded for picking up some shares now.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Todd Campbell owns shares of Gilead Sciences. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. Fierce competition in the hepatitis C market has caused Gilead Sciences ' (NASDAQ: GILD) sales and share price to slide, but the dividend-paying company remains profitable and there are catalysts on the horizon that could reignite interest. | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. Fierce competition in the hepatitis C market has caused Gilead Sciences ' (NASDAQ: GILD) sales and share price to slide, but the dividend-paying company remains profitable and there are catalysts on the horizon that could reignite interest. | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. Fierce competition in the hepatitis C market has caused Gilead Sciences ' (NASDAQ: GILD) sales and share price to slide, but the dividend-paying company remains profitable and there are catalysts on the horizon that could reignite interest. | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. The company's hepatitis C drug sales fell 65% year over year in Q2, yet they still totaled $1 billion. |
25364.0 | 2018-09-04 00:00:00 UTC | Vertex Inks Reimbursement Agreement for Orkambi in Australia | ABBV | https://www.nasdaq.com/articles/vertex-inks-reimbursement-agreement-for-orkambi-in-australia-2018-09-04 | nan | nan | Vertex Pharmaceuticals Inc.VRTX announced that an agreement has been finalized with the Australian Government, which will allow reimbursement on cystic fibrosis ("CF") drug, Orkambi (lumacaftor + ivacaftor) in the country. This follows the positive recommendation from Pharmaceutical Benefits Advisory Committee ("PBAC") last month. Per the agreement, the drug will be listed on the Pharmaceutical Benefits Scheme ("PBS") starting Oct 1, 2018.
Orkambi is approved for treating CF patients aged six years and above with two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in the country. We remind investors that this is the most common form of mutation in CF patients. There are approximately 1,300 patients in Australia who are eligible for treatment with Orkambi. The drug may see faster acceptance as it will improve the access to the drug, which in turn will drive sales.
Vertex is pursuing similar agreements in several European countries, following the first approval of the drug in the European Union in 2015. The company has successfully signed agreements in some countries including Germany, Ireland, Sweden and Italy. However, it is also facing resistance in some countries including the United Kingdom and France due to its high listing price, which has resulted in limited revenues from these countries.
The stock has gained 23% so far this year against the 1.7% decrease registered by the industry .
Orkambi is the major product revenue generator for Vertex, bringing in $665.3 million in sales in the first half of 2018. The company has two other CF drugs - Kalydeco (ivacaftor) and Symdeko - in its portfolio. We remind investors that, Symdeko is a combination of tezacaftor and ivacaftor, which was launched in the United States in February for treating CF patients. The drug has shown strong uptake so far and is under review in Europe.
The company has strong prospects as all the three drugs are performing well. According to the company, about 34,000 people worldwide are eligible for treatment with Vertex's CF medicines and it expects to consistently expand the number of eligible patients in 2018.
Vertex also has a strong CF pipeline which includes triple combination treatments for CF, which are expected to treat almost 90% of the global CF patients, if approved.
Meanwhile, in late June, Galapagos NV's GLPG lower-than-expected top-line results in a phase II study on its CF candidate, GLPG2737, turned out to be a positive for Vertex. Moreover, Galapagos' collaboration partner, AbbVie ABBV opted out of the development of a triple combination regimen for CF patients. Corbus Pharmaceuticals Holdings, Inc. CRBP is developing a CF candidate, lenabasum, in a mid-stage study.
Vertex Pharmaceuticals Incorporated Price
Vertex Pharmaceuticals Incorporated Price | Vertex Pharmaceuticals Incorporated Quote
Zacks Rank
Vertex currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Galapagos NV (GLPG): Free Stock Analysis Report
Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moreover, Galapagos' collaboration partner, AbbVie ABBV opted out of the development of a triple combination regimen for CF patients. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex Pharmaceuticals Inc.VRTX announced that an agreement has been finalized with the Australian Government, which will allow reimbursement on cystic fibrosis ("CF") drug, Orkambi (lumacaftor + ivacaftor) in the country. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, Galapagos' collaboration partner, AbbVie ABBV opted out of the development of a triple combination regimen for CF patients. Vertex Pharmaceuticals Incorporated Price Vertex Pharmaceuticals Incorporated Price | Vertex Pharmaceuticals Incorporated Quote Zacks Rank Vertex currently carries a Zacks Rank #3 (Hold). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, Galapagos' collaboration partner, AbbVie ABBV opted out of the development of a triple combination regimen for CF patients. Vertex also has a strong CF pipeline which includes triple combination treatments for CF, which are expected to treat almost 90% of the global CF patients, if approved. | Moreover, Galapagos' collaboration partner, AbbVie ABBV opted out of the development of a triple combination regimen for CF patients. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. The company has strong prospects as all the three drugs are performing well. |
25365.0 | 2018-09-04 00:00:00 UTC | These Monthly Dividend Stocks Are Set to Surge (and pay up to 6.8%) | ABBV | https://www.nasdaq.com/articles/these-monthly-dividend-stocks-are-set-surge-and-pay-68-2018-09-04 | nan | nan | By Brett Owens
If youaEURtmre like most folks, youaEURtmre so used to collecting dividends quarterly that it may not have occurred to you that your portfolio can pay you every month.
But itaEURtms true, thanks to a small set of stocks that delivers cash payouts month in and month out like clockwork (IaEURtmll reveal 3 with especially juicy dividend yieldsaEUR"up to 6.8%aEUR"below).
Monthly Checks YouDonaEURtmtHave to Work For
If youaEURtmre a retiree, this may take you back to your workdaysaEUR"when your paycheck rolled in at the same time as your monthly bills. Subtract one from the other and voila: you knew exactly how much disposable income you had.
But with your garden-variety quarterly dividend payers, a smooth income stream like that is next to impossible.
Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ):
A Lumpy Cash Stream
Your cash flow ranges from just $926 in January, April, July and October all the way up to $2,521 in February, May, August and November.
To be certain, weaEURtmll never be able to dump quarterly payers from our portfolios entirely, because pretty well all US blue chip stocks ship out their dividends every 3 months. But adding a few monthly payers (including the 3 high yielders IaEURtmll show you below) can do a lot to smooth out our cash flow.
There are a couple other overlooked benefits monthly payers give you, too:
They signal a top-notch investment: C-suite types know that a dividend is a promise to investors, and they wouldnaEURtmt commit to sending one out every month if they werenaEURtmt serious about keepingaEUR"or raisingaEUR"the payout.
They magnify your profits: If youaEURtmre not leaning on your portfolio for income, getting your dividend cash every month lets you reinvest it faster, boosting your gains (and income stream) in the long run.
So without further ado, letaEURtms dive into the 3 monthly payers I want to show you today, starting withaEUR
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in January, April, July and October all the way up to $2,521 in February, May, August and November. To be certain, weaEURtmll never be able to dump quarterly payers from our portfolios entirely, because pretty well all US blue chip stocks ship out their dividends every 3 months. But adding a few monthly payers (including the 3 high yielders IaEURtmll show you below) can do a lot to smooth out our cash flow. | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in January, April, July and October all the way up to $2,521 in February, May, August and November. But with your garden-variety quarterly dividend payers, a smooth income stream like that is next to impossible. So without further ado, letaEURtms dive into the 3 monthly payers I want to show you today, starting withaEUR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in January, April, July and October all the way up to $2,521 in February, May, August and November. They magnify your profits: If youaEURtmre not leaning on your portfolio for income, getting your dividend cash every month lets you reinvest it faster, boosting your gains (and income stream) in the long run. So without further ado, letaEURtms dive into the 3 monthly payers I want to show you today, starting withaEUR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in January, April, July and October all the way up to $2,521 in February, May, August and November. But with your garden-variety quarterly dividend payers, a smooth income stream like that is next to impossible. But adding a few monthly payers (including the 3 high yielders IaEURtmll show you below) can do a lot to smooth out our cash flow. |
25366.0 | 2018-08-31 00:00:00 UTC | Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-approval-of-nvs-abbv-cancer-drugs-mrks-hiv-drug-in-focus-2018-08-31 | nan | nan | This week was ruled by FDA and EU approvals for new cancer therapies as well as line extensions of cancer drugs. These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer.
The FDA also approved Merck's MRK two new HIV medicines containing its investigational medicine, doravirine. Meanwhile, Pfizer PFE presented late-stage study data on a rare disease candidate and announced termination of two studies on a candidate being developed for the treatment of Duchenne muscular dystrophy (DMD).
Recap of the Week's Most Important Stories
FDA Approves Merck's HIV Medicines: Merck announced that the FDA approved two new HIV drugs containing its investigational medicine, doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of patients who have not received any antiretroviral therapies before.
While doravirine approved as a once-daily single tablet in combination with other antiretroviral agents will be marketed by the trade name of Pifeltro, a once-daily fixed-dose combination regimen containing doravirine, lamivudine and tenofovir disoproxil fumarate will be sold as Delstrigo. The FDA's decision came almost two months in advance.
Pfizer Presents Data on Rare-Disease Candidate, Terminates DMD Candidate: Pfizer presented primary data from a phase III study , ATTR-ACT, evaluating its pipeline candidate tafamidis in patients with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy (ATTR-CM), a rare illness associated with progressive heart failure. Data from the study showed that treatment with tafamidis led to a significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations - the primary endpoint - compared with placebo at 30 months. Treatment with tafamidis led to a 30% reduction in the risk of mortality and 32% reduction in the rate of cardiovascular-related hospitalization compared to placebo. The data were presented at the European Society of Cardiology congress.
Pfizer also announced the termination of two studies evaluating its pipeline candidate domagrozumab (PF-06252616) for the treatment of DMD, a severe type of muscular dystrophy, due to lack of a "significant treatment effect". It clarified that the studies were not discontinued for safety issues and it will evaluate the total data set to see if the candidate has any prospect in the treatment of muscular diseases. Meanwhile, Pfizer is also evaluating a gene therapy, PF-06939926, for DMD.
Cancer Approvals in EU for Novartis: Novartis' chimeric antigen receptor T cell (CAR-T) therapy, Kymriah was approved by the European Commission for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) and r/r diffuse large B-cell lymphoma (DLBCL). Kymriah is already approved in the United States for this indication. Kymriah sales came in at $28 million in the first half of 2018.
Novartis' BRAF/MEK inhibitor combination, Tafinlar plus Mekinist also gained EU approval f or adjuvant treatment of BRAF V600 mutation-positive melanoma. This was the third indication for which the cancer combination is now approved in the EU. In the United States, the Tafinlar + Mekinist combination was approved for the same indication in April.
Also, Novartis' eye care division, Alcon, announced that it is voluntarily recalling its CyPass Micro-Stent for surgical glaucoma from the global markets. The withdrawal was based on five-year data from the COMPASS-XT long-term safety study, which showed cell loss in patients. Novartis said the decision is not expected to hurt the planned spin-off of Alcon in 2019.
AbbVie's Imbruvica+Rituxan Combo Gets FDA Nod for Rare Cancer: AbbVie and J&J's cancer drug Imbruvica was approved by the FDA to be used in combination with Roche's Rituxan for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. With the latest approval, Imbruvica is approved for nine indications across six different cancer types. (Read more: AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma )
J&J/Bayer's Xarelto Fails in Label Expansion Studies: J&J and Bayer's blood thinner, Xarelto failed to show statistical significant benefits in two studies - MARINER and COMMANDER HF - which were being conducted to expand the eligible patient population for Xarelto. In the MARINER study, Xarelto did not reduce venous thromboembolism (VTE), or blood clots, and VTE-related death in acute medically ill patients after discharge from hospital. The COMMANDER HF study was conducted to see if Xarelto was effective in reducing the risk of heart attack, stroke and death in sick patients with significant coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF) who experienced a recent episode of acute decompensated heart failure (ADHF).
In this study too, Xarelto did not impact overall mortality outcomes compared to standard of care. The results were presented at the European Society of Cardiology congress in Munich and also published in The New England Journal of Medicine. (Read more : Bayer's Blood Thinner Xarelto Fails in Line Extension Studies ).
EU Nod for label Expansion of AstraZeneca and Glaxo's Products:The European Commission approved AstraZeneca's Bydureon BCise injectable suspension, a new formulation of its diabetes medicine Bydureon in an improved once-weekly, single-dose pre-filled BCise device. This formulation was approved in the United States in October last year.
The regulatory agency also gave marketing approval for Glaxo's GSK Nucala as an add-on treatment for severe refractory eosinophilic asthma in the pediatric patient population (aged six up to 17 years) in Europe.
The NYSE ARCA Pharmaceutical Index rose 0.2% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions:
It was a mixed performance this week. While Pfizer declined the most (1.7%), AstraZeneca recorded the highest gain of 2.1% in the last five trading sessions.
In the past six months, Lilly remains the biggest gainer (37.9%) while Bristol-Myers declined the most (7.6%).
(See the last pharma stock roundup here: Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs )
What's Next in the Pharma World?
Watch out for several pipeline and regulatory updates next week
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. AbbVie's Imbruvica+Rituxan Combo Gets FDA Nod for Rare Cancer: AbbVie and J&J's cancer drug Imbruvica was approved by the FDA to be used in combination with Roche's Rituxan for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. (Read more: AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma ) J&J/Bayer's Xarelto Fails in Label Expansion Studies: J&J and Bayer's blood thinner, Xarelto failed to show statistical significant benefits in two studies - MARINER and COMMANDER HF - which were being conducted to expand the eligible patient population for Xarelto. | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. (Read more: AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma ) J&J/Bayer's Xarelto Fails in Label Expansion Studies: J&J and Bayer's blood thinner, Xarelto failed to show statistical significant benefits in two studies - MARINER and COMMANDER HF - which were being conducted to expand the eligible patient population for Xarelto. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's Imbruvica+Rituxan Combo Gets FDA Nod for Rare Cancer: AbbVie and J&J's cancer drug Imbruvica was approved by the FDA to be used in combination with Roche's Rituxan for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. AbbVie's Imbruvica+Rituxan Combo Gets FDA Nod for Rare Cancer: AbbVie and J&J's cancer drug Imbruvica was approved by the FDA to be used in combination with Roche's Rituxan for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. (Read more: AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma ) J&J/Bayer's Xarelto Fails in Label Expansion Studies: J&J and Bayer's blood thinner, Xarelto failed to show statistical significant benefits in two studies - MARINER and COMMANDER HF - which were being conducted to expand the eligible patient population for Xarelto. |
25367.0 | 2018-08-31 00:00:00 UTC | Do the Risks in Marijuana Stocks Outweigh the Rewards? | ABBV | https://www.nasdaq.com/articles/do-risks-marijuana-stocks-outweigh-rewards-2018-08-31 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Marijuana stocks are hot now, as is the social and political climate around them.
But true investors know that if you're going to be a successful investor you have to be able to spot objective opportunities and not be pulled by emotional or political feelings.
Few issues exemplify this more than the new wave of cannabis legislation sweeping the country.
At this point, recreational marijuana is legal in nine states and medical marijuana is legal in 30. That's 60% of the U.S. states that see some reason to legalize marijuana. And cannabidiol (CBD) a non-psychoactive ingredient found in marijuana is legal in 17 states to treat children with epilepsy or severe seizures.
Canada has also legalized recreational marijuana and it has some of the most mature cannabis companies in North America.
21 Beverage Stocks to Buy for the Contrarian-Minded
Because the U.S. is still a patchwork of states that allow limited, full or no use of legal cannabis, it's a challenge for an industry - and by extension marijuana stocks - to truly develop. What you have is companies that have moved into the most open cannabis markets to establish themselves in the hopes of being able to scale up their business nationally, when the time comes.
Like many other "next big thing" stocks - think dotcoms, blockchain or nanotechnology - it's certainly true there are significant opportunities. But there are also significant risks this early in the business cycle.
For example, there is still a very real issue about how financial institutions can get involved in this business without running afoul of federal and state laws. Cash management is a significant issue for this industry, even as it grows by leaps and bounds.
Usually thousands of companies launch, but over time they either wither or are overtaken by larger, better-financed and better-managed companies. We're still in this "let a 1,000 flowers bloom" stage of this market sector and marijuana stocks in general.
And we will be in that stage for some time.
That's not to say there aren't companies getting national recognition at this point.
Marijuana Stocks That Are Worth a Look
For example, GW Pharmaceuticals (NASDAQ: GWPH ) is a U.K.-based company that develops novel therapeutics using cannabinoid derivatives. It's basically a biotech that is building pharmaceuticals from cannabis' various ingredients.
Since it's a European company, it already has reach into a number of potential markets both inside and outside North America. And its biopharmaceutical structure means it has more credibility with regulators than other less structured start-ups.
But the big marijuana stock plays right now aren't the up-and-comers as much as it is the established companies that can take advantage of this new, growing market.
For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. It has been selling Marinol since the mid-1980s for AIDS patients and others that need help controlling nausea and vomiting due to illness or medications.
Marinol is a synthetic replacement for THC, the active ingredient in marijuana. It is a lab-created exact replica and it has been used for decades. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector.
On the other side of things, Scotts Miracle-Gro (NYSE: SMG ) was founded in 1868 and is best known for its grass seeds and fertilizer business. Having the massive distribution network and logistics that have been built over the past century and a half could spell big opportunities for this young industry.
What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks.
Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor , Breakthrough Stocks , Accelerated Profits and Platinum Growth . His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com . Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.
More From InvestorPlace
4 Tech Stocks That Are Running Hot (and 4 That Are Cooling Down)
5 Ridiculously Low-Cost ETFs
5 Mexican Stocks That Should Benefit From the Recent Trade Agreement
10 Hot Stocks to Invest In Right Now
Compare Brokers
The post Do the Risks in Marijuana Stocks Outweigh the Rewards? appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. |
25368.0 | 2018-08-28 00:00:00 UTC | AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma | ABBV | https://www.nasdaq.com/articles/abbvies-imbruvica-combo-gets-fda-nod-for-rare-lymphoma-2018-08-28 | nan | nan | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.
The approval was based on data from the phase III iNNOVATE study evaluating Imbruvica plus Rituxan compared to Rituxan alone for the treatment of adult patients with Waldenström's macroglobulinemia. Data from the study showed that the combination significantly reduced the risk of disease progression or death by 80% compared to placebo plus Rituxan.The data also showed that treatment with the combination led to a 30-month progression-free survival rate of 82% compared to 28% for patients on Rituxan alone. The approval came about two months ahead of expectations.
AbbVie's stock has risen 1.3% this year so far, underperforming the industry 's increase of 5.6%.
With the latest approval, Imbruvica is approved for nine indications across six different cancer types. It is jointly developed and commercialized by J&J and AbbVie.
Imbruvica is a key revenue driver at AbbVie and has multi-billion dollar potential. The drug generated revenues of $850 million in the second quarter of 2018, representing an increase of 35.6% year over year. Strong patient uptake including higher market share and growth across multiple indications, particularly chronic lymphocytic leukemia (CLL) led to the strong performance of Imbruvica. The latest label expansion approval for Imbruvica can drive sales higher in future quarters.
AbbVie is exploring the prospect of expanding Imbruvica's label into solid tumors and autoimmune diseases. Several studies on Imbruvica are ongoing to evaluate the drug alone or in combination in different patient segments. AbbVie expects Imbruvica peak sales of more than $7 billion and revenues of about $5 billion in 2020.
Another important cancer drug in AbbVie's oncology portfolio is Venclyxto/Venclexta. AbbVie is also studying Venclyxto/Venclexta to expand its label to address the broader relapsed/refractory CLL patient population, expand into earlier lines of therapy, and broaden into other hematologic malignancies like multiple myeloma and AML. Data from the phase III MURANO study of Venclexta plus Rituxan in relapse/refractory CLL presented in September showed that the combination led to a profound improvement in progression free survival compared to Teva's TEVA Treanda plus Rituxan.
Regulatory applications seeking approval for the combination use in this broader patient population were approved in the United States in June. Label expansion for this indication should expand the patient population for Venclexta significantly and boost its commercial potential. Also, in July, AbbVie filed U.S. regulatory application for Venclexta in first-line of acute myeloid leukemia (AML) while data from the late-stage program in multiple myeloma is expected in 2019.
AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. Also, in July, AbbVie filed U.S. regulatory application for Venclexta in first-line of acute myeloid leukemia (AML) while data from the late-stage program in multiple myeloma is expected in 2019. AbbVie's stock has risen 1.3% this year so far, underperforming the industry 's increase of 5.6%. | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's stock has risen 1.3% this year so far, underperforming the industry 's increase of 5.6%. | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's stock has risen 1.3% this year so far, underperforming the industry 's increase of 5.6%. | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma. AbbVie's stock has risen 1.3% this year so far, underperforming the industry 's increase of 5.6%. It is jointly developed and commercialized by J&J and AbbVie. |
25369.0 | 2018-08-28 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-2018-08-28 | nan | nan | In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. This move lagged the S&P 500's daily gain of 0.03%. Elsewhere, the Dow gained 0.06%, while the tech-heavy Nasdaq added 0.15%.
Coming into today, shares of the drugmaker had gained 7.18% in the past month. In that same time, the Medical sector gained 4.54%, while the S&P 500 gained 2.98%.
Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be October 26, 2018. The company is expected to report EPS of $2.01, up 42.55% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $8.20 billion, up 17.19% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.85 per share and revenue of $32.83 billion. These results would represent year-over-year changes of +40.18% and +16.35%, respectively.
It is also important to note the recent changes to analyst estimates for ABBV. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.23% higher within the past month. ABBV currently has a Zacks Rank of #3 (Hold).
Digging into valuation, ABBV currently has a Forward P/E ratio of 12.49. For comparison, its industry has an average Forward P/E of 16.23, which means ABBV is trading at a discount to the group.
Also, we should mention that ABBV has a PEG ratio of 0.89. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.06 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 82, which puts it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.85 per share and revenue of $32.83 billion. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be October 26, 2018. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be October 26, 2018. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.85 per share and revenue of $32.83 billion. In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be October 26, 2018. | ABBV currently has a Zacks Rank of #3 (Hold). In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be October 26, 2018. |
25370.0 | 2018-08-27 00:00:00 UTC | We Did The Math FTXH Can Go To $26 | ABBV | https://www.nasdaq.com/articles/we-did-math-ftxh-can-go-26-2018-08-27 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $26.46 per unit.
With FTXH trading at a recent price near $23.70 per unit, that means that analysts see 11.63% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Blueprint Medicines Corp (Symbol: BPMC), Heron Therapeutics Inc (Symbol: HRTX), and AbbVie Inc (Symbol: ABBV). Although BPMC has traded at a recent price of $69.08/share, the average analyst target is 32.46% higher at $91.50/share. Similarly, HRTX has 30.45% upside from the recent share price of $39.25 if the average analyst target price of $51.20/share is reached, and analysts on average are expecting ABBV to reach a target price of $109.07/share, which is 11.98% above the recent price of $97.40. Below is a twelve month price history chart comparing the stock performance of BPMC, HRTX, and ABBV:
Combined, BPMC, HRTX, and ABBV represent 9.04% of the First Trust Nasdaq Pharmaceuticals ETF. Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of BPMC, HRTX, and ABBV: Combined, BPMC, HRTX, and ABBV represent 9.04% of the First Trust Nasdaq Pharmaceuticals ETF. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Blueprint Medicines Corp (Symbol: BPMC), Heron Therapeutics Inc (Symbol: HRTX), and AbbVie Inc (Symbol: ABBV). Similarly, HRTX has 30.45% upside from the recent share price of $39.25 if the average analyst target price of $51.20/share is reached, and analysts on average are expecting ABBV to reach a target price of $109.07/share, which is 11.98% above the recent price of $97.40. | Similarly, HRTX has 30.45% upside from the recent share price of $39.25 if the average analyst target price of $51.20/share is reached, and analysts on average are expecting ABBV to reach a target price of $109.07/share, which is 11.98% above the recent price of $97.40. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Blueprint Medicines Corp (Symbol: BPMC), Heron Therapeutics Inc (Symbol: HRTX), and AbbVie Inc (Symbol: ABBV). Below is a twelve month price history chart comparing the stock performance of BPMC, HRTX, and ABBV: Combined, BPMC, HRTX, and ABBV represent 9.04% of the First Trust Nasdaq Pharmaceuticals ETF. | Similarly, HRTX has 30.45% upside from the recent share price of $39.25 if the average analyst target price of $51.20/share is reached, and analysts on average are expecting ABBV to reach a target price of $109.07/share, which is 11.98% above the recent price of $97.40. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Blueprint Medicines Corp (Symbol: BPMC), Heron Therapeutics Inc (Symbol: HRTX), and AbbVie Inc (Symbol: ABBV). Below is a twelve month price history chart comparing the stock performance of BPMC, HRTX, and ABBV: Combined, BPMC, HRTX, and ABBV represent 9.04% of the First Trust Nasdaq Pharmaceuticals ETF. | Below is a twelve month price history chart comparing the stock performance of BPMC, HRTX, and ABBV: Combined, BPMC, HRTX, and ABBV represent 9.04% of the First Trust Nasdaq Pharmaceuticals ETF. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Blueprint Medicines Corp (Symbol: BPMC), Heron Therapeutics Inc (Symbol: HRTX), and AbbVie Inc (Symbol: ABBV). Similarly, HRTX has 30.45% upside from the recent share price of $39.25 if the average analyst target price of $51.20/share is reached, and analysts on average are expecting ABBV to reach a target price of $109.07/share, which is 11.98% above the recent price of $97.40. |
25371.0 | 2018-08-27 00:00:00 UTC | AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-up-3.7-since-last-earnings-report%3A-can-it-continue-2018-08-27 | nan | nan | It has been about a month since the last earnings report for AbbVie (ABBV). Shares have added about 3.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance
AbbVie reported better-than-expected earnings and sales for the second quarter of 2018. Importantly, it raised its earnings expectations for 2018 for the second time this year.
Second-quarter 2018 earnings of $2.00 per share in the second quarter beat the Zacks Consensus Estimate of $1.98 by 1%. Also, the figure grew 40.8% year over year. Earnings also exceeded the guided range of $1.94 and $1.96 per share. Strong sales performance and lower tax rate led to the bottom-line beat.
Revenues of $8.28 billion in the reported quarter marginally beat the Zacks Consensus Estimate of $8.27 billion. Sales increased 19.2% year over year. Excluding a 1.8% favorable impact from foreign exchange rate fluctuations, operational revenues rose 17.1% backed by continued strong performances by Humira and Imbruvica and continued solid uptake of new HCV medicine, Mavyret. Operational revenue growth was better than management expectations of approximately 15%. Currency tailwinds of 1.8% were however less than approximately 3% expected by the company.
Quarter in Details
Humira recorded sales growth of 10% (8.2% on an operational basis) with revenues coming in at $5.2 billion, reflecting continued strong demand trends.
Sales in the United States increased 10% to $3.52 billion driven by strong prescription volume growth across all three major market categories. Humira sales in the ex-U.S. market were up 4.4% on an operational basis and 9.8% on reported basis to $1.67 billion, driven primarily by market growth across indications. Ex-U.S. Humira sales slightly exceeded management's expectation of approximately $1.6 billion.
Humira holds the leading market position as a front-line therapy in all three major market categories despite stiffer competition from new classes of drugs as well as an indirect biosimilar competition in the international markets
Internationally, Humira sales are expected to approach $6.4 billion in 2018, which includes the expected impact of biosimilar entrants in Europe in the fourth quarter.
Second-quarter net revenues from Imbruvica were $850 million, up 35.6% year over year. U.S. sales of Imbruvica grossed $693 million, up 31.1% from the year-ago figure. AbbVie logged $157 million of international profit sharing with J&J.
Strong patient uptake including higher market share and growth across multiple indications, particularly CLL led to the strong performance of Imbruvica.
In 2018, Imbruvica global revenues are expected to exceed $3.4 billion (previously $3.3 billion) with sales in the United States likely to cross $2.8 billion (previously $2.7 billion).
Other products that performed well include Lupron ($223 million, up 5.5% year over year), Creon ($219 million, up 11.4%), Duodopa ($108 million, up 25.1% year over year) and Sevoflurane ($113 million, up 6.9%).
Despite competitive dynamics in the HCV market, AbbVie HCV sales, including Viekira and Mavyret, were $973 million in the quarter, up 5.9% on a sequential basis. HCV sales exceeded expectations of $950 million.
Mavyret alone accounted for nearly $932 million in the quarter driven by better-than-expected launch uptake in the United States and international markets. Mavyret commands a market leading position in the United States and has also established a strong position in other major countries as well, such as Japan, Germany, Spain, and Italy.
In 2018, global HCV sales are expected to be higher than $3.5 billion, comparing favorably with previous expectation of being approximately $3.5 billion.
Adjusted gross margin declined 180 bps to 80.5% in the quarter. Adjusted SG&A expenses increased 16.5% to $1.64 billion. However, as a percentage of sales, SG&A expenses declined 40 bps to 19.9% in the quarter, reflecting sales leverage and operational efficiencies. R&D expenses rose 4% to $1.27 billion in the quarter due to greater investments in the pipeline. Adjusted operating margin was 45.3% of sales in the reported quarter, up 90 bps year over year.
2018 Outlook
AbbVie raised its adjusted EPS guidance to the range of $7.76-$7.86 for 2018 from $7.66-$7.76 predicted earlier. A strong first-half performance coupled with an optimistic outlook for stronger underlying business performance through the rest of the year propelled the increase in earnings guidance. The earnings guidance reflects a year-over-year surge of 39.5% at the mid-point versus 38% expected previously.
Revenues are expected to approach $32.5 billion (including currency impact), slightly less than the previous expectation of $32.6 billion. Currency impact is expected to benefit revenues by less than 1% in 2018 compared with 2% expected previously.
While R&D expense is expected to be approximately 16% of revised sales outlook, SG&A is expected to be about 20.5% of sales. Operating margin is expected to be above 44%, roughly 150 basis points above 2017 levels. Previously, AbbVie expected operating margin to be approximately 43.5% of sales.
Adjusted tax rate is expected to be approximately 9% in 2018. The normalized tax rate expectation over the next five years is 13%.
Third-Quarter 2018 Outlook
Third-quarter earnings are expected between $2.00 and $2.02 per share. Revenues are estimated to grow approximately 17% on an operational basis. Foreign exchange is expected to have approximately 1% unfavorable impact on sales in the third quarter.
U.S. Humira sales are expected to grow at approximately 11% year over year. Internationally, sales are expected to be approximately $1.6 billion. Imbruvica U.S. sales are expected to be approximately $725 million. Global HCV sales are expected to be approximately $850 million, which marks a sequential decline from the second quarter. This is because management expects reduction in patient volumes in the United States in the second half and softer demand in Japan.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates.
VGM Scores
At this time, AbbVie has a nice Growth Score of B, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Based on our scores, the stock is equally suitable for value, growth, and momentum investors.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, AbbVie has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the second quarter of 2018. | It has been about a month since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the second quarter of 2018. | It has been about a month since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the second quarter of 2018. | AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the second quarter of 2018. Previously, AbbVie expected operating margin to be approximately 43.5% of sales. It has been about a month since the last earnings report for AbbVie (ABBV). |
25372.0 | 2018-08-26 00:00:00 UTC | 3 Dividend Stocks to Buy on Sale | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-buy-sale-2018-08-26 | nan | nan | Buy high or buy low? Probably the best answer is to do both -- depending on the unit of measure.
Buying stocks with relatively high dividend yields can prove to be a really smart move over the long term. Over the last 10 years, nearly 30% of the total return generated by the S&P 500 index came from reinvesting dividends. Over the last 80 years, the level jumps to more than 40%.
Buying low can work well, too, with respect to valuation. There's a pretty good correlation between returns over a 10-year period and stock valuation.
I like the idea of combining these approaches by buying stocks with strong dividend yields and bargain valuations. What are some dividend stocks that you can buy on sale right now? I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list.
1. AbbVie
AbbVie claims one of the best dividends in the healthcare sector. Its yield currently stands at 3.93%. The drugmaker has an exceptionally strong track record of dividend increases, boosting its dividend by 140% since being spun off from Abbott Labs in 2013.
The pharma stock also ranks as one of the best healthcare bargains. AbbVie shares trade at less than 11 times expected earnings. The stock hasn't performed well so far in 2018 in part because of investors' concerns about the possibility of changes that could allow biosimilars to reach the market more quickly and eliminate the rebates paid by drugmakers to payers.
But AbbVie CEO Rick Gonzalez thinks those worries are overblown . Gonzalez stated in the company's Q2 earnings call that there were "probably more positives than negatives" for AbbVie related to changes proposed by the Trump administration. He also noted that AbbVie's top-selling drug, Humira, has competed very well in countries where there are no drug rebates.
Humira has been the primary driver of AbbVie's success in recent years. However, the company also has a couple of fast-rising stars: cancer drug Imbruvica and hepatitis C drug Mavyret. In addition, market research firm EvaluatePharma ranked AbbVie's pipeline No. 2 in the biopharmaceutical industry on the strength of potential blockbuster candidates like immunology drugs risankizumab and upadacitinib.
2. AT&T
AT&T boasts a juicy dividend yield of more than 6%. The telecommunications giant has increased its dividend for 34 consecutive years, making the company part of the elite group of Dividend Aristocrats .
The telecom stock is also really inexpensive right now, with shares trading at nine times expected earnings and only 6.4 times trailing-12-month earnings. Merrill Lynch upgraded AT&T stock in July , noting that the stock was then the cheapest it had been in 20 years based on its P/E multiple.
There are some reasons behind AT&T's bargain price. The company's second-quarter update wasn't very impressive. The U.S. Department of Justice (DOJ) is appealing a federal judge's decision allowing A&T to merge with Time Warner. And AT&T has a huge debt load of more than $190 billion.
But AT&T should profit as it rolls out high-speed 5G wireless networks that support lots of new applications. The company should be able to reduce its debt over time. And some observers think the DOJ's chances of winning the appeal are pretty slim. All in all, I think AT&T should be able to grow and continue paying its solid dividend well into the future.
3. Cummins
Global engine manufacturer Cummins doesn't have a long streak of dividend hikes like AT&T does. However, Cummins has increased its dividend by a whopping 551% since 2010. The dividend currently yields 3.18%.
Cummins CEO Tom Linebarger thinks his company's stock is "significantly undervalued." I think he's right. Cummins trades at less than 10 times expected earnings. The company likes this attractive valuation so much that it's accelerating stock buybacks.
The primary factors causing Cummins stock to be priced at a discount are the company's product recalls. Cummins is recalling around 232,000 Dodge Ram truck engines and recently announced another recall of 500,000 trucks. All of these recalls relate to emissions-control system problems.
Still, Cummins is firing on all cylinders financially. The company reported all-time high revenue in the second quarter . It's expecting significant year-over-year revenue growth for full-year 2018. Cummins is also expanding into new areas such as powertrains. I think this stock -- and its great dividends -- will keep on trucking for a long time to come.
Best pick
Which of these bargain dividend stocks is the best pick for investors? AT&T has the highest yield and the lowest valuation. However, I think that AbbVie could generate the highest total returns for investors because of its growth prospects.
Wall Street analysts project that AT&T will grow its earnings by an average annual rate of 6.2% over the next five years. They think Cummins will increase its earnings by 11.7% annually. But AbbVie's earnings are expected to grow more than 16% on average each year. This growth advantage, combined with its strong dividend yield, gives AbbVie an edge over AT&T and Cummins.
Are the Wall Street growth estimates for AbbVie overly optimistic? I don't think so. Even though the company faces biosimilar competition for Humira in Europe later this year, the drug will continue to rake in enormous amounts of cash for years. AbbVie's other current drugs and its very promising pipeline candidates should enable the company to deliver on growth expectations.
Buying stocks with high dividend yields and low valuations is a smart move for long-term investors. But I think that buying stocks that also have high earnings growth prospects -- like AbbVie -- is even smarter.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights owns shares of AbbVie and has performed consulting services in the past for Abbott Labs. The Motley Fool owns shares of and recommends Cummins. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie and has performed consulting services in the past for Abbott Labs. I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. | However, I think that AbbVie could generate the highest total returns for investors because of its growth prospects. I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. | But I think that buying stocks that also have high earnings growth prospects -- like AbbVie -- is even smarter. I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. | * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and AbbVie wasn't one of them! I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. |
25373.0 | 2018-08-25 00:00:00 UTC | 3 Top Value Stocks to Buy in August | ABBV | https://www.nasdaq.com/articles/3-top-value-stocks-buy-august-2018-08-25 | nan | nan | The idea of investing in "value" stocks is simple enough: to buy shares of a business that are trading for less than they're worth.
But if finding, buying, and holding the market's most attractive value stocks were easy, everyone would be doing it. So to help get you started, we asked three top Motley Fool contributors to each discuss a value stock they think investors should buy before the end of this month. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) .
Reports of Facebook's demise are greatly exaggerated
Steve Symington (Facebook): When shares of Facebook plummeted nearly 20% in a single day late last month, you might have thought the social-media giant had revealed crushing news indicative of a failing company. But that wasn't the case.
To the contrary, Facebook is still massively profitable and growing quickly. And keeping in mind that shares had only just climbed 36% in the three months leading up to its most recent quarterly report, the pullback merely brought Facebook stock back to levels we most recently saw in early May.
That said, the plunge was driven by two notable factors. First, its latest quarterly results were technically mixed relative to expectations; earnings per share grew 32% to $1.74, beating analysts' estimates by a few pennies. But revenue soared "only" 42% year over year to $13.2 billion, falling short of estimates for $13.4 billion. But more than that, investors balked at Facebook management's prediction that not only will revenue growth rates continue decelerating in the second half, but operating expense growth will also exceed revenue growth both this year and next.
However, the latter -- expense growth -- will be primarily driven by Facebook's efforts to improve the safety, privacy, and security of its platforms, notably including its namesake platform as well as Instagram and WhatsApp. These investments should serve to bolster Facebook's rapport with users, advertisers, and government regulators. With more than half of the world's population yet to connect to the internet, according to Facebook's Internet.org initiative, this is a crucial move that should serve to solidify the long-term health of its business.
Over the long run, I'm convinced Facebook's drop will represent little more than a blip in the radar. With its shares trading at a fair 21 times this year's expected earnings, I think it will prove to be a fantastic opportunity for patient investors to open or add to their positions.
Discount on aisle three
Demitri Kalogeropoulos (Kroger): Pessimism in the bricks-and-mortar retailing world has pushed Kroger stock to an unusually low valuation of just 10 times the past year's earnings. That's a far cry from the 20 times profit that investors had been paying back when the supermarket chain was growing sales at a robust 5% rate while boosting profits by at least 10%.
Yes, the tough selling environment has pushed revenue growth closer to 1% lately . Kroger is also expecting to post another modest earnings decline in 2018, which helps explain Wall Street's dour mood on the stock. On the other hand, the retailer is on track to capture market share for its 14th consecutive year as its popular in-store brands, like Simple Truth, continue to attract more customers.
It's not clear just how much of a negative impact the shift toward multichannel retailing will have on Kroger's long-term earnings power. But this market leader has many valuable assets it can employ in this fight, including price leadership and a large, growing base of loyal shoppers. Thus, value investors might want to take a closer look at this discounted stock as Kroger's sales rebound continues gaining steam.
A big pharma bargain
Keith Speights (AbbVie): When around 60% of a company's total revenue depends on one product that could be threatened on multiple fronts, it tends to weigh on a stock. That's what has happened for AbbVie lately. The company's fortunes hinge largely on Humira, which faces biosimilar competition in Europe later this year. A noted short-seller thinks proposed changes by the U.S. Food and Drug Administration (FDA) could further threaten Humira sales.
As a result of all of this, AbbVie stock trades at less than 11 times expected earnings -- much cheaper than most of its fellow S&P 500 members. And the company's future is much brighter than that valuation implies.
It's true that will soon Humira face biosimilar competition in Europe. However, AbbVie makes a lot more money on the drug in the U.S., where Humira shouldn't encounter biosimilar competition until 2023. As for proposed FDA changes, AbbVie CEO Rick Gonzalez thinks "there were probably more positives than there were negatives" for his company.
AbbVie claims other fast-rising products, though, with cancer drugs Imbruvica and Venclexta and hepatitis C drug Mavyret. It recently won approval for another potential blockbuster, endometriosis pain drug Orilissa. AbbVie's pipeline has also been ranked as the second best in the industry .
The big pharma company should be able to generate strong growth even with challenges for Humira. I think those growth prospects, combined with a solid dividend yield of over 4%, makes AbbVie a great value stock to buy in August.
The bottom line
There's no way to absolutely guarantee that these three stocks will go on to outperform the broader market. But whether we're talking about Facebook's massive pullback last month, industry pessimism driving Kroger to mouthwatering levels, or AbbVie's growth potential and high yield, we like their chances of doing just that.
Find out why Facebookis one of the 10 best stocks to buy now
Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. (In fact, the newsletter they run, Motley Fool Stock Advisor, has tripled the market!*)
Tom and David just revealed their ten top stock picks for investors to buy right now. Facebook is on the list -- but there are nine others you may be overlooking.
Click here to get access to the full list!
*Stock Advisor returns as of August 6, 2018
Demitrios Kalogeropoulos owns shares of Facebook. Keith Speights owns shares of AbbVie and Facebook. Steve Symington has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Facebook. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But whether we're talking about Facebook's massive pullback last month, industry pessimism driving Kroger to mouthwatering levels, or AbbVie's growth potential and high yield, we like their chances of doing just that. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A big pharma bargain Keith Speights (AbbVie): When around 60% of a company's total revenue depends on one product that could be threatened on multiple fronts, it tends to weigh on a stock. | But whether we're talking about Facebook's massive pullback last month, industry pessimism driving Kroger to mouthwatering levels, or AbbVie's growth potential and high yield, we like their chances of doing just that. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A big pharma bargain Keith Speights (AbbVie): When around 60% of a company's total revenue depends on one product that could be threatened on multiple fronts, it tends to weigh on a stock. | But whether we're talking about Facebook's massive pullback last month, industry pessimism driving Kroger to mouthwatering levels, or AbbVie's growth potential and high yield, we like their chances of doing just that. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A big pharma bargain Keith Speights (AbbVie): When around 60% of a company's total revenue depends on one product that could be threatened on multiple fronts, it tends to weigh on a stock. | However, AbbVie makes a lot more money on the drug in the U.S., where Humira shouldn't encounter biosimilar competition until 2023. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A big pharma bargain Keith Speights (AbbVie): When around 60% of a company's total revenue depends on one product that could be threatened on multiple fronts, it tends to weigh on a stock. |
25374.0 | 2018-08-25 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Merck & Co., Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-merck-co-inc-2018-08-25 | nan | nan | The number of American adults over the age of 85 will more than double over the next 22 years and this group's more dependent on expensive medicines than ever. This long-running megatrend will probably drive overall demand for products from AbbVie Inc. (NYSE: ABBV) and Merk & Co., Inc. (NYSE: MRK) in the right direction for decades to come.
Merck and AbbVie offer dividends driven by sales of innovative new drugs and a chance to enjoy strong sales growth in the years to come, but which is poised to grow along with the population of older adults in the U.S. and abroad? Let's stack them side by side to find out.
The case for AbbVie Inc.
This big drugmaker has a product lineup firing on all cylinders right now and some promising-looking rookies ready to make a difference. If you've seen television commercials over the past several years, you probably realize that Humira's an important drug, but did you know sales of the rheumatoid arthritis injection AbbVie launched 16 years ago will probably achieve $20 billion in sales this year?
Humira isn't the fastest-growing product in AbbVie's lineup, but it's expanding fast enough to make it the company's lead growth driver by a long shot. Humira sales rose 12% in the first half of the year, compared to the prior-year period to $9.9 billion, and it's not the only drug pushing the needle higher right now. AbbVie's share of sales from blood cancer tablet Imbruvica rose 37% in the first half to $1.6 billion, plus a new hepatitis C virus treatment called Mavyret appeared out of left field to produce a stunning $1.9 billion for the top line.
The company recently launched the first new option to treat endometriosis pain that women have seen in over a decade, and Orilissa could earn an important expansion to treat noncancerous growths that occur in perhaps three-quarters of all women during their lifetime. Uterine fibroids usually aren't a problem, but they are the most common reason women seek hysterectomies. It's hard to pin down just how many women with painful associated symptoms will convince their insurers to pay for Orilissa and find it useful enough to remain on the drug, but it's probably enough to drive sales past the $3 billion-per-year mark at its peak.
AbbVie's late-stage pipeline also sports two potential new blockbusters, risankizumab for psoriasis and upadacatinib for rheumatoid arthritis.
AbbVie shares currently offer a nice 3.9% yield that could keep rising into the future, if these rookies hit a few home runs. The company used just 44% of free cash flow generated over the past year to make dividend payments, which gives it plenty of room for significant bumps in the years ahead.
The case for Merck & Co.
Sales of this big pharma's aging type 2 diabetes pill, Januvia have flatlined, but its blockbuster cancer therapy's firing on all cylinders. Keytruda plus chemotherapy is quickly becoming a standard treatment for new patients diagnosed with the most common form of lung cancer in advanced stages. This coveted spot on oncologists' go-to lists helped Keytruda sales surge 114% in the first half of 2018 to $3.1 billion.
Merck spent $1.6 billion up front and promised $6.9 billion in potential milestone payments in order to strike a partnership deal with AstraZeneca (NYSE: AZN) earlier this year. The cross-Atlantic partners will co-commercialize and co-develop the British pharma's breast cancer tablet, Lynparza. Sales of the partnered tablet hit just $269 million in the first half but could rise several times over if the Food and Drug Administration approves an upcoming application for first-line ovarian cancer.
Merck shares offer a 2.8% yield that might not move much higher in the quarters ahead. The company needed 99.7% of free cash flow to make payments over the past year.
The better buy
With a meager pipeline and a dividend that looks stretched to the limit, Merck isn't looking so hot right now. AbbVie's already inked agreements that let us know we can reasonably expect steep Humira sales losses to begin in 2023, which gives risankizumab, upadacitinib, and Orilissa time to shine.
Although there's a chance that a major drug pricing policy shift will disrupt Humira sales much sooner , it looks like a risk worth taking. AbbVie's the better stock to buy right now, hands down.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Humira isn't the fastest-growing product in AbbVie's lineup, but it's expanding fast enough to make it the company's lead growth driver by a long shot. This long-running megatrend will probably drive overall demand for products from AbbVie Inc. (NYSE: ABBV) and Merk & Co., Inc. (NYSE: MRK) in the right direction for decades to come. Merck and AbbVie offer dividends driven by sales of innovative new drugs and a chance to enjoy strong sales growth in the years to come, but which is poised to grow along with the population of older adults in the U.S. and abroad? | Merck and AbbVie offer dividends driven by sales of innovative new drugs and a chance to enjoy strong sales growth in the years to come, but which is poised to grow along with the population of older adults in the U.S. and abroad? This long-running megatrend will probably drive overall demand for products from AbbVie Inc. (NYSE: ABBV) and Merk & Co., Inc. (NYSE: MRK) in the right direction for decades to come. The case for AbbVie Inc. | Merck and AbbVie offer dividends driven by sales of innovative new drugs and a chance to enjoy strong sales growth in the years to come, but which is poised to grow along with the population of older adults in the U.S. and abroad? If you've seen television commercials over the past several years, you probably realize that Humira's an important drug, but did you know sales of the rheumatoid arthritis injection AbbVie launched 16 years ago will probably achieve $20 billion in sales this year? AbbVie's share of sales from blood cancer tablet Imbruvica rose 37% in the first half to $1.6 billion, plus a new hepatitis C virus treatment called Mavyret appeared out of left field to produce a stunning $1.9 billion for the top line. | If you've seen television commercials over the past several years, you probably realize that Humira's an important drug, but did you know sales of the rheumatoid arthritis injection AbbVie launched 16 years ago will probably achieve $20 billion in sales this year? AbbVie's the better stock to buy right now, hands down. This long-running megatrend will probably drive overall demand for products from AbbVie Inc. (NYSE: ABBV) and Merk & Co., Inc. (NYSE: MRK) in the right direction for decades to come. |
25375.0 | 2018-08-23 00:00:00 UTC | AbbVie Posts Positive Data on Elagolix for Uterine Fibroids | ABBV | https://www.nasdaq.com/articles/abbvie-posts-positive-data-on-elagolix-for-uterine-fibroids-2018-08-23 | nan | nan | AbbVie Inc . ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. Outcomes from the phase III ELARIS UF-EXTEND (M12-816) trial demonstrated that Elagolix (300 mg twice daily) in combination with low-dose add-back therapy, reduced heavy menstrual bleeding in 87.9% of women with uterine fibroids at month 12 of the regime.
However, shares of AbbVie have lost 0.9% year to date versus the industry's increase of 5.4%.
Top-line data from the extension study was in line with two pivotal phase III programs, ELARIS UF-I and ELARIS UF-II. The results demonstrated that both 68.5% and 76.2% of uterine fibroids patients having received elagolix with add-back therapy for a period of six months, experienced reduction in heavy menstrual bleeding, respectively.
Findings from the extension evaluation will be presented at a medical conference later this year and will also be presented at a future medical meet. AbbVie plans to submit a regulatory application for elagolix with respect to the aforementioned indication by 2019.
Per the company's press release, uterine fibroids affect women at some point in their lives. Among them, some might experience symptoms such as heavy menstrual bleeding, painful periods, vaginal bleeding other than menstruation and anemia. At present, there are limited non-surgical treatment options for women suffering the ailment.
Elagolix has not been proven safe and effective as far as uterine fibroid is concerned. The disease is thus currently managed with oral contraceptives, progestins and GnRH agonists. Many such medicines are not specifically indicated for the treatment of uterine fibroid. Hence, approval of the candidate can address a market with significant unmet need and drive more sales for AbbVie.
We remind investors that another pharma company Allergan AGN also has Esmya/ulipristal acetate in its portfolio, presently under review for the treatment of uterine fibroids. Earlier this week, the FDA gave a complete response letter to the new drug application for Esmya on safety concerns. The regulatory body has requested additional information citing safety issues regarding Esmya's post-marketing reports outside the United States.
AbbVie Inc. Price and Consensus
AbbVie Inc. Price and Consensus | AbbVie Inc. Quote
Zacks Ranks
AbbVie currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the pharma sector are Gilead Sciences, Inc. GILD and Illumina, Inc. ILMN , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Gilead Sciences' earnings estimates have been moved 7.7% north for 2018 and 2.2% for 2019 over the past 60 days. The stock has gained 3% year to date.
Illumina's earnings estimates have been raised 11.1% for 2018 and 8.7% for 2019 over the past 60 days. The stock has soared 53.6% so far this year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan plc (AGN): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. AbbVie Inc . However, shares of AbbVie have lost 0.9% year to date versus the industry's increase of 5.4%. | ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Zacks Ranks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Zacks Ranks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc . | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Zacks Ranks AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie Inc . ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. |
25376.0 | 2018-08-22 00:00:00 UTC | Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-08222018-argxphgsngx-2018-08-22 | nan | nan | Top Health Care Stocks
JNJ -0.45%
PFE +0.14%
ABT +1.43%
MRK -0.16%
AMGN +0.46%
Health care stocks were edging higher Wednesday afternoon, including a nearly 0.2% gain for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 also were up almost 0.2% as a group while the Nasdaq Biotechnology index was cruising to a more than 0.7% advance today.
Among health care stocks moving on news:
+ argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. argenx also is eligible for tiered royalties based on product sales and also retains the right to co-promote ARGX-115-based products in the European Union and Swiss Economic Area.
In other sector news:
+ Philips ( PHG ) was higher during Wednesday trading after introducing its EPIQ CVx cardiovascular ultrasound system for commercial sales. The device has receiving market clearance from regulators in both the U.S. and the European Union and EPIQ CVx was designed to increase diagnostic confidence and simplify workflow for clinicians, providing them more time to interact with patients.
- Soligenix ( SNGX ) was almost 10% lower Wednesday afternoon, with the drugmaker receiving no apparent help from U.S. regulators this week isssuing a patent for its proprietary method of producing highly purified synthetic hypericin, which is believed to be act as an antibioti, anti-viral and kinase inhibitor and also leading to increased dopamine levels.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. The device has receiving market clearance from regulators in both the U.S. and the European Union and EPIQ CVx was designed to increase diagnostic confidence and simplify workflow for clinicians, providing them more time to interact with patients. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. | Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. Health care stocks were edging higher Wednesday afternoon, including a nearly 0.2% gain for the NYSE Health Care Index in recent trade. | Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. Health care stocks were edging higher Wednesday afternoon, including a nearly 0.2% gain for the NYSE Health Care Index in recent trade. |
25377.0 | 2018-08-22 00:00:00 UTC | 3 Undervalued Dividend Stocks to Buy | ABBV | https://www.nasdaq.com/articles/3-undervalued-dividend-stocks-to-buy-2018-08-22 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Finding undervalued stocks in today's market is a tricky business. If you're a value investor who is looking to beef up your retirement portfolio, it's essential to choose firms that have fallen out of favor with Mr. Market but look poised to make a comeback once the dust has settled.
Hot new tech stocks tend to grab the headlines when it comes to earnings growth, but if you're in the market for long-term plays, dividend stocks are the place to start looking. Not only are you gaining a passive income stream, but dividend stocks also offer investors a consistent, dependable return that growth plays simply can't.
5 Marijuana Stocks to Watch
Here's a look at three undervalued dividend stocks that are worth considering for your long-term portfolio.
Dividend Stocks to Buy: AbbVie (ABBV)
Source: Shutterstock
Dividend Yield: 3.9%
Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is one such bargain. ABBV stock is down 18% from its February highs on worries about slowing growth in the firm's key drug Humira.
The Humira concerns are certainly something to keep in mind - the drug makes up more than half of ABBV's overall revenue - but it's worth noting that the company has plenty of growth opportunities to rely on in the future. For one, even though competition is taking away from Humira's marketshare, the drug is expected to be the best-selling drug in the world through 2024.
On top of that, ABBV has a few other drugs in the works that should bolster the firm's earnings growth over the next few years. Dividend investors will like the firm's nearly 4% dividend yield that looks safe for the foreseeable future.
Dividend Stocks to Buy: Walgreens Boots Alliance (WBA)
Source: Mike Mozart via Flickr
Dividend Yield: 2.5%
It's rare to see a dividend aristocrat go on sale because their reliable, ever-increasing dividend payments often offset the effects of bad news. However, pharmacy chain Walgreens Boots Alliance (NASDAQ: WBA ) has seen its share price struggle over the past five years as uncertainty within the U.S. healthcare system weighed on investor sentiment.
Of course, it's worth noting that there are some very real risks to the pharmacy industry as healthcare in America changes shape and e-commerce shakes up the way people buy their medicine, but WBA looks solid enough to weather the storm while maintaining and raising its dividend payments.
First of all, WBA isn't just an American business - the firm also has a massive presence in the UK which will help mitigate any major shifts in the U.S. market. Right now the firm's dividend yield is a respectable 2.5% but that figure could continue increasing in the years to come - Walgreens has upped its dividend payments every year since 1976.
15 Cybersecurity Stocks to Watch As the Industry Heats Up
It's true that e-commerce could disrupt the way traditional pharmacies like Walgreens operate, but it's also worth noting that companies like WBA are much better prepared for a so-called "retail apocalypse" than, say, departments stores were. Adjusting to changing consumer behavior is a challenge for sure, but not something that's likely to put WBA out of business.
Dividend Stocks to Buy: International Business Machines (IBM)
Source: Shutterstock
Dividend Yield: 4.3%
Perhaps the most underappreciated stock on this list is tech company International Business Machines (NYSE: IBM ). Yes, the company has been telling investors that a turnaround is on the horizon for quite some time and yes, it hasn't quite materialized yet - but keep in mind that the company's massive size makes a large-scale strategy shift difficult to pull off quickly.
However, IBM has made a lot of progress toward its goal of expanding strategic imperatives and relying less on its antiquated hardware arm. CEO Ginni Rometty has shifted the firm's focus to high-growth technology like artificial intelligence, security and cloud computing, and that shift appears to finally be paying off. IBM's most recent earnings report showed that sales are finally back on the rise which is an encouraging sign for investors. However, more importantly, the company's strategic imperatives- the part of the business that houses AI and cloud computing - finally makes up the majority of the company's overall revenue.
Not only does IBM have a massive turnaround in store, but the company pays out a 4.3% dividend yield, making it an excellent long-term choice.
As of this writing, Laura Hoy did not hold a position in any of the aforementioned securities.
Compare Brokers
The post 3 Undervalued Dividend Stocks to Buy appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is one such bargain. ABBV stock is down 18% from its February highs on worries about slowing growth in the firm's key drug Humira. | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is one such bargain. ABBV stock is down 18% from its February highs on worries about slowing growth in the firm's key drug Humira. | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is one such bargain. ABBV stock is down 18% from its February highs on worries about slowing growth in the firm's key drug Humira. | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. The Humira concerns are certainly something to keep in mind - the drug makes up more than half of ABBV's overall revenue - but it's worth noting that the company has plenty of growth opportunities to rely on in the future. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is one such bargain. |
25378.0 | 2018-08-22 00:00:00 UTC | Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-08222018-exaspfeargxphgsngx-2018-08-22 | nan | nan | Top Health Care Stocks
JNJ -0.55%
PFE -0.21%
ABT +1.47%
MRK -0.12%
AMGN +0.38%
Health care stocks were poised to finish with a a small gain on Wednesday, including a nearly 0.2% rise for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 also were up almost 0.2% as a group while the Nasdaq Biotechnology index was cruising to a more than 0.8% advance today.
Among health care stocks moving on news:
+ Exact Sciences ( EXAS ) was more than 29% higher in late Wednesday trading, steadily extending its advance that followed the diagnostics company earlier announcing a three-year agreement with Pfizer ( PFE ) to co-promote its Cologuard stool DNA screening test for colorectal cancer. The combined marketing efforts are slated to begin during the final three months of 2018, with Exact Sciences having responsibility for manufacturing and laboratory operations of the testing kit while Pfizer will equally share gross profits and marketing expenses above an undisclosed baseline. The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece
In other sector news:
+ argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. argenx also is eligible for tiered royalties based on product sales and also retains the right to co-promote ARGX-115-based products in the European Union and Swiss Economic Area.
+ Philips ( PHG ) was more than 1% higher late in Wednesday trading after late yesterday introducing its EPIQ CVx cardiovascular ultrasound system for commercial sales. The device has receiving market clearance from regulators in both the U.S. and the European Union and EPIQ CVx was designed to increase diagnostic confidence and simplify workflow for clinicians, providing them more time to interact with patients.
- Soligenix (SNGX) was almost 10% lower Wednesday afternoon, with the drugmaker receiving no apparent help from U.S. regulators this week isssuing a patent for its proprietary method of producing highly purified synthetic hypericin, which is believed to be act as an antibioti, anti-viral and kinase inhibitor and also leading to increased dopamine levels.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. Among health care stocks moving on news: + Exact Sciences ( EXAS ) was more than 29% higher in late Wednesday trading, steadily extending its advance that followed the diagnostics company earlier announcing a three-year agreement with Pfizer ( PFE ) to co-promote its Cologuard stool DNA screening test for colorectal cancer. | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. Among health care stocks moving on news: + Exact Sciences ( EXAS ) was more than 29% higher in late Wednesday trading, steadily extending its advance that followed the diagnostics company earlier announcing a three-year agreement with Pfizer ( PFE ) to co-promote its Cologuard stool DNA screening test for colorectal cancer. | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. Health care stocks were poised to finish with a a small gain on Wednesday, including a nearly 0.2% rise for the NYSE Health Care Index in recent trade. | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie securing an exclusive global license to develop and commercialize ARGX-115-based products in exchange for up to $625 million in future payments as it reaches certain development, regulatory and commercial milestones of up to $625 million. Among health care stocks moving on news: + Exact Sciences ( EXAS ) was more than 29% higher in late Wednesday trading, steadily extending its advance that followed the diagnostics company earlier announcing a three-year agreement with Pfizer ( PFE ) to co-promote its Cologuard stool DNA screening test for colorectal cancer. |
25379.0 | 2018-08-21 00:00:00 UTC | Trade of the Day: AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/trade-of-the-day%3A-abbvie-abbv-2018-08-21 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today.
Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . Major drug-manufacturer ABBV is still trying to bounce back from the massive late-March decline it experienced when it announced it would be backing away from seeking accelerated approval for Rova-T after receiving disappointing test results on the drug, but we think it has an excellent opportunity to climb back up toward the top of the trading range it has been in since that time as healthcare spending continues to rise (it's nearing 20% of GDP in the U.S., according to the Wall Street Journal ) and as sales of ABBV's major pharmaceuticals continue to grow.
ABBV is the proud owner of the top-selling drug in the world: Humira. In 2017, Humira raked in $18.9 billion in sales and, according to the company's latest earnings announcement, that sales rate grew by 10% year-over-year during the second quarter. Sales of its cancer drugs are also soaring, with Imbruvica sales climbing by a whopping 35.6% year-over-year.
Wall Street is starting to pay attention to the stock again, and traders have pushed the ABBV up through down-trending resistance at ~$97 per share - completing an inverted "head-and-shoulders" bullish reversal pattern. Based on the height of this pattern and the bearish price gap that formed on March 22, we are targeting the $104 level with this trade.
Yes, the stock could climb back up toward its May high of $107.25, but, with this short-term trade in our current market environment, we believe a more conservative price target is appropriate.
Buy to open the ABBV September 21st $100 Call (ABBV180921C00100000) for a maximum price of $1.90.
Follow our Facebook page to receive each Trade of the Day direct to your News Feed - and join the conversation.
You can learn more about identifying price patterns and using them to project how far you think a stock is going to move in our Advanced Technical Analysis Program.
InvestorPlace advisers John Jagerson and S. Wade Hansen, both Chartered Market Technician (CMT) designees, are co-founders of LearningMarkets.com, as well as the co-editors of SlingShot Trader , a trading service designed to help you make options profits by trading the news. Get in on the next SlingShot Trader trade and get 1 free month today by clicking here.
Compare Brokers
The post Trade of the Day: AbbVie (ABBV) appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wall Street is starting to pay attention to the stock again, and traders have pushed the ABBV up through down-trending resistance at ~$97 per share - completing an inverted "head-and-shoulders" bullish reversal pattern. InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . Major drug-manufacturer ABBV is still trying to bounce back from the massive late-March decline it experienced when it announced it would be backing away from seeking accelerated approval for Rova-T after receiving disappointing test results on the drug, but we think it has an excellent opportunity to climb back up toward the top of the trading range it has been in since that time as healthcare spending continues to rise (it's nearing 20% of GDP in the U.S., according to the Wall Street Journal ) and as sales of ABBV's major pharmaceuticals continue to grow. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Major drug-manufacturer ABBV is still trying to bounce back from the massive late-March decline it experienced when it announced it would be backing away from seeking accelerated approval for Rova-T after receiving disappointing test results on the drug, but we think it has an excellent opportunity to climb back up toward the top of the trading range it has been in since that time as healthcare spending continues to rise (it's nearing 20% of GDP in the U.S., according to the Wall Street Journal ) and as sales of ABBV's major pharmaceuticals continue to grow. Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . Major drug-manufacturer ABBV is still trying to bounce back from the massive late-March decline it experienced when it announced it would be backing away from seeking accelerated approval for Rova-T after receiving disappointing test results on the drug, but we think it has an excellent opportunity to climb back up toward the top of the trading range it has been in since that time as healthcare spending continues to rise (it's nearing 20% of GDP in the U.S., according to the Wall Street Journal ) and as sales of ABBV's major pharmaceuticals continue to grow. |
25380.0 | 2018-08-20 00:00:00 UTC | 8 Undervalued Biotech Stocks to Watch | ABBV | https://www.nasdaq.com/articles/8-undervalued-biotech-stocks-to-watch-2018-08-20 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up double digits since January's opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.
But in the bigger picture, investors have an opportunity to use this weakness in biotech stocks to their advantage. In my opinion, biotech firms represent ideal contrarian opportunities due to their often binary nature. When a company hits or exceeds performance benchmarks, shares launch into low-earth orbit. However, failure often results in excessive selloffs that can endure for lengthy periods.
Understanding this dynamic, sector weakness is an ideal time to consider well-capitalized and fundamentally sound biotech stocks. Investors punish health-related companies with unusual vigor, even though their underlying financial situation may not have changed.
But don't forget some of the smaller names in this investment category. Many of them offer underappreciated therapies that could take off once the right conditions are met.
10 Dividend Aristocrats You Never Have to Worry About
So without further ado, here are eight undervalued biotech stocks to watch:
Undervalued Biotech Stocks to Watch: AbbVie (ABBV)
Source: Shutterstock
If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing three-year period, ABBV generated 12.4% top-line growth, which is better than 72% of the competition. Furthermore, the company has nearly 43% EBITDA growth, which places it in the top ten among biotech stocks.
Much of this financial success comes from AbbVie's standout drug, Humira. Doctors prescribe Humira to address pain and inflammation problems resultant from a variety of autoimmune diseases. These include rheumatoid arthritis, chronic plaque psoriasis and Crohn's disease.
Beyond helping countless patients ease their suffering, Humira brings a ton of green to the table. Between 2011 through 2017, Humira revenues jumped from $7.9 billion to $18.4 billion . Annually, this translates to an impressive 15% growth rate.
The markets, though, haven't been too hot on ABBV stock. Year-to-date, shares have only gained 4.6%. It's also down double digits since mid-March, providing opportunists with a blue-chip bargain.
Undervalued Biotech Stocks to Watch: Gilead Sciences (GILD)
Source: Shutterstock
Several top biotech stocks haven't lived up to expectations this year, and Gilead Sciences (NASDAQ: GILD ) is one of them. Against January's opener, GILD stock has only gained 2.5%, which is incredibly pedestrian. Even worse, it was having a decent go, putting in a double-digit performance until just recently.
So why the fallout? GILD was on the receiving end of two negative factors. First, while the company reported a solid second-quarter earnings report, investors noted that its hepatitis C drug revenues slipped 66% year-over-year.
Next, it incurred internal drama when the biotech giant announced that CEO John Milligan will step down at year's end. Taken as a whole, the markets didn't appreciate the news, and decided to sell off GILD stock.
7 Stocks Warren Buffett Can't Stop Buying
Although the bearishness is understandable, new investors should keep a close eye on GILD. The company still levers impressive financials, particularly with their excellent profitability margins. Also, it has a favorable cash-to-debt ratio relative to its peers.
Undervalued Biotech Stocks to Watch: Celgene (CELG)
Source: Shutterstock
Even compared to the laggards among biotech stocks, Celgene (NASDAQ: CELG ) suffers a distinctly poor outing. On a year-to-date basis, CELG stock has slipped more than 14%. Based on its current position, the company essentially hasn't moved since the middle of spring.
Actually, as my InvestorPlace colleague Aaron Levitt noted, Celgene's problems started in the fall . Levitt wrote:
"The firm's first failure came from the stoppage of Phase 3 clinical trials for its REVOLVE drug to treat Crohn's disease. Strike two came when Celgene was forced to reduced forward earnings forecasts based on that stoppage and the fact that REVOLVE won't be coming to market anytime soon."
That said, Levitt insists that you look at the longer-term picture, and I agree. For one thing, CELG is fundamentally undervalued, trading at 10.4-times forward earnings. Additionally, the company enjoys very strong profitability margins, as well as double-digit revenue and EBITDA growth.
Undervalued Biotech Stocks to Watch: Jazz Pharmaceuticals (JAZZ)
Source: Shutterstock
At first glance, Jazz Pharmaceuticals (NASDAQ: JAZZ ) doesn't appear as a candidate for undervalued biotech stocks. After all, JAZZ shares have lit up the markets, gaining an impressive 28.6% YTD. That puts it in a completely opposite category relative to so many other sector players.
But look a little deeper and you'll note that Jazz Pharmaceuticals isn't what you call an industry titan. At the present juncture, the company has a market capitalization of $10.5 billion. Yet it has some impressive financial metrics. Standouts include its operating and net margins, both of which are inside the top 10% of global biotech stocks.
Also, I'm digging the fact that its trailing three-year revenue and EBITDA growth are in double-digit territory. And while its cash-to-debt ratio isn't the most favorable I've seen in this sector, considering its relative upstart status, I view this as a sign of management's fiscal discipline.
4 Mega-Cap Stocks to Buy As They're Thrust Into the Spotlight
Finally, JAZZ stock trades at 13.4-times forward earnings, which suggests it has upside remaining.
Undervalued Biotech Stocks to Watch: Exelixis (EXEL)
Source: Shutterstock
I have no other way to describe it. Exelixis (NASDAQ: EXEL ) is having a catastrophically bad year. Since January's opening price, EXEL stock has hemorrhaged nearly 37% of market value. The only good news here is that it appears shares have hit a bottom. But is that reason enough to take a shot?
Let's recap how EXEL stock got into this mess. Shares dipped badly following its Q4 earnings report, which was in line with profitability estimates and beat revenue expectations. However, the company's $120.1 million in sales sharply contrasted with the prior Q3 haul of $152.5 million.
Later, the company produced two strong earnings results in Q1 and Q2, which helped stabilize EXEL stock. Nevertheless, shares haven't gone up meaningfully. In fact, over the last several days, the opposite is true.
I believe, though, this is a case where the markets are overly pessimistic. Exelixis, which specializes in tumor and cancer treatments, levers a viable drug pipeline. Moreover, it has strong financials, a highlight being a very favorable cash-to-debt ratio.
Undervalued Biotech Stocks to Watch: Alnylam Pharmaceuticals (ALNY)
Source: Shutterstock
All companies eventually face disappointing market performances. This is especially true for biotech stocks. But I'll argue that Alnylam Pharmaceuticals (NASDAQ: ALNY ) has one of the more depresing tales of volatility.
Straight off the bat, let me just say that analysts have largely treated ALNY stock as a speculative investment. Nevertheless, management has been banking on its key drug patisiran, which is now named Onpattro . Developed as a treatment for a rare hereditary disease that damages internal organs, Alnylam sought FDA approval for Onpattro.
They got it just a few weeks ago. Unfortunately, the news arrived along with some granular conditions, including that Alnylam cannot mention cardiac benefits associated with Onpattro. To do so would require further clinical trials, which could take years.
7 Esports Stocks to Watch as Gaming Goes Mainstream
But as The Motley Fool's Jim Crumly argued, the bearishness may be overplayed. Onpattro is an effective drug, and compares favorably to the competition. The markets may just need some extra time to properly digest the news.
Undervalued Biotech Stocks to Watch: Geron (GERN)
Source: Shutterstock
If you judged Geron (NASDAQ: GERN ) based on market performance alone, you wouldn't come to the conclusion that it's undervalued. Not when shares have skyrocketed 113% YTD, making GERN the best performing investment on this list of biotech stocks.
However, Geron is a small-cap company - it only has a market cap of $720 million - with significant upside potential. Geron specializes in oncology, and it has partnered with Johnson & Johnson (NYSE: JNJ ) for its only drug imetelstat . The treatment, which is aimed at hematologic myeloid malignancies, shows great promise; hence, the partnership with JNJ.
That said, as a lone-drug company, Geron's fate hinges on imetelstat's next clinical trial , which will come up shortly. A positive result could see an expanded partnership, or a JNJ buyout. On the flipside, a negative result could shutter Geron's doors.
Ultimately, GERN stock is a binary opportunity, but one that is quite compelling for the speculator.
Undervalued Biotech Stocks to Watch: Kamada (KMDA)
Source: Shutterstock
Technically, I can't call Kamada (NASDAQ: KMDA ) undervalued. On a YTD basis, KMDA stock has gained 12.4%, making it one of the better biotech stocks on this list.
I also can't say that the company is fundamentally undervalued. KMDA trades at 18-times trailing earnings, and a whopping 39-times forward earnings. So why am I talking about this drug maker?
Simply put, KMDA stock suffers from lack of interest. At the time of this writing, the volume readout indicated 5,449 shares. Bluntly stated, that's scary low. Much of the bearishness stems from Kamada's failure to answer FDA concerns about its Inhaled Alpha-1 Antitrypsin therapy . This played into long-held skepticism regarding an inhaled therapy for Alpha-1 Antitrypsin Deficiency.
However, its core fundamentals deserve better than its current awful lack of attention. Typical for Israeli companies, Kamada has very little debt relative to its cash position. It also features excellent profitability margins, and double-digit revenue growth.
5 Stocks to Buy at the Bottom
Of course, KMDA could turn into a "zombie" stock, so I don't rank it very highly. Still, this is worth putting on your watch list as it could surprise down the road.
As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities.
Compare Brokers
The post 8 Undervalued Biotech Stocks to Watch appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing three-year period, ABBV generated 12.4% top-line growth, which is better than 72% of the competition. Much of this financial success comes from AbbVie's standout drug, Humira. | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing three-year period, ABBV generated 12.4% top-line growth, which is better than 72% of the competition. Much of this financial success comes from AbbVie's standout drug, Humira. | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing three-year period, ABBV generated 12.4% top-line growth, which is better than 72% of the competition. Much of this financial success comes from AbbVie's standout drug, Humira. | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing three-year period, ABBV generated 12.4% top-line growth, which is better than 72% of the competition. Much of this financial success comes from AbbVie's standout drug, Humira. |
25381.0 | 2018-08-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 8/19/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-8192018-2018-08-19 | nan | nan | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
EMERGENT BIOSOLUTIONS INC ( EBS ) is a mid-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 100% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FRESENIUS MEDICAL CARE AG & CO. (ADR) ( FMS ) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company's segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment. The Company develops and manufactures a range of dialysis machines, systems and disposable products. As of December 31, 2016, the Company sold its products to customers in more than 120 countries and also used in its internal healthcare service operations. The Company's Care Coordination services include coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services, ambulatory surgery center services and urgent care services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
UNIVERSAL HEALTH SERVICES, INC. ( UHS ) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 81% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Universal Health Services, Inc. is a holding company. The Company's principal business is owning and operating, through its subsidiaries, acute care hospitals and outpatient facilities, and behavioral healthcare facilities. The Company's segments include Acute Care Hospital Services, Behavioral Health Services and Other. As of August 1, 2018, the Company owned and/or operated more than 326 inpatient facilities, and 32 outpatient and other facilities, located in 37 states, Washington, District of Columbia, the United Kingdom, Puerto Rico and the United States Virgin Islands. The Company's hospitals provide a range of services, such as oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. As of February 28, 2017, its acute care facilities located in the United States included 26 inpatient acute care hospitals; four free-standing emergency departments, and four outpatient surgery/cancer care centers and one surgical hospital.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
HCA HEALTHCARE INC ( HCA ) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on John Neff is 79% based on the firm's underlying fundamentals and the stock's valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: HCA Healthcare, Inc., formerly HCA Holdings, Inc., is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia. As of December 31, 2016, the American Group included 80 hospitals, which were located in Colorado, northern Georgia, Kansas, southern Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, Tennessee and Texas. As of December 31, 2016, the Company operated six hospitals in England. The Company owns, manages or operates hospitals, freestanding surgery centers and freestanding emergency care facilities, walk-in clinics, diagnostic and imaging centers, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on John Neff has returned 153.84% vs. 156.33% for the S&P 500. For more details on this strategy, click here
About John Neff : While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea : Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. For a full detailed analysis using NASDAQ's Guru Analysis tool, click here UNIVERSAL HEALTH SERVICES, INC. ( UHS ) is a large-cap growth stock in the Healthcare Facilities industry. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's principal business is owning and operating, through its subsidiaries, acute care hospitals and outpatient facilities, and behavioral healthcare facilities. |
25382.0 | 2018-08-14 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2018-08-14 | nan | nan | Perhaps no blending of words applies to the pharmaceutical industry better than "frenemies" -- the combination of "friends" and "enemies." The word accurately describes the relationships of quite a few big pharma companies, including two of the biggest: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) .
The two giant drugmakers partner on one of the hottest cancer drugs on the market, Imbruvica. They also compete in multiple areas. One of these stocks, though, appears to be a much better pick for investors right now. Here's how these two frenemies compare.
The case for AbbVie
The first reason to buy AbbVie is its growth prospects. Wall Street expects the company to grow earnings by 16% annually on average over the next five years. A key driver for this growth will be AbbVie's strong current lineup of products.
Although Humira faces biosimilar competition in Europe later this year, it's still likely to reign as the top-selling drug in the world for years to come . But AbbVie's primary sources of growth from its current lineup of approved products will be cancer drugs Imbruvica and Venclexta, hepatitis C drug Mavyret, and endometriosis drug Orilissa. All of these drugs except Mavyret should benefit from expansion into new indications.
AbbVie's pipeline, which market research firm EvaluatePharma ranked as the second-best in the industry , is even more important to the company's growth. Humira could soon be joined by two new immunology blockbusters, risankizumab and upadacitinib. AbbVie hopes to win approval for its late-stage cancer drug, veliparib.
The second reason to buy AbbVie stock is its valuation. AbbVie's shares currently trade at less than 11 times expected earnings. Factoring in the company's strong growth prospects over the next few years makes its valuation look even more attractive.
Last but not least, there's the dividend. AbbVie's dividend yield stands at 4.1%, one of the highest among big pharma stocks. Tthe company has increased its dividend by 140% since 2013, making AbbVie's dividend one of the fastest-growing dividends on the market.
The case for Johnson & Johnson
Does Johnson & Johnson beat AbbVie on growth prospects, valuation, and dividend yield? No, no, and no. Wall Street thinks J&J will increase earnings by around 8% annually on average over the next five years. The stock trades at 15 times expected earnings, and J&J's dividend currently yields 2.74% -- solid, but not as good as AbbVie's yield.
However, there is a compelling argument for buying Johnson & Johnson stock. J&J is one of the most diversified and steady investments in healthcare that you can find.
Johnson & Johnson is a global leader in three different areas of healthcare: consumer health, medical devices, and pharmaceuticals. Last year, these three segments generated $13.6 billion, $26.6 billion, and $36.3 billion, respectively. These segments consist of more than 260 operating companies doing business in nearly every country across the world.
Thanks to these businesses, Johnson & Johnson is a cash-generating machine. The company's levered free cash flow over the last 12 months totaled $17.8 billion. J&J uses that cash to further solidify its market position through investing in research and development and by making strategic acquisitions.
These investments help make J&J one of the most stable pharma stocks around. The stock's beta value , an indicator of volatility, stands at 0.6 -- a little over half that of AbbVie's. There aren't many stocks that have been around since 1887 and still rank among the largest companies in the world, but Johnson & Johnson does.
This stability has enabled J&J to achieve one of the most enviable dividend track records on the market. The company has increased its dividend for 56 consecutive years, an accomplishment that makes J&J one of the top members of the elite group of Dividend Aristocrats .
Better buy
I don't think you can go wrong over the long run by buying Johnson & Johnson stock. It's one of the bluest of the blue-chip stocks -- and deservedly so. However, in my view, it's hard to top AbbVie's total package.
There has been some negativity recently about the potential for Humira's sales to be hurt by U.S. regulatory changes related to biosimilars and drug rebates. AbbVie's management thinks these concerns are overblown , and I agree. The company has plenty of time for its other drugs to start picking up the slack from Humira. At least for the next few years, I think AbbVie stock will generate better total returns for investors than J&J's will.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of Johnson & Johnson and has the following options: short October 2018 $135 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's pipeline, which market research firm EvaluatePharma ranked as the second-best in the industry , is even more important to the company's growth. The word accurately describes the relationships of quite a few big pharma companies, including two of the biggest: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) . The case for AbbVie The first reason to buy AbbVie is its growth prospects. | The case for Johnson & Johnson Does Johnson & Johnson beat AbbVie on growth prospects, valuation, and dividend yield? The stock trades at 15 times expected earnings, and J&J's dividend currently yields 2.74% -- solid, but not as good as AbbVie's yield. At least for the next few years, I think AbbVie stock will generate better total returns for investors than J&J's will. | Tthe company has increased its dividend by 140% since 2013, making AbbVie's dividend one of the fastest-growing dividends on the market. The case for Johnson & Johnson Does Johnson & Johnson beat AbbVie on growth prospects, valuation, and dividend yield? The word accurately describes the relationships of quite a few big pharma companies, including two of the biggest: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) . | But AbbVie's primary sources of growth from its current lineup of approved products will be cancer drugs Imbruvica and Venclexta, hepatitis C drug Mavyret, and endometriosis drug Orilissa. Tthe company has increased its dividend by 140% since 2013, making AbbVie's dividend one of the fastest-growing dividends on the market. The word accurately describes the relationships of quite a few big pharma companies, including two of the biggest: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) . |
25383.0 | 2018-08-13 00:00:00 UTC | Noteworthy ETF Inflows: MTUM, BA, JPM, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-mtum-ba-jpm-abbv-2018-08-13 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $153.6 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 82,100,000 to 83,450,000). Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average:
Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $114.45. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $153.6 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 82,100,000 to 83,450,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $114.45. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $153.6 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 82,100,000 to 83,450,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $114.45. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $153.6 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 82,100,000 to 83,450,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $114.45. |
25384.0 | 2018-08-13 00:00:00 UTC | Why Enanta Stock Is Still a Strong Buy With Huge Upside | ABBV | https://www.nasdaq.com/articles/why-enanta-stock-still-strong-buy-huge-upside-2018-08-13 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Enanta Pharmaceuticals (NASDAQ: ENTA ) has been in the news recently. Unfortunately, it isn't for the reasons that I'm so bullish on ENTA stock.
Although Enanta stock is off almost 30% in the past month, it is still up 52% year-to-date and up nearly 130% for the past 12 months.
Before I get around to what's been happening with ENTA stock recently, it may help to get a broader understanding of how the company operates and what exactly it does.
The world of biotech and pharma companies has changed a great deal in the past couple decades. What used to be a fairly typical model, where you discover a drug, run it through the various drug trials, build a marketing plan and sell the drug, has now become much more focused.
Even the big pharma companies that still have this kind of integrated structure are now more likely to go out and buy a small company in a strategic sector rather than hire researchers to look for candidates in-house.
7 3D-Printing Stocks to Buy As the Space Keeps Growing
And that can be said of many operations these days. Now a whole industry of focused drug companies has emerged. Some companies simply focus on getting drugs through drug trials. Others focus on manufacturing. Some focus on blending and dosages.
Still others, like ENTA, do the R&D that used to be done in-house. It specializes in small molecule drugs for viral infections and liver diseases. As it finds promising candidates, it talks to larger pharmas about partnering on development. ENTA gets funding for research and then profits from drugs that make it to market.
For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). Both are focused on the hepatitis C virus. ABBV sells them as MAVYRET and VIEKIRA PAK. MAVYRET was approved last year for use as an HCV treatment, which is why ENTA has had such a good year.
The short-term trouble that ENTA stock ran into recently was an announcement from pharmacy benefit management company Express Scripts (NASDAQ: ESRX ) will drop MAVYRET from its formulary in favor of lower-priced alternatives and other HCV drugs that have better rebates. This action will take effect in 2019.
Why ENTA Stock Is Still Worth a Look
The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market share in this lucrative sector. But most of this selloff is an overreaction to a surprise decision. And no other PBMs have followed ESRX.
What's more, ENTA has a lot more drugs in its pipeline beyond these HCV drugs. It has six drugs at various trial stages that treat the hepatitis B virus, non-alcoholic steatohepatitis and respiratory syncytial virus.
All these represent significant opportunities. RSV for example attacks the virus that is the No. 1 cause of pneumonia in children less than one-year-old and it's responsible for 20% of children's hospitalizations and 18% of emergency room visits. It also would be very valuable of immune-compromised individuals and the elderly.
Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth , Emerging Growth, Ultimate Growth , Family Trust and Platinum Growth . His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com . Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.
More From InvestorPlace
The 10 Best Stocks to Buy Right Now
7 High Short-Interest Stocks
5 Retail Stocks Set to Steal the Show This Earnings Season
3 Cybersecurity Stocks to Add to Your Buy List
Compare Brokers
The post Why Enanta Stock Is Still a Strong Buy With Huge Upside appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market share in this lucrative sector. For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells them as MAVYRET and VIEKIRA PAK. | For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells them as MAVYRET and VIEKIRA PAK. Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market share in this lucrative sector. | For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells them as MAVYRET and VIEKIRA PAK. Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market share in this lucrative sector. | For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells them as MAVYRET and VIEKIRA PAK. Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market share in this lucrative sector. |
25385.0 | 2018-08-08 00:00:00 UTC | Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut | ABBV | https://www.nasdaq.com/articles/mylan-myl-q2-earnings-and-revenues-miss-guidance-cut-2018-08-08 | nan | nan | MylanMYL reported dismal results for second-quarter 2018 as earnings and sales both missed estimates. The company also lowered its guidance.
Adjusted earnings of $1.07 per share missed the Zacks Consensus Estimate of $1.23 and were down from $1.10 reported in the year-ago quarter.
Second-quarter revenues of $2.81 billion missed the Zacks Consensus Estimate of $2.96 billion and were down 5% from the prior-year period.
Subsequently, the shares are trading down. Mylan's stock has lost 16.5% in the year so far compared with the industry's growth of 5.3%.
Concurrently, the company announced that the Board has formed a strategic review committee and is actively evaluating a wide range of alternatives. This will further dampen investors' sentiments.
Quarter in Detail
The company posts results in three segments on a geographic basis namely North America, Europe and Rest of World.
North America segment's net sales came in at $1.0 billion, down 22%, primarily due to significantly lower volumes on existing products including EpiPen, partially offset by new product sales. Lower volumes were primarily driven by the timing of purchases and actions associated with the restructuring and remediation program at the Morgantown manufacturing facility including the discontinuation of a number of products and the significantly negative impact on production levels, product supply and operations. Pricing also declined slightly. Sales were negatively impacted by the implementation of new accounting standards.
Sales from Europe were $990.6 million, up 4% as new product sales offset the negative impact of pricing and volume.
Rest of World segment's net sales of $764.1 million was up 10%, driven by new products primarily from the anti-retroviral franchise.
Adjusted gross margin of 53.3% was slightly down from 53.8% in the year-ago quarter.
2018 Outlook Lowered
Mylan updated its outlook as a result of the change in expected complex product launch and utilization assumptions and resizing of product opportunities in the United States, and the negative impact on operations of the restructuring and remediation program in Morgantown.
Mylan now expects 2018 total revenues in the range of $11.25 billion to $12.25 billion, down from the previous projection of $11.75-$13.25 billion, while the Zacks Consensus Estimate stands at $12.24 billion. Mylan anticipates adjusted EPS around $4.55-$4.90, down from the earlier estimate of $5.20-$5.60, while the Zacks Consensus Estimate is pegged at $5.28.
Our Take
Mylan's second-quarter results were dismal as challenges in North America persist prompting management to evaluate strategic alternatives.
Mylan N.V. Price and Consensus
Mylan N.V. Price and Consensus | Mylan N.V. Quote
Mylan continues to gain traction with its biosimilar portfolio. Mylan and partner Biocon obtained the FDA approval for Fulphila, a biosimilar of Neulasta. The CHMP also issues a positive opinion on the biosimilar of AbbVie's ABBV Humira. The company earlier received the FDA approval for a biosimilar version of Roche Holdings' RHHBY Herceptin.
However, these new approvals might not be enough to combat the persistent decline in North America. The company earlier suffered a setback when the FDA decided to not approve its Abbreviated New Drug Application for the generic version of GlaxoSmithKline's GSK asthma drug, Advair Diskus yet again.
Zacks Rank
Mylan carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The CHMP also issues a positive opinion on the biosimilar of AbbVie's ABBV Humira. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Concurrently, the company announced that the Board has formed a strategic review committee and is actively evaluating a wide range of alternatives. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP also issues a positive opinion on the biosimilar of AbbVie's ABBV Humira. North America segment's net sales came in at $1.0 billion, down 22%, primarily due to significantly lower volumes on existing products including EpiPen, partially offset by new product sales. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP also issues a positive opinion on the biosimilar of AbbVie's ABBV Humira. Mylan now expects 2018 total revenues in the range of $11.25 billion to $12.25 billion, down from the previous projection of $11.75-$13.25 billion, while the Zacks Consensus Estimate stands at $12.24 billion. | The CHMP also issues a positive opinion on the biosimilar of AbbVie's ABBV Humira. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. North America segment's net sales came in at $1.0 billion, down 22%, primarily due to significantly lower volumes on existing products including EpiPen, partially offset by new product sales. |
25386.0 | 2018-08-07 00:00:00 UTC | Get Paid While You Wait: 3 Top Dividend Stocks in Healthcare | ABBV | https://www.nasdaq.com/articles/get-paid-while-you-wait-3-top-dividend-stocks-healthcare-2018-08-07 | nan | nan | Don't underestimate the power of dividends -- especially when you reinvest those dividends over a long period of time. You might be surprised by how much reinvesting dividends can boost your total returns.
But what dividend stocks should you buy? I'd recommend turning your attention to the healthcare sector. It accounts for nearly one-fifth of the U.S. economy and claims plenty of solid dividend stocks. Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . These top healthcare dividend stocks pay you to wait as each company's growth picks up momentum.
1. AbbVie
AbbVie's dividend currently yields a little over 4%. The company has boosted its dividend by 140% since becoming a stand-alone entity in 2013. AbbVie should have plenty of financial flexibility to keep those dividend hikes coming in future years, too.
The big drugmaker appears to have a good plan in place to reduce its dependence on Humira, the world's best-selling drug. AbbVie already has two other blockbusters with cancer drug Imbruvica and hepatitis C virus (HCV) drug Mavyret. Two other already approved products should be huge winners over the next few years -- endometriosis pain drug Orilissa and leukemia drug Venclexta.
AbbVie's pipeline includes several candidates with tremendous potential. Risankizumab and upadacitinib could join Humira to solidify AbbVie's position at the top in immunology. The company is also hoping to add new approved indications for existing drugs such as Imbruvica and Orilissa.
Don't write off Humira yet, either. Market research firm EvaluatePharma predicts that Humira will still be the top-selling drug in the world at least through 2024 . That's plenty of time for AbbVie's other drugs and pipeline candidates to ramp up sales. In the meantime, investors can look forward to the big pharma company's nice dividend payments.
2. Pfizer
Pfizer has paid a dividend every quarter in every year since late 1938. That's an impressive streak that I expect will remain unbroken for a long time to come. The dividend is also quite attractive, with a current yield of nearly 3.7%.
But while Pfizer's dividend looks great, the drugmaker hasn't generated tremendous growth in recent years. One big reason why is that Pfizer continues to face declining sales for several drugs that have lost exclusivity. In addition, the company has had product shortages with its sterile injectables business that weighed on sales.
The good news for Pfizer is that both of these issues should improve in the not-too-distant future. Pfizer CEO Ian Read stated in the company's Q2 earnings conference call that year-over-year comparisons for its sterile injectables business should improve beginning in the third quarter of 2018. Read has also expressed optimism that the negative impact from older drugs that have lost exclusivity will become much less of an anchor for the company after 2020.
Meanwhile, Pfizer claims several drugs with strong momentum. Anticoagulant Eliquis, which Pfizer co-markets with Bristol-Myers Squibb , and breast cancer drug Ibrance are at the top of the list. Pfizer anticipates even stronger growth for immunology drug Xeljanz. And the company has its best pipeline in years, with several promising drugs awaiting regulatory approval or in late-stage clinical testing.
3. Welltower
I have referred to Welltower as a retiree's dream stock -- in large part because of the company's fantastic dividend. Welltower's dividend yield currently stands at 5.4%. As a real-estate investment trust (REIT), Welltower must return at least 90% of taxable income to shareholders in the form of dividends.
Welltower ranks as the largest healthcare-focused REIT in the world. The company owned 1,077 properties as of June 30, 2018. These properties include senior housing communities, post-acute care communities, and outpatient medical facilities.
Where those properties are located is also appealing. Welltower's strategy is to focus primarily on high-growth urban markets. Not only do these markets have more potential customers for its properties, there also tend to be relatively high barriers to entry.
My prediction is that Welltower should enjoy solid growth over the long term. That's a pretty easy prediction to make. The number of Americans in the age groups most likely to move into senior housing or post-acute care communities is projected to increase dramatically over the next two decades.
The shortest wait
All three of these healthcare dividend stocks pay investors to wait for higher growth. I suspect, though, that the wait will be shortest for AbbVie.
Pfizer will probably return to solid growth after 2020. Welltower's growth is likely to really pick up midway through the next decade. AbbVie, however, has several major catalysts on the way relatively soon. The company could win FDA approvals for risankizumab and upadacitinib next year.
I like all three of these stocks over the long run. However, I think AbbVie is the most compelling buy right now. AbbVie has a great dividend and tremendous growth prospects, and the stock looks really cheap, with shares trading at less than 11 times expected earnings.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Keith Speights owns shares of AbbVie and Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has a great dividend and tremendous growth prospects, and the stock looks really cheap, with shares trading at less than 11 times expected earnings. Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields a little over 4%. | Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields a little over 4%. AbbVie should have plenty of financial flexibility to keep those dividend hikes coming in future years, too. | AbbVie has a great dividend and tremendous growth prospects, and the stock looks really cheap, with shares trading at less than 11 times expected earnings. Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields a little over 4%. | AbbVie AbbVie's dividend currently yields a little over 4%. That's plenty of time for AbbVie's other drugs and pipeline candidates to ramp up sales. Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . |
25387.0 | 2018-08-05 00:00:00 UTC | Better Buy: Pfizer Inc. vs. AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-pfizer-inc-vs-abbvie-inc-2018-08-05 | nan | nan | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Despite a recent thumping, the stock has delivered a 236% total return to investors who have held on since its inception in 2013. Investors who bought the stock earlier this year, though, have a lot less to smile about. A clinical trial flop and a fresh round of concerns for the company's lead drug knocked the stock down 21% from a peak it reached in February.
Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue climbing over the long haul. Which of these big pharma stocks is in a better position to deliver market-beating gains in the years ahead? Read on to find out.
The case for Pfizer Inc.
This pharma's aging Viagra brand is getting hammered by generic competition, but four recently launched blockbuster drugs are picking up the slack, and a couple are poised to accelerate. In the second quarter, Pfizer's half of U.S. Xtandi revenue rose 21% from last year. At an annualized run rate of $636 million, it isn't the company's leading contributor, but sales of the prostate cancer drug will get a major boost now that it's approved in the U.S. for treating patients with tumors that haven't spread yet.
Pfizer's rheumatoid arthritis tablet, Xeljanz, recently earned label expansions in the U.S. and EU that will make it a sorely needed new option for the treatment of ulcerative colitis. Sales of the drug soared 38% to a $1.9 billion run rate in the second quarter, and ulcerative colitis patients coming online now could allow the popular pill to continue its climb.
Pfizer also saw revenue from its blood thinner, Eliquis, soar 47% to a $3.6 billion run rate, while its breast cancer tablet, Ibrance, jumped 20% to a $4.1 billion run rate. At the moment Pfizer's awaiting approval decisions regarding four cancer drug applications under priority review at the FDA, which means there's a good chance the company can leverage its oncology relationships much further in the quarters ahead.
Four priority reviews at once would be enough for most pharmas, but not Pfizer. The company sees enough potential for 25 to 30 approvals through 2022, 15 of which could go on to achieve 10-figure sales.
The case for AbbVie Inc.
This company's rheumatoid arthritis drug, Humira, commands a leading share of the U.S. market despite earning its first approval 16 years ago. The company's cash cow is on pace to generate a stunning $20 billion in sales in 2018, but disagreements over its future are turning AbbVie into a battleground stock.
AbbVie's main patents have expired, but the company's bulls argue that additional patents will keep already approved biosimilar versions of Humira from eating into its market share. While that may be the case, the White House is currently considering a proposal that could put a stop to rebates that AbbVie uses to persuade insurers to keep patients on Humira instead of switching them to competing drugs.
Humira's responsible for around 63% of AbbVie's total revenue. Without a rebate lever, the company could have some big losses to offset sooner than expected. Luckily, the company's share of blood cancer drug Imbruvica soared 36% in the second quarter to an annualized run rate of $3.4 billion, and its new antiviral Mavyret pushed total hepatitis C revenue up to $3.9 billion run rate.
Right now, AbbVie's launching a sorely needed new treatment for endometriosis pain that scored high marks during clinical trials supporting its approval. Orlissa's expected to generate more than $1 billion in annual sales within several years, and it isn't the only blockbuster candidate emerging from AbbVie's pipeline.
The company's experimental rheumatoid arthritis drug, upadacitinib, succeeded in five pivotal trials, and an application to be submitted later this year seems like a slam dunk. In the meantime, AbbVie expects approval decisions regarding a psoriasis drug candidate that regulators in the U.S. and EU are currently reviewing.
Playing it safe
At the moment, AbbVie stock comes with a juicy 4% yield that looks more attractive than Pfizer, which offers 3.4% at recent prices. Over the past year, AbbVie and Pfizer have used 42% and 53% of free cash flow to make dividend payments, respectively, which means both companies have plenty of room to make big increases in the years ahead.
AbbVie's bigger payout is tempting, but investors could suffer losses if Humira sales get squeezed sooner than expected. Several large pharmas, including Pfizer, have indirectly endorsed a new rebate curbing policy by postponing regular price increases until after the November elections.
Pfizer probably has the most diverse product lineup in the business and it's getting bigger fast. That should allow for many more years of steady growth, which makes it the better buy today.
10 stocks we like better than Walmart
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, the Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
The author(s) may have a position in any stocks mentioned.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue climbing over the long haul. The case for AbbVie Inc. | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue climbing over the long haul. The case for AbbVie Inc. | Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue climbing over the long haul. Over the past year, AbbVie and Pfizer have used 42% and 53% of free cash flow to make dividend payments, respectively, which means both companies have plenty of room to make big increases in the years ahead. This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue climbing over the long haul. The case for AbbVie Inc. |
25388.0 | 2018-08-03 00:00:00 UTC | Noteworthy ETF Outflows: MTUM, BA, ABBV, COST | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows-mtum-ba-abbv-cost-2018-08-03 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $169.5 million dollar outflow -- that's a 1.8% decrease week over week (from 83,600,000 to 82,100,000). Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average:
Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $113.04. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $113.04. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $113.04. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $169.5 million dollar outflow -- that's a 1.8% decrease week over week (from 83,600,000 to 82,100,000). For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $113.04. | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.58 per share, with $115.3316 as the 52 week high point - that compares with a last trade of $113.04. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
25389.0 | 2018-07-31 00:00:00 UTC | 5 Top Stock Trades for Wednesday — Is Procter Finally a Buy? | ABBV | https://www.nasdaq.com/articles/5-top-stock-trades-for-wednesday-is-procter-finally-a-buy-2018-07-31 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Tech stocks rebounded slightly while bank stocks lost some traction Tuesday. After a few good days for banks and a tough few days for tech, that's not much of a surprise.
What could really shake things up though? Apple (NASDAQ: AAPL ), which reports after the close. We'll address that stock after we see the numbers. For now, let's look at some top stock trades for companies that have already reported earnings this quarter.
Top Stock Trades for Tomorrow #1: P&G (PG)
Procter & Gamble (NYSE: PG ) reported a mixed bag when it comes to earnings. However, the stock shook off its early losses and was able to rally higher on the day. That can be seen in the short-term chart above.
10 Best Tech Stocks to Buy on This Dip
Now above all three major moving averages and following its trend-line higher, its hard to too bearish on PG in the short-term. Below trend would be a different story, though.
Click to Enlarge On the adjacent long-term chart, you can see just how well P&G follows some of its trend-lines. While a run to the $84 to $85 range would be welcomed, I'd expect PG to hit some resistance in that area. Keep that in mind if you're going long.
Top Stock Trades for Tomorrow #2: Sogou (SOGO)
Boy, have some of those hot Chinese tech stock cooled off or what ? Right now we have Sogou (NYSE: SOGO ), which is back to single digits despite beating on earnings and revenue after traffic acquisition costs soared in the quarter.
So what now? I love to use Fibonacci levels on these names, but have left them off in this case. We can see that the $8.75 area is a pretty important level. Short-term investors can use that as a level to trade against.
An area of interest below that mark would be $8. While it would require a big fall, don't forget Sogou was down there just a few months ago. If the potential decline happens quickly enough, it may also find the backside of its prior downtrend line.
That would give us a great buying opportunity.
Top Stock Trades for Tomorrow #3: Caterpillar (CAT)
Despite raising guidance and beating earnings , Caterpillar (NYSE: CAT ) isn't having an easy time rallying. (Apologies on the marked up chart above).
Shares have been in a trading range between roughly $140 and $155, although it did overshoot those marks a few times. Anyway, strong support sits down on the low-$130s, while potential resistance is sitting somewhere between $152.50 and $155.
That's where a few downtrend lines come into play, depending on which peaks we are connecting. Either way, CAT is running into all three major moving averages right now and would need to clear those first.
There's too much resistance overhead to get me excited. I'd be more interested on a pullback to the $137.50 to $140 range, or in the low-$130s.
Top Stock Trades for Tomorrow #4: AbbVie (ABBV)
Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play.
Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. However, all three major moving averages are also nearby and could act as resistance.
The conservative play? Wait for a close over the 200-day moving average and look for a run up toward $104 to $105. If we get it, it's a quick 4% to 5% rally and that's just fine in my book.
Top Stock Trades for Tomorrow #5: Emerging Market ETF (EEM)
The Emerging Markets ETF (NYSEARCA: EEM ) is making a similar move, albeit with a slightly different setup.
While under some downtrend drawings the EEM has already broken over resistance, I do not want to give this one the benefit of the doubt given the current market climate. That's why we drew a more conservative downtrend line above (blue).
A close over this level would essentially lock EEM as a buy for short-term bulls. Aggressive traders who want to own the EEM ahead of this possible breakout can do so and use the 50-day moving average is their level to trade against. This mark was once resistance, but is now acting as support.
Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell . As of this writing, Bret Kenwell is long AAPL.
More From InvestorPlace
20 Automation Stocks for the Revolution in Robotics
15 Subscription Service Stocks With Massive Growth Potential
10 Strong Buy Stocks From the Best Analysts on Wall Street
7 Momentum Stocks for High-Risk Appetites
Compare Brokers
The post 5 Top Stock Trades for Wednesday - Is Procter Finally a Buy? appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. 10 Best Tech Stocks to Buy on This Dip Now above all three major moving averages and following its trend-line higher, its hard to too bearish on PG in the short-term. | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tech stocks rebounded slightly while bank stocks lost some traction Tuesday. | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tech stocks rebounded slightly while bank stocks lost some traction Tuesday. | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tech stocks rebounded slightly while bank stocks lost some traction Tuesday. |
25390.0 | 2018-07-31 00:00:00 UTC | Seattle Genetics' Latest Approval Is the Best Yet | ABBV | https://www.nasdaq.com/articles/seattle-genetics-latest-approval-best-yet-2018-07-31 | nan | nan | Seattle Genetics (NASDAQ: SGEN) saw sales of its only approved drug Adcetris jump substantially in the second quarter, thanks to the Food and Drug Administration approval for the frontline treatment of stage III and IV Hodgkin lymphoma, which was granted in the first quarter .
Seattle Genetics results: The raw numbers
Data source: Seattle Genetics.
What happened with Seattle Genetics this quarter?
Sales of Adcetris increased 65% year over year during the first full quarter that the drug was approved as a frontline treatment for Hodgkin lymphoma.
Royalty revenue, which is mostly from sales of Adcetris outside the U.S. and Canada by Seattle Genetics' partner Takeda , increased 66%.
Collaboration revenue was down year over year, but that category tends to be lumpy with milestone payments. This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) .
The biotech posted a net income during the quarter, but that was solely due to a $105 million increase in values of stock holdings, primarily in Immunomedics (NASDAQ: IMMU) . The mark-to-market accounting could just as likely result in a loss in future quarters.
The frontline Hodgkin lymphoma data was submitted to Health Canada, putting an expected approval in the first half of 2019. Takeda submitted the data package to EU authorities and expects a decision by the first quarter of 2019.
Turning to the pipeline, enfortumab vedotin, which Seattle Genetics is developing with AstellasPharma, completed enrollment in the pivotal trial testing the drug in patients with metastatic urothelial cancer who received a platinum-based chemotherapy agent and a checkpoint inhibitor. That puts the trial on target for data in the first half of next year.
What management had to say
"This is the highest sequential quarter-to-quarter growth rate since the product was launched," said Darren Cline, Seattle Genetics' executive vice president of commercial, which shows how big the approval for frontline Hodgkin lymphoma was for the company.
Nevertheless, CEO Clay Siegall cautioned investors that the initial increase in usage might not continue at the same rate:
Looking forward
Management is guiding for third-quarter Adcetris sales in the range of $130 million to $135 million, a 6.2% to 10.3% quarter-over-quarter increase.
The next growth opportunity for Adcetris will come from mature T-cell lymphoma in a clinical trial called Echelon-2, which is scheduled to read out early in the fourth quarter. The number of potential patients with mature T-cell lymphoma is about the same as frontline Hodgkin lymphoma, but the current treatment isn't particularly good. So it may be easier to get rapid adoption in mature T-cell lymphoma if the Echelon-2 results show Adcetris is substantially better than the current standard of care.
10 stocks we like better than Seattle Genetics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Seattle Genetics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . The biotech posted a net income during the quarter, but that was solely due to a $105 million increase in values of stock holdings, primarily in Immunomedics (NASDAQ: IMMU) . Turning to the pipeline, enfortumab vedotin, which Seattle Genetics is developing with AstellasPharma, completed enrollment in the pivotal trial testing the drug in patients with metastatic urothelial cancer who received a platinum-based chemotherapy agent and a checkpoint inhibitor. | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . Seattle Genetics results: The raw numbers Data source: Seattle Genetics. The frontline Hodgkin lymphoma data was submitted to Health Canada, putting an expected approval in the first half of 2019. | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . Seattle Genetics (NASDAQ: SGEN) saw sales of its only approved drug Adcetris jump substantially in the second quarter, thanks to the Food and Drug Administration approval for the frontline treatment of stage III and IV Hodgkin lymphoma, which was granted in the first quarter . Seattle Genetics results: The raw numbers Data source: Seattle Genetics. | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . Sales of Adcetris increased 65% year over year during the first full quarter that the drug was approved as a frontline treatment for Hodgkin lymphoma. Royalty revenue, which is mostly from sales of Adcetris outside the U.S. and Canada by Seattle Genetics' partner Takeda , increased 66%. |
25391.0 | 2018-07-30 00:00:00 UTC | AbbVie's Stock Is Incredibly Cheap | ABBV | https://www.nasdaq.com/articles/abbvies-stock-incredibly-cheap-2018-07-30 | nan | nan | At around 10-times forward-looking earnings, AbbVie (NYSE: ABBV) sports one of the cheapest valuations among either big pharma or Dividend Aristocrat stocks right now. In fact, Celgene Corporation and Teva Pharmaceutical Industries Ltd. are the only large-cap drug manufacturers trading at lower multiples than AbbVie. What's behind this rock bottom valuation?
Wall Street is dismayed by the company's inability to diversify its revenue stream ahead of Humira's date with the patent cliff. Humira is set to face biosimilar competition in Europe later this year and in the United Stated in mid-2023. The core problem is that this single drug still makes up over 60% of AbbVie's annual revenues.
Despite this looming competitive threat, I think AbbVie is actually an incredible long-term buy at these levels.
Help is on the way
When AbbVie was originally carved out as a stand-alone business in 2013, Abbott Laboratories did so primarily to isolate itself from the biosimilar threat to Humira. AbbVie's management team was thus tasked with building a clinical pipeline capable of producing revenue growth even as Humira went off patent. While that task was certainly no small feat, I believe AbbVie's management has accomplished this herculean goal.
Despite the biotech's $5.8 billion misstep with the solid tumor medicine Rova-T earlier this year, AbbVie has still managed to build out an impressive array of future growth products that are starting to come online right now. As evidence, the biotech was recently granted an approval by the Food and Drug Administration (FDA) for Orilissa as a treatment for moderate to severe pain associated with endometriosis. Orilissa represents a potential megablockbuster commercial opportunity for the company.
AbbVie and its partner Roche have also successfully expanded the label of their potent blood cancer drug Venclexta. Wall Street thinks this next-generation cancer medicine can thus achieve upwards of $3 billion in peak sales as soon as 2022.
On the immunology front, AbbVie appears set to bring two new major drugs to market within the next year, namely upadacitinib and risankizumab. The drugmaker estimates that these two drugs could generate combined peak sales of between $10 billion to $12 billion. Therefore, AbbVie should not only have little problem offsetting Humira's decline, but the drugmaker should be able to continue generating top notch revenue growth well into the future.
Buy the fear
The truly odd part about AbbVie's slide of late is that Humira is forecast to retain its title as the world's best-selling drug all the way through till 2024 . Put simply, biosimilars aren't expected to have a major impact on Humira's revenue stream anytime soon.
The primary reason is that unlike generics for traditional small-molecule drugs, biosimilars don't offer massive price discounts relative to the branded product. Doctors thus have little incentive to switch patients to an off-brand drug they aren't all that familiar with.
The take away is that AbbVie should be able to keep delivering healthy levels of revenue growth for years, thanks both to Humira's built-in competitive moat as a biologically based medicine and the company's stellar clinical pipeline that is already starting to produce major new growth products. So, in my view, AbbVie's cellar-dwelling valuation is actually a gift for investors willing to wait out some near-term volatility.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
George Budwell owns shares of AbbVie and Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Despite the biotech's $5.8 billion misstep with the solid tumor medicine Rova-T earlier this year, AbbVie has still managed to build out an impressive array of future growth products that are starting to come online right now. At around 10-times forward-looking earnings, AbbVie (NYSE: ABBV) sports one of the cheapest valuations among either big pharma or Dividend Aristocrat stocks right now. In fact, Celgene Corporation and Teva Pharmaceutical Industries Ltd. are the only large-cap drug manufacturers trading at lower multiples than AbbVie. | AbbVie's management team was thus tasked with building a clinical pipeline capable of producing revenue growth even as Humira went off patent. The take away is that AbbVie should be able to keep delivering healthy levels of revenue growth for years, thanks both to Humira's built-in competitive moat as a biologically based medicine and the company's stellar clinical pipeline that is already starting to produce major new growth products. At around 10-times forward-looking earnings, AbbVie (NYSE: ABBV) sports one of the cheapest valuations among either big pharma or Dividend Aristocrat stocks right now. | AbbVie's management team was thus tasked with building a clinical pipeline capable of producing revenue growth even as Humira went off patent. Despite the biotech's $5.8 billion misstep with the solid tumor medicine Rova-T earlier this year, AbbVie has still managed to build out an impressive array of future growth products that are starting to come online right now. The take away is that AbbVie should be able to keep delivering healthy levels of revenue growth for years, thanks both to Humira's built-in competitive moat as a biologically based medicine and the company's stellar clinical pipeline that is already starting to produce major new growth products. | AbbVie's management team was thus tasked with building a clinical pipeline capable of producing revenue growth even as Humira went off patent. Therefore, AbbVie should not only have little problem offsetting Humira's decline, but the drugmaker should be able to continue generating top notch revenue growth well into the future. At around 10-times forward-looking earnings, AbbVie (NYSE: ABBV) sports one of the cheapest valuations among either big pharma or Dividend Aristocrat stocks right now. |
25392.0 | 2018-07-30 00:00:00 UTC | Worried About AbbVie? 5 Things the Big Pharma's CEO Just Said You'll Want to Know | ABBV | https://www.nasdaq.com/articles/worried-about-abbvie-5-things-big-pharmas-ceo-just-said-youll-want-know-2018-07-30 | nan | nan | There's been considerable negativity in the investment community about AbbVie (NYSE: ABBV) lately. Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates.
This negativity was evident last week when AbbVie reported its second-quarter results. Despite posting fantastic revenue and earnings growth and raising its full-year 2018 guidance for the third time, AbbVie's share price dropped following its quarterly update.
AbbVie CEO Rick Gonzalez was asked about investors' lack of confidence during the company's earnings conference call. Here are five things he said that you'll want to know. (Quotes courtesy of S&P Global Market Intelligence .)
1. Look at the company's performance
Gonzalez acknowledged that there was some skepticism about AbbVie right now. However, his first response was to look at the company's performance in its five-and-a-half years as a stand-alone entity. Gonzalez stated that AbbVie has "never once disappointed investors" and that in most quarters, like it did in its recent Q2 results, the company has beaten expectations.
He went on to say that "there's not a company that I'm aware of that's performing better than us, and there's not a company that has performed better over the past 5 years." Gonzalez pointed out that AbbVie will deliver 40% earnings per share (EPS) growth this year with 25% operational EPS growth excluding tax benefits. He said couldn't think of any other company AbbVie's size delivering that level of growth.
2. Overblown worries about Humira
But what about the worries about how changes for biosimilars and drug rebates proposed by the Trump administration will impact Humira? Gonzalez replied that while some concerns are reasonable, "some of it is driven by people who want to elicit fear for their own personal gain."
As for the proposed changes from the Trump administration, Gonzalez said that "there were probably more positives than there were negatives" from AbbVie's perspective. He noted that Humira was "in the middle or slightly below the middle from a percent rebate standpoint" and in the cost of therapy when compared to competitors. Gonzalez added that Humira has competed very well in socialized healthcare markets where there are no rebates.
Gonzalez also stated that "there is nothing in the feedback we've seen so far around the biosimilar plan that is significantly different than what we already assume." He said that AbbVie was prepared to execute on its strategies to defend Humira's market share in countries where it will go up against biosimilar competition later this year, but that he wouldn't "telegraph" those plans to competitors. He also denied that the company was exploiting any loopholes or gaming the system with respect to its licensing agreements with Amgen and Mylan that keep Humira biosimilars off the U.S. market until 2023.
3. Two other megablockbuster assets right now
AbbVie has come a long way from just being "the Humira company," according to Gonzalez. He pointed to two non-Humira assets that are each approaching $4 billion in annualized sales -- cancer drug Imbruvica and hepatitis C virus (HCV) drug Mavyret.
Imbruvica generated revenue of $850 million in Q2, up nearly 36% year over year. AbbVie thinks the drug can achieve peak annual sales in the ballpark of $7 billion. Mavyret made $932 million in the second quarter. The HCV drug has quickly captured enormous market share in the U.S. and in international markets. However, AbbVie CFO Bill Chase said the company expects Q3 revenue for its HCV franchise, which primarily consists of Mavyret sales, to drop to $850 million as patient volumes in the U.S. and Japan decline.
4. More blockbusters on the way
Gonzalez namechecked a list of assets that he thinks will be blockbuster success stories for AbbVie in addition to Humira, Imbruvica, and Mavyret. Venclexta was at the top of the list. AbbVie recently won Food and Drug Administration approval for the drug in combination with Rituxan as a second-line treatment for chronic lymphocytic leukemia (CLL). Venclexta could secure another key approval next year in treating acute myeloid leukemia (AML).
AbbVie also just won FDA approval for Orilissa (elagolix) in treating pain associated with endometriosis. While the company expects a relatively slow ramp-up, with sales of less than $50 million this year, Gonzalez said that AbbVie got "everything that we hoped for in the label" for the drug and sees Orilissa as a multibillion-dollar opportunity.
Two potentially best-in-class successors to Humira could also be on the way. AbbVie hopes to win FDA approvals for risankizumab and upadacitinib in 2019. Gonzalez stated that with the trio of Humira, risankizumab, and upadacitinib, AbbVie has "the most competitive and best portfolio in immunology."
5. No need for a major deal to be successful
A comment made by Gonzalez last month resulted in speculation that AbbVie was on the cusp of making a big acquisition worth $20 billion to $30 billion. Gonzalez said that comment "took on a life of its own far greater than I would've anticipated." He clarified that AbbVie doesn't have any big acquisitions on the horizon right now and would more likely look at smaller deals.
The biggest issue right now is that valuations are too high for AbbVie to get the level of return on investment it would like. If the right opportunity came along, though, Gonzalez said that the company would jump on it. For now, he thinks that AbbVie's pipeline will enable the drugmaker to be successful for years to come.
Believe it or not?
Rick Gonzalez obviously has an incentive to spin things in the most positive way possible for AbbVie. That's his job. Investors have to make up their own minds whether to believe what he or folks like Andrew Left are saying.
In my view, Gonzalez made some good points about AbbVie's track record and its strategy. I don't think sales for Humira are going to fall off a cliff anytime soon. Actually, I agree with market research firm EvaluatePharma that Humira will remain the world's top-selling drug for several more years .
Will Imbruvica, Mavyret, Venclexta, and AbbVie's lead pipeline candidates make as much as AbbVie thinks they will? Perhaps not. However, in my view, their combined growth should more than compensate for any sales declines for Humira.
As a result of investors' negativity about AbbVie, the stock now trades at only 10 times expected earnings. With solid growth prospects and a dividend yield of nearly 4%, I continue to see AbbVie as a cheap big pharma stock to buy and hold for years to come .
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Keith Speights owns shares of AbbVie. The Motley Fool recommends Amgen and Mylan. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates. However, AbbVie CFO Bill Chase said the company expects Q3 revenue for its HCV franchise, which primarily consists of Mavyret sales, to drop to $850 million as patient volumes in the U.S. and Japan decline. While the company expects a relatively slow ramp-up, with sales of less than $50 million this year, Gonzalez said that AbbVie got "everything that we hoped for in the label" for the drug and sees Orilissa as a multibillion-dollar opportunity. | Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates. Gonzalez pointed out that AbbVie will deliver 40% earnings per share (EPS) growth this year with 25% operational EPS growth excluding tax benefits. AbbVie recently won Food and Drug Administration approval for the drug in combination with Rituxan as a second-line treatment for chronic lymphocytic leukemia (CLL). | Two other megablockbuster assets right now AbbVie has come a long way from just being "the Humira company," according to Gonzalez. While the company expects a relatively slow ramp-up, with sales of less than $50 million this year, Gonzalez said that AbbVie got "everything that we hoped for in the label" for the drug and sees Orilissa as a multibillion-dollar opportunity. Will Imbruvica, Mavyret, Venclexta, and AbbVie's lead pipeline candidates make as much as AbbVie thinks they will? | Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates. Gonzalez stated that AbbVie has "never once disappointed investors" and that in most quarters, like it did in its recent Q2 results, the company has beaten expectations. There's been considerable negativity in the investment community about AbbVie (NYSE: ABBV) lately. |
25393.0 | 2018-07-29 00:00:00 UTC | 3 Cheap Big Pharma Dividend Stocks That You Can Buy Now and Hold for Years | ABBV | https://www.nasdaq.com/articles/3-cheap-big-pharma-dividend-stocks-you-can-buy-now-and-hold-years-2018-07-29 | nan | nan | One of the greatest enemies of investors is trading too frequently. Jumping in and out of stocks too often dramatically reduces returns over the long run. That's why it pays to find stocks that you can buy and hold onto for years.
Stocks that meet three criteria often make the best long-term picks. First, their valuations should be attractive. Stock valuations tend to revert to their means over time. Second, they should pay great dividends. Don't underestimate how important reinvested dividends are to total returns. Third, the stocks should have solid long-term growth prospects.
I think three big pharma stocks currently meet all of these criteria: AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) . Here's why these are three cheap dividend stocks that you can buy now and hold for years to come.
1. AbbVie
AbbVie stock is definitely cheap right now. The big drugmaker's share price trades at a little over 10 times expected earnings, well below the S&P 500's forward earnings multiple of 16.7. With growth projections factored into the equation, AbbVie's valuation looks even more attractive. The stock's price-to-earnings-to-growth (PEG) ratio is a low 0.73.
The company also claims one of the juiciest dividends among big pharma stocks. AbbVie's dividend yield currently stands at 3.96%. Investors have enjoyed nice dividend increases every year since 2013 when AbbVie was spun off as a separate company. During that time, AbbVie hiked its dividend by a whopping 140%.
What about growth? Wall Street thinks that AbbVie's earnings will grow by more than 16% annually on average over the next five years. While sales for AbbVie's top-selling drug, Humira, will decrease in the future in the wake of biosimilar competition, it's still projected to be the No. 1 best-seller in the world in 2024 .
AbbVie should be able to make up for Humira sales declines and still generate solid growth. Cancer drugs Imbruvica and Venclexta, hepatitis C virus (HCV) drug Mavyret, and recently approved endometriosis drug Orlissa (elagolix) are expected to be key to the company's fortunes. Market research firm EvaluatePharma ranks AbbVie's pipeline as the second-best in the industry , with potential blockbuster drugs including risankizumab and upadacitinib likely on the way.
2. Gilead Sciences
Gilead Sciences also looks inexpensive, with shares trading at 12 times expected earnings. But where the company's low enterprise value-to-EBITDA (EV/EBITDA) multiple of 7.35 really highlights Gilead's attractive valuation.
Although Gilead didn't initiate a dividend program until 2015, the company has prioritized returning profits to shareholders through dividends. Gilead has increased its dividend payout by more than 10% each year on average. The dividend currently yields a little over 3%.
Growth has been a challenge for Gilead in recent years due to sinking sales for its hepatitis C virus (HCV) franchise. The good news, though, is that the biotech expects HCV sales to stabilize in 2018 as it battles AbbVie for market share. This should cause investors' attention to shift more toward Gilead's HIV drugs. That HIV lineup now includes Biktarvy, which is likely to be the biggest new drug launched in 2018 and could be on the way to annual sales of $6 billion or more.
Gilead should be able to return to growth thanks to its strong HIV franchise, increased momentum for cancer drug Yescarta, and a promising pipeline. The company's late-stage rheumatoid arthritis candidate, filgotinib, should rake in at least $2 billion in peak annual sales and possibly significantly more with other indications. Gilead also could be a leader in the potentially lucrative non-alcoholic steatohepatitis (NASH) space with late-stage candidate selonsertib.
3. Pfizer
Pfizer stock trades at a little over 12 times expected earnings -- only slightly higher than Gilead's forward earnings multiple. Pfizer's EV/EBITDA multiple of 11.6 is also well below historical levels for healthcare stocks.
The company has been a favorite among income-seeking investors for a long time and still is with a dividend yield of 3.66%. Over the past five years, the drugmaker has boosted its dividend by nearly 42%. How important is Pfizer's dividend? Consider that the stock price doubled over the last 10 years. If you bought Pfizer 10 years ago and reinvested its dividends, though, you'd have a total return that tripled your initial investment.
Pfizer's revenue and earnings growth in recent years haven't been impressive. That's largely because of falling sales for drugs that have lost exclusivity and continued product shortages with its sterile injectables business. However, the negative impact from the older off-patent drugs should decrease over the next few years. Pfizer also expects to resolve the issues hurting its sterile injectables sales.
In my view, Pfizer has its best pipeline in years. The company thinks that it will win approval for up to 15 new drugs or new indications for existing drugs with blockbuster sales potential over the next five years. In addition, Pfizer's growth should continue to be fueled by big winners like anticoagulant Eliquis and cancer drug Ibrance, both of which EvaluatePharma ranks among the top five drugs with the fastest sales growth this year.
Only for long-term investors
If you're looking for stocks that will skyrocket in just a few months, AbbVie, Gilead Sciences, and Pfizer probably aren't for you. Some with short-term perspectives might worry that biosimilar competition for Humira in Europe could hurt AbbVie starting in the fourth quarter of 2018. They might fret if Gilead doesn't see HCV sales stabilization soon. They could be bothered if Pfizer's problems aren't resolved immediately.
But if you're a patient investor with a long-term mindset, these three big pharma stocks should be solid picks. Their valuations are certainly attractive, as are their dividends. I like the growth prospects for all three companies. Investors who buy and hold AbbVie, Gilead, and Pfizer stocks should win over the long run.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Market research firm EvaluatePharma ranks AbbVie's pipeline as the second-best in the industry , with potential blockbuster drugs including risankizumab and upadacitinib likely on the way. I think three big pharma stocks currently meet all of these criteria: AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) . AbbVie AbbVie stock is definitely cheap right now. | I think three big pharma stocks currently meet all of these criteria: AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) . Investors who buy and hold AbbVie, Gilead, and Pfizer stocks should win over the long run. AbbVie AbbVie stock is definitely cheap right now. | Only for long-term investors If you're looking for stocks that will skyrocket in just a few months, AbbVie, Gilead Sciences, and Pfizer probably aren't for you. Investors who buy and hold AbbVie, Gilead, and Pfizer stocks should win over the long run. I think three big pharma stocks currently meet all of these criteria: AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) . | Only for long-term investors If you're looking for stocks that will skyrocket in just a few months, AbbVie, Gilead Sciences, and Pfizer probably aren't for you. Investors who buy and hold AbbVie, Gilead, and Pfizer stocks should win over the long run. I think three big pharma stocks currently meet all of these criteria: AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) . |
25394.0 | 2018-07-27 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.7% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-636-follow-through-indicator-47-sensitive-2018-07-27 | nan | nan | Expected Earnings Release: 07/27/2018, Premarket
Avg. Extended-Hours Dollar Volume: $8,119,533
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings announcement. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close.
Last 12 Qtrs Positive Only Price Reactions
Percent of time added to extended-hours gains: 85.7%
Average next regular session additional gain: 3.4%
Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 85.7% of the time (6 events) the stock posted additional gains in the following regular session by an average of 3.4%.
Last 12 Qtrs Negative Only Price Reactions
Percent of time added to extended-hours losses: 25%
Average next regular session additional loss: 1.7%
Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 1.7% by the following regular session close.
Data provided by the MT Pro service at MTNewswires.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 85.7% Average next regular session additional gain: 3.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 85.7% of the time (6 events) the stock posted additional gains in the following regular session by an average of 3.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 25% Average next regular session additional loss: 1.7% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 1.7% by the following regular session close. Extended-Hours Dollar Volume: $8,119,533 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 85.7% Average next regular session additional gain: 3.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 85.7% of the time (6 events) the stock posted additional gains in the following regular session by an average of 3.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 25% Average next regular session additional loss: 1.7% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 1.7% by the following regular session close. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 85.7% Average next regular session additional gain: 3.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 85.7% of the time (6 events) the stock posted additional gains in the following regular session by an average of 3.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 25% Average next regular session additional loss: 1.7% Over that same historical period, when shares of ABBV dropped in the extended-hours in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 1.7% by the following regular session close. Extended-Hours Dollar Volume: $8,119,533 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | Extended-Hours Dollar Volume: $8,119,533 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 85.7% Average next regular session additional gain: 3.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 85.7% of the time (6 events) the stock posted additional gains in the following regular session by an average of 3.4%. |
25395.0 | 2018-07-27 00:00:00 UTC | AbbVie (ABBV) Tops Q2 Earnings and Revenues, View Up | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q2-earnings-and-revenues-view-up-2018-07-27 | nan | nan | North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment).
Among new products, Mavyret (HCV) has exceeded expectations and performance of Duodopa and Creon are also encouraging.
Humira, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on pipeline updates.
AbbVie's performance has been impressive, with the pharmaceuticals company delivering positive surprises in all of the past four quarter. The average earnings beat over the last four quarters is 2.39%.
Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AbbVie's second-quarter earnings came in at $2.00 per share, beating the Zacks Consensus Estimate of $1.98.
Revenues: AbbVie posted revenues of $8.28 billion, which marginally beat the Zacks Consensus Estimate of $8.27 billion.
Key Stats: Humira sales came in at $5.2 billion, up 8.2% year over year excluding currency impact. Second-quarter Imbruvica net revenues were $850 million, up 35.6% year over year. HCV sales more than doubled year-over year to $973 million on strong sales of Mavyret.
2018 Outlook: AbbVie updated its outlook for 2018. The company raised its adjusted EPS in the range of $7.76 to $7.86 compared to $7.66 to $7.76 expected previously. The Zacks Consensus Estimate is currently pegged at $7.80 per share.
Share Price Impact: Shares rose more than 0.7% in pre-market trading .
Check back later for our full write up on this AbbVie earnings report.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's performance has been impressive, with the pharmaceuticals company delivering positive surprises in all of the past four quarter. Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Revenues: AbbVie posted revenues of $8.28 billion, which marginally beat the Zacks Consensus Estimate of $8.27 billion. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote 5 Medical Stocks to Buy Now Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's second-quarter earnings came in at $2.00 per share, beating the Zacks Consensus Estimate of $1.98. AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote 5 Medical Stocks to Buy Now Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. | We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's second-quarter earnings came in at $2.00 per share, beating the Zacks Consensus Estimate of $1.98. Revenues: AbbVie posted revenues of $8.28 billion, which marginally beat the Zacks Consensus Estimate of $8.27 billion. North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. |
25396.0 | 2018-07-27 00:00:00 UTC | AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-q2-earnings-beat-estimates-2018-view-up-2018-07-27 | nan | nan | AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. Moreover, the company raised its expectations for 2018 bottom line. However, shares fell almost 1.8% in pre-market trading .
Shares of AbbVie have declined 2.9% in a year's time against the industry 's 1.2% rise.
The biopharmaceutical company reported earnings of $2.00 per share in the second quarter, beating the Zacks Consensus Estimate of $1.98 by 1%. Also, the figure grew 40.8% year over year. Earnings also exceeded the guided range of $1.94 and $1.96 per share.
The company posted revenues of $8.28 billion in the quarter under review, marginally beating the Zacks Consensus Estimate of $8.27 billion. The top line also increased 19.2% year over year. Excluding a 1.8% favorable impact from foreign exchange rate fluctuations, operational revenues rose 17.1%. Revenues growth was higher than the projection of approximately 15% on an operational basis.
Quarter in Detail
Key drug, Humira recorded sales growth of 8.2% on an operational basis with revenues coming in at $5.2 billion. Sales in the United States increased 10% to $3.5 billion, in line with expectations. Humira sales in the ex-U.S. market were up 4.4% on an operational basis and 9.8% on reported basis to $1.67 billion, exceeding the projected figure of $1.6 billion.
Second-quarter net revenues from Imbruvica were $850 million, up 35.6% year over year. U.S. sales of Imbruvica grossed $693 million, up 31.1% from the year-ago figure. AbbVie logged $157 million of international profit sharing with Johnson & Johnson JNJ .
Other products that delivered an impressive performance include Duodopa. It recorded revenue growth of 25.1% on operational and 32.9% on reported basis. Another product called Creon witnessed an increase of 11.4% in revenues on both operational and reported basis.
HCV (chronic hepatitis C virus) products recorded sales of $973 million, up more than 100% year-over-year on the back of strong demand for Mavyret, which was launched in the second half of 2017. The company's expectation for HCV sales was $950 million.
Adjusted SG&A expenses increased 16.5% to $1.64 billion while R&D expenses escalated 4% to $1.27 billion in the second quarter. Adjusted operating margin was 45.3% of sales.
Other Updates
In July, AbbVie and partner Neurocrine Biosciences announced FDA approval for their pain drug, Orilissa (elagolix), for management of moderate-to-severe pain associated with endometriosis.
In June, the FDA approved label expansion of cancer drug, Venclexta, in combination with Roche's RHHBY Rituxan (rituximab) for treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, in second or later-line setting.
During the quarter, AbbVie entered a license agreement with Mylan N.V. MYL , which will grant non-exclusive license relating to Humira in the United States and other countries, excluding Europe. The agreement restricts Mylan from launching a biosimilar version of the drug till Jul 31, 2023.
2018 Outlook
AbbVie raised its adjusted EPS guidance to the range of $7.76-$7.86 for 2018 from $7.66-$7.76 predicted earlier. The earnings guidance reflects a year-over-year surge of 39.5% at the mid-point. The Zacks Consensus Estimate for current year earnings is pegged at $7.80 per share.
AbbVie Inc. Price, Consensus and EPS Surprise
AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. Shares of AbbVie have declined 2.9% in a year's time against the industry 's 1.2% rise. AbbVie logged $157 million of international profit sharing with Johnson & Johnson JNJ . | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. | AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. Shares of AbbVie have declined 2.9% in a year's time against the industry 's 1.2% rise. AbbVie logged $157 million of international profit sharing with Johnson & Johnson JNJ . |
25397.0 | 2018-07-27 00:00:00 UTC | Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales | ABBV | https://www.nasdaq.com/articles/roche-rhhby-1h18-revenues-up-y-y-on-solid-new-drug-sales-2018-07-27 | nan | nan | Swiss pharma giant Roche Holding AGRHHBY reported solid sales growth in the first half of 2018 as well as in the second quarter, propelled by growth in sales of new drugs. The company also upped its annual guidance for the second time in 2018.
The strong performance should boost investors' sentiment. Roche's stock has declined 0.9% in the year so far compared with the industry 's decline of 2.3%.
Sales for the first half of 2018 came in at CHF 28.1 billion, up 7% from the year-ago period. Earnings per share came in at CHF 9.84 in the first half, up from CHF 8.23 in the year-ago quarter. The company reported sales of CHF 14.5 billion in the second quarter of 2018, up 7% from the year-ago period.
The company reports results under two divisions - Pharmaceuticals and Diagnostics. All growth rates mentioned below are on a year-over-year basis and at constant exchange rates.
Sales at the Pharmaceuticals division increased 7%, driven by strong growth in Ocrevus, Tecentriq, Alecensa and Perjeta. Diagnostics division sales climbed 8% primarily on the back of strong immunodiagnostic business.
Results in Detail
Herceptin sales grew 2%, due to demand in the United States. Perjeta sales grew 23%, following increased demand in the neoadjuvant and metastatic settings. Sales also got a boost from the FDA approval of Perjeta for use in combination with Herceptin and chemotherapy for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence in late 2017. In total, the HER2-franchise (Herceptin, Perjeta and Kadcyla) was up 7%.
Strong Ocrevus sales further boosted the top line. The drug, used to treat two forms of multiple sclerosis (MS), continued to gain traction worldwide with sales of $1.0 billion. Approximately 50,000 patients were being treated globally as of June 2018.
Immuno-oncology drug, Tecentriq (for advanced bladder cancer and advanced lung cancer), recorded 37% growth in sales. Sales growth was driven by post-launch uptake in Europe, particularly in Germany. Lung cancer drug, Alcenesa sales were up 91% and witnessed solid growth across all regions.
Performance of the immunology franchise was driven by increased sales of Actemra/RoActemra (13%) and Xolair (10%). Gazyva/Gazyvaro sales were up 32%, due to growth in the United States and Europe.
Ophthalmology drug, Lucentis' sales were up 16%. The growth was driven by the launch of prefilled syringes and sales increases were reported for all approved indications. Sales of Xolair (+10%) was driven by demand in chronic idiopathic urticaria.
Tamiflu contributed with high sales at the beginning of the year due to a severe flu season.
However, sales of Avastin were flat due to decline in the United States and Europe. Sales of Rituxan/MabThera were also down 9%, due to entry of biosimilars in Europe. Sales of Tarceva declined (32%), due to growing use of other therapeutic options. Sales of Xeloda (7%) continue to be hit by generic competition.
Revenues at the Diagnostics division climbed 6% on the back of solid performance of the Centralised and Point of Care Solutions (+6%) unit, which was, in turn, propelled by Immunodiagnostics (+9%). Tissue Diagnostics (+11%) and Molecular Diagnostics (+5%) also performed impressively. Diabetes Care sales increased 1%.
2018 Outlook Raised
Roche's sales are expected to grow in mid-single digits compared to the earlier guidance of growth in low-single digits. The company expects core earnings to grow in mid-teen digits compared to the previous estimate of growth in high-single digits.
Pipeline Progress
The European Commission approved Perjeta in combination with Herceptin and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.
The FDA also approved the subcutaneous formulation of Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older. The FDA also granted approval to MabThera/Rituxan for the treatment of adults suffering from moderate to severe pemphigus vulgaris.
Roche and partner AbbVie ABBV also won the FDA approval for Venclexta in combination with Rituxan/MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma.
The FDA also granted Priority Review to Hemlibra for adults and children with haemophilia A without factor VIII inhibitors. The FDA also granted Breakthrough Therapy Designation for the combination of Tecentriq and Avastin as an initial (first-line) treatment for patients suffering from advanced or metastatic hepatocellular carcinoma (HCC). The FDA also granted priority review to baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in patients 12 years and older.
Roche also entered into a merger agreement with Foundation Medicine. The transaction will close in the second half of 2018. The acquisition will advance molecular insights and the broad availability of high-quality comprehensive genomic profiling, both key enablers for the development of new cancer treatments and optimal patient care.
Our Take
Roche's performance in the first half of 2018 was impressive. Strong sales of Ocrevus, Perjeta, Tecentriq and Alecensa more than offset the decline from legacy drugs Rituxan, Avastin and Tarceva. In particular, MS drug Ocrevus witnessed strong growth, driven by increased demand.
The increase in guidance was encouraging too. Meanwhile, the company continues to progress with its pipeline as it looks to restructure its portfolio beyond oncology into MS and hemophilia among others. Approval of new drugs and a potential label expansion of existing drugs bode well for Roche, as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars. Novartis NVS has already launched its biosimilar version of Rituxan/ MabThera in Europe. Amgen AMGN also obtained the FDA approval for a biosimilar version of Avastin for treatment of five types of cancers.
Roche is also looking to restructure its operations for better efficiency.
Zacks Rank
Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Roche and partner AbbVie ABBV also won the FDA approval for Venclexta in combination with Rituxan/MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Progress The European Commission approved Perjeta in combination with Herceptin and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Roche and partner AbbVie ABBV also won the FDA approval for Venclexta in combination with Rituxan/MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. Pipeline Progress The European Commission approved Perjeta in combination with Herceptin and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Roche and partner AbbVie ABBV also won the FDA approval for Venclexta in combination with Rituxan/MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. Swiss pharma giant Roche Holding AGRHHBY reported solid sales growth in the first half of 2018 as well as in the second quarter, propelled by growth in sales of new drugs. | Roche and partner AbbVie ABBV also won the FDA approval for Venclexta in combination with Rituxan/MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Sales at the Pharmaceuticals division increased 7%, driven by strong growth in Ocrevus, Tecentriq, Alecensa and Perjeta. |
25398.0 | 2018-07-27 00:00:00 UTC | 2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited | ABBV | https://www.nasdaq.com/articles/2-reasons-market-frowned-after-abbvies-blowout-q2-and-1-reason-it-should-be-excited-2018 | nan | nan | AbbVie (NYSE: ABBV) did it again. The big drugmaker posted fantastic numbers in its first-quarter results reported in April. AbbVie announced more great results with its second-quarter earnings update on Friday.
Net revenue jumped 19% year over year to $8.28 billion. Adjusted earnings per share (EPS) soared nearly 41% in the second quarter to $2. Both numbers topped Wall Street estimates. AbbVie even boosted its full-year 2018 adjusted EPS guidance from between $7.66 and $7.76 to between $7.76 and $7.86.
Despite AbbVie's blowout Q2 results, the market frowned. The big pharma company's share price declined in early trading on Friday. Here are two reasons behind this surprising response -- and one big reason why investors actually should be excited about AbbVie's Q2 update.
1. Slowing growth for Humira
The first thing investors look for in AbbVie's quarterly results after the top-line and bottom-line numbers is Humira's sales figure. That's understandable since the drug generates 63% of the company's total revenue.
So how did Humira do in the second quarter? Pretty good. The drug's sales totaled $5.19 billion, up 10% year over year. However, there are a couple of things to note about Humira's performance.
First, the revenue figure was helped by foreign exchange. On an operational basis, Humira's sales increased by only 8.2% from the prior-year period. Second, this year-over-year growth was subpar compared to the historical performance for the blockbuster drug.
Slower growth could be the new norm for Humira, though, with biosimilar competition in Europe coming later this year. However, I mentioned in a preview of AbbVie's Q2 earnings that lower growth for Humira should be expected in the second quarter due to the timing of shipments in the first quarter. AbbVie still expects the drug to make more than $20 billion this year.
2. Mavyret momentum slowing, too
It's not hard to spot the main reason for AbbVie's great second quarter. The company reported hepatitis C virus (HCV) treatment sales of $973 million, with Mavyret generating most of that amount. In the same period last year, HCV drug Viekira's sales totaled $225 million and were quickly dropping.
While investors were no doubt happy about Mavyret's sales, they also realized that Mavyret's momentum is slowing somewhat. The easy wins are probably over. Now, AbbVie and Gilead Sciences (NASDAQ: GILD) have to fight harder for any incremental market share.
Gilead's executives foresaw this scenario. They predicted in the first quarter that their HCV treatment sales would begin to stabilize in mid-2018. That's exactly what appears to be happening now . Stabilization for Gilead's HCV drug franchise, however, also means that AbbVie's HCV drug sales will also stabilize.
In one of her late '80s hit songs, Janet Jackson asked, "What have you done for me lately?" That's kind of how the stock market operates. Mavyret is a tremendous success story for AbbVie and will probably generate billions of dollars each year for the company for a long time to come. But the HCV drug could already be turning into yesterday's news for the market.
A big reason to be excited
There were actually several reasons why investors should have responded more enthusiastically to AbbVie's impressive Q2 results. However, I think I can roll the main reasons for excitement into one statement: Non-Humira growth should be the big storyline for AbbVie going forward.
Of course, Mavyret will continue to be a key way that AbbVie's non-Humira sales grow. But we can't leave out Imbruvica. Q2 sales for the cancer drug soared nearly 36% year over year. Approvals for more indications could be on the way.
Speaking of approvals, AbbVie just snagged a big one for Orilissa (elagolix). The FDA approved the drug in managing pain associated with endometriosis on July 24. AbbVie is also evaluating Orilissa in a late-stage study targeting treatment of uterine fibroids.
In April, AbbVie submitted for FDA approval of risankizumab in treating psoriasis. The drug, along with another candidate, upadacitinib, is an important component of AbbVie's strategy to maintain its dominance in the immunology market even after Humira loses patent protection. They're also key reasons why market research firm EvaluatePharma ranks AbbVie's pipeline as No. 2 in the industry .
But could sinking sales for Humira keep the spotlight off of AbbVie's other bright spots? Maybe. However, don't believe the doomsayers predicting that AbbVie is in trouble. The company recently signed an agreement to keep Mylan 's biosimilar to Humira off the U.S. market until 2023 in a similar deal that it made last year with Amgen . AbbVie should have plenty of time for its current drugs and pipeline candidates to generate growth and offset any decline in sales for Humira.
Is the negative reaction to AbbVie's second quarter warranted? I don't think so. Imbruvica, Mavyret, Orilissa, a loaded pipeline, and a great dividend should turn investors' frowns into smiles over the long run.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Amgen and Mylan. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The drug, along with another candidate, upadacitinib, is an important component of AbbVie's strategy to maintain its dominance in the immunology market even after Humira loses patent protection. AbbVie should have plenty of time for its current drugs and pipeline candidates to generate growth and offset any decline in sales for Humira. AbbVie (NYSE: ABBV) did it again. | AbbVie (NYSE: ABBV) did it again. AbbVie announced more great results with its second-quarter earnings update on Friday. AbbVie even boosted its full-year 2018 adjusted EPS guidance from between $7.66 and $7.76 to between $7.76 and $7.86. | Slowing growth for Humira The first thing investors look for in AbbVie's quarterly results after the top-line and bottom-line numbers is Humira's sales figure. Stabilization for Gilead's HCV drug franchise, however, also means that AbbVie's HCV drug sales will also stabilize. AbbVie should have plenty of time for its current drugs and pipeline candidates to generate growth and offset any decline in sales for Humira. | Slowing growth for Humira The first thing investors look for in AbbVie's quarterly results after the top-line and bottom-line numbers is Humira's sales figure. AbbVie (NYSE: ABBV) did it again. AbbVie announced more great results with its second-quarter earnings update on Friday. |
25399.0 | 2018-07-27 00:00:00 UTC | Health Care Sector Update for 07/27/2018: NBRV,ABBV,TNXP | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-07272018-nbrvabbvtnxp-2018-07-27 | nan | nan | Top Health Care Stocks
JNJ +1.39%
PFE +0.58%
ABT -0.67%
MRK -1.08%
AMGN -0.69%
Health care stocks were declining Friday, including a nearly 0.5% retreat for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were down nearly 0.9% as a group while the Nasdaq Biotechnology index was falling almost 2.4%.
Among health care stocks moving on news:
- Nabriva Therapeutics AG ( NBRV ) dropped to a record low on Friday, sinking almost 22% to a worst-ever $2.41 per share, after the anti-infectives drugmaker priced a $50 million public offering of nearly 18.2 million shares of its common stock at $2.75 a piece, representing a 10.7% discount relative to Thursday's closing price. Underwriters participating in the deal received an option to buy up to 2.7 million additional shares to cover potential overallotments. Nabriva expects to use net proceeds to fund regulatory submissions in the United States and Europe for its Lefamulin and Contepo drug candidates to treat community-acquired bacterial pneumonia and chronic urinary tract infections, respectively.
In other sector news:
- AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. It also increased its forecast for net income this year by $0.10 per share over its prior guidance, now expecting $7.76 to $7.86 per share compared with the Street view expecting $7.80 per share.
- Tonix Pharmaceuticals ( TNXP ) plunged more than 77% to a worst-ever 89 cents a share after the early-stage biotech company said it was stopping Phase III testing of its Tonmya drug candidate to treat military-related post-traumatic stress disorder. Although Tonmya failed to demostrate adequate separation from a placebo on the primary endpoint of the study after 12 weeks, the company said meaningful improvement in overall PTSD symptoms was observed through the first four weeks of the trial. There also were no serious or unexpected adverse events.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. Among health care stocks moving on news: - Nabriva Therapeutics AG ( NBRV ) dropped to a record low on Friday, sinking almost 22% to a worst-ever $2.41 per share, after the anti-infectives drugmaker priced a $50 million public offering of nearly 18.2 million shares of its common stock at $2.75 a piece, representing a 10.7% discount relative to Thursday's closing price. Nabriva expects to use net proceeds to fund regulatory submissions in the United States and Europe for its Lefamulin and Contepo drug candidates to treat community-acquired bacterial pneumonia and chronic urinary tract infections, respectively. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. Top Health Care Stocks | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. Health care stocks were declining Friday, including a nearly 0.5% retreat for the NYSE Health Care Index in recent trade. Among health care stocks moving on news: - Nabriva Therapeutics AG ( NBRV ) dropped to a record low on Friday, sinking almost 22% to a worst-ever $2.41 per share, after the anti-infectives drugmaker priced a $50 million public offering of nearly 18.2 million shares of its common stock at $2.75 a piece, representing a 10.7% discount relative to Thursday's closing price. | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. Top Health Care Stocks Health care stocks were declining Friday, including a nearly 0.5% retreat for the NYSE Health Care Index in recent trade. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.